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ABSTRACT	  
	  
It	  has	  long	  been	  proposed	  that	  a	  high	  intake	  of	  dietary	  fibre	  promotes	  good	  intestinal	  
health.	  Work	  performed	  previously	  by	  our	  research	  group	  suggests	  that	  soluble	  dietary	  fibre	  
might	   have	   a	   particularly	   beneficial	   impact	   on	   intestinal	   health	   via	   its	   ability	   to	   inhibit	  
potentially	  harmful	   interactions	  between	  bacterial	  pathogens	  and	   the	  gut	  epithelium.	  The	  
aims	  of	  this	  thesis	  were	  to	  evaluate	  soluble	  plantain	  NSP	  for	  its	  ability	  to	  disrupt	  the	  epithelial	  
interactions	  of	  diarrhoeal	  pathogens	  C.	  difficile	  and	  Enterotoxigenic	  Escherichia	  coli	  (ETEC),	  as	  
well	   as	   other	   bacterial	   components	   implicated	   in	   diarrhoeal	   disease.	   Work	   was	   also	  
performed	  to	  characterise	  the	  specific	  inhibitory	  fraction	  of	  plantain	  NSP,	  and	  in	  addition,	  to	  
establish	  the	  molecular	  mechanism	  underlying	  its	  inhibitory	  activity.	  	  
A	   range	   of	   soluble	   dietary	   fibres	   were	   shown	   to	   significantly	   inhibit	   the	   in	   vitro	  
epithelial	  adhesion	  of	  C.	  difficile	  and	  ETEC,	  but	  out	  of	  all	  the	  fibres	  tested,	  soluble	  plantain	  
NSP	   exhibited	   the	   highest	   efficacy.	   Plantain	   NSP	   also	   significantly	   inhibited	   the	   epithelial	  
adhesion	  of	  eleven	  C.	  difficile	  clinical	  isolates,	  irrespective	  of	  their	  toxin	  expression	  or	  ribotype	  
status.	  Furthermore,	  plantain	  NSP	  blocked	  the	  epithelial	  interactions	  of	  five	  purified	  C.	  difficile	  
spore	  preparations.	  In	  addition	  to	  its	  anti-­‐adhesive	  effects,	  soluble	  plantain	  NSP	  significantly	  
down-­‐regulated	   the	   pro-­‐inflammatory,	   cytotoxicity	   and	   apoptotic	   response	   induced	   by	  C.	  
difficile	  and	  its	  toxins.	  Similar	  effects	  were	  also	  found	  with	  respect	  to	  mucosally-­‐associated	  E.	  
coli	   isolated	   from	  ulcerative	   colitis	   (UC)	  patients,	   as	  well	   as	  bacterial	   components	   such	  as	  
flagellin	  and	  LPS.	  	  
Results	  demonstrated	  that	  the	  inhibitory	  activity	  of	  plantain	  NSP	  was	  mediated	  by	  its	  
acidic	  polysaccharide	  fraction,	  which	  is	  mainly	  composed	  of	  pectic	  material.	  In	  addition,	  it	  was	  
	   VI	  
shown	  that	  soluble	  plantain	  disrupted	  bacterial-­‐epithelial	  interactions	  via	  an	  interaction	  with	  
the	  intestinal	  epithelium.	  Whilst	  plantain	  NSP	  induced	  increased	  cellular	  chloride	  secretion,	  
this	  mechanism	  was	   not	   responsible	   for	   inhibitory	   activity.	   It	   was	   also	   hypothesised	   that	  
plantain	  NSP	  might	  mimic	  intestinal	  MUC2	  glycans	  by	  interacting	  with	  cell-­‐surface	  galectin-­‐3,	  
with	   consequent	   nuclear	   localisation	   of	   β-­‐catenin	   and	   down-­‐regulation	   of	   inflammatory	  
cytokines.	  Whilst	  plantain	  NSP	  was	  shown	  to	  induce	  activation	  of	  β-­‐catenin,	  the	  knockdown	  
of	   surface	   galectin-­‐3	   expression	   had	   no	   effect	   on	   inhibitory	   activity.	   Thus,	   the	   specific	  
mechanism	  underlying	  the	  inhibitory	  activity	  of	  plantain	  NSP	  requires	  further	  investigation.	  
This	   work	   supports	   the	   hypothesis	   that	   soluble	   plantain	   fibre	   can	   inhibit	   harmful	  
interactions	  between	  bacteria	   and	   the	  human	   intestinal	   epithelium.	   Indeed,	   these	   studies	  
provide	  convincing	  evidence	  to	  suggest	  that	  soluble	  plantain	  fibre,	  acting	  as	  a	  ‘contrabiotic’,	  
could	  be	  developed	  as	  a	  potential	  prophylaxis	  or	  treatment	  against	  C.	  difficile	  and	  ETEC,	  which	  
represent	   the	   main	   cause	   of	   antibiotic-­‐associated	   diarrhoea	   and	   traveller’s	   diarrhoea,	  
respectively.	  In	  addition,	  dietary	  supplementation	  with	  soluble	  plantain	  NSP	  may	  also	  confer	  
a	  therapeutic	  benefit	  in	  inflammatory	  bowel	  disease	  (IBD).	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   Antibiotic-­‐associated	  diarrhoea	  	  
AIEC	   	   	   Adherent	  invasive	  E.	  coli	  	  
AK	   	   	   Adenylate	  kinase	  	  
AMP	   	   	   Adenosine	  monophosphate	  
AUL	   	   	   Arbitrary	  units	  of	  luminescence	  	  
BHI	   	   	   Brain	  heart	  infusion	  	  
BSA	   	   	   Bovine	  serum	  albumin	  	  
CCNA	   	   	   Cytotoxicity	  neutralisation	  assay	  
CD	   	   	   Crohn’s	  disease	  	  
CDAD	   	   	   C.	  difficile	  associated	  disease	  
CDI	   	   	   C.	  difficile	  infection	  
CDRN	   	   	   C.	  difficile	  Ribotyping	  Network	  
CF	   	   	   Colonisation	  factor	  	  
CFTR	   	   	   Cystic	  fibrosis	  transmembrane	  regulator	  
CFTR-­‐inh-­‐172	   	   Cystic	  fibrosis	  transmembrane	  regulator	  inhibitor	  172	  
CFU	   	   	   Colony	  forming	  unit	  	  
CHO	   	   	   Chinese	  hamster	  ovarian	  	  
CLE	   	   	   Cortex	  lytic	  enzymes	  
CSPG4	  	  	   	   Chondroitin	  sulphate	  proteoglycan	  4	  
DAPI	  	   	   	   4’,6-­‐diamidino-­‐2-­‐phenylindole	  
DC	   	   	   Dendritic	  cell	  
DE	   	   	   Dextrose	  equivalent	  	  
DEAC	   	   	   Diffusely	  adherent	  E.	  coli	  	  
DMEM	  	   	   Dulbecco’s	  Modified	  Eagle’s	  Medium	  	  
	   X	  
DPA	   	   	   Dipicolinic	  acid	  	  
DPX	   	   	   Distrene,	  Plasticiser,	  Xylene	  	  
DSS	   	   	   Dextran	  sulphate	  sodium	  	  
EIA	   	   	   Enzyme	  immunoassay	  
EAEC	   	   	   Enteroaggregative	  E.	  coli	  	  
ECACC	  	  	   	   European	  Collection	  of	  Authenticated	  Cell	  Cultures	  	  
EPEC	   	   	   Enteropathogenic	  E.	  coli	  	  
ETEC	  	   	   	   Enterotoxigenic	  E.	  coli	  
FAE	   	   	   Follicle-­‐associated	  epithelium	  	  
FCS	   	   	   Foetal	  calf	  serum	  	  
FDA	   	   	   Food	  and	  Drug	  Administration	  
FMT	   	   	   Faecal	  microbiota	  transplantation	  	  
GalA	   	   	   Galacturonate	  
GBF	   	   	   Germinated	  barley	  foodstuff	  	  
GDH	   	   	   Glutamate	  dehydrogenase	  	  
GMP	   	   	   Guanosine	  monophosphate	  
GR	   	   	   Germinant	  receptor	  	  
GRO-­‐	  α	  	   	   Growth-­‐related	  oncogene	  alpha	  
HG	   	   	   Homogalacturonan	  
HPA	   	   	   Health	  Protection	  Agency	  
HR	   	   	   Hazard	  ratio	  	  
HRP	   	   	   Horseradish	  peroxidase	  	  
H2	  	   	   	   Histamine	  receptor	  2	  
IBD	   	   	   Inflammatory	  bowel	  disease	  
IBS	   	   	   Irritable	  bowel	  syndrome	  
IKK	   	   	   IκB	  kinase	  
	   XI	  
IL	   	   	   Interleukin	  
Ig	   	   	   Immunoglobulin	  	  
ISC	   	   	   Transmucosal	  short	  circuit	  current	  	  
IVIG	   	   	   Intravenous	  immunoglobulin	  
LacNac	  	   	   N-­‐acetyllactosamine	  
LB	   	   	   Luria	  Burtani	  
LPS	   	   	   Lipopolysaccharide	  	  
LT	   	   	   Heat-­‐labile	  toxin	  
MAb	   	   	   Monoclonal	  antibodies	  	  
M-­‐cell	   	   	   Microfold	  cell	   	  
MCP-­‐1	  	   	   Monocyte-­‐chemotactic	  protein	  1	  
MOI	   	   	   Multiplicity	  of	  infection	  	  
NAAT	   	   	   Nucleic	  acid	  amplification	  test	  
NeuGc	  	   	   N-­‐glycolylneuraminic	  acid	  	   	  
NF-­‐κβ	   	   	   Nuclear	  factor	  kappa	  β	  
NICE	   	   	   National	  Institute	  for	  Health	  and	  Care	  Excellence	  	  
NOD	   	   	   Nucleotide	  oligomerisation	  domain	  
NPPB	   	   	   5-­‐nitro-­‐2-­‐(-­‐3-­‐phenylpropyl-­‐amino)	  benzoic	  acid	  
NSAID	   	   	   Non-­‐steroidal	  anti-­‐inflammatory	  drug	  
NSP	   	   	   Non-­‐starch	  polysaccharide	  	  
OD	   	   	   Optical	  density	  	  
OMV	   	   	   Outer	  membrane	  vesicle	  	  
OPD	   	   	   O-­‐phenylenediamine	  
OR	   	   	   Odds	  ratio	  	  
PBS	   	   	   Phosphate-­‐buffered	  saline	  
PC	   	   	   Phosphatidylcholine	  	  
	   XII	  
PFA	   	   	   Paraformaldehyde	  
PG	   	   	   Peptidoglycan	  
PMC	   	   	   Pseudomembranous	  colitis	  
PPI	   	   	   Proton	  pump	  inhibitor	  	  
PVRL3	   	   	   Poliovirus	  receptor-­‐like	  3	  
RG	   	   	   Rhamnogalacturonan	  
RR	   	   	   Relative	  risk	  
SCFA	  	   	   	   Short	  chain	  fatty	  acid	  
SMC	   	   	   Sorbitol	  MacConkey	  
Spp.	   	   	   Species	  	  
ST	   	   	   Heat-­‐stable	  toxin	  	  
TEER	   	   	   Transepithelial	  electrical	  resistance	  	  
TEM	   	   	   Transmission	  electron	  microgram	  
TGY	   	   	   Tryptic	  glucose	  yeast	  
TLR	   	   	   Toll-­‐like	  receptor	  
TNBS	   	   	   2,4,6-­‐trinitrobenzenesulfonic	  acid	  	  
Tslp	   	   	   Thymic	  stromal	  lymphopoietin	  	  
UC	   	   	   Ulcerative	  colitis	  	  
VE	   	   	   Villous	  epithelium	  	  
VRE	   	   	   Vancomycin-­‐resistant	  enterococci	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  not	  affected	  by	  the	  expression	  of	  cell-­‐surface	  galectin-­‐3	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1.1  DIARRHOEAL	  DISEASES	  	  
	  
1.1.1   Diarrhoea	  –	  a	  definition	  
Diarrhoea	  is	  a	  perturbation	  of	  normal	  bowel	  movement,	  which	  is	  characterised	  by	  an	  
increase	  in	  the	  water	  content,	  volume	  or	  frequency	  of	  stools	  (Baldi	  et	  al.	  2009).	  The	  World	  
Health	  Organisation	  (WHO)	  defines	  diarrhoea	  as	  three	  or	  more	  loose	  or	  watery	  stools	  (taking	  
the	  shape	  of	  the	  container	  in	  which	  it	  is	  collected)	  in	  a	  24-­‐hour	  period	  (Abba	  et	  al.	  2009).	  	  
	  
1.1.2   Acute,	  persistent	  and	  chronic	  diarrhoea	  
From	   a	   clinical	   perspective,	   diarrhoea	   can	   be	   classified	   according	   to	   certain	  
characteristics,	   such	   as	   episode	   length.	   Diarrhoeal	   episodes	   lasting	   less	   than	   2	  weeks	   are	  
defined	  as	  acute	  whilst	  diarrhoea	  lasting	  between	  2-­‐4	  weeks	  is	  termed	  as	  persistent.	  Episodes	  
of	  diarrhoea	  lasting	  longer	  than	  4	  weeks	  are	  classed	  as	  chronic	  (Abba	  et	  al.	  2009;	  Thiagarajah	  
et	  al.	  2015).	  
Most	  cases	  of	  acute	  diarrhoea	  occur	  due	  to	  an	  infectious	  agent	  or	  pathogen	  such	  as	  a	  
bacterium,	  virus	  or	  parasite	  (Baldi	  et	  al.	  2009;	  Abba	  et	  al.	  2009).	  Also	  known	  as	  pathogen-­‐
related	   diarrhoea,	   this	   diarrhoeal	   subtype	   represents	   a	   global	   problem	   that	   persistently	  
causes	   significant	  mortality	   and	  morbidity,	   resulting	   in	   1.8	  million	  deaths	   annually	   (World	  
Health	  Organisation	  2007)	  .	  Pathogen-­‐related	  diarrhoea	  is	  of	  bacterial	  aetiology	  in	  1.5	  –	  5.6%	  
of	  cases	   (Baldi	  et	  al.	  2009).	   In	  developing	  countries,	   the	  most	  common	  causes	  of	  bacterial	  
mediated	   diarrhoea	   include	   enterotoxin-­‐producing	   Vibrio	   cholerae	   and	   Enterotoxigenic	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Escherichia	  coli	  (ETEC)	  (Thiagarajah	  et	  al.	  2015;	  Baldi	  et	  al.	  2009).	  In	  developed	  countries,	  main	  
bacterial	  causes	  of	  diarrhoeal	  disease	  include	  enterotoxin-­‐producing	  Clostridium	  difficile,	  as	  
well	  as	  enteroinvasive	  Salmonella	  species	  (spp.)	  and	  Campylobacter	  spp.	  (Thiagarajah	  et	  al.	  
2015).	   Most	   common	   causes	   of	   chronic	   diarrhoea	   include	   intestinal	   inflammatory	   and	  
autoimmune	   conditions,	   which	   include	   inflammatory	   bowel	   disease	   (IBD),	   irritable	   bowel	  
syndrome	  (IBS)	  and	  coeliac	  disease	  (Thomas	  et	  al.	  2003).	  	  
For	  the	  purpose	  of	  this	  thesis,	  three	  important	  causes	  of	  diarrhoea	  will	  be	  reviewed	  that	  
cause	   significant	  disease	  and	  are	   somewhat	  problematic	   in	   terms	  of	   their	   treatment.	   This	  
includes	  acute	  infectious	  diarrhoeal	  disease	  caused	  by	  C.	  difficile,	  which	  represents	  one	  of	  the	  
leading	   causes	  of	   antibiotic-­‐associated	  diarrhoea	   in	   a	  healthcare	   setting	   (Ananthakrishnan	  
2011).	  Acute	  infectious	  diarrhoea	  caused	  by	  ETEC	  will	  also	  be	  reviewed,	  which	  represents	  the	  
main	  cause	  of	  Traveller’s	  diarrhoea	  and	  a	  common	  cause	  of	  infantile	  diarrhoea	  in	  developing	  
countries	  (Qadri	  et	  al.	  2005).	  Lastly,	  ulcerative	  colitis	  (UC),	  a	  major	  form	  of	  IBD	  (Danese	  and	  
Fiocchi	  2011),	  will	  be	  reviewed	  as	  a	  chronic	  cause	  of	  diarrhoeal	  disease.	  	  
	  
1.2  C.	  DIFFICILE	  INFECTION	  –	  AN	  ACUTE	  DIARRHOEAL	  DISEASE	  
C.	   difficile	   is	   a	   Gram-­‐positive,	   spore-­‐forming,	   anaerobic	   bacillus,	   which	   belongs	   to	   the	  
phylum	  Firmicutes	  (Clostridium	  cluster	  XI)	  (Cairns	  et	  al.	  2012).	  The	  bacterium	  resides	  in	  the	  
environment	  (soil,	  water	  and	  animal	  faeces)	  and	  in	  the	  human	  gut	  where	  it	  can	  act	  as	  a	  normal	  
commensal	  (Bruggemann	  and	  Gottschalk	  2008).	  Indeed,	  some	  populations	  are	  carriers	  of	  C.	  
difficile	  but	  do	  not	  develop	  symptoms	  of	  infection.	  C.	  difficile	  infection	  (CDI)	  refers	  to	  patients	  
who	  exhibit	  symptoms	  of	  gastrointestinal	  illness	  (Dawson	  et	  al.	  2009).	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C.	  difficile	  was	  first	  isolated	  from	  the	  stool	  of	  a	  healthy	  infant	  by	  Hall	  and	  O’Toole	  in	  1935,	  
and	  the	  species	  name	  chosen	  to	  reflect	  the	  difficulty	  with	  its	  isolation	  and	  culture	  (Carroll	  and	  
Bartlett	  2011).	  Over	  the	  next	  40	  years,	  there	  were	  infrequent	  reports	  of	  C.	  difficile	  isolation,	  
with	  limited	  findings	  to	  suggest	  that	  the	  organism	  could	  actually	  contribute	  towards	  disease.	  
It	   was	   not	   until	   1978	   that	   C.	   difficile	   was	   shown	   to	   be	   the	   primary	   isolate	   in	   patients	  
undergoing	   clindamycin	   treatment	   and	   the	   causative	   agent	   of	   pseudomembranous	   colitis	  
(PMC)	  (Bartlett	  et	  al.	  1978).	  Today,	  C.	  difficile	  is	  recognised	  as	  the	  worldwide	  leading	  cause	  of	  
antibiotic-­‐associated	   diarrhoea	   (AAD),	   with	   CDI	   attributing	   15-­‐25%	   of	   all	   cases	  
(Ananthakrishnan	  2011).	  	  
	  
1.2.1   Pathogenesis	  of	  CDI	  
Asymptomatic	   carriage	   of	   C.	   difficile	   is	   common	   in	   both	   a	   community	   and	   hospital	  
setting,	  which	  is	  illustrated	  by	  the	  small	  proportion	  patients	  (approximately	  35-­‐50%)	  who	  go	  
on	   to	   develop	   active	   disease	   (Goudarzi	   et	   al.	   2014;	   Donskey	   et	   al.	   2015).	   This	   clearly	  
demonstrates	  that	  a	  number	  of	  events	  must	  first	  take	  place	  to	  induce	  symptomatic	  infection.	  
Indeed,	  the	  pathogenesis	  of	  CDI	  can	  be	  characterised	  by	  four	  main	  steps.	  These	  include	  the	  
perturbation	   of	   the	   normal	   intestinal	  microbiota	   (Seekatz	   and	   Young	   2014),	   successful	  C.	  
difficile	   colonisation	  of	   the	   intestinal	   epithelium	  and	   the	   subsequent	   release	  of	  C.	   difficile	  
toxins	  (Voth	  and	  Ballard	  2005).	  It	  has	  also	  become	  evident	  that	  dormant	  C.	  difficile	  spores	  play	  
an	  important	  role	  in	  CDI	  transmission	  and	  pathogenesis	  (Sarker	  and	  Paredes-­‐Sabja	  2012).	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1.2.1.1  Disruption	  of	  the	  normal	  intestinal	  microbiota	  
The	  intestinal	  microbiota	  plays	  an	  essential	  role	  in	  CDI	  pathogenesis	  (Seekatz	  and	  Young	  
2014).	  C.	  difficile	  is	  considered	  a	  poor	  competitor	  with	  the	  normal	  intestinal	  microbiota,	  and	  
as	  such,	  a	  healthy	  microbiota	  provides	  colonisation	  resistance	  against	  the	  bacterium	  (Britton	  
and	  Young	  2014).	  Conversely,	  disruption	  of	  the	  intestinal	  microbiota	  leads	  to	  the	  creation	  of	  
an	  ecological	  niche	  in	  which	  opportunistic	  C.	  difficile	  can	  flourish	  and	  effectively	  colonise	  the	  
intestinal	  epithelium	  (Britton	  and	  Young	  2014;	  Seekatz	  and	  Young	  2014).	  Many	  of	   the	  risk	  
factors	   associated	   with	   CDI	   therefore	   result	   in	   perturbation	   of	   the	   normal	   intestinal	  
microbiota	  (as	  reviewed	  in	  Section	  1.2.3).	  
	  
1.2.1.2  Colonisation	  of	  the	  intestinal	  epithelium	  
C.	  difficile	  colonisation	  of	  the	  intestinal	  epithelium	  represents	  an	  early	  and	  essential	  
step	  in	  the	  pathogenesis	  of	  CDI.	  Following	  the	  disruption	  of	  the	  colonic	  microbiota,	  C.	  difficile	  
penetrates	   the	   mucus	   layer	   overlying	   enterocytes,	   subsequently	   colonising	   the	   intestinal	  
epithelium.	  Indeed,	  numerous	  studies	  have	  demonstrated	  that	  C.	  difficile	  can	  adhere	  in	  vitro	  
to	  various	  cell	  lines	  such	  as	  Caco2	  cells	  and	  Vero	  cells,	  as	  well	  as	  in	  vivo	  to	  the	  caecal	  mucus	  
of	  mice	  (GomezTrevino	  et	  al.	  1996;	  Cerquetti	  et	  al.	  2002;	  Karjalainen	  et	  al.	  1994).	  	  
A	  number	  of	  different	  colonisation	  factors	  have	  been	  identified	  which	  are	  thought	  to	  
mediate	   this	   process.	   	   These	   include	   proteolytic	   enzymes,	   such	   as	   the	   cysteine	   protease	  
Cwp84	  (Janoir	  et	  al.	  2007),	  and	  flagella	  components	  flagellin	  (FliC)	  and	  flagellar	  cap	  protein	  
(FliD)	  (Tasteyre	  et	  al.	  2001).	  Multiple	  adhesins	  have	  also	  been	  characterised,	  which	  include	  S-­‐
layer	  P36	  and	  P47	  proteins	  (Calabi	  et	  al.	  2002;	  Cerquetti	  et	  al.	  2000),	  a	  66-­‐kDa	  cell-­‐wall	  protein	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Cwp66	  (Waligora	  et	  al.	  2001),	  the	  GroEL	  heat-­‐shock	  protein	  (Hennequin	  et	  al.	  2001)	  and	  a	  68-­‐
kDa	  fibronectin-­‐binding	  protein	  (Hennequin	  et	  al.	  2003).	  	  
	  	   It	  has	  been	  demonstrated	  that	  C.	  difficile	  colonisation	  factors	  exhibit	  carbohydrate-­‐
binding	  (lectin)	  activity	  (Stevenson	  et	  al.	  2015).	  These	  surface	  proteins	  recognise	  and	  bind	  to	  
complementary	   carbohydrates	   on	   the	   surface	   of	   host	   cells,	   promoting	   bacteria-­‐epithelial	  
adherence	   (Sharon	   2006).	   Importantly,	   close	   proximity	   or	   adhesion	   of	   C.	   difficile	   to	   the	  
intestinal	  mucosa	  is	  likely	  to	  be	  necessary	  for	  the	  release	  of	  its	  toxins	  (Voth	  and	  Ballard	  2005).	  
Therefore,	  this	  initial	  phase	  of	  infection	  is	  an	  essential	  mediator	  of	  pathogenesis.	  	  
	  
1.2.1.3  Release	  of	  toxins	  
Pathogenic	   strains	  of	  C.	  difficile	  secrete	   two	  potent	  exotoxins,	  Toxin	  A	  and	  Toxin	  B	  
(TcdA	  and	  TcdB,	  respectively),	  which	  induce	  mucosal	  inflammation	  and	  diarrhoea.	  In	  addition	  
to	   these	   exotoxins,	   some	   C.	   difficile	   strains	   produce	   an	   adenosine	   diphosphate	   (ADP)-­‐
ribosylating	  binary	  toxin	  (CDT),	  however,	  its	  role	  in	  disease	  is	  somewhat	  less	  understood	  (Voth	  
and	  Ballard	  2005).	  
TcdA	  (308	  kDa)	  and	  TcdB	  (270	  kDa)	  belong	  to	  the	  family	  of	  large	  clostridial	  toxins,	  and	  
are	  amongst	  the	  largest	  bacterial	  toxins	  reported	  to	  date	  (Voth	  and	  Ballard	  2005;	  Just	  and	  
Gerhard	  2004).	  The	  precise	  mechanism	  of	  toxin	  uptake	  into	  the	  cells	  is	  unclear,	  but	  there	  is	  
sufficient	  evidence	  to	  suggest	  that	  the	  mechanism	  can	  be	  characterised	  into	  certain	  stages	  
(Figure	   1.1).	   Receptor	   binding	   is	   the	   first	   essential	   step	   in	   toxin	   cell	   entry,	   thought	   to	   be	  
mediated	  by	  carbohydrate	  structures	  present	  on	  the	  host	  cell	  surface	  (Voth	  and	  Ballard	  2005;	  
Just	  and	  Gerhard	  2004).	  	  
	  	   7	  
Although	   TcdA	   and	   TcdB	   are	   homologues,	   they	   are	   thought	   to	   have	   different	  
receptors,	  based	  on	  differences	  in	  sensitivities	  among	  cell	  types	  in	  vitro	  (Chaves-­‐Olarte	  et	  al.	  
1997;	   Dingle	   et	   al.	   2010).	  Multiple	   receptors	   for	   TcdA	   have	   been	   identified	   including	   the	  
disaccharide	  Galβ1-­‐4GlcNAc,	  which	  is	  expressed	  on	  I,	  X	  and	  Y	  carbohydrate	  antigens	  present	  
on	   the	  human	   intestinal	  epithelium	  (Tucker	  and	  Wilkins	  1991).	   In	   line	  with	   these	   findings,	  
treatment	  of	  cells	  or	  tissue	  with	  β-­‐galactosidase	  reduces	  binding	  by	  TcdA	  (Clark	  et	  al.	  1987;	  
Smith	   et	   al.	   1997).	   Other	   proposed	   TcdA	   receptors	   include	   rabbit	   sucrase	   isomaltase	  
(Pothoulakis	   et	   al.	   1996)	   and	   glycoprotein	   (gp)-­‐96	   (Na	   et	   al.	   2008).	   TcdB	   receptors	   are	  
somewhat	   more	   elusive,	   and	   until	   recently,	   they	   were	   completely	   undefined	   (Voth	   and	  
Ballard	  2005).	  Yuan	  and	  colleagues	  demonstrated	  the	  first	  identification	  of	  a	  TcdB	  receptor.	  
In	   this	   landmark	   study,	   it	  was	   shown	   that	   chondroitin	   sulphate	  proteoglycan	  4	   (CSPG4)	   is	  
critical	  for	  TcdB	  cell	  attachment,	  inducing	  cytoskeleton	  disruption	  and	  cell	  death	  (Yang	  et	  al.	  
1993).	  Poliovirus	  receptor-­‐like	  3	  (PVRL3)	  has	  also	  recently	  been	  characterised	  as	  an	  epithelial	  
cell	  receptor	  responsible	  for	  TcdB-­‐induced	  cytotoxicity	  (LaFrance	  et	  al.	  2015).	  	  	  
	  
	  


















Figure	   1.1	  Summary	   of	   the	  mechanism	   of	  C.	   difficile	   TcdA	   and	   TcdB.	   Adapted	   from	   (Voth	   and	  
Ballard	  2005).	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Subsequent	   to	   binding	   carbohydrate	  membrane	   structures,	   toxin	   internalisation	   is	  
induced	  by	  receptor-­‐mediated	  endocytosis	  (Voth	  and	  Ballard	  2005).	  Studies	  have	  shown	  that	  
this	  step	  requires	  a	  low	  pH,	  which	  is	  likely	  due	  to	  the	  toxins	  undergoing	  important	  structural	  
changes.	  An	  acidic	  endosomal	  pH	  induces	  toxin	  refolding	  which	  leads	  to	  the	  exposure	  of	  the	  
hydrophobic	   transmembrane	   domain,	   and	   aids	   insertion	   into	   the	   target	   endosomal	  
membrane	   (Qa'Dan	   et	   al.	   2000).	   It	   is	   understood	   that	   TcdA	   and	   TcdB	   next	   undergo	  
autoproteolysis,	  allowing	  only	  the	  catalytic	  domain	  to	  be	  translocated	  into	  the	  cytoplasm	  of	  
the	  cell,	  where	   it	   finally	  catalyses	  the	  mono-­‐glucosylation	  of	  small	  regulatory	  Rho-­‐GTPases	  
(Rho,	  Rac	  and	  Cdc42)	  (Voth	  and	  Ballard	  2005).	  	  
The	   irreversible	   modification	   of	   Rho	   proteins	   prevents	   their	   interaction	   with	  
downstream	  regulators,	  resulting	  in	  their	  ensuing	  inactivation	  (Sehr	  et	  al.	  1998).	  This	  leads	  to	  
the	  disruption	  of	  vital	  cell	  signalling	  pathways	  and	  a	  number	  of	  toxin	  mediated	  effects,	  which	  
include	   increased	   cell	   rounding,	   loss	   of	   actin	   stress	   fibres,	   disruption	   of	   intercellular	   tight	  
junctions	  and	  resultant	  diarrhoea	  (Voth	  and	  Ballard	  2005).	  
Other	  cellular	  effects	  of	  TcdA	  and	  TcdB	  include	  the	  induction	  of	  the	  pro-­‐inflammatory	  
response	  through	  the	  release	  of	  cytokine	  interleukin	  8	  (IL-­‐8),	  mediated	  by	  the	  activation	  of	  
nuclear	   factor	   kappa	   β	   (NF-­‐κβ)	   (Kim	   et	   al.	   2006).	  C.	   difficile	   TcdA	   and	   TcdB	   also	  mediate	  
apoptosis	  through	  the	  activation	  of	  both	  the	  intrinsic	  and	  extrinsic	  apoptotic	  pathways,	  and	  
subsequent	  activator	  of	  executioner	  caspase-­‐3	  (Gerhard	  et	  al.	  2008).	  
The	  role	  of	  CDT	  in	  infection	  is	  not	  well	  characterised,	  but	  it	  is	  known	  that	  its	  structure	  
consists	   of	   two	   unlinked	   polypeptides;	   enzymatic	   component	   CdtA	   and	   transporter	  
component	  CdtB.	  CdtA	   is	  a	  G-­‐actin	   specific,	  mono	  ADP-­‐ribosyl	   transferase	  which	  becomes	  
internalised	   into	  the	  host	  cell,	  most	   likely	  via	  a	  CdtB	  heptamer	  on	  the	  cell	  surface.	  Studies	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suggest	   that	   in	   the	   cytosol,	   CdtA	   irreversibly	   ADP-­‐ribosylates	   G-­‐actin	   which	   inhibits	   its	  
polymerisation	  to	  F-­‐actin	  thus	  disrupting	  the	  actin	  cytoskeleton,	  resulting	  in	  cell	  rounding	  and	  
cell	  death	  (Carman	  et	  al.	  2011;	  Davies	  et	  al.	  2011).	  Studies	  have	  also	  suggested	  that	  CDT	  may	  
increase	  bacterial	  adhesion	  to	  target	  cells	  through	  the	  formation	  of	  microtubule	  protrusions	  
(Schwan	  et	  al.	  2009).	  	  
	  
1.2.1.4  C.	  difficile	  spores	  
When	   environmental	   conditions	   become	   unfavourable,	   such	   as	   through	   a	   lack	   of	  
nutrients,	   C.	   difficile	   has	   the	   ability	   to	   rapidly	   produce	   highly	   resistant	   and	   dormant	  
endospores	   (Barra-­‐Carrasco	   and	   Paredes-­‐Sabja	   2014;	   Paredes-­‐Sabja	   et	   al.	   2014).	   During	  
infection,	  C.	  difficile	   initiates	  an	  efficient	  sporulation	  cycle	  whereby	  patients	  enter	  a	  highly	  
contagious	   ‘super-­‐shedder’	   state	  with	   high	   levels	   of	   spore	   excretion	   into	   the	   surrounding	  
environment	   (Barra-­‐Carrasco	   and	   Paredes-­‐Sabja	   2014).	   Studies	   have	   also	   shown	   that	  
compared	  with	  non-­‐carriers,	   asymptomatic	  patients	  exhibit	  high	   rates	  of	   skin	   (61%	  versus	  
19%,	   P	   =	   0.001)	   and	  environmental	  C.	   difficile	   spore	   contamination	   (59%	  versus	   24%,	   P	   =	  
0.004)	  (Riggs	  et	  al.	  2007).	  As	  such,	  C.	  difficile	  spores	  are	  considered	  the	  key	  vehicle	  of	  CDI	  
transmission	  (Sarker	  and	  Paredes-­‐Sabja	  2012;	  Paredes-­‐Sabja	  et	  al.	  2014).	  	  
C.	  difficile	  spores	  are	  resistant	  to	  commonly	  used	  disinfectants,	   therefore,	  they	  can	  
survive	  indefinitely	  outside	  of	  the	  host	  and	  persist	  on	  clinical	  surfaces	  for	  long	  periods	  of	  time	  
(Sarker	  and	  Paredes-­‐Sabja	  2012;	  Barra-­‐Carrasco	  and	  Paredes-­‐Sabja	  2014).	  Once	  ingested	  by	  
a	  susceptible	   individual,	  spores	  return	  to	  vegetative	  growth	  through	  germination,	  which	   is	  
particularly	  triggered	  by	  primary	  bile	  acids	  (Wilson	  1983;	  Wilson	  et	  al.	  1982).	  Under	  optimal	  
conditions,	  this	  can	  result	  in	  colonisation,	  toxin	  release	  and	  subsequent	  active	  disease	  (Burns	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et	  al.	  2010).	  C.	  difficile	  spores	  can	  also	  persist	  in	  the	  colonic	  tract	  of	  patients,	  contributing	  to	  
recurrent	  infection	  (Drekonja	  et	  al.	  2011).	  Consequently,	  C.	  difficile	  spores	  play	  an	  important	  
role	  in	  disease	  pathogenesis.	  	  
Much	  of	  the	  understanding	  about	  C.	  difficile	  sporulation	  is	  rather	  limited	  and	  relies	  on	  
comparisons	   with	   other	   spore-­‐forming	   bacteria,	   such	   as	   the	   model	   spore-­‐forming	   Gram	  
positive	  organism	  Bacillus	  subtilis,	  also	  found	  in	  soil	  and	  the	  gastrointestinal	  tract	  of	  mammals	  
(Edwards	  and	  McBride	  2014).	  The	  process	  of	  C.	  difficile	  sporulation	  is	  almost	  identical	  to	  that	  
of	  B.	  subtilis,	  and	  is	  typically	  characterised	  into	  seven	  morphological	  stages	  (as	  summarised	  
in	   Figure	   1.2)	   (Leggett	   et	   al.	   2012).	   The	   molecular	   mechanisms	   underlying	   C.	   difficile	  
sporulation	  are	  less	  clearly	  understood.	  In	  many	  Bacillus	  and	  Clostridium	  species,	  the	  decision	  
to	  enter	  sporulation	  is	  regulated	  by	  several	  orphan	  histidine	  kinases	  that	  can	  phosphorylate	  
the	  master	  regulator	  of	  sporulation	  Spo0A	  (Edwards	  and	  McBride	  2014).	  	  






	   	   	  
	   	   	  	  	  
	   	   	  	   	  
	   	   	   	  
	   	   	   	   	  
	   	   	  






















Figure	   1.2.	   Summary	   of	   the	  morphological	   changes	   that	   take	   place	   during	  C.	   difficile	   sporulation.	  	  
Stage	  0)	  Normal	  vegetative	  growth.	  Stage	  I/II)	  Vegetative	  cell	  undergoes	  asymmetric	  cell	  division,	  which	  
forms	  two	  compartments	  separated	  by	  the	  septum.	  The	  smaller	  of	  the	  two	  compartments	  is	  termed	  
the	  pre-­‐spore.	  Stage	  III)	  Pre-­‐spore	  engulfed	  by	  the	  mother	  cell	  to	  form	  a	  distinct	  cell	  termed	  the	  fore-­‐
spore	  bound	  by	  inner	  and	  outer	  fore-­‐spore	  membranes.	  Stage	  IV)	  Spore	  cortex	  formation	  between	  inner	  
and	   outer	   fore-­‐spore	  membranes.	   Stage	   V/VI)	  Mother	   cell	   synthesises	   spore	   specific	   pyridine-­‐2,	   6-­‐
dicarboxylic	  acid	  (dipicolinic	  acid;	  DPA),	  which	  accumulates	  in	  the	  fore-­‐spore	  and	  reduces	  fore-­‐spore	  
water	  content.	  This	  is	  accompanied	  by	  spore	  maturation	  and	  increased	  density	  of	  spore	  coat.	  Stage	  VII)	  
Lysis	  of	  the	  mother	  cell	  and	  release	  of	  mature	  spore.	  Resistant	  nature	  of	  the	  mature	  spore	  ensures	  it	  
survives	  until	  conditions	  become	  more	  favourable	  for	  vegetative	  cell	  growth.	  The	  dormant	  spore	  is	  then	  
re-­‐activated	  and	  undergoes	  germination	  and	  outgrowth.	  Figure	  adapted	  from	  (Leggett	  et	  al.	  2012).	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Following	  Spo0A	  phosphorylation,	  gene	  expression	  shifts	  to	  support	  spore	  formation	  
rather	   than	   vegetative	   growth	   (Edwards	   and	   McBride	   2014).	   Sequencing	   analyses	   have	  
demonstrated	   that	  C.	   difficile	   strain	   630	   genome	  encodes	   five	  orphan	  histidines	   (CD1352,	  
CD1492,	  CD1579,	  CD1949	  and	  CD2492)	  (Underwood	  et	  al.	  2009)	  and	  it	  is	  thought	  that	  these	  
may	   undergo	   autophosphorylation	   to	   directly	   phosphorylate	   Spo0A	   (Paredes-­‐Sabja	   et	   al.	  
2014).	  Studies	  have	  shown	  that	  knockdown	  of	  CD2492	  reduces	  C.	  difficile	  spore	  formation	  by	  
3.5-­‐fold,	   whilst	   mutation	   of	   spo0A	   completely	   abolishes	   spore	   formation,	   indicating	   an	  
essential	  role	  in	  the	  process	  (Underwood	  et	  al.	  2009).	  	  
Bacterial	  spores	  differ	  considerably	  from	  their	  vegetative	  counterparts,	  both	  in	  their	  
structure	  and	  chemical	  composition	  (Paredes-­‐Sabja	  et	  al.	  2014;	  Leggett	  et	  al.	  2012)	  (Figure	  
1.3).	  Several	  groups	  have	  published	  transmission	  electron	  micrograms	  (TEMs)	  of	  C.	  difficile	  
spores,	  demonstrating	   that	   the	  basic	  ultrastructural	   layers	   are	   similar	   to	  B.	   subtilis	   and	  B.	  
anthracis	   (Barra-­‐Carrasco	   and	   Paredes-­‐Sabja	   2014).	   	   In	   the	   centre	   of	   the	   spore	   lies	   the	  
dehydrated	  spore	  core	  (77%	  of	  the	  spore	  core	  wet	  weight)	  that	  contains	  the	  spore’s	  DNA,	  
RNA,	  ribosomes	  and	  most	  of	  its	  enzymes	  (Barra-­‐Carrasco	  and	  Paredes-­‐Sabja	  2014).	  The	  core	  
also	  contains	  high	  levels	  of	  pyridine-­‐2,	  6-­‐dicarboxylic	  acid	  (dipicolinic	  acid;	  DPA),	  which	  exists	  
as	  a	  1:1	  chelate	  with	  divalent	  cations,	  most	  notably	  Ca2+	  (Ca-­‐DPA)	  (Leggett	  et	  al.	  2012).	  The	  
spore	  core	  is	  surrounded	  by	  a	  remarkably	  impermeable	  inner	  membrane	  that	  acts	  to	  protect	  
the	   core	   from	   DNA-­‐damaging	   chemicals	   (Paredes-­‐Sabja	   et	   al.	   2014;	   Barra-­‐Carrasco	   and	  
Paredes-­‐Sabja	  2014).	  Surrounding	  the	  inner	  membrane	  is	  the	  germ	  cell	  wall,	  composed	  of	  a	  
peptidoglycan	  (PG)	  cortex	  with	  a	  similar	  structure	  to	  that	  of	  growing	  cells	  (Paredes-­‐Sabja	  et	  
al.	  2014).	  The	  germ	  cell	  wall	   layer	   is	  surrounded	  by	  a	  spore-­‐specific	  cortex	  which	  provides	  
protection	  against	   cellular	   cortex	  hydrolases	   through	  unique	  glycan	   residue	  modifications,	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and	  an	  outer	  membrane	  that	  plays	  a	  key	  role	  in	  spore	  formation	  but	  has	  little	  effect	  on	  spore	  
resistance	   (Leggett	   et	   al.	   2012;	   Barra-­‐Carrasco	   and	   Paredes-­‐Sabja	   2014).	   These	   layers	   are	  
surrounded	   by	   a	   proteinaceous	   spore	   coat,	   which	   provides	   protection	   against	   reactive	  
chemicals,	   as	  well	   as	   lytic	  and	  microbial	  enzymes	   (Leggett	   et	  al.	   2012;	  Barra-­‐Carrasco	  and	  
Paredes-­‐Sabja	  2014).	  The	  electrodense	  exosporium	  layer	  represents	  the	  outermost	  part	  of	  
the	  C.	  difficile	  spore,	  the	  structure	  of	  which	  varies	  considerably	  between	  C.	  difficile	  strains	  
(Escobar-­‐Cortes	  et	  al.	  2013)	  (Figure	  1.3).	  Recent	  studies	  have	  suggested	  that	  the	  exosporium	  
of	  C.	  difficile	  spores	  may	  play	  a	  key	  role	  in	  adherence	  to	  epithelial	  cells	  and	  contribute	  to	  spore	  
surface	   hydrophobicity	   and	   spore	   dormancy	   (Paredes-­‐Sabja	   and	   Sarker	   2012;	   Joshi	   et	   al.	  




























Figure	  1.3.	  Representative	  diagram	  of	  C.	  difficile	  spore	  structure.	  Structure	  is	  not	  drawn	  
to	  scale.	  Modified	  from	  (Leggett	  et	  al.	  2012).	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Spore	   germination	   is	   triggered	   when	   cognate	   germinant	   receptors	   (GRs)	   bind	  
germinant	   factors.	   A	   number	   of	   spore	   germinant	   factors	   have	   been	   characterised,	   which	  
include	   specific	   primary	   bile	   acids	   cholate,	   taurocholate	   and	   glycocholate	   (Wilson	   1983;	  
Wilson	  et	  al.	  1982).	  More	  recently,	  studies	  have	  suggested	  that	  glycine,	   ι-­‐phenylalanine,	   ι-­‐
arginine	   (Howerton	   et	   al.	   2011)	   and	   histidine	   can	   also	   act	   as	   co-­‐germinants	  with	   cholate	  
derivatives	  (Howerton	  et	  al.	  2011;	  Sorg	  and	  Sonenshein	  2008;	  Wheeldon	  et	  al.	  2011),	  whilst	  
secondary	  bile	  acids	  such	  as	  chenodeoxycholate	   inhibit	  germination	   (Sorg	  and	  Sonenshein	  
2010;	   Sorg	   and	   Sonenshein	   2009).	   	   Germinant	   factor	   binding	   prompts	   the	   release	   of	  
monovalent	  cations	  (H+,	  Na+	  and	  K+)	  and	  the	  spore	  core’s	  large	  depot	  of	  Ca-­‐DPA.	  These	  events	  
initiate	  hydrolysis	  of	  the	  spore	  PG	  cortex,	  allowing	  spore	  core	  expansion	  and	  water	  uptake.	  
When	  the	  water	  content	  in	  the	  spore	  core	  reaches	  similar	  levels	  to	  that	  found	  in	  vegetative	  
cells,	  enzyme	  activity	  is	  restored,	  cell	  metabolism	  is	  initiated	  and	  spore	  outgrowth	  takes	  place	  
(Sarker	   and	   Paredes-­‐Sabja	   2012).	   The	   signals	   that	   activate	   cortex	   hydrolysis	   in	   C.	   difficile	  
spores	   are	   currently	   unknown,	   however,	   in	   Bacillus	   species,	   hydrolysis	   occurs	   via	   direct	  
activation	  of	  cortex	  lytic	  enzymes	  (CLEs)	  (Paredes-­‐Sabja	  et	  al.	  2011).	  
Interestingly,	  it	  has	  been	  shown	  that	  the	  disruption	  of	  the	  intestinal	  microbiota	  might	  
result	   in	   increased	   C.	   difficile	   spore	   germination.	   In	   individuals	   with	   a	   healthy	   intestinal	  
microbiota,	   co-­‐germinants	   such	   as	   cholate	   and	   its	   derivatives	   are	   quickly	   metabolised,	  
reducing	  the	  relative	  abundance	  of	  germinants,	  thus	  preventing	  C.	  difficile	  spore	  germination.	  
However,	  following	  antibiotic	  treatment,	  disruption	  of	  the	  intestinal	  microbiota	  may	  lead	  to	  
an	   increase	   in	   the	  availability	  of	  germinants,	   thus	  promoting	  C.	  difficile	  spore	  germination	  
(Sarker	  and	  Paredes-­‐Sabja	  2012).	  A	  study	  by	  Giel	  and	  colleagues	  provides	  evidence	  towards	  
this,	   whereby	   caecal	   extracts	   from	   antibiotic-­‐treated	   mice	   contained	   elevated	   levels	   of	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primary	  bile	   salts	  and	   increased	  colony	   formation	  of	  C.	  difficile	  spores	   in	  comparison	  with	  
caecal	  extracts	  from	  untreated	  mice	  (Giel	  et	  al.	  2010).	  	  Studies	  have	  also	  demonstrated	  that	  
CDI	  disease	  severity	  is	  correlated	  to	  germination	  rates	  of	  C.	  difficile	  clinical	  isolates	  (Carlson	  
et	  al.	  2015)	  
	  
1.2.2   Epidemiology	  of	  CDI	  	  
	  
	  
1.2.2.1  Incidence	  rates	  
	  
In	  recent	  years,	  there	  has	  been	  a	  significant	  change	  in	  the	  epidemiology	  of	  CDI.	  Prior	  to	  
2000,	   the	  annual	  CDI	   rate	  was	   relatively	   stable.	  However,	   since	   the	   turn	  of	   the	  century,	  a	  
continuous	   rise	   in	   CDI	   incidence	   has	   been	   observed	   across	   the	  Western	   world,	   including	  
Canada	  (Pepin	  et	  al.	  2004),	  the	  USA	  (Dallal	  et	  al.	  2002)	  and	  Europe	  (Jones	  et	  al.	  2013;	  Kuijper	  
et	  al.	  2008).	  	  
Dramatic	   increases	   in	   CDI	   rates	   were	   reported	   initially	   in	   Quebec,	   Canada,	   where	  
incidence	  increased	  from	  35.6	  cases	  per	  100,000	  of	  the	  general	  population	  in	  1991	  to	  156.3	  
cases	  per	  100,000	  of	  the	  population	  in	  2003	  (Pepin	  et	  al.	  2004).	  Amongst	  patients	  65	  years	  or	  
more,	  incidence	  rates	  increased	  8-­‐fold	  from	  102.0	  per	  100,000	  to	  886.5	  per	  100,000	  of	  the	  
population	   (Pepin	   et	   al.	   2004).	  A	  parallel	   increase	  was	  observed	   in	  North	  America,	  where	  
there	  was	  a	  5-­‐fold	  increase	  in	  CDI	  incidence	  in	  the	  whole	  population,	  with	  a	  disproportionate	  
8-­‐fold	  increase	  in	  the	  elderly	  population	  (McDonald	  et	  al.	  2006).	  A	  similar	  pattern	  has	  also	  
been	  observed	  in	  Europe.	  	  Increased	  CDI	  rates	  were	  first	  observed	  in	  the	  UK	  between	  2003-­‐
2004,	   then	   in	   the	   Netherlands	   and	   Belgium	   from	   2005,	   followed	   by	   France	   and	   other	  
European	  countries	  (Kuijper	  et	  al.	  2008;	  Bassetti	  et	  al.	  2012).	  Other	  observed	  epidemiological	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changes	   include	   increased	   disease	   severity,	   increased	   complications,	   higher	  mortality	   and	  
increased	  risk	  of	  recurrence	  (Pepin	  et	  al.	  2004).	  This	  changing	  pattern	  of	  disease	  has	  been	  
attributed	  largely	  to	  the	  emergence	  of	  the	  hypervirulent	  and	  epidemic	  BI/NAP1/027	  strain	  
(Freeman	  et	  al.	  2010).	  
	  
1.2.2.2  A	  United	  Kingdom	  (UK)	  perspective	  
In	  the	  UK,	  the	  first	  known	  outbreak	  caused	  by	  the	  BI/NAP1/027	  strain	  occurred	  at	  Stoke	  
Mandeville	  Hospital	  (Buckinghamshire	  Hospitals	  NHS	  Trust)	  in	  2003,	  which	  involved	  174	  cases	  
and	  19	  deaths	  attributable	  to	  CDI	   (Smith	  2005).	  Over	  the	  coming	  years,	  disease	  outbreaks	  
became	  widespread	  across	  England	  with	  more	  than	  55,000	  CDI	  cases	  reported	  in	  2007/08,	  of	  
which	  20%	  were	  in	  younger	  age	  groups	  previously	  not	  considered	  as	  high	  risk	  (Wilcox	  et	  al.	  
2012).	  Due	  to	  the	  increase	  in	  disease	  incidence	  and	  severity,	  the	  Health	  Protection	  Agency	  
(HPA)	  introduced	  an	  enhanced	  C.	  difficile	  surveillance	  programme	  in	  2007,	  in	  which	  all	  NHS	  
hospitals	  in	  England	  were	  required	  to	  report	  all	  CDI	  cases	  on	  a	  mandatory	  basis	  (Wilcox	  et	  al.	  
2012).	   Reduction	   targets	   (30%	   annual	   decrease	   in	   CDI	   incidence)	   were	   also	   established,	  
alongside	  the	  introduction	  of	  the	  C.	  difficile	  Ribotyping	  Network	  (CDRN)	  (Freeman	  et	  al.	  2010).	  
Dramatic	  declines	  in	  CDI	  incidence	  were	  observed	  rapidly	  following	  the	  introduction	  of	  
enhanced	   surveillance,	   and	   incidence	   rates	   have	   continued	   to	   fall	   on	   an	   annual	   basis.	   	   In	  
2013/14,	  the	  total	  number	  of	  reported	  CDI	  cases	  reached	  the	  lowest	  level	  (13,361	  cases)	  since	  
mandatory	  surveillance	  began.	  However,	  this	  annual	  decline	  has	  slowed	  substantially,	  with	  
only	  a	  9.1%	  reduction	  between	  2012/13	  and	  2013/14,	  in	  comparison	  to	  a	  19.1%	  reduction	  
between	  2011/12	  and	  2012/13	  (Public	  Health	  England	  2014)	  .	  Furthermore,	  there	  has	  been	  a	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slower	  decline	  in	  community-­‐acquired	  CDI	  (Public	  Health	  England	  2014)	  ,	  with	  an	  increase	  in	  
the	  proportion	  of	  C.	  difficile	  deaths	  occurring	  in	  care	  homes	  (5.3	  -­‐	  6.7%	  increase	  in	  proportion	  
between	  2007-­‐09	  and	  2010-­‐12),	  homes	  (1.3	  -­‐	  1.9%)	  and	  hospices	  (0.8	  -­‐	  1.4%)	  (Cole	  2013).	  	  
	  
1.2.3   Risk	  factors	  of	  CDI	  	  
1.2.3.1  Antibiotic	  exposure	  
The	   main	   risk	   factor	   for	   CDI	   is	   exposure	   to	   antibiotics.	   Broad-­‐spectrum	   antibiotics,	  
particularly	  those	  that	  target	  anaerobic	  bacteria,	  alter	  the	  normal	  ratio	  of	  different	  intestinal	  
microbial	   communities	   (Ananthakrishnan	   2011).	   As	   described	   in	   several	   studies,	   the	  
administration	   of	   antibiotics	   causes	   a	   decrease	   in	   carbohydrate-­‐fermenting	   and	   butyrate-­‐
producing	   bacteria	   members	   of	   Bacteroidetes	   and	   Firmicutes	   phyla	   (Antonopoulos	   et	   al.	  
2009;	   Jernberg	   et	  al.	   2007;	  Manges	   et	  al.	   2010).	   It	   is	   thought	   that	   the	   resultant	   intestinal	  
dysbiosis	  creates	  an	  ecological	  niche	  that	  favours	  the	  multiplication	  of	  C.	  difficile,	  allowing	  it	  
to	  become	  an	  established	  gut	  pathogen.	  As	  such,	  most	  CDI	  patients	  have	  been	  exposed	  to	  
antimicrobials	  several	  weeks	  to	  several	  months	  before	  diagnosis	  (Owens	  et	  al.	  2008).	  In	  one	  
retrospective	  study,	  more	  than	  two-­‐thirds	  of	  CDI	  patients	  had	  received	  antibiotics	   in	  the	  2	  
months	   preceding	   diagnosis	   (Pepin	   et	   al.	   2004).	   In	   another	   case-­‐controlled	   study,	   it	   was	  
reported	  that	  up	  to	  94%	  of	  hospitalised	  CDI	  patients	  had	  received	  antibiotics	  at	  some	  point	  
either	  before	  or	  during	  their	  stay	  (Loo	  et	  al.	  2005).	  	  
Almost	  all	  antibiotics	  have	  been	  associated	  with	  the	  development	  of	  CDI,	  but	  some	  carry	  
a	   higher	   risk	   than	   others	   (Sullivan	   et	   al.	   2001).	   Indeed,	   these	   associations	   may	   parallel	  
temporal	  changes	  in	  the	  frequency	  of	  use	  of	  each	  antibiotic	  category	  (Ananthakrishnan	  2011).	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Initially,	   antibiotics	   that	   held	   the	   greatest	   association	   with	   CDI	   development	   included	  
clindamycin,	   cephalosporins	   and	   amoxicillin	   (Ananthakrishnan	   2011).	   More	   recently,	  
fluoroquinolones	  have	  also	  emerged	  as	  a	  significant	  risk	  factor	  for	  CDI	  (Pepin	  et	  al.	  2005).	  In	  
a	  study	  by	  Pepin	  and	  colleagues,	  the	  use	  of	  fluoroquinolones	  was	  associated	  with	  a	  three-­‐fold	  
increase	  in	  the	  risk	  of	  CDI	  among	  hospitalised	  patients	  (hazard	  ratio	  [HR]	  3.4,	  95%	  confidence	  
interval	  [CI]	  2.7-­‐4.5)	  (Pepin	  et	  al.	  2004).	  This	  is	  likely	  due	  to	  the	  widespread	  use	  of	  these	  drugs	  
to	   treat	   a	   variety	   of	   infections,	   leading	   to	   the	   emergence	   of	   fluoroquinolone-­‐resistant	   C.	  
difficile	  strains	  (Ananthakrishnan	  2011;	  Bassetti	  et	  al.	  2012).	  Other	  microbial	  CDI	  risk	  factors	  
include	  the	  use	  of	  multiple	  antibiotics	  (Gerding	  et	  al.	  1986;	  Thibault	  et	  al.	  1991;	  Nelson	  et	  al.	  
1994;	  Chang	  and	  Nelson	  2000),	  as	  well	  as	  prolonged	  duration	  of	  antibiotic	  treatment	  (Pepin	  
et	  al.	  2004;	  Gaynes	  et	  al.	  2004;	  Zimmerman	  1991)	  
	  
1.2.3.2  Increased	  age	  
Older	  age	  is	  also	  a	  well-­‐recognised	  CDI	  risk	  factor	  (Ananthakrishnan	  2011;	  Bartlett	  2010;	  
Carroll	  and	  Bartlett	  2011;	  Bartlett	  and	  Gerding	  2008).	  Most	  reports	  show	  a	  sharp	  increase	  in	  
CDI	  incidence	  and	  mortality	  in	  those	  above	  65	  years	  old	  (Bassetti	  et	  al.	  2012),	  with	  CDI	  rates	  
up	  to	  20-­‐fold	  higher	  in	  this	  sub-­‐population	  when	  compared	  to	  younger	  individuals	  (Pepin	  et	  
al.	  2005;	  Loo	  et	  al.	  2005;	  Aronsson	  et	  al.	  1984;	  Karlstrom	  et	  al.	  1998).	  This	  could	  be	  due	  to	  a	  
number	   of	   contributing	   factors;	   the	   elderly	   population	   is	   more	   likely	   to	   have	   increased	  
comorbidity,	   increasing	   the	   probability	   of	   hospitalisation	   and	   antibiotic	   usage	  
(Ananthakrishnan	   2011).	   Immunosenescence	   may	   also	   play	   a	   role	   in	   an	   increased	   CDI	  
incidence	  in	  the	  elderly	  population	  (Carroll	  and	  Bartlett	  2011;	  Ananthakrishnan	  2011).	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1.2.3.3  Healthcare	  exposure	  
Recent	  healthcare	  exposure	  also	  poses	  a	  significant	  patient	  risk	  factor	  for	  CDI,	  whether	  
this	  includes	  residence	  at	  long-­‐term	  care	  facilities	  or	  short-­‐term	  stay	  at	  acute-­‐care	  hospitals	  
(Bartlett	  2006).	  C.	  difficile	  colonisation	  occurs	  in	  20-­‐40%	  of	  hospitalised	  patients	  compared	  to	  
only	  2-­‐3%	  of	  normal,	  healthy	  adults	  (Heinlen	  and	  Ballard	  2010;	  Bartlett	  2006),	  which	  reflects	  
the	  widespread	  contamination	  of	  hospital	  environments.	  The	  duration	  of	  hospital	  stay	  has	  
also	  been	  identified	  as	  increasing	  CDI	  risk.	  One	  study	  reported	  a	  4%	  increase	  in	  CDI	  risk	  with	  
each	  additional	  day	  of	  hospitalisation	  (Debast	  et	  al.	  2009),	  with	  a	  five-­‐fold	  increase	  associated	  
with	  hospitalisations	  lasting	  longer	  than	  one	  week	  (Pepin	  et	  al.	  2005).	  Hospitalisation	  poses	  a	  
major	  risk	  because	  it	  brings	  together	  multiple	  major	  issues,	  including	  exposure	  to	  antibiotics	  
and	  a	  vulnerable,	  elderly	  population.	  Furthermore,	  the	  healthcare	  system	  provides	  a	  setting	  
where	  highly	   infectious	  C.	  difficile	  spores	  are	  encountered	   (Bartlett	  2010).	  This	  problem	   is	  
exacerbated	  through	  sub-­‐optimal	  hand	  hygiene	  of	  healthcare	  workers,	  resulting	  in	  the	  rapid	  
transmission	  of	  CDI	  through	  the	  hospital	  environment	  (Depestel	  and	  Aronoff	  2013).	  	  
	  
1.2.3.4  Anti-­‐toxin	  antibodies	  
	  A	  patient’s	  ability	  to	  mount	  an	  adequate	  immune	  response	  against	  C.	  difficile	  may	  also	  
be	  a	  significant	  risk	  for	  CDI	  development	  and	  recurrence	  (Rupnik	  et	  al.	  2009).	  In	  adults,	  the	  
ability	  to	  produce	  anti-­‐toxin	  antibodies	  may	  be	  a	  key	  determinant	  of	  asymptomatic	  disease	  
versus	  active	  infection	  (Ananthakrishnan	  2011).	  Studies	  have	  illustrated	  that	  individuals	  who	  
produce	  lower	  levels	  of	  immunoglobulin	  G	  (IgG)	  directed	  against	  C.	  difficile	  toxin	  A	  or	  B	  are	  
more	  likely	  to	  develop	  CDI,	  and	  could	  also	  be	  at	  a	  higher	  risk	  of	  developing	  recurrent	  disease	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(Kyne	  et	  al.	  2000;	  Kyne	  et	  al.	  2001).	  One	  such	  study,	  by	  Kyne	  and	  colleagues,	  illustrated	  that	  
CDI	  patients	  with	  low	  IgG	  titres	  against	  C.	  difficile	  toxin	  A	  showed	  a	  48-­‐fold	  increased	  risk	  of	  
developing	   recurrent	   disease	   (Kyne	   et	   al.	   2001).	   In	   contrast,	   individuals	   who	   produce	  
adequate	  levels	  of	  IgG	  are	  more	  likely	  to	  remain	  asymptomatic	  carriers	  of	  infection	  (Kyne	  et	  
al.	  2000).	  	  
1.2.3.5  Other	  risk	  factors	  
Immune	   compromised	   patients,	   including	   those	   undergoing	   chemotherapy	   or	   organ	  
transplant,	  are	  at	  increased	  risk	  of	  CDI	  (Alonso	  and	  Marr	  2013;	  Tsapepas	  et	  al.	  2015;	  Chopra	  
et	  al.	  2010).	  Patients	  with	  underlying	  IBD	  have	  also	  been	  identified	  as	  high	  risk	  (Nitzan	  et	  al.	  
2013;	  Reddy	  and	  Brandt	  2013;	  Berg	  et	  al.	  2013).	  	  These	  groups	  of	  patients	  are	  more	  likely	  to	  
experience	  disruption	  of	  colonic	  mucosal	  barrier	  function,	  dysbiosis	  of	  intestinal	  microbiota,	  
immunosuppression	  owed	  to	  the	  use	  of	  drugs,	  as	  well	  as	  malnutrition,	  and	  it	  is	  thought	  that	  
these	  all	  contribute	  to	  the	  increased	  risk	  of	  disease	  (Ananthakrishnan	  2011).	  
	  
Exposure	   to	   stomach	   acid-­‐reducing	   agents,	   such	   as	   histamine	   receptor	   2	   (H2)	  
antagonists	   and	   proton	   pump	   inhibitors	   (PPIs),	   may	   also	   promote	   CDI.	   Gastric	   acid	  
suppression	  is	  thought	  to	  promote	  the	  persistence	  of	  ingested	  C.	  difficile	  spores,	  therefore	  
contributing	  to	  an	  increased	  CDI	  risk.	  Using	  a	  case-­‐control	  study	  design,	  Diel	  and	  colleagues	  
identified	   1,672	   CDI	   cases	   in	   the	   UK,	   and	   matched	   each	   case	   with	   10	   healthy	   controls.	  
Multivariate	  analysis	  demonstrated	  that	  PPI	  use	  was	  associated	  with	  a	  three-­‐fold	  increased	  
risk	  of	  CDI	  (Odds	  ratio	  [OR]	  2.9%,	  95%	  confidence	  interval	  [CI]	  2.4-­‐3.4),	  with	  a	  lower	  but	  still	  
significant	  increased	  risk	  associated	  with	  the	  use	  of	  H2	  antagonists	  (OR	  2.0%,	  95%	  CI	  1.6-­‐2.7)	  
(Dial	  et	  al.	  2005;	  Dial	  et	  al.	  2004).	  There	  has	  been	  some	  question	  as	  to	  whether	  these	  agents	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truly	   contribute	   towards	   CDI	   risk,	   or	   if	   there	   are	   confounding	   factors	   present	   due	   to	  
underlying	  disease.	  However,	  there	  is	  accumulating	  evidence	  to	  support	  that	  PPIs	  in	  particular	  
pose	  an	  increased	  risk	  of	  CDI,	  including	  data	  that	  shows	  a	  dose-­‐dependent	  response	  (Howell	  
et	  al.	  2010;	  Biswal	  2014).	  	  
1.2.4   Clinical	  presentation	  of	  CDI	  	  
C.	  difficile	  causes	  a	  broad	  spectrum	  of	  clinical	  symptoms,	  ranging	  from	  mild	  diarrhoea	  
to	   severe	   and	   life-­‐threatening	   illness	   (Ananthakrishnan	   2011;	   Heinlen	   and	   Ballard	   2010).	  
Symptomatic	  patients	  most	  commonly	  present	  with	  C.	  difficile-­‐associated	  diarrhoea	  (CDAD),	  
which	  is	  sometimes	  accompanied	  by	  lower	  abdominal	  cramps	  (Goudarzi	  et	  al.	  2014).	  Stools	  
are	  usually	  watery	  with	  a	  characteristic	  foul	  odour,	  although	  mucoid	  or	  soft	  stools	  can	  also	  
occur	   (Bartlett	  2010;	  Bartlett	   and	  Gerding	  2008).	  An	   individual	  with	  CDAD	  can	  experience	  
more	  than	  10	  bowel	  movements	  per	  day	  (Ananthakrishnan	  2011).	  Symptoms	  usually	  begin	  
during	  or	  shortly	  after	  antibiotic	  therapy,	  but	  occasionally	  these	  may	  be	  delayed	  for	  several	  
weeks	  (Goudarzi	  et	  al.	  2014).	  	  
More	  severe	  forms	  of	  CDI	  include	  colitis	  and	  PMC.	  C.	  difficile	  colitis	  is	  characterised	  by	  
abdominal	   cramps,	   fever,	   leukocytosis	   and	   severe	   high-­‐volume	   diarrhoea	  which	   can	   have	  
some	  trace	  blood.	  Colonic	  inflammation	  can	  be	  visualised	  by	  endoscopy	  (Bassetti	  et	  al.	  2012;	  
Bartlett	   and	   Gerding	   2008).	   PMC	   is	   a	   systemic	   illness	   that	   has	  many	   causes;	   however,	  C.	  
difficile	   is	   responsible	   for	   almost	   all	   cases.	   Patients	   experience	   abdominal	   pain	   and	  
tenderness,	  fever	  and	  severe	  bloody	  diarrhoea.	  Fever	  and	  leukocytosis	  may	  also	  be	  severe	  in	  
patients,	   with	   temperatures	   occasionally	   reaching	   40°C	   and	  white	   blood	   cell	   counts	   over	  
20,000	   cells/mm3.	  Hypoalbuminemia	   is	   also	   common,	  which	   is	   the	   result	   of	   large	   protein	  
losses	  attributable	  to	  leakage	  of	  albumin	  (<	  3.0	  g/dL	  albumin)	  (Bartlett	  and	  Gerding	  2008).	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PMC	   is	   characterised	   by	   inflammatory	   lesions	   with	   coalesce	   within	   the	   colon	   creating	   a	  
pseudomembrane	   of	   immune	   cells,	   mucous	   and	   necrotic	   tissue.	   Endoscopic	   visualisation	  
shows	  the	  presence	  of	  classic	  pseudomembranes,	  which	  appear	  as	  raised	  yellow	  plaques	  2-­‐
10	  mm	  in	  diameter	  scattered	  over	  the	  colorectal	  mucosa	  (Heinlen	  and	  Ballard	  2010).	  
CDI	  presents	  as	  fulminant	  colitis	  in	  approximately	  3%	  of	  patients	  and	  accounts	  for	  the	  
majority	   of	   serious	   complications.	   These	   include	  bowel	   perforation,	   prolonged	   ileus,	   toxic	  
megacolon	   and	  death	   (Cairns	   et	   al.	   2012;	  Ananthakrishnan	  2011).	   Fulminant	   CDI	   can	   also	  
necessitate	  a	  total	  colectomy,	  which	  carries	  a	  high	  average	  mortality	  rate,	  occurring	  at	  67%	  
(Heinlen	  and	  Ballard	  2010).	  Rising	  serum	  lactate	  levels	  (≥	  5	  mmol/L)	  (Butala	  and	  Divino	  2010),	  
leukocytosis	  (≥	  35	  x	  104	  white	  blood	  cells/µL)	  (Sailhamer	  et	  al.	  2009;	  Henrich	  et	  al.	  2009),	  acute	  
renal	   failure	   (Khanna	   et	   al.	   2013)	   and	   respiratory	  distress	   (Sailhamer	   et	   al.	   2009)	   are	  also	  
associated	  with	  poor	  prognosis	  and	  high	  mortality.	  
	  
1.2.5   Diagnosis	  of	  CDI	  	  
Laboratory	   analysis	   of	   stool	   samples	   is	   the	   standard	  diagnostic	   test	   for	  CDI,	   and	   is	  
recommended	  for	  adults	  and	  children	  (≥	  1	  year	  old)	  who	  present	  with	  unexplained	  diarrhoea	  
associated	  with	   recent	  antibiotic	  use	   (Bartlett	  and	  Gerding	  2008).	   Several	   laboratory	   tests	  
have	  been	  developed	  for	  the	  diagnosis	  of	  CDI.	  	  
The	  cell	  cytotoxicity	  neutralisation	  assay	  (CCNA)	  has	  historically	  been	  considered	  as	  
the	  gold	  standard	  for	  CDI	  diagnosis	  (Iv	  et	  al.	  2014).	  In	  this	  assay,	  faecal	  filtrates	  are	  evaluated	  
for	   their	   ability	   to	   induce	   toxin-­‐induced	   cytopathic	   cell	   rounding.	   If	   a	   cytopathic	   effect	   is	  
observed,	  neutralisation	  with	  an	  antiserum,	  either	  C.	  sordellii	  antitoxin	  or	  C.	  difficile	  antitoxin,	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is	  performed	  (Carroll	  and	  Bartlett	  2011;	  Iv	  et	  al.	  2014).	  Alternatively,	  toxigenic	  culture	  of	  CDI	  
detection	  consists	  of	  isolating	  C.	  difficile	  from	  stool	  samples	  using	  selective	  media,	  followed	  
by	  further	  testing	  by	  enzyme	  immunoassay	  (EIA)	  or	  CCNA	  methods	  to	  confirm	  C.	  difficile	  toxin	  
production.	  These	  tests	  have	  proven	  superior	  in	  terms	  of	  their	  specificity	  and	  sensitivity,	  but	  
they	  are	  labour	  intensive	  and	  have	  a	  long	  turnaround	  time	  (Iv	  et	  al.	  2014).	  As	  a	  result,	  their	  
application	  is	  now	  considered	  limited	  in	  routine	  diagnostic	  testing.	  However,	  toxigenic	  culture	  
in	  particular	  is	  essential	  to	  allow	  for	  strain	  typing	  in	  C.	  difficile	  epidemiology	  studies	  following	  
an	  outbreak,	  and	  antibiotic	  susceptibility	  testing	  (Bassetti	  et	  al.	  2012).	  
EIAs	   represent	   the	  most	  widely	  used	  clinical	  diagnostic	   tests	   (Iv	  et	  al.	  2014).	  These	  
rapid	   and	   relatively	   inexpensive	   tests	   use	   polyclonal	   or	  monoclonal	   antibodies	   to	   directly	  
detect	  the	  presence	  of	  C.	  difficile	  toxins.	  Initial	  toxin	  EIAs	  were	  limited	  and	  had	  suboptimal	  
sensitivity	  as	  they	  detected	  TcdA	  only.	  Newer	  EIAs	  have	  been	  developed	  to	  detect	  both	  toxins.	  
Commercial	  EIAs	  produced	  by	  several	  different	  manufacturers	  generally	  show	  high	  specificity	  
(90-­‐95%),	  but	  low	  to	  moderate	  sensitivity,	  lying	  in	  the	  60-­‐90%	  range.	  Therefore,	  these	  tests	  
are	  not	  recommended	  for	  standalone	  use	  and	  are	  often	  used	  in	  two	  or	  three-­‐step	  diagnostic	  
algorithms	   (Planche	   et	  al.	   2008).	  Other	  EIAs	  detect	   the	  present	  of	   the	  common	  C.	  difficile	  
antigen	  glutamate	  dehydrogenase	  (GDH),	  which	  have	  higher	  sensitivity	  (90-­‐95%)	  but	  lower	  
specificity	  (85-­‐90%)	  than	  toxin	  EIAs	  (Shetty	  et	  al.	  2011).	  	  
A	  more	  recently	  available	  test	  for	  CDI	  is	  a	  real-­‐time	  PCR	  nucleic	  acid	  amplification	  test	  
(NAAT)	  that	  detects	  C.	  difficile	  toxin	  genes	  (i.e.	  tcdA	  and	  tcdB	   that	  encode	  TcdA	  and	  TcdB,	  
respectively).	  This	  test	  has	  a	  rapid	  turnaround	  time	  with	  a	  high	  sensitivity	  (90%)	  and	  specificity	  
(96%)	  (Deshpande	  et	  al.	  2011).	  Two	  NAATs	  have	  now	  been	  approved	  for	  use	  by	  the	  Food	  and	  
Drug	  Administration	   (FDA),	   but	   their	   role	   in	   routine	   clinical	   practice	  might	   require	   further	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evaluation	  (Carroll	  and	  Bartlett	  2011).	  For	  example,	  NAATs	  target	  DNA	  encoding	  C.	  difficile	  
toxins	  and	  not	  the	  toxins	  themselves,	  hence	  they	  do	  not	  provide	  evidence	  that	  the	  toxins	  are	  
actually	  being	  expressed	  in	  vivo	  	  (Gilligan	  2015).	  NAATs	  should	  therefore	  be	  associated	  with	  a	  
more	  specific	   test	  that	  directly	  detects	  the	  expression	  of	  C.	  difficile	  toxins	   (such	  as	  EIAs	  or	  
toxigenic	  culture)	  (Bassetti	  et	  al.	  2012).	  	  
At	   present,	   no	   single	   commercially	   available	   test	   offers	   both	   high	   sensitivity	   and	  
specificity	   in	   combination	   with	   rapid	   turnaround	   time	   and	   low	   cost.	   To	   more	   effectively	  
distinguish	  between	  CDI	  patients	  and	  those	  without	  infection,	  two-­‐	  or	  three-­‐step	  diagnostic	  
algorithms	   have	   been	   developed	   (Bassetti	   et	   al.	   2012).	   Indeed,	   a	   two-­‐step	   protocol	   is	  
currently	  used	  in	  NHS	  laboratories	  in	  England,	  which	  comprises	  an	  EIA	  for	  GDH	  detection	  or	  
NAAT,	  followed	  by	  a	  toxin	  EIA	  (Wilcox	  2012).	  	  
	  
1.2.6   Treatment	  of	  CDI	  
1.2.6.1  Antibiotics	  
Current	   treatment	   guidelines	   for	   CDI	   include	   supportive	   care	   and	   withdrawal	   of	  
implicated	   antibiotics,	   as	  well	   as	   administration	   of	   antimicrobial	   therapy	   (Lo	   Vecchio	   and	  
Zacur	   2012).	   Metronidazole	   (250	   mg	   every	   6	   hours	   or	   500	   mg	   every	   8	   hours	   orally)	   is	  
recommended	  for	  treatment	  of	  mild-­‐moderate	  CDI	  (Leffler	  and	  Lamont	  2009).	  Vancomycin	  is	  
administered	   to	   patients	  with	   severe	   CDI	   or	   to	   those	  who	   cannot	   tolerate	  metronidazole	  
(Leffler	   and	   Lamont	   2009).	   Originally,	   limited	   use	   of	   vancomycin	   was	   recommended	   to	  
prevent	  the	  emergence	  of	  vancomycin-­‐resistant	  enterococci	  (VRE)	  (Leffler	  and	  Lamont	  2009).	  
However,	  studies	  have	  shown	  that	  metronidazole	  also	  selects	  for	  VRE	  (Donskey	  et	  al.	  2000;	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Carmeli	  et	  al.	  2002),	  and	  in	  fact,	  VRE	  colonisation	  rates	  appear	  similar	  in	  patients	  treated	  with	  
vancomycin	  and	  metronidazole	  (Al-­‐Nassir	  et	  al.	  2008).	  
Despite	  initial	  response	  rates	  of	  greater	  than	  90%	  (Wilcox	  and	  Howe	  1995;	  Fekety	  et	  al.	  
1989),	  15-­‐30%	  of	  patients	  experience	  a	  relapse	  in	  symptoms	  following	  successful	  antibiotic	  
therapy	   (Fekety	   et	   al.	   1997).	   Patients	   who	   experience	   a	   first	   relapse	   are	   retreated	   with	  
metronidazole	   or	   vancomycin	   (same	   agent	   as	   used	   originally)	   (Leffler	   and	   Lamont	   2009;	  
Heinlen	  and	  Ballard	  2010),	  however,	  up	  to	  50%	  of	  these	  patients	  go	  on	  to	  experience	  multiple	  
relapses	   (Fekety	   et	   al.	   1997).	   Recently,	   the	   number	   of	   treatment	   failures	   in	   response	   to	  
metronidazole	  have	  also	  increased	  (Aslam	  et	  al.	  2005),	  suggesting	  that	  alternative	  treatment	  
options	  are	  needed	  to	  effectively	  combat	  CDI.	  	  
	  
1.2.6.2  Probiotics	  
Probiotics	  are	  defined	  as	  living	  organisms	  that	  confer	  a	  health	  benefit	  to	  the	  host	  (de	  
Vrese	  and	  Schrezenmeir	  2008).	  	  There	  is	  increasing	  evidence	  to	  support	  the	  use	  of	  probiotics	  
in	  a	  range	  of	  gastrointestinal	  diseases,	  but	  their	  role	  in	  the	  treatment	  and	  prevention	  of	  CDI	  
is	   unclear	   (Martin	   et	   al.	   2013;	   Evans	   and	   Johnson	   2015).	   In	   vitro	   and	   in	   vivo	   animal	  
experiments	  suggest	  that	  probiotics	  such	  as	  Lactobacilli	  and	  Saccharomyces	  boulardii	  exhibit	  
inhibitory	  activity	  against	  C.	  difficile	  (Trejo	  et	  al.	  2006;	  Castagliuolo	  et	  al.	  1999),	  and	  can	  also	  
modulate	  the	  host	  response	  (Chen	  et	  al.	  2006;	  Qamar	  et	  al.	  2001).	   	  However,	  their	  clinical	  
application	  is	  limited	  by	  a	  lack	  of	  clinical	  evidence.	  A	  Cochrane	  review	  in	  2012	  	  (Johnston	  et	  
al.	   2012)	   analysed	   20	   randomised	   controlled	   trials	   including	   adult	   or	   pediatric	   patients	  
receiving	  antibiotics.	  These	  trials	  evaluated	  the	  efficacy	  of	  any	  strain	  or	  dose	  of	  a	  probiotic	  in	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reducing	   CDI	   incidence	   rates,	   compared	  with	   placebo	   or	   no	   treatment	   control.	   Probiotics	  
were	  shown	  to	  reduce	  incidence	  of	  CDI	  by	  66%	  (pooled	  relative	  risk	  [RR]	  of	  0.34;	  95%	  CI,	  0.24-­‐
0.49),	  with	  no	  significant	  adverse	  effects	  reported	  (Johnston	  et	  al.	  2012).	  However,	  a	  recent	  
large,	  randomised,	  double-­‐blind,	  placebo-­‐controlled	  trial	  (PLACIDE	  trial)	  showed	  that	  a	  multi-­‐
strain	  preparation	  of	  Lactobacilli	  and	  Bifidobacteria	  showed	  no	  benefit	  when	  compared	  to	  
placebo	  at	  preventing	  AAD	  or	  CDI	  	  (Allen	  et	  al.	  2013)	  
There	   is	   therefore	   a	   lack	   of	   sound	  evidence	   to	   support	   the	   role	   of	   probiotics	   in	   the	  
treatment	  and	  prevention	  of	  CDI,	  and	  as	  such,	  they	  are	  not	  currently	  recommended	  for	  use	  
(Martin	   et	   al.	   2013;	   Dickinson	   and	   Surawicz	   2014).	   Moreover,	   treatment	   with	   probiotics	  
represents	   a	   potential	   risk	   factor	   for	   fungemia	   in	   immunodeficient	   or	   critically	   ill	   patients	  
(Munoz	  et	  al.	  2005).	  
	  
1.2.6.3  Immunotherapy	  
Previous	  studies	  have	  indicated	  that	  an	  inadequate	  antibody	  response	  against	  C.	  difficile	  
toxins	  might	  contribute	  towards	  an	  increased	  risk	  of	  symptomatic	  and	  recurrent	  infection	  (as	  
already	   described	   in	   Section	   1.2.3.4).	   Passive	   immunity	   against	   C.	   difficile	   toxins	   might	  
therefore	  protect	  against	  infection.	  As	  such,	  monoclonal	  antibodies	  (MAbs)	  directed	  against	  
C.	  difficile	  toxins	  have	  been	  evaluated	  as	  an	  alternative	  CDI	  treatment	  option.	  Experimental	  
hamster	   models	   have	   demonstrated	   that	   MAb	   administration	   reduces	   the	   severity	   and	  
duration	  of	  diarrhoea,	  death	   rate	  and	   rate	  of	   recurrence	   following	  C.	  difficile	   innoculation	  
(Davies	  et	  al.	  2013).	  A	  randomised,	  double-­‐blind	  Phase	  II	  placebo-­‐controlled	  trial	  of	  two	  novel,	  
fully	   human	   MAbs	   against	   C.	   difficile	   TcdA	   (CDA1)	   and	   TcdB	   (CDB1)	   was	   also	   able	   to	  
demonstrate	  a	  lower	  CDI	  recurrence	  rate	  with	  adminstration	  of	  a	  single	  infusion	  of	  10	  mg/kg	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MAb	   compared	   to	   placebo	   in	   patients	   receiving	   either	   metronidazole	   or	   vancomycin.	  
Recurrent	  infection	  developed	  in	  7%	  of	  the	  MAb	  group	  compared	  with	  25%	  of	  the	  placebo	  
group,	  reflecting	  an	  RR	  of	  72%	  	  (95%	  CI:	  7-­‐29,	  P	  <	  0.001)	  (Lowy	  et	  al.	  2010).	  	  
However,	  a	  number	  of	  questions	  remain	  regarding	  the	  application	  of	  MAb	  therapy	  to	  
treat	   CDI.	   Whilst	   clinical	   trials	   have	   demonstrated	   that	   MAb	   administration	   reduces	   CDI	  
recurrence	  rates,	  it	  has	  no	  effect	  on	  the	  duration	  or	  severity	  of	  diarrhoea	  (Lowy	  et	  al.	  2010;	  
Safdar	  2010).	  In	  addition,	  disease	  progression	  varies	  considerably	  between	  different	  patient	  
populations,	   i.e.	   the	   elderly,	   so	   the	   clinical	   application	   of	   MAb	   therapy	   across	   these	  
populations	  needs	  to	  be	  further	  investigated	  (Parks	  et	  al.	  2010).	  Additional	  Phase	  III	  human	  
studies	  now	  currently	  underway	  might	  provide	  further	  clarification	  to	  the	  role	  of	  MAb	  therapy	  
as	  an	  effective	  CDI	  treatment	  option	  (Iv	  et	  al.	  2014;	  To	  and	  Napolitano	  2014).	  	  
Also	  likely	  to	  emerge	  in	  the	  future	  is	  the	  application	  of	  new	  MAbs	  (PA-­‐50	  and	  PA-­‐41)	  
that	  specifically	  bind	  to	  epitopes	   in	  the	  neutralising	  regions	  of	  TcdA	  and	  TcdB.	  These	  have	  
shown	  promise	  in	  experimental	  animal	  models,	  where	  the	  dual	  administration	  of	  PA-­‐50/PA-­‐
41	  dramatically	  increased	  survival	  rate	  in	  a	  hamster	  CDI	  model	  (long	  term	  survival	  rate	  of	  95%	  
for	   MAb	   versus	   0%	   for	   placebo)	   (Marozsan	   et	   al.	   2012).	   In	   addition,	   intravenous	  
immunoglobulin	  (IVIG)	  prepared	  from	  pooled	  human	  serum	  has	  been	  studied	  with	  respect	  to	  
both	   recurrent	   and	   severe	   CDI,	   but	   has	   yielded	   inconsistent	   results	   (Juang	   et	   al.	   2007;	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1.2.6.4  Fecal	  microbiota	  transplantation	  
Faecal	   microbiota	   transplantation	   (FMT)	   involves	   the	   instillation	   of	   the	   faecal	  
microbiota	   from	   a	   healthy	   donor	   into	   the	   gut	   of	   a	   CDI	   patient,	   usually	   administered	   by	  
nasogastric	   tube,	   endoscope	   or	   enema	   (Weissman	   and	   Coyle	   2012).	   FMT	   allows	   the	  
reconstitution	  of	  the	  normal	  intestinal	  microbiota,	  and	  an	  increasing	  number	  of	  studies	  have	  
reported	  that	  it	  is	  an	  effective	  treatment	  for	  recurrent	  CDI	  (Monier	  and	  Barbut	  2014).	  Indeed,	  
case	  series	  and	  systematic	  reviews	  of	  published	  studies	  have	  reported	  cure	  rates	  of	  more	  than	  
90%	  with	  no	  serious	  adverse	  effects	  (Gough	  et	  al.	  2011;	  Brandt	  et	  al.	  2012;	  Kelly	  et	  al.	  2012;	  
Kassam	  et	  al.	  2012;	  Bakken	  et	  al.	  2011).	  Similar	  results	  were	  also	  observed	   in	  a	  successful	  
randomised,	  controlled	  trial	  by	  van	  Nood	  and	  colleagues	  (van	  Nood	  et	  al.	  2013).	  In	  this	  study,	  
94%	  patients	  experienced	  resolution	  of	  CDI	  following	  an	  infusion	  of	  donor	  faeces	  through	  a	  
nasoduodenal	   tube,	   compared	   to	   only	   31%	  patients	   receiving	   vancomycin	   alone	   and	   23%	  
patients	  receiving	  vancomycin	  with	  bowel	  lavage	  (van	  Nood	  et	  al.	  2013).	  
	  
Due	   to	   such	   promising	   results	   regarding	   its	   efficacy	   and	   safety,	   FMT	   has	   now	   been	  
approved	  by	  the	  National	  Institute	  for	  Health	  and	  Care	  Excellence	  (NICE)	  for	  its	  use	  to	  treat	  
recurrent	  CDI,	  however,	  the	  procedure	  should	  only	  be	  considered	  for	  recurrent	  CDI	  patients	  
that	   are	   non-­‐responsive	   to	   antibiotics	   and	   other	   treatments	   (NICE	   2014).	   It	   is	   also	  worth	  
noting	  that	  some	  concerns	  exist	  regarding	  the	  long-­‐term	  outcomes	  of	  FMT,	  as	  well	  as	  the	  lack	  
of	   standardardised	   procedure	   for	   donor	   selection	   (Borgia	   et	   al.	   2015).	   As	   such,	   further	  
research	   into	  FMT	   is	  encouraged	  to	  establish	  optimal	  dosage,	  mode	  of	  administration	  and	  
choice	  of	  donor	  (NICE	  2014).	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1.2.7   Animal	  models	  of	  CDI	  
The	  continued	  development	  of	  alternative	  therapeutics	  is	  essential	  for	  the	  treatment	  
and	  prevention	  of	  CDI.	  This,	  alongside	  the	  need	  to	  increase	  the	  understanding	  of	  C.	  difficile	  
pathogenesis,	  has	  meant	  that	  a	  number	  of	  C.	  difficile	  experimental	  animal	  models	  have	  been	  
developed.	   Indeed,	  many	  different	  animal	  models	  have	  been	  used	   to	   study	  CDI,	   including	  
small	  animals	  such	  as	  hamsters,	  mice,	  rats,	  rabbits,	  hares,	  guinea	  pigs,	  prairie	  dogs	  and	  quails.	  
In	  addition,	  a	  limited	  number	  of	  studies	  have	  utilised	  larger	  animals	  including	  foals,	  piglets	  
and	  monkeys.	   Zebrafish	   embryos	   have	   also	   recently	   been	   used	   to	   study	   the	   action	   of	   C.	  
difficile	  toxins	  (Best	  et	  al.	  2012).	  	  
Hamster	  models,	  in	  particular	  Syrian	  hamsters,	  have	  been	  most	  extensively	  utilised	  for	  
the	   study	   of	   CDI	   (Best	   et	   al.	   2012).	   This	   is	   because	   CDI	   in	   hamsters	  mirrors	   some	   of	   the	  
recognised	  pathophysiological	   features	  of	  CDI	  observed	   in	  humans.	   Similar	   to	  human	  CDI,	  
infection	   in	   hamsters	   must	   be	   induced	   by	   disrupting	   the	   microbiota	   through	   the	  
administration	  of	  antibiotics	   (usually	   clindamycin),	   followed	  by	  challenge	  with	   toxigenic	  C.	  
difficile	   strains	   (Hutton	   et	   al.	   2014).	   This	   results	   in	   an	  overall	   deterioration	  of	   the	   animal,	  
alongside	  changes	  in	  the	  appearance	  of	  the	  gastrointestinal	  tract,	  particularly	  the	  colon	  and	  
cecum.	  Redness,	  inflammation,	  fluid	  accumulation	  and	  enlargement	  of	  the	  colon	  are	  usually	  
observed,	  accompanied	  by	  a	  decrease	  in	  gut	  motility	  (Best	  et	  al.	  2012).	  	  
However,	  certain	  clinical	  features	  of	  CDI	  in	  hamsters	  differs	  from	  that	  in	  humans.	  One	  
potential	  drawback	  is	  that	  hamsters	  do	  not	  typically	  develop	  diarrhoea.	  Instead,	  they	  present	  
with	  ‘wet	  tail’,	   in	  which	  the	  hamster	  exhibits	  lethargy,	  ruffled	  fur,	  hunching,	  irritability	  and	  
the	  refusal	  of	  food,	  which	  ultimately	  leads	  to	  death	  (Best	  et	  al.	  2012).	  Indeed,	  if	  left	  untreated,	  
disease	  is	  rapidly	  fatal	  in	  hamsters,	  and	  thus,	  the	  endpoint	  of	  any	  experiment	  is	  the	  survival	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rate	  in	  days.	  Therefore,	  the	  hamster	  model	  is	  essentially	  a	  prevention	  of	  death	  model	  (Best	  
et	   al.	   2012).	   	   This	   rapidly	   fatal	   disease	   pattern	   is	   not	   characteristic	   of	   human	   CDI.	  
Nevertheless,	  hamsters	  are	  an	  important	  and	  relevant	  model	  of	  C.	  difficile	  disease,	  and	  their	  
main	   uses	   have	   included	   toxin	   and	   strain	   characterisation,	   evaluation	   of	   new	   treatment	  
stategies	   and	   different	   diets,	   colonisation	   studies,	   investigation	   into	   virulence	   factors	   and	  
characterisation	  of	  immune	  responses	  (Best	  et	  al.	  2012;	  Hutton	  et	  al.	  2014).	  
In	  addition,	  three	  mouse	  models	  are	  being	   increasingly	  utilised	  to	  study	  CDI.	  These	  
include	  the	  gnotobiotic/germ-­‐free	  mouse	  model,	  the	  antibiotic	  cocktail	  mouse	  model	  and	  the	  
single	  antibiotic	  mouse	  model	  of	  CDI	  (Hutton	  et	  al.	  2014;	  Lawley	  and	  Young	  2013).	  
	  
1.3  ENTEROTOXIGENIC	  E.COLI	  INFECTION	  –	  AN	  ACUTE	  DIARRHOEAL	  DISEASE	  
Enterotoxigenic	  E.	  coli	  	  (ETEC),	  one	  of	  six	  recognised	  diarrheagenic	  E.	  coli,	  is	  a	  Gram-­‐
negative	  bacterium	  that	  colonises	  the	  small	  intestine.	  ETEC	  is	  characterised	  by	  the	  production	  
of	  one	  or	  both	  of	  two	  enterotoxins;	  heat-­‐labile	  toxin	  (LT)	  and	  heat-­‐stable	  toxin	  (ST),	  both	  of	  
which	  lead	  to	  fluid	  secretion	  from	  small	  intestinal	  epithelial	  cells	  and	  subsequent	  diarrhoea	  
(Clements	  et	  al.	  2012).	  Human	  ETEC	  infections	  occur	  through	  consumption	  of	  contaminated	  
water	   and	   food	   products	   or	   via	   direct	   person	   to	   person	   spread	   from	   poor	   hand	   hygiene	  
(Berger	  et	  al.	  2010;	  Clements	  et	  al.	  2012).	  
ETEC	  was	  discovered	  more	  than	  50	  years	  ago	  when	  De	  and	  colleagues	  isolated	  pure	  E.	  
coli	  	  culture	  from	  patients	  with	  symptoms	  typical	  of	  cholera,	  caused	  by	  Vibrio	  cholerae.	  These	  
E.	  coli	   isolates	  also	  produced	  a	  strong	  cholera-­‐like	  secretory	  response	   in	  rabbit	   ileal	   loops,	  
with	  similar	  results	  found	  in	  other	  studies	  (De	  et	  al.	  1956).	  In	  vivo	  	  studies	  also	  demonstrated	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that	   these	  E.	   coli	  strains	  were	   responsible	   for	  diarrhoeal	  disease	   in	   several	  animal	   species	  
(Carlton	  and	  Barnum	  1969;	  Smith	  and	  Halls	  1967)	  which	  was	  confirmed	  by	  oral	  challenge	  of	  
human	  volunteers	  (DuPont	  et	  al.	  1971;	  Levine	  et	  al.	  1979).	  Since	  its	  initial	  discovery,	  there	  has	  
been	   a	   concerted	   effort	   to	   characterise	   the	   previously	   unknown	   ETEC	   enterotoxins	   and	  
virulence	  factors.	  Today,	  ETEC	  is	  recognised	  as	  a	  common	  cause	  of	  diarrhoea	  in	  adults	  and	  
children	  in	  developing	  countries,	  and	  a	  major	  cause	  of	  traveller’s	  diarrhoea	  in	  people	  visiting	  
or	  returning	  from	  endemic	  regions	  	  (Qadri	  et	  al.	  2005).	  
	  
1.3.1   Pathogenesis	  of	  ETEC	  infection	  	  
The	  pathogenesis	  of	  ETEC	  infection	  can	  be	  divided	  into	  two	  important	  stages;	  effective	  
colonisation	  of	  the	  intestinal	  epithelium,	  followed	  by	  successful	  release	  of	  its	  toxins.	  
	  
1.3.1.1  Colonisation	  of	  the	  intestinal	  epithelium	  
Colonisation	   of	   the	   intestinal	   epithelium	   represents	   an	   essential	   step	   in	   the	  
pathogenesis	  of	  ETEC	   infection.	  This	   is	  mediated	  by	  plasmid-­‐encoded	   fimbrial	   colonisation	  
factors	   (CFs),	  which	  bind	   to	   enterocytes	   in	   the	   small	   intestine,	   allowing	   the	   expression	  of	  
enterotoxins	   ST	   and	   LT	   in	   close	   proximity	   to	   the	   intestinal	   epithelium	   (Fleckenstein	   et	   al.	  
2010).	  Studies	  have	  also	  demonstrated	  that	  fimbrial	  CFs	  possess	  lectin	  activity.	  For	  example,	  
F17	   fimbriae	   present	   on	  E.	   coli	  K99	   exhibits	   carbohydrate-­‐binding	   specificity	   and	  binds	   to	  
surface	   glycolipids	   containing	  N-­‐glycolylneuraminic	   acid	   (NeuGc)	   in	   the	   form	  of	  NeuGcα2-­‐
3Galβ4Glc	  (Sharon	  2006).	  CFs	  are	  considered	  to	  be	  key	  virulence	  factors	  as	  illustrated	  by	  a	  
number	  of	  in	  vivo	  animal	  and	  human	  studies	  which	  have	  shown	  that	  CF-­‐positive	  bacteria,	  but	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not	   spontaneous	   CF-­‐negative	   derivatives,	   colonise	   the	   intestinal	   mucosa	   and	   induce	  
diarrhoea	  (Qadri	  et	  al.	  2005;	  Evans	  et	  al.	  1978;	  Levine	  et	  al.	  1979;	  Svennerholm	  et	  al.	  1990)	  .	  	  
To	   date,	   over	   25	   unique	   CF	   types	   and	   putative	   colonisation	   factors	   have	   been	  
characterised,	  which	  can	  be	  subdivided	  into	  five	  groups	  based	  on	  their	  genetic	  and	  structual	  
homologies	  (Table	  1)(Sizemore	  et	  al.	  2004).	  	  
	  
Table	  1.1.	  Colonisation	  factors	  found	  in	  human	  ETEC	  strains.	  Adapted	  from	  (Sizemore	  et	  al.	  
2004).	  
Group	   Group	  Members	   Characteristics	  
CFA/1	   CFA/1,	  CS1,	  CS2,	  CS4,	  CS14,	  
CS17,	  CS19	  
Highly	  genetically	  related.	  	  
Fimbriae	  composed	  of	  a	  
single	  structural	  subunit.	  




CS5	   CS5,	  CS7,	  CS13,	  CS18,	  CS20	   Sequence	  similarities	  to	  
fimbriae	  of	  animal	  ETEC	  
strains	  (particularly	  porcine	  
isolates)	  
	  
Bundle-­‐forming	   CS8,	  CS21	   Most	  closely	  related	  to	  Type	  
IV	  pili	  expressed	  by	  EPEC.	  
Longest	  pilus	  	  >20	  µm	  long.	  
CS15	   CS15,	  CS22	   Antigenically	  cross-­‐reactive.	  	  
Closely	  related	  to	  SE14	  
fimbriae	  of	  Salmonella	  
enteriditis	  
Distinct	   CS3,	  CS6,	  CS10,	  CS11,	  CS12	   No	  known	  homology	  with	  




	  	   35	  
Whilst	  there	  is	  significant	  regional	  variation	  in	  CF	  expression	  profiles,	  epidemiological	  
studies	  have	  suggested	  that	  the	  most	  prevalent	  CFs	  include	  CFA/1,	  CS1-­‐CS7,	  CS14,	  CS17	  and	  
CS21,	  which	  are	  expressed	  either	  alone	  or	  in	  combination	  (Gaastra	  and	  Svennerholm	  1996;	  
Isidean	  et	  al.	  2011;	  Qadri	  et	  al.	  2005).	  It	  is	  worth	  noting	  that	  on	  approximately	  30-­‐50%	  of	  ETEC	  
strains	  worldwide,	  there	  are	  no	  known	  CFs	  detected.	  This	  could	  be	  due	  to	  the	  true	  absence	  
of	  CFs,	  to	  loss	  of	  CF	  properties	  in	  subculturing,	  or	  to	  a	  lack	  of	  specific	  tools	  for	  their	  detection	  
(Qadri	  et	  al.	  2005;	   Isidean	  et	  al.	  2011).	  Two	  other	   factors	  are	  also	  ultilised	  to	  characterise	  
ETEC;	   O	   serogroups	   and	   H	   serogroups,	   associated	   with	   antigens	   found	   on	   cell	   wall	  
lipopolysaccharides	  (LPS)	  and	  flagella,	  respectively	  (Fleckenstein	  et	  al.	  2010;	  Qadri	  et	  al.	  2005;	  
Wolf	  1997).	  
	  
1.3.1.2  Release	  of	  toxins	  
Following	   the	   successful	   colonisation	   of	   the	   intestinal	   epithelium,	   ETEC	   mediates	  
pathogencity	   through	   the	   release	   of	   at	   least	   one	   of	   two	   separate	   plasmid	   encoded	  
enterotoxins;	  LT	  and	  ST.	  
LT	  (84	  kDa)	  has	  a	  similar	  homology	  and	  structure	  to	  the	  cholera	  toxin,	  as	  well	  as	  a	  similar	  
mode	  of	  action.	  Like	  the	  cholera	  toxin,	  LT	   is	  a	  heterohexameric	  molecule,	  composed	  of	  an	  
active	  (A)	  subunit	  surrounded	  by	  pentameric	  binding	  (B)	  subunits	  (Fleckenstein	  et	  al.	  2010).	  
Following	  colonisation	  and	  LT	  secretion,	  LTB	  subunits	  bind	  irreversibly	  to	  GM1	  gangliosides	  
on	  the	  surface	  of	  intestinal	  epithelial	  cells	  whilst	  internalised	  LTA	  activates	  adenylate	  cyclase,	  
resulting	  in	  an	  increase	  of	  intracellular	  cyclic	  adenosine	  monophosphate	  (AMP).	  Subsequent	  
activation	   of	   protein	   kinases	   then	   stimulates	   chloride	   secretion	   at	   crypt	   cells	   through	   the	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cystic	   fibrosis	   transmembrane	   regulator	   channel	   (CFTR),	   whilst	   inhibiting	   neutral	   sodium	  
chloride	  absorption	  at	  the	  villus	  tips.	  Ultimately,	  this	  leads	  to	  a	  net	  loss	  of	  salt	  and	  water	  into	  
the	  intestinal	  lumen,	  and	  when	  these	  actions	  exceed	  the	  absorptive	  capacity	  of	  the	  bowel,	  a	  














Figure	  1.4.	  Summary	  of	  the	  mechanism	  of	  ETEC	  heat-­‐labile	  (LT)	  enterotoxin.	  Adapted	  
from	  (Dubreuil	  2012).	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ST	   is	  a	  nonantigenic	   low-­‐molecular	  weight	  peptide	  consisting	  of	  18-­‐19	  amino	  acids,	  
and	  whilst	  it	  works	  independently	  of	  LT,	  it	  produces	  a	  similar	  physiological	  effect	  (Clements	  
et	  al.	  2012;	  Fleckenstein	  et	  al.	  2010).	  Released	  in	  the	  small	  intestine,	  ST	  binds	  irreversibly	  to	  
guanylate	  cyclase	  resulting	  in	  increased	  levels	  of	  cyclic	  guanosine	  monophosphate	  (GMP).	  As	  
with	  LT,	   this	   results	   in	   increased	  chloride	  secretion	  at	  crypt	  cells	  with	   inhibition	  of	  neutral	  
sodium	  chloride	  absorption	  which	  leads	  to	  an	  outpour	  of	  watery	  diarrhoea	  (Fleckenstein	  et	  
al.	  2010;	  Qadri	  et	  al.	  2005)	  
	  
1.3.2   Epidemiology	  of	  ETEC	  infection	  	  
1.3.2.1  Incidence	  rates	  
Accurate	  figures	  of	  the	  incidence	  of	  enteric	  E.	  coli	  	  infections	  are	  difficult	  to	  determine	  
as	  the	  causative	  agents	  of	  diarrhogenic	  infections	  are	  often	  not	  identified.	  However,	  ETEC	  is	  
reported	  to	  be	  the	  most	  commonly	  isolated	  enteropathogen	  in	  children	  under	  5	  years	  of	  age	  
in	  developing	  countries,	  accounting	  for	  approximately	  20%	  of	  cases	  (Qadri	  et	  al.	  2005).	  It	  is	  
estimated	  that	  280	  million	  -­‐	  400	  million	  ETEC-­‐associated	  diarrhoea	  cases	  occur	  annually	  each	  
year	  in	  children	  under	  five	  years,	  with	  a	  further	  100	  million	  cases	  in	  children	  over	  5	  years	  of	  
age,	  resulting	   in	  approximately	  300,000	  –	  500,000	  deaths	  annually	  (Zhang	  and	  Sack	  2012).	  
ETEC	   is	   also	   the	   most	   common	   cause	   of	   traveller’s	   diarrhoea,	   accounting	   for	   10-­‐60%	   of	  
infections	  depending	  on	  the	  region	  visited	  (Clements	  et	  al.	  2012;	  Gascón	  et	  al.	  1998;	  Black	  
1990).	  Extrapolation	  of	   these	   figures	  suggests	   that	   there	  may	  be	  approximately	  10	  million	  
cases	  of	  traveller’s	  diarrhoea	  caused	  by	  ETEC	  each	  year	  (Clements	  et	  al.	  2012).	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1.3.2.2  Relation	  to	  presence	  of	  LT,	  ST	  and	  colonisation	  factors	  
ETEC	  expressing	  LT	  only	  are	  more	  frequently	  isolated	  from	  healthy	  individuals	  than	  from	  
symptomatic	  patients,	  and	  are	  therefore	  considered	  less	  pathogenic	  (Qadri	  et	  al.	  2005).	  This	  
could	  be	  related	  to	  the	  low	  prevalence	  of	  CFs	  expressed	  on	  LT-­‐producing	  ETEC	  strains	  when	  
compared	  with	  ST-­‐	  and	  LT/ST-­‐producing	  strains	   (<10%	  versus	  >60%,	   respectively)	   (Gaastra	  
and	  Svennerholm	  1996;	  McConnell	  et	  al.	  1991).	  Indeed,	  predominant	  CF	  types	  (as	  discussed	  
in	  Section	  1.3.1.1)	  are	  also	  more	  commonly	  found	  on	  ST-­‐	  and	  LT/ST-­‐producing	  ETEC	  strains	  
(Qadri	  et	  al.	  2005).	  Perhaps	  unsurprisingly,	  clinic-­‐based	  studies	  have	  also	  reported	  that	  ST-­‐	  
and	  LT/ST-­‐producing	  strains	  cause	  more	  serious	  disease	  than	  their	  LT-­‐expressing	  counterparts	  
(Qadri	  et	  al.	  2000).	  	  
	  
1.3.3   Risk	  factors	  of	  ETEC	  
1.3.3.1  Age	  
Infants	  and	  young	  children	  are	  much	  more	  susceptible	  to	  ETEC	  infection,	  as	  evidenced	  
by	  high	  incidence	  rates	  in	  this	  age	  group.	  Studies	  over	  recent	  years	  have	  demonstrated	  that	  
ETEC	  is	  a	  frequent	  cause	  of	  diarrhoea	  in	  infants	  younger	  than	  2	  years	  of	  age	  (Qadri	  et	  al.	  2000;	  
Rao	   et	   al.	   2003;	   Steinsland	   et	   al.	   2002).	   For	   example,	   90%	   of	   ETEC	   cases	   reported	   to	  
Bangladeshi	  hospitals	  were	  accounted	  by	  children	  aged	  3	  months	  to	  2	  years	  old	  (Qadri	  et	  al.	  
2000).	  The	  incidence	  of	  ETEC	  infections	  in	  developing	  countries	  decreases	  between	  the	  ages	  
of	  5-­‐	  to	  15	  years.	  Incidence	  increases	  again	  in	  those	  over	  15	  years	  old,	  with	  approximately	  
25%	   of	   infection	   seen	   in	   adults	   (Merson	   et	   al.	   1980;	   Qadri	   et	   al.	   2000).	   Whilst	   limited	  
epidemiological	  information	  exists	  regarding	  adult	  infection,	  hospitalised	  adults	  often	  present	  
	  	   39	  
with	  more	   severe	   forms	   of	   ETEC	   diarrhoea	   than	   children	   and	   infants	   (Qadri	   et	   al.	   2005).	  
Further	  analyses	  have	  also	  indicated	  that	  the	  elderly	  are	  also	  susceptible	  to	  more	  severe	  ETEC	  
infection	   requiring	   hospitalisation,	   with	   ETEC	   identified	   as	   the	   second	   most	   frequently	  
isolated	   (13%)	  bacterial	  pathogen	  after	  V.	  cholerae	   (20%)	   in	  patients	  over	  65	  years	  of	  age	  
(Faruque	  et	  al.	  2004).	  Some	  explanation	  as	  to	  why	  ETEC	  incidence	  varies	  between	  different	  
age	  groups	  might	  be	  from	  results	  obtained	  from	  experimental	  animal	  models,	  which	  indicated	  
indicated	  age-­‐dependent	  changes	   in	  the	  presence	  of	   intestinal	  cell	  surface	  receptors	  for	  E.	  
coli	  	  K99	  fimbrial	  antigen	  (Runnels	  et	  al.	  1980).	  	  
	  
1.3.3.2  Geographical	  location	  
ETEC	  infection	  is	  predominantly	  confined	  to	  developing	  countries	  where	  water	  supplies	  
and	  sanitation	  are	  inadequate	  (Clements	  et	  al.	  2012).	  Surface	  waters	  in	  developing	  countries,	  
such	  as	  Bangladesh,	  have	  been	  found	  to	  harbour	  high	  levels	  of	  ETEC	  (Begum	  et	  al.	  2005;	  Ohno	  
et	   al.	   1997)	  As	   such,	   ETEC	   transmission	   commonly	  occurs	  while	   bathing	   and/or	   using	   this	  
water	  for	  food	  preparation.	  Studies	  in	  communities	  where	  personal	  hygiene,	  education	  and	  
living	  conditions	  are	  poor	  have	  also	   shown	   that	   infection	  can	   spread	   rapidly	  within	   family	  
groups.	  In	  one	  study,	  it	  was	  shown	  that	  ETEC	  spread	  to	  11%	  of	  contacts	  within	  a	  10-­‐day	  study	  
period	   (Black	   et	   al.	   1981).	   Mothers	   of	   the	   family	   have	   also	   been	   identified	   as	   potential	  
resevoirs	  of	  infection	  as	  they	  are	  primary	  food	  handlers	  (Black	  et	  al.	  1981).	  	  	  
In	   visitors	   to	   developing	   countries,	   the	   phenotypes	   of	   ETEC	   strains	   exhibit	   country-­‐
country	  variation.	  For	  example,	  LT-­‐producing	  ETEC	  was	  more	  commonly	  isolated	  from	  visitors	  
to	  Jamaica	  (58%)	  (Jiang	  et	  al.	  2002),	  LT/ST-­‐producing	  strains	  most	  often	  seen	   in	  visitors	  to	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India	  (45%)	  (Jiang	  et	  al.	  2002),	  	  whilst	  ST-­‐producing	  ETEC	  was	  most	  frequently	  isolated	  from	  
visitors	   to	   Kenya	   (51%)	   (Shaheen	   et	   al.	   2003).	   Thus,	   strains	   that	   are	   predominant	   in	   a	  
particular	  country,	  infecting	  children	  and	  contaminating	  water	  and	  food	  sources,	  are	  likely	  to	  
determine	  the	  particular	  ETEC	  strain	  infecting	  the	  travellers	  (Qadri	  et	  al.	  2005).	  
	  
1.3.3.3  Malnutrition	  
Pre-­‐existing	  malnutrition	  is	  considered	  a	  risk	  factor	  for	  ETEC	  infection,	  and	  studies	  have	  
found	  that	  it	  can	  lead	  to	  more	  severe	  infection	  in	  children	  (Mathur	  et	  al.	  1985).	  This	  might	  be	  
due	  to	  the	  immunocompromised	  nature	  of	  the	  host,	  which	  might	  predispose	  the	  individual	  
to	  a	  greater	  bacterial	  load	  (Brown	  2003).	  Micronutrient	  deficiency,	  such	  as	  vitamin	  A	  and	  zinc,	  
is	   also	   common	   in	   developing	   countries.	   Indeed,	   it	   has	   been	   estimated	   that	   40%	   of	  
Bangladeshi	  children	  under	  the	  age	  of	  5	  years	  may	  have	  a	  zinc	  deficiency	  (Qadri	  et	  al.	  2004;	  
Sarker	  et	  al.	  1985),	  which	  has	  been	  associated	  with	  higher	  rates	  of	  morbidity	  due	  to	  diarrhoeal	  
illness	  (Rahman	  et	  al.	  2001;	  Raqib	  et	  al.	  2004).	  	  
	  
1.3.4   Clinical	  presentation	  of	  ETEC	  infection	  
ETEC	   infections	   are	   classically	   associated	   with	   acute	   watery	   diarrhoea,	   which	   can	  
range	  from	  mildly	  symptomatic	  to	  severe	  profuse	  diarrhoea	  (Fleckenstein	  et	  al.	  2010).	  Studies	  
have	   also	   revealed	   the	   existence	   of	   short	   term,	   assymptomatic	   carriers	   of	   the	   bacterium	  
(Qadri	  et	  al.	  2005).	  As	  the	  pathophysiology	  of	  ETEC	  diarrhoea	  is	  essentially	  the	  same	  as	  that	  
caused	  by	  V.	  cholerae,	  the	  two	  infections	  cannot	  be	  distinguised	  on	  clinical	  grounds	  (Sack	  et	  
al.	  1977).	  A	  sudden	  onset	  of	  watery	  stool	  leads	  to	  the	  loss	  of	  fluids	  and	  electrolytes,	  resulting	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in	  rapid	  dehydration	  within	  a	  few	  hours	  (Finkelstein	  et	  al.	  1976;	  Sack	  1975).	  Other	  signs	  and	  
symptoms	  of	  ETEC	  infection	  include	  headache,	  nausea	  and	  vomiting	  (Fleckenstein	  et	  al.	  2010).	  
Usually	  diarrhoea	  lasts	  only	  3-­‐4	  days	  and	  is	  self-­‐limited,	  however,	  some	  patients	  may	  have	  
prolonged	  diarrhoea	  lasting	  a	  week	  or	  more	  (Qadri	  et	  al.	  2005;	  Fleckenstein	  et	  al.	  2010).	  In	  
these	  cases,	  patients	  are	  at	  risk	  of	  severe	  dehydration	  which	  results	   in	  a	  dry	  mouth,	  rapid	  
pulse,	   lethargy,	   decreased	   skin	   turgor,	   decreased	   blood	   pressure,	   muscle	   cramps	   and	  
eventually	  shock	   in	  most	  severe	  froms,	  which	  can	  be	  fatal	  (Centre	  for	  Disease	  Control	  and	  
Prevention	  2004).	  	  	  
	  
1.3.5   Diagnosis	  of	  ETEC	  infection	  	  
As	  ETEC	  infection	  is	  mediated	  by	  the	  release	  of	  its	  enterotoxins,	  effective	  diagnosis	  of	  
disease	  has	  long	  relied	  on	  detection	  of	  either	  LT	  and/or	  ST.	  ST	  was	  initially	  detected	  using	  the	  
rabbit	  ileal	  loop	  model	  (De	  et	  al.	  1956),	  and	  subsequently	  the	  suckling	  mouse	  assay	  (Dean	  et	  
al.	  1972).	  The	  traditional	  bioassay	  for	  LT	  involves	  the	  use	  of	  cell	  culture,	  whereby	  treatment	  
of	   Y1	   adrenal	   cells	   and	   Chinese	   hamster	   ovarian	   (CHO)	   cells	  with	   LT	   results	   in	   LT-­‐specific	  
morphological	   changes	   which	   can	   be	   neutralised	   by	   antitoxin	   (Donta	   and	   Smith	   1974;	  
Guerrant	   et	   al.	   1974).	   These	   diagnostic	   tests	   were	   considered	   gold	   standard	   until	   the	  
development	  of	  simpler	  molecular	  immunoassays.	  	  
During	  recent	  years,	  DNA	  probes	  with	  either	  radioactive	  or	  non-­‐radioactive	  labelling	  
have	  become	  widely	  used	  to	  detect	  the	  presence	  of	  LT	  and	  ST	  genes.	  This	  method	  has	  both	  
high	   sensitivity	   and	   specificity,	   and	   is	   useful	   in	   detecting	   ETEC	   both	   in	   clinical	   and	  
environmental	   samples	   (Echeverria	   et	   al.	   1982;	   Hill	   et	   al.	   1983).	   Other	   commonly	   used	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diagnostic	  tests	  include	  multiplex	  PCR	  which	  can	  simultaneously	  detect	  LT-­‐	  and	  ST-­‐	  producing	  
strains,	  as	  well	  as	  other	  diarrheagenic	  E.	  coli	  	  (Stacy-­‐Phipps	  et	  al.	  1995;	  Toma	  et	  al.	  2003;	  Vidal	  
et	  al.	  2004).	  EIAs	  that	  use	  monoclonal	  antibodies	  to	  detect	  the	  presence	  of	  ST	  and	  LT	  are	  also	  
widely	  used	  (Qadri	  et	  al.	  2005).	  DNA	  probes,	  EIAs	  and	  PCR	  	  methods	  can	  also	  be	  applied	  to	  
detect	  the	  presence	  of	  known	  CFs	  (Qadri	  et	  al.	  2005;	  Steinsland	  et	  al.	  2003).	  
In	  spite	  of	  these	  available	  techniques,	  which	  are	  amenable	  to	  clinical	  laboratories	  in	  
the	  Western	  world,	   there	  are	  still	  no	  simple,	   readily	  available	  diagnostic	   tests	   that	  can	  be	  
performed	   effectively	   in	   minimally	   equipped	   laboratories.	   As	   such,	   many	   laboratories	  
conducting	  research	  of	  diarrhoea	  in	  endemic	  countries	  do	  not	  include	  ETEC	  in	  their	  routine	  
diagnostic	   testing,	   and	   instead,	   special	   referral	   laboratories	   are	   required	   to	   identify	   these	  
bacteria.	  This	  explains	  the	  lack	  of	  epidemiological	  data	  regarding	  ETEC	  infection	  (Qadri	  et	  al.	  
2005).	  	  
	  
1.3.6   Treatment	  of	  ETEC	  infection	  
1.3.6.1  Vaccine	  development	  
There	   is	   much	   interest	   in	   the	   development	   of	   vaccines	   for	   the	   prevention	   of	   ETEC	  
disease.	  However,	  ETEC	  are	  extremely	  heterogenous	  in	  their	  nature,	  and	  at	  present,	  there	  is	  
no	  broadly	  protective	  vaccine	  for	  ETEC	  suitable	  for	  public	  health	  use	  (Zhang	  and	  Sack	  2012).	  
An	  ideal	  broad-­‐coverage	  ETEC	  vaccine	  should	  contain	  fimbrial	  antigens	  representative	  of	  the	  
most	  prevalent	  ETEC	  groups.	  Unfortunately,	  the	  large	  diversity	  of	  ETEC	  serotypes,	  particularly	  
with	  regard	  to	  O	  and	  H	  antigens,	  renders	  such	  antigens	  less	  attractive	  as	  vaccine	  components	  
(Zhang	  and	  Sack	  2012).	  Instead,	  vaccines	  have	  focussed	  on	  combining	  the	  most	  prevalent	  CFs	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to	  achieve	  broad	  coverage.	  CFs	  are	  often	  combined	  with	  either	  cholera	  toxin	  or	  LT	  toxoids,	  
such	  as	  non-­‐toxigenic	  B	   subunit	   LTB	  or	   LT	  mutants,	  which	   retain	  both	   their	  anti-­‐toxin	  and	  
inherent	   adjuvant	   properties	   (Fleckenstein	   et	   al.	   2014).	   It	   has	   been	   postulated	   that	   a	  
multivalent	   vaccine	   containing	   CFA/I	   and	   CS1-­‐CS6	   in	   conjunction	  with	   an	   LT	   toxoid	  might	  
provide	   protection	   against	   80-­‐90%	   of	   ETEC	   strains	   in	  most	   geographic	   areas	   (Qadri	   et	   al.	  
2005).	  A	  number	  of	  different	  strategies	  have	  been	  evaluated	  for	  the	  delivery	  of	  ETEC	  fimbrial	  
antigens	   and	   toxoids	   to	   the	   human	   immune	   system,	  which	   include	   killed	  whole	   cell	   ETEC	  
vaccines	  (Savarino	  et	  al.	  1998;	  Tobias	  and	  Svennerholm	  2012)	  and	  live	  attenuated	  oral	  ETEC	  
vaccines	   (Turner	   et	   al.	   2011),	   as	   well	   as	   vaccines	   that	   contain	   pure	   CF	   and	   enterotoxoid	  
preparations	   (Katz	   et	   al.	   2003).	   To	   date,	   these	   approaches	   have	   not	   yielded	   a	   broadly	  
protective	   vaccine	   and	   further	   research	   is	   therefore	   needed	   to	   accelerate	   development	  
(Fleckenstein	  et	  al.	  2014).	  	  
	  
1.3.6.2  Antimicrobials	  
The	  use	  of	  antibiotic	  therapy	  to	  treat	  ETEC	  infection	  is	  effective.	  Indeed,	  several	  studies	  
have	  illustrated	  that	  it	  can	  reduce	  both	  the	  duration	  and	  severity	  of	  ETEC-­‐mediated	  diarrhoea	  
(Black	   et	   al.	   1982;	  Merson	   et	   al.	   1980).	   However,	   in	   endemic	   regions,	   the	   application	   of	  
antimicrobial	   therapy	   is	   limited	   by	   the	   lack	   of	   simple	   laboratory	   tests	   in	   place	   to	   rapidly	  
diagnose	   ETEC	   infection.	   In	   regions	   where	   sanitation	   and	   water	   supplies	   are	   inadequate,	  
diarrhoeal	   disease	   can	   result	   from	   infection	   with	   a	   range	   of	   different	   bacterial	   and	   viral	  
agents,	   which	   all	   present	  with	   similar	   clinical	   symptoms	   (Baldi	   et	   al.	   2009).	   Furthermore,	  
effective	  agents	  might	  not	  be	  widely	  available	  where	  incidence	  rates	  are	  high.	  Thus,	  antibiotic	  
treatment	   is	  not	   amenable	   to	  most	   cases	  of	   ETEC	   infection,	   and	   instead,	  oral	   rehydration	  
therapy	  is	  considered	  more	  important	  in	  managing	  the	  disease	  (Nataro	  and	  Kaper	  1998).	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Antibiotic	   therapy	   is	   more	   appropriate	   in	   the	   treatment	   of	   traveller’s	   diarrhoea,	   of	  
which	   ETEC	   is	   known	   to	   be	   the	  most	   frequent	   pathogen.	   The	   antimicrobial	   treatment	   of	  
diarrhoea	  has	  changed	  over	  the	  years	  due	  to	  increasing	  antibiotic	  resistance	  of	  ETEC	  strains	  
(Nataro	  and	  Kaper	  1998).	  At	  present,	  it	  is	  recommended	  that	  adult	  travellers	  presenting	  with	  
ETEC	  infection	  undergo	  a	  short	  course	  of	  ciprofloxacin	  (500	  mg	  every	  12	  hours	  for	  one	  day)	  
or	  rifaximin	  (200	  mg	  twice	  a	  day	  for	  three	  days)	  (Hong	  and	  Kim	  2011).	  Azithromycin	  is	  also	  
used	  to	  treat	  ETEC	  infection	  in	  children	  (10	  mg	  per	  kg	  per	  day	  for	  two	  days)	  (Qadri	  et	  al.	  2005).	  
However,	  if	  traveller’s	  diarrhoea	  occurs	  whilst	  the	  individual	  is	  still	  visiting	  the	  affected	  region,	  
antimicrobial	  treatment	  is	  usually	  not	  given	  because	  diagnosis	  is	  not	  easily	  made	  and	  there	  
may	  be	  a	  low	  availability	  of	  microbial	  agents	  (Nataro	  and	  Kaper	  1998).	  Therefore,	  travellers	  
should	  also	  be	  aware	  of	  the	  importance	  of	  oral	  rehydration	  solutions	  in	  managing	  infection.	  	  
	  
1.3.6.3  Nutritional	  therapy	  
Studies	  have	  indicated	  that	  malnutrition	  is	  a	  likely	  predisposing	  factor	  to	  ETEC	  infection.	  
Nutritional	  therapy	  is	  therefore	  an	  integral	  part	  of	  ETEC	  treatment,	  particularly	  with	  respect	  
to	  children	  and	  infants.	  Indeed,	  it	  has	  been	  shown	  that	  breastfeeding	  decreases	  the	  severity	  
and	  incidence	  of	  ETEC	  infections	  (Clemens	  et	  al.	  1997;	  Long	  et	  al.	  1994),	  which	  might	  be	  due	  
to	  the	  presence	  of	  secretory	  immunoglobulin	  A	  (IgA)	  antibodies	  to	  CFs	  and	  enterotoxins	  in	  
mothers’	  breast	  milk	  from	  endemic	  countries	  	  (Cruz	  et	  al.	  1991;	  Long	  et	  al.	  1994).	  Whilst	  not	  
yet	   studied	   directly	   in	   ETEC,	   studies	   have	   also	   demonstrated	   that	   zinc	   supplementation	  
increases	  the	  adaptive	  immune	  response	  to	  cholera	  vaccination	  in	  children	  and	  adults	  (Albert	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et	  al.	  2003;	  Karlsen	  et	  al.	  2003;	  Qadri	  et	  al.	  2004),	  as	  well	  as	  in	  children	  with	  shigellosis	  (Raqib	  
et	  al.	  2004).	  	  
	  
1.3.6.4  Rehydration	  therapy	  
As	   patients	   infected	   with	   ETEC	   associated	   diarrhoea	   often	   suffer	   with	   dehydration,	  
which	  can	  be	   fatal,	   rehydration	   is	  extremely	   important.	  Patients	  suffering	  dehydration	  are	  
administered	  with	  oral	   rehydration	   solutions,	  which	  are	  used	  until	   the	  diarrhoeal	   episode	  
ceases.	   For	   patients	   with	   severe	   dehydration,	   intravenous	   fluids	   are	   administered	   until	  
symptoms	  disappear	  which	  is	  then	  followed	  by	  oral	  rehydration	  therapy	  (Centre	  for	  Disease	  
Control	  and	  Prevention	  2004)	  .	  However,	  it	  must	  be	  remembered	  that	  rehydration	  therapy	  
does	   not	   actually	   treat	   the	   cause	   of	   infection,	   but	   instead	   only	  manages	   the	   symtoms	   of	  
disease.	  	  
	  
1.3.6.5  Improved	  sanitation	  and	  drinking	  water	  
The	   long	   term	   prevention	   of	   ETEC	   is	   clearly	   related	   to	   improvements	   in	   sanitation	  
systems	   and	   water	   supply,	   meaning	   that	   individuals	   would	   be	   less	   likely	   to	   consume	  
contaminated	  food	  products	  and	  water.	  However,	  it	  is	  likely	  to	  take	  a	  long	  time	  to	  implement	  
such	  drastic	  improvements	  on	  a	  large	  scale	  basis.	  For	  example,	  it	  has	  been	  estimated	  that	  it	  
would	  take	  US$200	  billion	  to	  make	  the	  improvements	  neccesary	  to	  prevent	  faecally	  spread	  
diseases	  in	  South	  America	  alone	  (Qadri	  et	  al.	  2005).	  Other	  improvements	  are	  taking	  place,	  but	  
on	  a	  much	  smaller	  scale.	  These	  include	  building	  safe-­‐water	  tube	  wells,	  building	  or	  improving	  
latrines,	  as	  well	  as	  the	  chlorination,	  filtration	  or	  heating	  of	  drinking	  water	  (Quick	  et	  al.	  1996).	  
These	  attempts	  to	  prevent	  transmission	  are	  effective,	  but	  only	  at	  a	  local	  scale.	  Therefore,	  it	  is	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of	  great	  importance	  to	  develop	  alternative	  therapeutic	  treatments	  to	  reduce	  the	  public	  health	  
burden	  from	  ETEC.	  	  	  
	  
1.3.7   Animal	  models	  of	  ETEC	  infection	  
It	   has	   been	   suggested	   that	   the	   development	   of	   vaccines	   and	   other	   therapies	   to	   treat	  
human	  ETEC	  infection	  has	  largely	  been	  hampered	  by	  a	  lack	  of	  viable	  small-­‐animal	  models.	  A	  
number	  of	  animal	  models	  have	  been	  used	  in	  previous	  studies	  of	  ETEC,	  which	  include	  infant	  
and	  adult	  mice,	  rat,	  rabbits	  and	  pigs	  (Allen	  et	  al.	  2006).	  However,	  major	  drawbacks	  have	  been	  
reported	  in	  these	  animal	  models,	  such	  as	  difficulties	  in	  utilisation,	  as	  well	  as	  animals	  requiring	  
anaethesia	  and/or	  significant	  surgical	  manipulation.	   In	  addition,	  some	  animal	  models	  have	  
not	  been	  thoroughly	  evaluated	  for	  their	  viability	  (Allen	  et	  al.	  2006).	  	  	  
	  
1.4  ULCERATIVE	  COLITIS	  –	  A	  CHRONIC	  DIARRHOEAL	  DISEASE	  
Alongside	   Crohn’s	   disease	   (CD),	   UC	   is	   a	   major	   form	   of	   IBD,	   characterised	   by	   chronic	  
inflammation	  that	  extends	  proximally	  from	  the	  rectum.	  First	  characterised	  in	  the	  1800s,	  UC	  is	  
a	  cause	  of	  significant	  morbidity	  worldwide	  and	  its	   incidence	  and	  prevalence	  appears	  to	  be	  
increasing	  with	  time.	  Patients	  with	  UC	  typically	  experience	  episodes	  of	  bloody	  diarrhoea	  with	  
or	  without	  mucus,	  abdominal	  pain,	  fever	  and	  weight	  loss	  (Arors	  and	  Shen,	  2015).	  Due	  to	  the	  
relatively	  unknown	  aetiology	  of	  UC,	  as	  well	  as	  its	  high	  risk	  of	  recurrence	  and	  poor	  prognosis,	  
the	  disease	  is	  a	  clinical	  challenge	  in	  terms	  of	  treatment.	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1.4.1   Pathogenesis	  of	  UC	  
UC	   is	   thought	   to	   result	   from	   an	   aberrant	   intestinal	   immune	   response	   to	   bacterial	  
microbiota	   in	   a	   genetically	   susceptible	   host	   (Cooney	   and	   Jewell	   2009).	   The	   exact	  
pathophysiology	   of	   UC	   is	   not	   clearly	   understood,	   however,	   it	   is	   likely	   that	   a	   complex	  
interaction	  of	  genetic,	  environmental	  and	  microbial	  factors	  play	  a	  role	  in	  disease	  development	  
and	  progression.	  	  
1.4.1.1  Genetic	  factors	  
Large	  scale	  population	  studies	  and	  twin	  studies	  have	  suggested	  that	  there	  is	  a	  significant	  
heriditary	   component	   in	   IBD.	  However,	   these	   studies	   suggest	   that	   such	  genetic	   influences	  
might	  play	  a	  greater	  role	  in	  CD	  than	  in	  UC.	  The	  relative	  risk	  of	  developing	  IBD	  for	  first-­‐degree	  
relatives	  of	  a	  CD	  patient	  is	  estimated	  to	  be	  5%	  in	  non	  Jewish	  and	  8%	  of	  Jewish	  patients,	  whilst	  
the	   corresponding	   relative	   risk	  of	  UC	   is	   lower,	   at	   1.6%	  and	  5.2%,	   respectively	   (Yang	   et	   al.	  
1993).	   Similar	   results	   have	   been	   found	   in	   twin	   studies,	   which	   have	   reported	   stronger	  
concordance	  rates	  with	  CD	  (20-­‐50%	  for	  monozygotic	  twins,	  10%	  for	  dizygotic	  twins)	  than	  with	  
UC	  (16%	  and	  4%,	  respectively)	  (Halfvarson	  et	  al.	  2003;	  Orholm	  et	  al.	  2000;	  Thompson	  et	  al.	  
1996).	  
Due	  to	  advances	   in	  genetic	  testing	  and	  analysis	  technologies,	  a	   large	  number	  of	   IBD-­‐
associated	  susceptibility	  loci	  have	  now	  been	  identified.	  Thus	  far,	  there	  are	  a	  total	  of	  163	  IBD-­‐
associated	  loci,	  of	  which	  110	  are	  associated	  with	  both	  diseases	  (Waterman	  et	  al.	  2011;	  Jostins	  
et	  al.	  2012),	  as	  well	  as	  30	  loci	  specific	  to	  CD	  and	  23	  loci	  specific	  to	  UC	  (Zhang	  and	  Li	  2014;	  
Thompson	  and	  Lees	  2011).	  Interestingly,	  the	  three	  strongest	  gene	  associations	  reported	  are	  
CD-­‐specific	  (NOD2/CARD15,	  ATG16L1	  and	  IRGM),	  again	  suggesting	  that	  genetic	  factors	  might	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play	   a	  more	   important	   role	   in	  CD	  pathogenesis	   (Cho	  2008).	  Despite	   this,	   a	   number	  of	  UC	  
specific	   loci	   have	   been	   implicated	   in	   dysfunction	   of	   the	   intestinal	  mucosal	   barrier,	   which	  
include	   ECM1,	   HNF4A,	   CHD1	   and	   LAMB1	   (Thompson	   and	   Lees	   2011).	   Several	   other	  
susceptibility	  loci	  linked	  with	  immune	  system-­‐mediated	  diseases	  are	  also	  associated	  with	  UC,	  
particularly	  HLA-­‐DR	  and	  genes	  that	  encode	  cytokine	  and	  inflammatory	  markers,	  such	  as	  IL10,	  
IL7R,	  IL23R	  and	  IFN-­‐ϒ(Danese	  and	  Fiocchi	  2011;	  Thompson	  and	  Lees	  2011).	  	  
	  
1.4.1.2  Environmental	  factors	  
Whilst	   studies	   have	   identified	   that	   genetic	   factors	   increase	   an	   individual’s	  
predisposition	   to	  UC,	   it	   appears	   this	   alone	   is	  not	   sufficient	   for	   the	  onset	  of	   inflammation.	  
Indeed,	  evidence	  suggests	  that	  numerous	  environmental	  factors	  also	  play	  an	  important	  role	  
in	   disease	   pathogenesis	   (Ananthakrishnan	   2015;	   Molodecky	   and	   Kaplan	   2010).	   Smoking	  
remains	   the	   most	   widely	   studied	   trigger	   of	   IBD,	   with	   surprising	   results.	   Studies	   have	  
demonstrated	  that	  whilst	  smoking	  contributes	  to	  a	  two-­‐fold	  increased	  risk	  of	  CD	  and	  greater	  
likelihood	  of	  aggressive	  disease	  (Cosnes	  2004;	  Cosnes	  2008),	  it	  confers	  protection	  against	  UC	  
(Higuchi	  et	  al.	  2012;	  Mahid	  et	  al.	  2006).	  The	  effect	  of	  diet	  on	  the	  development	  of	  IBD	  remains	  
a	  challenging	  association	  to	  monitor	  due	  to	  its	  time-­‐varying	  nature,	  as	  well	  as	  the	  difficulty	  in	  
tracking	  it	  through	  the	  course	  of	  childhood	  and	  adult	  life	  (Ananthakrishnan	  2015).	  However,	  
several	  large	  cohort	  studies	  in	  the	  United	  States	  and	  Europe	  have	  shown	  that	  diet	  is	  likely	  to	  
be	   an	   important	   IBD	   factor.	   In	   a	   large	   prospective	   cohort	   study	   including	   170,776	   female	  
registered	  nurses,	  followed	  over	  26	  years,	  it	  was	  shown	  that	  intake	  of	  fruit	  fibre	  in	  the	  highest	  
quintile	  (median	  24	  grams	  per	  day)	  was	  associated	  with	  a	  significant	  reduction	  in	  CD	  risk	  (HR	  
0.59,	  95%,	  CI	  0.39-­‐0.90),	  however,	  this	  had	  no	  effect	  on	  UC	  (Ananthakrishnan	  et	  al.	  2013).	  In	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addition,	  it	  has	  been	  demonstrated	  that	  a	  diet	  high	  in	  long-­‐chain	  poly	  unsaturated	  fatty	  acids	  
(PUFA)	  is	  associated	  with	  a	  reduced	  risk	  of	  UC	  (HR	  0.72,	  95%	  CI	  0.51-­‐1.01)	  whilst	  high	  trans-­‐
unsaturated	  fatty	  acid	  intake	  is	  associated	  with	  a	  greater	  UC	  incidence	  risk	  (HR	  1.34,	  95%	  CI	  
0.94	  –	  1.92).	  However,	  neither	  total	  fat	  nor	  specific	  fatty	  acid	   intake	  has	  been	  reported	  to	  
have	  an	  effect	  on	  the	  incidence	  of	  CD	  (Ananthakrishnan	  et	  al.	  2014).	  Studies	  have	  also	  shown	  
that	  Vitamin	  D	  deficiency	   is	   common	   in	   IBD	  patients,	   and	   is	   associated	  with	   an	   increased	  
susceptibility	  for	  the	  disease	  (Leslie	  et	  al.	  2008;	  Zhang	  and	  Li	  2014).	  The	  use	  of	  medication	  can	  
too	  be	  a	  risk	  factor	  for	  the	  development	  of	  IBD;	  for	  example,	  frequent	  use	  of	  non-­‐steroidal	  
anti-­‐inflammatory	   drugs	   (NSAIDs)	   is	   associated	  with	   an	   increased	   risk	   of	   both	  UC	   and	   CD	  
(Ananthakrishnan	  et	  al.	  2012).	  Other	  potential	  IBD	  risk	  factors	  include	  elevated	  stress	  (Zhang	  
and	  Li	  2014)	  and	  air	  pollution	  (Kaplan	  et	  al.	  2010),	  which	  have	  both	  been	  shown	  previously	  to	  
correlate	  with	  UC	  development.	  	  
1.4.1.3  Microbial	  factors	  
Predisposition	  to	  the	  genetic	  and	  environmental	   factors	  described	  above	  can	   lead	  to	  
alterations	  in	  barrier	  function	  of	  the	  intestinal	  mucosa,	  as	  well	  as	  changes	  in	  the	  intestinal	  


















1.4.1.3.1   Defects	  in	  barrier	  function	  
The	  first	  physical	  barrier	  that	  intestinal	  bacteria	  come	  into	  contact	  with	  at	  the	  mucosal	  
surface	  is	  represented	  by	  the	  mucus	  layer	  (Torres	  and	  Rios	  2008).	  Colonic	  mucus	  is	  secreted	  
by	  goblet	  cells,	  and	  is	  mainly	  composed	  of	  secretory	  MUC2	  mucin.	  Upon	  secretion	  from	  goblet	  
cells,	   the	   mucus	   expands	   and	   rapidly	   forms	   a	   stratified,	   dense	   inner	   layer,	   close	   to	   the	  
epithelium.	  Further	  from	  the	  epithelial	  surface,	  a	  more	  soluble	  and	  less	  organised	  mucus	  layer	  
exists,	  and	  studies	  have	  shown	  that	  this	  is	  where	  gut	  commensal	  bacteria	  reside	  (Johansson	  
et	  al.	  2014).	  	  
Figure	  1.5.	  Summary	  of	  the	  pathogenesis	  of	  IBD.	  Adapted	  from	  (Simpson	  
and	  Campbell	  2015)	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It	  has	  previously	  been	  hypothesised	  that	  defects	  in	  the	  mucus	  layer	  might	  contribute	  
towards	  the	  pathogenesis	  of	  UC.	  Evidence	  to	  support	  this	  includes	  the	  depletion	  of	  goblet	  cells	  
in	  UC	  patients,	   as	  well	   as	   the	  development	  of	   spontaneous	   colitis	   in	  MUC2	  deficient	  mice	  
(Johansson	   2014).	   	   The	   erosion	   of	   the	   normally	   continuous	   colonic	   adherent	  mucus	   layer	  
results	  in	  an	  increased	  interaction	  between	  bacteria	  and	  the	  intestinal	  epithelium.	  One	  study	  
in	  particular	  reported	  that	  in	  the	  absence	  of	  MUC2,	  bacteria	  were	  able	  to	  directly	  adhere	  and	  
interact	   with	   intestinal	   epithelial	   cells	   (Geremia	   et	   al.	   2014).	   Bacterial	   antigens	   can	   then	  
interact	  with	  toll-­‐like	  receptors	  (TLRs)	  or	  nucleotide	  oligomerisation	  domain	  (NOD)	  receptors	  
on	  dendritic	  cells	  (DCs)	  and	  intestinal	  epithelial	  cells,	  which	  triggers	  the	  activation	  of	  the	  innate	  
and	  adaptive	  immune	  responses	  (Ordas	  et	  al.	  2012;	  Subramanian	  et	  al.	  2008).The	  activation	  
of	   TLRs	   results	   in	   the	   subsequent	   activation	   of	   NF-­‐κβ	   signalling,	   and	   release	   of	   pro-­‐
inflammatory	  cytokines	  such	  as	  TNF-­‐α,	  IL-­‐12,	  IL-­‐23,	  IL-­‐	  6	  and	  IL-­‐1β.	  It	  has	  been	  shown	  these	  
cytokines	  are	  involved	  in	  the	  synthesis	  of	  IL-­‐8,	  which	  is	  a	  potent	  neutrophil	  chemoattractant	  
(Mitsuyama	   et	   al.	   1994).	   Infiltration	   by	   neutrophils	   is	   a	   striking	   histological	   feature	   in	   the	  
lesions	   of	   active	   UC,	   and	   they	   have	   been	   shown	   to	   perpetuate	   the	   cycle	   of	   inflammation	  
typically	  seen	  in	  the	  disease	  (Mitsuyama	  et	  al.	  1994).	  	  
In	   addition,	   IBD	   patients	   exhibit	   an	   increase	   in	   the	   permeability	   of	   the	   intestinal	  
epithelium	  due	  to	  a	  redistribution	  of	  tight	  junctions	  between	  intestinal	  epithelial	  cells	  (Zhang	  
and	   Li	   2014).	   Impaired	   epithelial	   adhesion	   processes	   have	   also	   been	   implicated	   in	   UC	  
pathogenesis,	   and	  a	  number	  of	   genes	  encoding	  proteins	   involved	   in	   key	   roles	   in	   epithelial	  
adhesion	   have	   been	   identified,	   including	   hepatocyte	   nuclear	   factor-­‐4α,	   laminin-­‐β1	   and	   E-­‐
cadherin	  (Zhang	  and	  Li	  2014)	  	  Impaired	  cell	  adhesion,	  as	  well	  as	  defective	  regulation	  of	  tight	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junctions,	   can	   lead	   to	   an	   increase	   in	   the	   permeability	   of	   the	   intestinal	   epithelium	   that	   is	  
concurrent	  with	  UC	  disease.	  	  
	  
1.4.1.3.2   Role	  of	  the	  intestinal	  microbiota	  
Both	   quantitative	   and	   qualitative	   changes	   in	   the	  microbial	   composition	   have	   been	  
reported	  in	  IBD	  (Manichanh	  et	  al.	  2012).	  Many	  studies	  have	  examined	  the	  gut	  flora	  in	  CD	  and	  
UC,	   in	   both	   inflamed	   and	   non-­‐inflamed	   segments,	   and	   found	   that	   there	   is	   a	   significantly	  
reduced	  biodiversity	  in	  the	  faecal	  microbiome	  of	  these	  disease	  conditions	  in	  comparison	  to	  
healthy	  controls	  	  (Frank	  et	  al.	  2007;	  Hold	  et	  al.	  2014;	  Lepage	  et	  al.	  2011)	  Researchers	  have	  
previously	   detected	   fewer	   Bacteroides	   and	   Clostridium	   spp.	   in	   the	   faecal	   samples	   of	   UC	  
patients,	  with	  higher	  levels	  of	  Enterococcus	  spp.	  and	  Gammaproteobacteria	  (Nemoto	  et	  al.	  
2012).	  Frank	  and	  colleagues	  used	  culture-­‐independent	  rRNA	  sequence	  analysis	  of	  GI	  tissue	  
samples	   obtained	   from	   CD	   patients,	   UC	   patients	   and	   non-­‐IBD	   controls,	   where	   they	   too	  
detected	  reduced	  Bacteroidetes	  and	  Firmicutes	  in	  a	  subset	  of	  UC	  samples	  (Frank	  et	  al.	  2007).	  
Similar	   results	   have	   been	   illustrated	   in	   a	   twin	   study	   by	   Lepage	   and	   colleagues,	   where	  
microbiota	  profiling	  of	  mucosal	  biopsies	  revealed	  that	  UC	  patients	  had	  dysbiosis	  characterised	  
by	  a	  reduction	  in	  the	  number	  of	  Bacteroidetes,	  with	  an	  increase	  in	  the	  level	  of	  Actinobacteria	  
and	  Proteobacteria	  (Lepage	  et	  al.	  2011).	  Other	  studies	  have	  demonstrated	  a	  reduction	  in	  the	  
level	   of	   beneficial	   butyrate	   producing	   bacteria	   in	   UC	   patients,	   which	   includes	   Roseburia	  
hominis	  and	  Faecalibacterium	  prausnitzii	  (Kumari	  et	  al.	  2013;	  Sokol	  et	  al.	  2006;	  Sokol	  et	  al.	  
2009).	  Indeed,	  Varela	  and	  colleagues	  found	  that	  low	  levels	  of	  F.	  prausnitzii	  were	  associated	  
with	  short-­‐term	  UC	  remission	  and	  relapse,	  whilst	  levels	  increased	  during	  remission	  (Varela	  et	  
al.	  2013).	  Furthermore,	  a	  reduction	  in	  SCFA-­‐producing	  Firmicutes	  has	  also	  been	  shown	  to	  be	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associated	  with	  an	  increased	  abundance	  of	  opportunistic	  pathogens	  including	  Fusobacterium	  
spp.,	  Helicobacter	  spp.,	  Campylobacter	  spp.	  and	  Clostridium	  difficile	  (Rajilic-­‐Stojanovic	  et	  al.	  
2013).	  An	  increased	  presence	  of	  these	  enteric	  bacteria	  in	  the	  colonic	  mucosa	  of	  UC	  patients	  
has	   also	   been	   reported	   elsewhere,	   where	   they	   have	   been	   implicated	   in	   the	   induction	   of	  
inflammation	  (Chen	  et	  al.	  2014a).	  
Several	  independent	  studies	  have	  now	  also	  reported	  a	  specific	  increase	  of	  adherent	  
and	  invasive	  E.	  coli	  (AIEC)	  in	  CD	  (Darfeuille-­‐Michaud	  et	  al.	  1998;	  Martin	  et	  al.	  2004)	  as	  well	  as	  
in	  UC	  (Kotlowski	  et	  al.	  2007;	  Mylonaki	  et	  al.	  2005;	  Sokol	  et	  al.	  2006;	  Swidsinski	  et	  al.	  2002)	  	  
and	  colon	  cancer	  (Swidsinski	  et	  al.	  1998).	  Similar	  E.	  coli	  strains	  have	  also	  been	  shown	  to	  be	  
associated	  with	  granulomatous	  colitis	  in	  boxer	  dogs	  (Simpson	  et	  al.	  2006).	  AIEC	  are	  present	  
in	   both	   non-­‐inflamed	   and	   inflamed	   mucosa	   (Martin	   et	   al.	   2004;	   Kotlowski	   et	   al.	   2007),	  
suggesting	  that	  they	  are	  not	  just	  recruited	  as	  a	  consequence	  of	  inflammation,	  but	  instead	  play	  
an	  important	  role	  in	  the	  pathogenesis	  of	  disease.	  Although	  there	  is	  evidence	  of	  tissue	  invasion	  
by	  E.	  coli	  in	  CD,	  whereby	  AIEC	  have	  been	  identified	  within	  mucosal	  macrophages	  and	  inside	  
granulomata	  (Ryan	  et	  al.	  2004),	  there	  is	  a	  lack	  of	  evidence	  to	  suggest	  that	  they	  invade	  the	  
mucosa	  in	  UC	  (Martin	  et	  al.	  2004).	  Instead,	  it	  is	  thought	  that	  mucosally	  associated	  UC	  E.	  coli	  
mediate	  IL-­‐8	  release	  from	  colonic	  epithelial	  cells	  via	  an	  interaction	  between	  E.	  coli	  flagellin	  
and	  TLR5	  (Subramanian	  et	  al.	  2008).	  Flagellin	  receptor	  TLR5	  is	  expressed	  on	  the	  basolateral	  
aspect	  of	  intestinal	  epithelial	  cells.	  As	  such,	  in	  the	  healthy	  intestinal	  mucosa,	  it	  is	  unlikely	  that	  
bacterial	  components	  could	  interact	  with	  TLR5	  without	  direct	  invasion	  of	  UC	  E.	  coli.	  However,	  
impaired	  barrier	  function	  in	  UC	  is	  likely	  to	  be	  sufficient	  to	  allow	  flagellin	  to	  access	  basolateral	  
TLR5	  in	  vivo,	  triggering	  an	  aberrant	  immune	  response	  (Subramanian	  et	  al.	  2008).	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1.4.2   Epidemiology	  of	  UC	  
1.4.2.1  Incidence	  rates	  
The	  occurrence	  of	  UC	  has	  increased	  on	  a	  worldwide	  basis	  in	  recent	  years.	  IBD	  is	  common	  
in	  the	  industrialised	  world,	  particularly	  with	  respect	  to	  North	  America	  and	  Western	  Europe.	  
However,	   reports	   suggest	   that	   incidence	   rates	   are	   also	   beginning	   to	   increase	   in	   some	  
developing	  countries	  such	  as	  Asia,	  Latin	  America	  and	  Eastern	  Europe	  (da	  Silva	  et	  al.	  2014).	  
The	  incidence	  rate	  of	  UC	  may	  vary	  from	  0.5	  to	  31.5	  per	  100,000	  people	  each	  year,	  depending	  
on	  the	  studied	  population	  (Burisch	  and	  Munkholm	  2015).	  The	  majority	  of	  UC	  patients	  are	  in	  
the	  age	  group	  of	  30-­‐40	  years	  at	  diagnosis	  (Cosnes	  et	  al.	  2011).	  UC	  is	  typically	  less	  common	  in	  
children,	   but	   recent	   studies	   have	   illustrated	   an	   increase	   in	   the	   number	   of	   cases	   seen	   in	  
pediatric	  patients	  and	  adolescents.	  For	  example,	  Pant	  and	  colleagues	  demonstrated	  that	  in	  
the	  United	  States,	  between	  2000	  and	  2009,	  the	  number	  of	  pediatric	  hospitalisations	  due	  to	  
UC	  increased	  from	  4171	  to	  7127	  per	  year	  (Pant	  et	  al.	  2013).	  Similar	  results	  have	  also	  been	  
observed	   in	   the	   UK;	   in	   Scotland,	   UC	   incidence	   rates	   in	   individuals	   under	   16	   years	   of	   age	  
increased	  from	  1.59	  per	  100,000	  per	  year	  in	  1990-­‐1995	  to	  2.06	  per	  100,000	  per	  year	  in	  2003-­‐
2008	  (95%	  CI:	  1.70-­‐2.47;	  P	  =	  0.023)	  (Henderson	  et	  al.	  2012).	  Gender	  studies	  have	  reported	  
mixed	   findings,	   but	   most	   have	   illustrated	   male	   predominance	   or	   an	   equal	   distribution	  
between	  genders	  (Cosnes	  et	  al.	  2011).	  
	  
1.4.3   Clinical	  presentation	  of	  UC	  
The	   hallmark	   clinical	   symptom	   of	   UC	   is	   bloody	   diarrhoea,	   with	   or	  without	  mucus.	  
Depending	   on	   the	   severity	   of	   disease,	   diarrhoea	   can	   be	   accompanied	   by	   abdominal	   pain,	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urgency,	  tenesmus,	  fever,	  malaise	  and	  weight	  loss	  (Feuerstein	  and	  Cheifetz	  2014).	  The	  onset	  
of	   disease	   is	   typically	   gradual,	   whilst	   the	   clinical	   course	   is	   marked	   by	   exacerbations	   and	  
remissions	   that	   may	   occur	   spontaneously	   in	   response	   to	   treatment	   changes	   or	   illness	  
(Kornbluth	  et	  al.	  2010;	  Danese	  and	  Fiocchi	  2011).	  	  
The	  severity	  of	  UC	  can	  be	  characterised	  as	  mild,	  moderate,	  severe	  or	  fulminant.	  Mild	  
disease	   is	   characterised	   as	   fewer	   than	   4	   stools	   (with	   or	   without	   blood)	   per	   day	   without	  
systemic	   signs	   of	   toxin	   effects	   and	   normal	   inflammatory	   markers.	   Moderate	   disease	   is	  
described	   as	   4	   or	  more	   bloody	   stools	   per	   day	  with	  minimal	   signs	   of	   toxic	   effects.	   Severe	  
disease	  is	  classified	  as	  more	  than	  6	  bloody	  stools	  per	  day	  with	  some	  evidence	  of	  toxic	  effects,	  
which	   include	   fever,	   tachycardia,	   anaemia	   or	   elevated	   inflammatory	   markers.	   Fulminant	  
disease	   is	   classified	  as	  more	   than	  10	  bloody	  stools	  and	  clear	  clinical	   signs	  of	   toxin	  effects,	  
including	  abdominal	  distension,	  severe	  loss	  of	  blood	  requiring	  transfusion	  and	  colonic	  dilation	  
(Feuerstein	   and	   Cheifetz	   2014).	   UC	   can	   also	   be	   categorised	   on	   the	   basis	   of	   the	   extent	   or	  
location	   of	   disease;	   proctitis	   (inflammation	   limited	   to	   the	   rectum),	   proctosigmoiditis	  
(inflammation	  affecting	  the	  rectum	  and	  sigmoid	  colon),	  left	  sided	  colitis	  (inflammation	  that	  
does	  not	  extend	  beyond	  the	  splenic	  flexure)	  and	  extensive	  colitis	  (inflammation	  that	  extends	  
beyond	  splenic	  flexure)	  (Danese	  and	  Fiocchi	  2011;	  Kornbluth	  et	  al.	  2010).	  	  
In	  addition,	  UC	  is	  also	  associated	  with	  a	  number	  of	  extraintestinal	  manifestations	  that	  
can	  primarily	  affect	  the	  skin,	   joints,	  eyes	  and	  liver	  (Feuerstein	  and	  Cheifetz	  2014).	  Arthritis	  
represents	  the	  most	  common	  extraintestinal	  manifestation	  affecting	  joints	  (Dorofeyev	  et	  al.	  
2009),	  whilst	  erythema	  nodosum	  and	  pyoderma	  gangrenosum	  are	  the	  two	  most	  common	  skin	  
lesions	  associated	  with	  UC	  (Feuerstein	  and	  Cheifetz	  2014;	  Huang	  et	  al.	  2012).	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1.4.4   Diagnosis	  of	  UC	  
An	   accurate	   diagnosis	   of	  UC	   is	  made	   on	   the	   basis	   of	   typical	   symptoms,	   as	  well	   as	  
endoscopic	  evidence	  of	  the	  extent	  and	  severity	  of	  colonic	  inflammation	  (Dignass	  et	  al.	  2012;	  
Kornbluth	   et	   al.	   2010).	   Colonoscopy	   reveals	  mucosal	   changes	   characteristic	   of	   UC,	   which	  
include	  loss	  of	  vascular	  pattern,	  granularity	  and	  friability.	  These	  changes	  typically	  affect	  the	  
distal	  rectum	  and	  proceed	  proximally	  in	  a	  symmetric	  and	  continuous	  fashion	  to	  involve	  all	  or	  
part	  of	  the	  colon.	  Erosions	  or	  micro-­‐ulcerations	  are	  also	  evident	  in	  moderate	  disease,	  whereas	  
shallow	  ulcerations	  with	  spontaneous	  bleeding	  are	  observed	  in	  severe	  cases	  (Simpson	  and	  
Papadakis	  2008;	  Kornbluth	  et	  al.	  2010).	  Colonoscopy	  aids	  in	  differentiating	  UC	  from	  CD,	  which	  
is	  characterised	  by	  a	  cobblestone-­‐patterned	  mucosa,	  rectal	  sparing,	  skip	  lesions	  and	  apthous	  
ulcers	  (Danese	  and	  Fiocchi	  2011).	  
Histological	   findings	   obtained	   from	   biopsy	   specimens	   are	   commonly	   used	   to	  
distinguish	  UD	  from	  infectious	  colitis	  or	  CD	  (Kornbluth	  et	  al.	  2010).	  Typically,	  UC	  inflammation	  
is	  limited	  to	  the	  mucosal	  layers	  with	  infiltrates	  varying	  in	  density	  and	  composition	  depending	  
on	  whether	  the	  patient	  is	  experiencing	  active	  disease	  or	  a	  period	  of	  remission.	  Predominant	  
inflammatory	  infiltrates	  include	  lymphocytes,	  plasma	  cells	  and	  granulocytes	  (Loddenkemper	  
2009).	  Other	  histological	  features	  include	  distortion,	  separation	  and	  atrophy	  of	  crypts,	  as	  well	  
as	   goblet	   cell	   depletion	   and	  Paneth	   cell	  metaplasia	   (Loddenkemper	   2009).	   To	   rule	   out	   an	  
infectious	  cause,	  it	  is	  also	  recommended	  that	  stool	  cultures	  be	  assessed	  for	  the	  presence	  of	  
C.	   difficile,	   Campylobacter	   spp.	   and	   E.	   coli	   (Kornbluth	   et	   al.	   2010).	   Laboratory	   tests	   for	  
elevated	   inflammatory	   markers	   are	   also	   used	   to	   assess	   disease	   severity,	   and	   include	  
erythrocyte	  sedimentation	  rate,	  as	  well	  as	  levels	  of	  C-­‐reactive	  protein,	  faecal	  calprotectin	  and	  
faecal	  lactoferrin	  (Vermeire	  et	  al.	  2006;	  Sipponen	  2013).	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1.4.5   Treatment	  of	  UC	  
1.4.5.1  Mesalazine	  
The	   first	   line	   therapy	   for	  mild-­‐moderate	  UC	   limited	   to	   the	   rectum	   is	  mesalazine	   (5-­‐
aminosalicylate;	   5-­‐ASA)	   (Dignass	   et	   al.	   2012;	   Lichtenstein	   et	   al.	   2006).	  Mesalazine	   can	   be	  
administered	  orally,	  topically	  or	  both.	  Topical	  administration	  of	  mesalazine	  is	  more	  effective	  
than	  oral	  mesalazine.	  Indeed,	  a	  Cochrane	  systematic	  review	  of	  38	  clinical	  trials	  confirmed	  the	  
superiority	   of	   this	   therapy	   over	   placebo	   for	   inducing	   symptomatic,	   endoscopic	   and	  
histological	  improvement	  and	  remission	  (Marshall	  et	  al.	  2010).	  Combining	  topical	  mesalazine	  
with	  oral	  mesalazine	  or	  topical	  steroid	  is	  more	  effective	  than	  either	  alone,	  and	  as	  such,	  should	  
be	  considered	  for	  treatment	  escalation	  in	  non-­‐responders	  (Marteau	  et	  al.	  2005;	  Mulder	  et	  al.	  
1996).	  Mesalazine	  intolerance	  occurs	  in	  up	  to	  15%	  of	  patients.	  Diarrhoea	  (3%),	  headache	  (2%),	  
nausea	   (2%),	   rash	   (1%)	   and	   thrombocytopenia	   (<1%)	   are	   reported,	   however,	   systematic	  
reviews	  have	  demonstrated	  that	  newer	  5-­‐ASA	  agents	  cause	  fewer	  adverse	  effects	  (Loftus	  et	  
al.	  2004).	  	  
	  
1.4.5.2  Glucocorticoids	  
Patients	  that	  do	  not	  respond	  to	  mesalazine	  are	  candidates	  for	  glucocorticoid	  treatment,	  
either	  in	  combination	  with	  mesalazine,	  or	  alone	  (Kornbluth	  et	  al.	  2010).	  Steroids	  are	  effective	  
at	  inducing	  remission,	  but	  are	  not	  acceptable	  as	  a	  means	  to	  maintain	  remission	  (Feuerstein	  
and	   Cheifetz	   2014).	   If	   UC	   is	   limited	   to	   proctosigmoiditis,	   steroid	   enemas	   are	   effective	   at	  
improving	   symptoms	   (Kornbluth	   et	   al.	   2010).	  UC	  patients	  with	   severe	   disease	  who	   fail	   to	  
respond	   to	   maximal	   doses	   (oral	   or	   topical)	   of	   5-­‐ASA	   and	   corticosteroids	   warrant	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hospitalisation	   for	   the	   administration	   of	   intravenous	   corticosteroids,	   typically	   prednisone.	  
Intravenous	  steroids	  are	  effective	  at	  inducing	  remission	  in	  up	  to	  70%	  of	  patients	  (Turner	  et	  al.	  
2007).	   Long-­‐term	  therapy	  with	  corticosteroids	   is	  associated	  with	   significant	  complications,	  
and	   as	   such,	   they	   are	   not	   used	   to	   maintain	   remission	   in	   UC	   (Lichtenstein	   et	   al.	   2006).	  
Therefore,	  any	  patient	  treated	  with	  steroids	  should	  be	  bridged	  to	  a	  medication	  that	  is	  proven	  
to	  maintain	  remission	  (Dignass	  et	  al.	  2012).	  	  
	  
1.4.5.3  Thiopurines	  
Thiopurines	   (azathioprine	   and	   mercaptopurine)	   are	   the	   most	   commonly	   used	  
immunosuppressants	   in	   UC.	   Rather	   than	   induce	   remission,	   they	   are	   used	   to	   maintain	  
remission	   in	   quiescent	   disease	   induced	   by	   other	   treatments,	   particularly	   glucocorticoids	  
(Sands	  2006).	  This	  might	  be	  explained	  by	  their	  slow	  onset	  of	  action,	  which	  is	  typically	  6	  –	  12	  
weeks	  (Sandborn	  2001).	   	  Despite	  their	  widespread	  use,	  the	  evidence	  base	  to	  support	  their	  
efficacy	  is	  not	  strong.	  A	  recent	  systematic	  review	  and	  meta-­‐analysis	  identified	  only	  three	  RCTs	  
involving	   127	   patients.	   Pooled	   data	   illustrated	   that	   azathioprine	   was	   significantly	   more	  
effective	  than	  placebo	  at	  preventing	  relapse	  (RR=0.60;	  95%	  CI	  =	  0.37-­‐0.95).	  The	  meta-­‐analysis	  
also	  identified	  two	  RCTs	  in	  130	  active	  UC	  patients,	  and	  perhaps	  unsurprisingly,	  azathioprine	  
had	  no	  significant	  effect	  (RR	  =	  0.64,	  95%	  CI	  =	  0.34	  –	  1.23)	  (Khan	  et	  al.	  2011).	  Potentially	  serious	  
adverse	  effects	  of	  thiopurine	  therapy	  include	  myelosuppression	  and	  associated	  opportunistic	  
infections,	   acute	   and	   chronic	   effects	   on	   liver	   function,	   and	   hypersensitivity	   reactions,	  
including	  pancreatitis.	  Long-­‐term	  use	  may	  also	  be	  associated	  with	  an	  increased	  risk	  of	  cancer	  
(Ford	  et	  al.	  2013)	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1.4.5.4  Anti-­‐tumour	  necrosis	  factor	  (TNF)	  agents	  
Anti-­‐TNF	  agents	  are	  monoclonal	  antibodies	  that	  are	  directed	  against	  tumour	  necrosis	  
factor	  α	  (TNF-­‐α)	  (Kornbluth	  et	  al.	  2010).	  Currently,	  three	  main	  anti-­‐TNF	  agents	  are	  used	  to	  
treat	   moderate	   to	   severe	   UC	   that	   include	   infliximab,	   adalimumab,	   and	   more	   recently,	  
golimumab	   (Kornbluth	   et	   al.	   2010;	   Lowenberg	   et	   al.	   2014).	   All	   three	   agents	   have	   similar	  
efficacy	  and	  safety	  profiles,	  but	  it	  has	  been	  suggested	  that	  Infliximab	  has	  a	  superior	  clinical	  
effect	  (Mei	  et	  al.	  2015).	  A	  systematic	  review	  of	  the	  efficacy	  of	  infliximab	  for	  treating	  patients	  
with	   moderate	   to	   severe	   UC	   refractory	   to	   corticosteroids	   and/or	   immunosuppressants	  
concluded	  that	   it	  was	  effective	  for	   inducing	  clinical	  remission,	  clinical	  response,	  promoting	  
mucosal	  healing	  and	  reducing	  the	  need	  for	  colectomy	  in	  the	  short	  term	  (Lawson	  et	  al.	  2006).	  
Similar	  results	  were	  also	  found	  in	  two	  large	  Active	  Ulceration	  Colitis	  Trials	  (ACT1	  and	  ACT2,	  
respectively)	   involving	   728	   patients	  with	  moderate-­‐severe	  UC.	   Results	   demonstrated	   that	  
patients	  treated	  with	  infliximab	  at	  0,	  2	  and	  6	  weeks	  and	  every	  8	  weeks	  thereafter	  were	  more	  
likely	  to	  have	  a	  clinical	  response	  at	  weeks	  8,	  30	  and	  54	  than	  those	  receiving	  placebo	  (Rutgeerts	  
et	  al.	  2005).	  Anti-­‐TNF	  therapy	  is	  considered	  a	  relatively	  safe	  treatment	  option,	  but	  common	  
side	   effects	   include	   injection	   site	   reactions,	   nausea,	   vomiting,	   arthralgia	   and	   myalgia	  
(Lichtenstein	  et	  al.	  2012).	  Whilst	  serious	  adverse	  effects	  are	  rare,	  all	  biological	  agents	  carry	  a	  
risk	   of	   serious	   infection	   and	   demyelinating	   disease.	   Additionally,	   long-­‐term	   treatment	   in	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1.4.5.5  Other	  therapies	  targeting	  the	  microbiota	  
Whilst	  a	  considerable	  number	  of	  UC	  patients	  can	  maintain	  remission	  when	  treated	  with	  
the	  standard	  therapies	  described	  above,	  a	  significant	  number	  experience	  persistent	  disease	  
activity	   and	   ultimately	   require	   a	   colectomy	   (Chen	   et	   al.	   2014b;	   Danese	   2011).	   The	  
development	   of	   alternative	   effective	   therapies	   is	   therefore	   extremely	   important.	   It	   is	  
becoming	  evident	  that	  the	  interaction	  between	  the	  enteric	  microbiota	  and	  the	  host	  immune	  
system	  drives	   inflammation	   in	  UC;	   therefore,	   the	  manipulation	  or	   restoration	  of	   intestinal	  
dysbiosis	  or	  mucosal	  barrier	  might	  represent	  an	  attractive	  therapeutic	  approach.	  	  
The	  administration	  of	  probiotics	  and/or	  prebiotics	  sounds	  an	  attractive	  concept	  for	  the	  
treatment	   of	   UC.	   Indeed,	   probiotic	   mixtures	   such	   as	   VSL3	   (consisting	   of	   4	   strains	   of	  
Lactobacilli,	   3	   strains	   of	   Bifidobacteria	   and	   1	   strain	   of	   Streptococcus	   thermophiles)	   are	  
effective	  at	  maintaining	  and	  inducing	  remission	   in	  both	  child	  and	  adult	  patients	  with	  mild-­‐
moderate	   active	  UC,	   either	   in	   combination	  with	   standard	   therapies	   or	   alone	   (Miele	   et	   al.	  
2009;	  Sood	  et	  al.	  2009).	  Similar	  results	  have	  been	  seen	  with	  E.	  coli	  Nissle	  1917	  (Kruis	  et	  al.	  
2004)	  and	  Lactobacillus	  GG	  (Zocco	  et	  al.	  2006).	  Prebiotic	  agents	  such	  as	  germinated	  barley	  
foodstuff	   (GBF),	   inulin	   and	   pysillium	   have	   also	   been	   shown	   to	   effectively	   maintain,	   and	  
sometimes	   induce,	   remission	   in	   patients	   with	  mild-­‐moderate	   active	   UC	   (Scaldaferri	   et	   al.	  
2013;	  Bamba	   et	  al.	   2002;	  Kanauchi	   et	  al.	   2002;	  Casellas	   et	  al.	   2007;	  Kanauchi	   et	  al.	   2013;	  
Fernandez-­‐Banares	  et	  al.	  1999).	  Whilst	  this	  approach	  would	  be	  safe	  and	  cost-­‐effective,	  studies	  
are	  still	  in	  their	  infancy	  and	  clinical	  evidence	  is	  limited	  by	  a	  lack	  of	  human	  studies	  involving	  
only	  a	  small	  number	  of	  patients.	  	  
Other	  approaches	  include	  FMT,	  which	  aims	  to	  reverse	  the	  intestinal	  dysbiosis	  implicated	  
in	  disease	  pathogenesis.	  Whilst	  studies	  indicate	  clinical	  improvement	  following	  the	  procedure	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(Borody	  et	  al.	  2003;	  Kunde	  et	  al.	  2013),	  some	  report	  that	  this	  effect	  is	  only	  short-­‐term	  and	  
that	  FMT	  cannot	  induce	  remission	  in	  UC	  patients	  (Kump	  et	  al.	  2013)	  (Angelberger	  et	  al.	  2013).	  
More	  recent	  studies	  suggest	  that	  FMT	  is	  effective	  in	  inducing	  remission	  in	  some,	  but	  not	  all	  
UC	  patients	  (Moayyedi	  et	  al.	  2015;	  Rossen	  et	  al.	  2015).	  As	  such,	  further	  studies	  are	  needed	  to	  
assess	  the	  effectiveness	  of	  FMT	  in	  treating	  UC,	  as	  well	  as	  to	  address	  the	  potential	  safety	  issues	  
associated	  with	  the	  procedure	  (Rubin	  2013).	  	  
Phosphatidylcholine	   (PC),	   a	   major	   mucus	   phospholipid	   significantly	   reduced	   in	   UC	  
patients	  and	  easily	  obtained	  from	  a	  variety	  of	  dietary	  sources	  (such	  as	  egg	  yolk,	  soy	  beans	  
etc.)	   (Torres	  et	  al.	  2013)	  has	  also	  been	   investigated	  as	  a	  treatment	  for	  UC,	  with	  promising	  
results.	  One	  study	  reported	  that	  90%	  of	  patients	  receiving	  a	  retarded-­‐release	  PC	  preparation	  
reached	  clinical	  remission	  or	  significantly	  improved	  by	  over	  50%	  compared	  with	  only	  10%	  in	  
the	  placebo	  group	  (Stremmel	  et	  al.	  2005).	  In	  an	  open-­‐label	  follow	  up	  treatment,	  continuous	  
remission	  was	  maintained	  in	  33%	  of	  PC	  treated	  patients	  versus	  10%	  of	  controls.	  Results	  from	  
a	  recent	  Phase	  IIb	  placebo-­‐controlled	  dose-­‐finding	  study	  using	  an	  optimised	  highly	  enriched	  
PC	   preparation	   have	   also	   proved	   promising	   results	   (Torres	   et	   al.	   2013),	   however,	   larger	  
studies	  will	  be	  needed	  to	  confirm	  its	  effectiveness	  in	  maintaining	  UC	  remission.	  	  
	  
1.4.5.6  Animal	  models	  of	  colitis	  
In	  recent	  years,	  a	  large	  number	  of	  experimental	  animal	  models	  have	  led	  to	  a	  greater	  
understanding	   of	   the	   pathogenesis	   in	   IBD.	   In	   addition,	   their	   study	   has	   also	   enabled	   the	  
identification	  of	   disease	   targets	   and	  evaluation	  of	   novel	   treatments	   in	  pre-­‐clinical	   testing.	  
Experimental	  colitis	  models	  with	  epithelial	  barrier	  defects	  and	  innate	  immunity	  defects	  have	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both	  been	  extensively	  employed	  (Khanna	  et	  al.	  2014).	  Here,	  the	  former	  will	  be	  discussed	  as	  
UC	  pathogenesis	  is	  largely	  mediated	  by	  dysfunction	  of	  the	  intestinal	  epithelial	  barrier.	  	  	  
	  
Administration	  of	  chelating	  agent	  dextran	  sulphate	  sodium	  (DSS)	  in	  the	  drinking	  water	  of	  
mice	  causes	  acute	  colonic	  inflammation,	  which	  presents	  as	  weight	  loss,	  diarrhoea	  and	  gross	  
rectal	  bleeding	  (Okayasu	  et	  al.	  1990).	  The	  acute	  DSS	  model	  shares	  a	  number	  of	  pathological	  
features	  with	  UC,	  including	  mucin	  depletion,	  epithelial	  degeneration,	  neutrophil	  infiltration,	  
formation	  of	  crypt	  abscesses	  and	  mucosal	  erosions	  (Valatas	  et	  al.	  2015).	  Other	  experimental	  
colitis	  models	   include	   the	   2,4,6-­‐trinitrobenzenesulfonic	   acid	   (TNBS)-­‐induced	   colitis	  mouse	  
model,	  which	   employs	   the	   intra-­‐rectal	   administration	  of	   TNBS	   and	   induces	   severe	   colonic	  
inflammation	   that	   is	   similar	   to	   the	   clinical	   and	   histopathological	   findings	   observed	   in	   CD	  
(Scheiffele	   and	   Fuss	   2001).	   Muc2-­‐/-­‐	   mice,	   which	   exhibit	   defective	   mucin	   production,	  
spontaneously	  develop	  colitis	  that	  reflects	  the	  clinical	  and	  cellular	  features	  of	  UC	  (Van	  der	  
Sluis	  et	  al.	  2006).	  The	  murine	  multiple	  drug	  resistance	  1	  a	  (Mdr1a)	  gene	  is	  implicated	  in	  the	  
regulation	  of	  epithelial	   transcellular	  permeability,	  and	  as	   such,	  Mdr1a-­‐/-­‐	  mice	  also	  develop	  
spontaneous,	  flora-­‐dependent	  colonic	  inflammation	  typical	  of	  UC	  (Panwala	  et	  al.	  1998).	  	  
	  
1.5  BACTERIAL-­‐EPITHELIAL	   INTERACTIONS	  MEDIATE	  THE	  PATHOGENESIS	  OF	  DIARRHOEAL	  
DISEASE	  
Adhesion	  of	  pathogenic	  bacteria	  to	  host	  tissues	  represents	  an	  early,	  but	  critical	  step	  
in	  the	  pathogenesis	  of	  virtually	  all	  infections	  (Lehmann	  et	  al.	  2006).	  With	  respect	  to	  diarrhoeal	  
gut	  pathogens	  C.	  difficile	  and	  ETEC,	  it	   is	  thought	  that	  their	  close	  proximity	  to	  the	  intestinal	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epithelium	  is	  critical	  for	  the	  subsequent	  release	  of	  their	  respective	  toxins.	  As	  such,	  epithelial	  
adhesion	  represents	  an	  essential	  mediator	  of	  disease	  pathogenesis.	  	  
With	  regards	  to	  UC,	  it	  is	  becoming	  increasingly	  evident	  that	  enteric	  bacteria	  play	  an	  
important	   role	   in	   the	  mediation	   of	   inflammation.	   Indeed,	   the	   loss	   of	   protective	   intestinal	  
barrier	   function	   results	   in	   direct	   contact	   between	   bacteria,	   bacterial	   components	   such	   as	  
flagellin	  and	  LPS	  and	  the	  surface	  epithelium,	  with	  a	  major	  potential	  for	  interaction	  with	  TLRs	  
and	  consequent	  release	  of	  pro-­‐inflammatory	  cytokines.	  	  
Therefore,	  the	  ability	  to	  prevent	  these	  harmful	  bacterial-­‐epithelial	  interactions	  is	  an	  
attractive	  therapeutic	  strategy.	  	  
	  
1.5.1   Soluble	  plant	  fibres	  (non-­‐starch	  polysaccharides)	  can	  inhibit	  the	  epithelial	  adhesion	  
of	  a	  range	  enteric	  pathogens	  
During	  studies	  in	  our	  own	  laboratory,	  we	  have	  previously	  demonstrated	  that	  soluble	  
plant	  fibre,	  or	  non-­‐starch	  polysaccharides	  (NSPs),	  can	  disrupt	  potentially	  harmful	  interactions	  
between	  bacteria	  and	  the	  gut	  epithelium.	  	  
As	  part	  of	  this	  work,	  a	  range	  of	  soluble	  fibres	  were	  first	  investigated	  for	  their	  ability	  to	  
block	   the	   in	   vitro	   adhesion	   and	   invasion	   of	   a	   range	   Crohn’s	   associated	   AIEC	   isolates	   to	  
intestinal	   epithelial	   cells.	   Here,	   it	   was	   shown	   that	   soluble	   NSP	   extracted	   from	   plantain	  
bananas	  (Musa	  spp.)	  exhibited	  particular	  efficacy,	  and	  moreover,	  it	  could	  significantly	  inhibit	  
bacterial	  translocation	  across	  ex-­‐vivo	  explants	  of	  villous	  or	  follicle-­‐associated	  epithelium	  (FAE)	  
mounted	  on	  Ussing	  chambers	  (Martin	  et	  al.	  2004;	  Roberts	  et	  al.	  2010;	  Roberts	  et	  al.	  2013).	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Interestingly,	  it	  seems	  that	  soluble	  plantain	  fibre	  can	  also	  inhibit	  the	  adherence	  of	  a	  
range	  of	  other	  gut	  pathogens,	   such	  as	  Salmonella	  spp.,	  and	  Shigella	  sonnei	   (Roberts	  et	  al.	  
2013).	   Importantly,	   this	  has	   also	  been	  demonstrated	   in	   vivo,	  where	   supplementation	  of	   a	  
commercial	   feed	   with	   soluble	   plantain	   fibre	   was	   shown	   to	   significantly	   block	   Salmonella	  
colonisation	  in	  the	  chicken	  (Parsons	  et	  al.	  2014).	  Furthermore,	  preliminary	  results	  have	  also	  
suggested	   that	   soluble	   plantain	   fibre	   can	   significantly	   inhibit	   the	   epithelial	   adhesion	   of	  
diarrhoeal	  pathogens	  Clostridium	  difficile	  and	  ETEC	  (Roberts	  et	  al.	  2013).	  	  	  
Overall,	  our	  previous	  findings	  raise	  the	  possibility	  that	  dietary	  supplementation	  with	  
specific	  soluble	  plant	  NSPs	  could	  be	  beneficial	  for	  the	  maintenance	  of	  intestinal	  health	  and	  
prevention	  of	  diarrhoeal	  disease.	  Previous	  clinical	  studies	  also	  provide	  evidence	  to	  support	  
the	  beneficial	  role	  of	  soluble	  plant	  fibres,	  where	  banana	  flakes	  supplemented	  to	  enteral	  feed	  
have	  been	  shown	  to	  control	  diarrhoeal	  episodes	  (Emery	  et	  al.	  1997).	  Additionally,	  the	  juice	  
from	  boiled	  green	  bananas,	  that	  would	  contain	  soluble	  fibre,	  has	  been	  reported	  to	  reduce	  the	  
severity	   and	   duration	   of	   persistent	   diarrhoeas	   (Rabbani	   et	   al.	   2004;	   Rabbani	   et	   al.	   2001),	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2.1	  HYPOTHESIS	  
	  
Soluble	  NSPs	  may	  have	  a	  beneficial	  effect	  on	  intestinal	  health	  by	  their	  ability	  to	  

































1.   To	  evaluate	  soluble	  plantain	  NSP,	  as	  well	  as	  a	  range	  of	  other	  soluble	  fibres	  for	  their	  
efficacy	  at	  inhibiting	  the	  epithelial	  adhesion	  of	  C.	  difficile	  and	  ETEC	  
	  
2.   To	   evaluate	  whether	   soluble	   plantain	  NSP	   can	   inhibit	   the	   epithelial	   adhesion	   of	  C.	  
difficile	  spores	  
	  
3.   To	  evaluate	  whether	  soluble	  plantain	  NSP	  can	  reduce	  the	  epithelial	  damage	  induced	  
by	  purified	  C.	  difficile	  toxins	  	  
	  
4.   To	  evaluate	  whether	  soluble	  plantain	  NSP	  can	  reduce	  the	  epithelial	  damage	  induced	  
by	  mucosally	  associated	  UC	  E.	  coli,	  purified	  flagella	  and	  LPS	  
	  
5.   To	  characterise	  the	  polysaccharide	  component	  present	  in	  plantain	  NSP	  that	  confers	  
its	  inhibitory	  activity	  
	  
6.   To	  characterise	  the	  molecular	  mechanism	  of	  the	  inhibitory	  action	  of	  plantain	  NSP	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4.1  MATERIALS	  	  
Unless	   indicated	   otherwise,	   all	   chemicals	   used	   herein	   were	   obtained	   from	   Sigma	  
Aldrich	  (Gillingham,	  UK).	  Bacto™	  agar,	  Bacto™	  tryptone	  and	  Bacto™	  yeast	  extract	  for	  use	  in	  
bacterial	   culture	   were	   supplied	   by	   BD	   Biosciences	   (Oxford,	   UK),	   whilst	   all	   other	   bacterial	  
culture	  media	  was	  supplied	  by	  Oxoid	  (Hampshire,	  UK).	  All	  plastics	  for	  human	  cell	  culture	  were	  
obtained	   from	   Corning/Costar	   (High	   Wycombe,	   UK),	   as	   were	   plastics	   for	   liquid	   (broth)	  
bacterial	  culture.	  Solid	  (agar)	  bacterial	  culture	  was	  performed	  using	  plastics	  obtained	  from	  
Sterilin	  (Caerphilly,	  UK).	  For	  recipes	  of	  commonly	  used	  buffers	  and	  reagents,	  see	  Appendix	  1.	  
	  
4.2  CELL	  CULTURE	  	  
4.2.1   Human	  cell	  lines	  used	  in	  the	  study	  
4.2.1.1  Caco2	  
A	  human	  derived	  colorectal	  adenocarcinoma	  cell	   line,	  obtained	   from	  the	  European	  
Collection	  of	  Authenticated	  Cell	  Cultures	  (ECACC)	  (Wiltshire,	  UK;	  EACC	  Number	  86010202).	  
The	   Caco2	   cell	   line	   was	   selected	   for	   the	   majority	   of	   these	   studies	   as	   it	   represents	   an	  
established	   in	  vitro	  model	  of	   the	   intestinal	  epithelial	  barrier.	  Used	  at	  sub	  confluent	   levels,	  
these	  cells	  are	  models	  of	  isolated	  colonic	  epithelial	  cells.	  Upon	  reaching	  confluence,	  the	  cells	  
undergo	   spontaneous	   differentiation	   to	   express	   several	   morphological	   and	   biochemical	  
characteristics	  typically	  observed	  in	  the	  mature	  enterocyte	  (Sambuy	  et	  al.	  2005).	  	  
	  
	  
	  	   71	  
4.2.1.2  HT29	  	  
A	   human	   derived	   colorectal	   adenocarcinoma	   cell	   line	   with	   epithelial	   morphology,	  
obtained	  from	  the	  ECACC	  (ECACC	  Number	  85061109)	  (Kimball	  et	  al.	  1981).	  
	  
4.2.1.3  SW620	  
A	  human	  derived	  colorectal	  adenocarcinoma	  cell	  line	  isolated	  from	  a	  metastatic	  lymph	  
node,	  also	  obtained	  from	  the	  ECACC	  (ECACC	  Number	  87051203)	  (Leibovitz	  et	  al.	  1976).	  
	  
4.2.2   Cell	  line	  maintenance	  
Caco2,	  HT29	  and	  SW620	  cells	  were	  maintained	  Dulbecco’s	  Modified	  Eagle’s	  Medium	  
(DMEM)	  supplemented	  with	  10%	  (v/v)	  FBS,	  100	  U/mL	  penicillin,	  100	  µg/mL	  streptomycin	  and	  
8	  mM	  glutamine	  (complete	  DMEM),	   in	  T150	  tissue	  culture	  flasks	  until	  70	  –	  80%	  confluent.	  
Cells	  were	  maintained	  at	  37°C	  in	  a	  humidified	  atmosphere	  of	  5%	  CO2,	  95%	  air.	  	  
To	  passage	  cells,	  media	  was	  removed	  and	  the	  cells	  washed	  with	  pre-­‐warmed	  (37°C)	  
sterile	  phosphate-­‐buffered	  saline	  (PBS;	  pH	  7.4).	  Cells	  were	  then	  detached	  from	  their	  flasks	  by	  
treatment	  with	  5	  mL	  of	  1X	  trypsin-­‐EDTA	  solution	  (0.25%	  (v/v)	  trypsin,	  0.02%	  (w/v)	  EDTA	  in	  
PBS),	  which	  was	  neutralised	  by	  the	  addition	  of	  an	  equal	  volume	  of	  complete	  DMEM.	  The	  cell	  
suspension	  was	  then	  split	  at	  a	  ratio	  of	  1:5	  into	  new	  T150	  flasks	  alongside	  20	  mL	  of	  fresh	  culture	  
media.	   To	   reduce	   potential	   passage	   number	   effects,	   cells	  were	   only	  maintained	   between	  
passages	  1	  –	  30	  (Briske-­‐Anderson	  et	  al.	  1997).	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4.2.3   Suppression	  of	  galectin-­‐3	  expression	  in	  SW620	  cells	  
Colonic	  SW620	  cells	  were	  transfected	  with	  short	  hairpin	  RNA	  (shRNA)	  or	  the	  empty	  
vector	   control	   to	   generate	   stable	   galectin-­‐3	   knockdown	   cells	   (SW620Gal3-­‐)	   and	   galectin-­‐3	  
expressing	  cells	  (SW620Gal3+),	  respectively.	  Transfection	  was	  performed	  by	  Paulina	  Sindrewicz	  
(Gastroenterology	  Research	  Unit,	  Department	  of	  Cellular	  &	  Molecular	  Physiology,	  University	  
of	  Liverpool),	  as	  described	  in	  Duckworth	  et	  al.	  (Duckworth	  et	  al.	  2015).	  
	  
4.3  SOLUBLE	  NON	  STARCH	  POLYSACCHARIDES	  (NSPs)	  	  
Soluble	  NSP	  fibres	  were	  provided	  by	  Dr	  Niamh	  O’Kennedy	  (Provexis	  plc;	  Windsor,	  UK).	  
A	  range	  of	  NSP	  fibres	  were	  selected	  to	  represent	  common	  monocotyledon	  (i.e.	  having	  one	  
seed	   leaf,	  or	  cotyledon)	  or	  dicotyledon	  (i.e.	  plants	  with	  two	  seed	   leaves)	  source	  of	  dietary	  
fibre.	   Apple,	   bean,	   blueberry,	   leek,	   pear,	   strawberry	   and	   tomato	   NSP	   are	   classified	   as	  
monocots,	  whilst	  oat	  and	  plantain	  are	  classified	  as	  dicots.	  The	  monosaccharide	  composition	  
of	  the	  NSP	  fibres	  used	  in	  the	  study	  is	  summarised	  in	  Appendix	  2.	  	  
	  
4.3.1   Preparation	  of	  soluble	  non	  starch	  polysaccharides	  (NSPs)	  
Our	  preferred	   source	  of	   soluble	  non-­‐starch	  NSP	  was	   from	  green	  plantain	   (ripeness	  
stage	  1)	  flour	  produced	  in	  Ecuador	  from	  locally	  grown	  cultivars	  Musa	  AAB	  (Horn)	  variation	  
Domino	   (See	   Appendix	   2).	   The	   plantain	   NSP	   preparations	   used	   in	   this	   study	   were	   from	  
Confoco	  plantain	  flour	  (Trobana	  Green	  Plantain	  flour;	  Confoco	  International	  Ltd;	  Ripley,	  UK)	  
and	   were	   prepared	   by	   Provexis	   Plc	   (Windsor,	   UK)	   at	   the	   Teagasc	   Food	   Research	   Centre	  
	  	   73	  
(Moorepark,	   Ireland),	   as	   described	   previously	   (Parsons	   et	   al.	   2014;	   Roberts	   et	   al.	   2010;	  
Simpson	  and	  Campbell	  2014)	  	  
Briefly,	  dry	  plantain	  flour	  was	  homogenised	  in	  reverse-­‐osmosis	  purified	  water	  (ratio	  
1:2)	  and	  then	  heated	  to	  90°C	  –	  100°C	  for	  10	  min	  with	  continuous	  high-­‐shear	  mixing	  to	  effect	  
starch	  swelling	  and	  gelatinisation.	  The	  homogenate	  was	  then	  cooled	  to	  25°C	  and	  treated	  with	  
fungal	  α-­‐amylase	  Fungamyl®	  (Novozymes;	  Bagsvaerd,	  Denmark)	  for	  2	  h	  (pH	  6-­‐7)	  to	  hydrolyse	  
native	   starch.	   The	   mixture	   was	   then	   heated	   to	   72°C	   for	   20	   min	   to	   fully	   inactivate	   the	  
Fungamyl®	   enzyme.	   Insoluble	   NSP	  was	   removed	   by	   centrifugation	   and	   subsequently,	   low	  
molecular	   weight	   components	   (<300	   Da),	   including	   starch	   degradation	   products,	   were	  
removed	  from	  the	  soluble	  NSP	  by	  nanofiltration.	  The	  concentrated	  retentate	  (containing	  in	  
addition	   up	   to	   45%	   by	   weight	   plantain-­‐derived	   maltodextrin	   carrier	   as	   part	   of	   the	   bulk-­‐
manufacturing	   process	   to	   counter	   difficulties	   in	   freeze	   drying/resolubilisation)	   was	   spray-­‐
dried	  to	  a	  fine	  dry	  powder	  with	  a	  particle	  size	  distribution	  of	  50	  –	  100	  µm	  and	  a	  bulk	  density	  
of	  175	  g/L.	  Other	  soluble	  NSPs	  used	  in	  the	  study	  were	  prepared	  to	  the	  same	  specification.	  	  
	  
4.3.2   Preparation	  of	  acidic	  and	  neutral	  polysaccharide	  fractions	  of	  plantain	  NSP	  
Acidic	  and	  neutral	  polysaccharide	  fractions	  of	  soluble	  plantain	  NSP	  were	  prepared	  in	  
two	   batches	   by	   Q-­‐Sepharose	   anion-­‐exchange	   chromatography,	   as	   previously	   described	  
(Parsons	  et	  al.	  2014).	  	  	  
	  
4.3.2.1  Small	  scale,	  analytical	  strong	  anion-­‐exchange	  fractionation	  
Initially,	   acidic	   and	   neutral	   polysaccharide	   fractions	  were	   prepared	   by	   small	   scale,	  
analytical	  fractionation,	  using	  a	  HiPrepTM	  Q-­‐Sepharose	  FF	  16/10	  column	  on	  the	  AKTA	  Prime	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Plus	   chromatography	   system.	   Briefly,	   1.6	   g	   soluble	   plantain	   NSP	   was	   dissolved	   in	   50	   mL	  
equilibration	  buffer	  (50	  mM	  Tris-­‐HCl,	  pH	  7.4)	  and	  loaded	  onto	  the	  column	  at	  a	  flow	  rate	  of	  5	  
mL/min.	  The	  column	  was	  then	  washed	  with	  40	  mL	  equilibration	  buffer	  to	  collect	  the	  unbound,	  
neutral	  polysaccharide	  fraction	  of	  plantain	  NSP.	  The	  bound,	  acidic	  polysaccharide	  fraction	  of	  
plantain	  NSP	  was	   eluted	   step-­‐wise	  with	   0.1M,	   0.5M	   and	   1M	  NaCl	   in	   equilibration	   buffer.	  
Subsequently,	  both	  neutral	  and	  acidic	  fractions	  were	  desalted	  on	  PD	  MidiTrap	  G-­‐10	  columns	  
(GE	  Healthcare	  Sciences,	  Buckinghamshire,	  UK),	  performed	  according	  to	  the	  manufacturer’s	  
instructions.	  These	  columns	  have	  an	  exclusion	  limit	  of	  >	  700	  Da,	  and	  as	  approximately	  95%	  
plantain	  NSP	   is	   <	   5	   kDa	   in	   size,	   they	   are	   suitable	   for	  desalting	   samples	   containing	   soluble	  
plantain	  fibre.	  	  
	  
4.3.2.2  Scaled-­‐up,	  preparative	  scale	  strong	  anion-­‐exchange	  fractionation	  
Based	  on	  the	  results	  from	  the	  small-­‐scale	  analytical	  fractionation	  of	  plantain	  NSP,	  a	  
bulk	   preparation	   of	   purified	   neutral	   and	   acidic	   fractions	   of	   soluble	   plantain	   fibre	   was	  
performed.	  This	  was	  also	  carried	  out	  by	  strong	  anion-­‐exchange	  chromatography,	  but	  in	  the	  
absence	   of	   a	   column	   (Clark	   1976),	   performed	   using	   Q-­‐Sepharose	   FastFlow	   beads	   (GE	  
Healthcare	  Life	  Sciences)	  in	  large	  2.5	  L	  mixing	  vessels.	  Each	  300	  mL	  batch	  of	  Q-­‐Sepharose	  was	  
reconstituted	  in	  1	  L	  deionised	  water,	  transferred	  into	  the	  vessel	  and	  rotated	  for	  15	  min,	  which	  
was	  repeated	  three	  times.	  The	  Q-­‐Sepharose	  beads	  were	  then	  equilibrated	  twice	  with	  600	  mL	  
sterile-­‐filtered	  50	  mM	  Tris-­‐HCl	  buffer	  (pH	  7.4).	  	  
Twenty-­‐five	  grams	  of	  soluble	  plantain	  NSP	  was	  added	  to	  780	  mL	  50	  mM	  Tris-­‐HCl,	  pH	  
7.4.	  The	  ‘solution’	  was	  left	  overnight	  at	  4°C	  to	  settle	  and	  the	  majority,	  clear	  upper	  layer	  was	  
removed	   and	   filtered	   under	   vacuum	   through	   a	   scintered	   glass	   separating	   funnel	   and	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Whatmann	  #1	  filter	  paper.	  This	  resulted	  in	  a	  volume	  of	  approximately	  700	  mL.	  The	  solubilised	  
plantain	  NSP	  was	  then	  added	  to	  the	  2.5	  L	  vessel	  containing	  300	  mL	  Q-­‐Sepharose	  and	  rotated	  
for	  1	  h.	  The	  unbound,	  neutral	  polysaccharide	  fraction	  of	  soluble	  plantain	  NSP	  was	  collected	  
and	  filtered	  using	  a	  scintered	  glass	  separating	  funnel.	  To	  ensure	  the	  removal	  of	  all	  unbound	  
material,	  the	  Q-­‐Sepharose	  beads	  underwent	  two	  15	  min	  washes	  with	  300	  mL	  equilibration	  
buffer,	  which	  was	  then	  pooled	  with	  the	  Q-­‐Sepharose	  unbound	  fraction.	  	  
The	  Q-­‐Sepharose-­‐bound	  acidic	  polysaccharide	  fraction	  from	  plantain	  NSP	  was	  eluted	  
with	  400	  mL	  0.5	  M	  NaCl	  in	  equilibration	  buffer,	  rotated	  overnight	  in	  4°C.	  Any	  unbound	  acidic	  
polysaccharides	  were	  further	  eluted	  by	  two	  15	  min	  washes	  with	  200	  mL	  0.5	  M	  NaCl,	  and	  an	  
overnight	  wash	  with	  400	  mL	  1M	  NaCl.	  Finally,	  Q-­‐Sepharose	  was	  cleaned	  overnight	  with	  400	  
mL	   1M	  NaOH.	   	   Only	   the	   0.5M	  NaCl	   overnight	   fraction	   and	  washes	   were	   pooled	   prior	   to	  
desalting.	  	  
	  
4.3.2.3  Desalting	  of	  neutral	  and	  acidic	  polysaccharide	  plantain	  fractions	  
The	  neutral	  and	  acidic	  fractions	  were	  both	  desalted	  using	  multiple	  PD	  MidiTrap	  G-­‐10	  gravity	  
mini-­‐columns	   (GE	   Healthcare	   Sciences),	   as	   per	   the	   manufacturer’s	   instructions	   (at	   1	   mL	  
sample	  per	  column).	  To	  determine	  the	  G-­‐10	  column	  fractionation	  elution	  profiles	  for	  neutral	  
and	  acidic	  fractions,	  total	  hexose	  content	  was	  determined	  using	  a	  phenol-­‐sulphuric	  acid	  assay.	  
















Figure	  4.1	  Desalting	  of	  Q-­‐Sepharose®	  anion-­‐exchange	  chromatography	  fractions	  from	  soluble	  plantain	  
NSP.	   Following	   preparative	   anion-­‐exchange	   chromatography,	   sodium	   chloride-­‐eluted	   A)	   acidic	  
polysaccharides	   and	   B)	   unbound	   neutral	   polysaccharide	   fractions	   were	   desalted	   into	   water	   using	  
multiple	  PD	  MidiTrap™	  G-­‐10	  columns.	  Carbohydrate	  content	  of	  eluted	  fractions	  was	  measured	  using	  a	  
phenol-­‐sulphuric	  acid	  assay	  (blue	  line).	  Columns	  were	  pre-­‐calibrated	  with	  the	  low	  molecule	  size	  marker	  
phenol	  red	  (354	  Da),	  measured	  as	  A560	  (red	  line).	  The	  arrow	  indicates	  total	  column	  volume	  (Vt).	  The	  
solid	  bar	  indicates	  the	  elution	  fraction	  collected	  for	  lyophilisation	  and	  bioassay	  (Vo	  indicates	  the	  void	  
volume	  of	  the	  column).	  Desalted	  acidic	  and	  neutral	  fractions	  were	  then	  freeze	  dried	  and	  lyophilised,	  as	  
depicted	  in	  images	  C)	  and	  D),	  respectively.	  	  
A   B  
C   D  
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4.3.2.4  Hexose	  Assay	  
Fractions	  collected	   from	  the	  G-­‐10	  desalting	  columns	  were	  assayed	  for	   total	  hexose	  
using	  a	  modified	  method	  of	  Dubois	  (1956)	  (DuBois	  et	  al.	  1956).	  Briefly,	  10	  µL	  fractions	  were	  
added	  to	  96-­‐well	  microtitre	  plates	  in	  triplicate,	  and	  100	  µL	  of	  4%	  (w/v)	  phenol	  dissolved	  in	  
deionised	  water	  was	  added,	  at	  room	  temperature	  for	  5	  min.	  Concentrated	  H2SO4	  (150	  µL)	  was	  
then	  rapidly	  added	  to	  wells	  and	  aspirated	  to	  generate	  heat.	  Plates	  were	  left	  to	  cool	  for	  20	  
min.	  Optical	  density	  (OD)	  was	  then	  measured	  at	  560	  nm.	  D-­‐glucose	  standards	  (0-­‐20	  ng/mL)	  
and	  water	  blanks	  were	  also	  included.	  Hexose	  content	  of	  samples	  was	  determined	  using	  a	  D-­‐












Figure	  4.2	  D-­‐Glucose	  calibration	  curve	  used	  to	  determine	  the	  unknown	  hexose	  content	  of	  
neutral	   and	   acidic	   polysaccharide	   fractions	   of	   plantain	   NSP.	   D-­‐Glucose	   standards	   (0-­‐20	  
ng/mL)	  were	  added	  in	  triplicate	  and	  hexose	  content	  determined	  using	  a	  phenol-­‐sulphuric	  acid	  
assay,	  with	  the	  absorbance	  measured	  spectrophotometrically	  at	  optical	  density	  (OD)	  560	  nm	  
(N=1,	  n=3)	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4.3.2.5  Lyophilisation	  of	  neutral	  and	  acidic	  plantain	  NSP	  fractions	  
Desalted	   neutral	   and	   acidic	   fractions	  were	   freeze-­‐dried	   overnight	   in	   round-­‐bottom	  
flasks	  (Edwards	  Modulyo	  4K	  Freeze	  Drier;	  operating	  temperature	  -­‐55	  ±	  5°C;	  maximum	  vacuum	  
atmospheric	  pressure	  215	  psi).	  To	  facilitate	  freeze	  drying,	  the	  sample	  was	  shell-­‐frozen	  over	  a	  
large	  surface	  area	  of	  each	  round	  bottom	  flask	  by	  immersion	  and	  rapid	  rotation	  in	  a	  bath	  of	  
ethanol	  and	  dry	  ice.	  Flasks	  were	  stored	  for	  at	  least	  20	  min	  at	  -­‐80°C	  before	  lyophilisation.	  	  	  
4.3.2.6  Yield	  projections	  	  
Whilst	  only	  a	  portion	  of	  neutral	  and	  acidic	  fractions	  had	  been	  desalted	  and	  lyophilised	  
at	  the	  time	  of	  writing,	  initial	  yields	  from	  total	  starting	  material	  of	  75	  g	  plantain	  NSP	  can	  be	  
extrapolated.	  From	  800	  mL	  of	  the	  NaCl	  Q-­‐Sepharose	  eluted	  acidic	  fraction	  (total	  volume	  3.6	  
L),	  the	  yield	  of	  material	  was	  1.16	  g.	  Therefore,	  a	  projected	  yield	  of	  acidic	  fraction	  is	  estimated	  
at	  5.21	  g.	  From	  the	  120	  mL	  of	  the	  Q-­‐Sepharose	  unbound	  neutral	  fraction	  (total	  volume	  2.1	  L),	  
the	  yield	  of	  material	  was	  0.72	  g,	  giving	  a	  projected	  total	  yield	  estimated	  at	  12.60	  g.	  Additional	  
material	  within	  the	  Q-­‐Sepharose	  unbound	  wash	  step	  and	  1	  M	  NaOH	  clean-­‐up	  fractions	  have	  
yet	  to	  be	  determined.	  	  
	  
4.4  BACTERIAL	  CULTURE	  
4.4.1   Bacterial	  strains	  used	  in	  the	  study	  
4.4.1.1  C.	  difficile	  isolates	  
Clinical	  laboratory	  reference	  strain	  C.	  difficile	  080042	  (Ribotype	  [Rb]	  027a)	  was	  kindly	  
donated	   by	   Dr	   Godfrey	   Smith	   (Medical	   Microbiology,	   Royal	   Liverpool	   and	   Broadgreen	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University	  Hospitals	  NHS	   Trust,	  Merseyside,	  UK).	   Eleven	   further	  C.	   difficile	   clinical	   isolates	  
were	   obtained	   from	  Dr	   Fabio	  Miyajima	   (Institute	   of	   Translational	  Medicine,	   University	   of	  
Liverpool,	  UK)	  and	  Mr	  Paul	  Roberts	  (Royal	  Liverpool	  and	  Broadgreen	  University	  Hospitals	  NHS	  
Trust)	  A	  further	  C.	  difficile	  isolate	  1342	  (Rb	  005)	  was	  generously	  provided	  by	  Dr	  Gillian	  Douce	  
and	  Dr	  Anthony	   Buckley	   (Institute	   of	   Infection,	   Immunity	   and	   Inflammation,	  University	   of	  
Glasgow,	  UK).	  The	  characteristics	  (source,	  toxinotype	  and	  ribotype)	  of	  the	  C.	  difficile	  clinical	  
isolates	  used	  in	  this	  study	  are	  summarised	  in	  Table	  4.1.	  
	  






Strain	  Number	   Ribotype	   Toxin	  A	   Toxin	  B	   Binary	  Toxin	   Origin	  
98011	   027	   +	   +	   +	   Liverpool	  
108536	   027	   +	   +	   +	   Japan	  
98078	   078	   +	   +	   +	   Liverpool	  
98231	   078	   +	   +	   +	   Liverpool	  
108526	   018	   +	   +	   -­‐	   Japan	  
108906	   012	   +	   +	   -­‐	   Malawi	  
98359	   106	   +	   +	   -­‐	   Liverpool	  
108963	   017	   -­‐	   +	   -­‐	   Liverpool	  
108519	   017	   -­‐	   +	   -­‐	   Japan	  
108520	   368	   -­‐	   +	   -­‐	   Japan	  
98220	   010	   -­‐	   -­‐	   -­‐	   Liverpool	  
1342	   005	   -­‐	   -­‐	   -­‐	   Glasgow	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4.4.1.2  Enterotoxigenic	  E.	  coli	  	  
ETEC	  C410	  (serotype	  0160,	  LT+/ST+)	  was	  a	  kind	  gift	  from	  Dr	  Godfrey	  Smith	  (Medical	  
Microbiology,	  Royal	  Liverpool	  and	  Broadgreen	  University	  Hospitals	  NHS	  Trust,	  UK).	  
4.4.1.3  Mucosally-­‐associated	  E.	  coli	  isolated	  from	  patients	  with	  UC	  
E.	  coli	  strains	  (HM250,	  HM295,	  HM378,	  HM380	  and	  HM387)	  were	  previously	  isolated	  
from	  colonic	  mucosal	  biopsies	  of	  five	  patients	  with	  UC,	  as	  described	  elsewhere	  (Martin	  et	  al.	  
2004)	  (Subramanian	  et	  al.	  2008).	  Their	  characteristics	  are	  summarised	  in	  Appendix	  3.	  
4.4.1.4  Salmonella	  enteric	  serovar.	  Typhimurium	  
S.	   Typhimurium	   LT2	   was	   generously	   donated	   by	   Professor	   Craig	   Winstanley	  
(Department	  of	  Clinical	  Infection,	  Microbiology	  and	  Immunology,	  Institute	  of	  Global	  Health	  
and	  Infection,	  University	  of	  Liverpool,	  UK).	  
	  
4.4.2   Bacterial	  growth	  conditions	  
For	   most	   purposes,	   bacterial	   strains	   were	   grown	   from	   frozen	   stocks,	   which	   were	  
stored	   down	   on	   Protect	   beads	   at	   -­‐80°C	   (Lab	  M;	   Lancashire,	   UK).	  C.	   difficile	   isolates	  were	  
routinely	  grown	  on	  Brain	  Heart	  Infusion	  (BHI)	  agar	  supplemented	  with	  0.1%	  (w/v)	  L-­‐cysteine	  
and	  5	  mg/mL	  yeast	  extract	  (BHIS	  agar)	  in	  anaerobic	  conditions,	  at	  37°C	  for	  48	  h.	  Anaerobic	  
conditions	   were	   generated	   by	   incubating	   C.	   difficile	   in	   sealed	   2.5	   L	   AnaeroJars	   (Oxoid)	  
containing	   an	  AnaeroGen	   sachet	   (Oxoid).	   	   All	   other	   bacterial	   strains	  were	   grown	  on	   Luria	  
Burtani	  (LB)	  agar	  in	  aerobic	  conditions,	  at	  37°C	  for	  24	  h.	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Prior	  to	  infection	  of	  cultured	  epithelial	  cells,	  approximately	  5	  bacterial	  colonies	  were	  
removed	  from	  solid	  phase	  culture	  and	  suspended	  in	  sterile	  phosphate-­‐buffered	  saline	  (PBS,	  
pH	  7.4).	  The	  bacterial	  culture	  was	  centrifuged	  at	  10,000	  x	  g	  for	  5	  minutes	  and	  washed	  3	  times	  
before	  being	  resuspended	  to	  an	  OD600nm,	  which	  was	  equivalent	  to	  1	  x	  109	  colony	  forming	  units	  
(CFU)/mL.	  
	  
4.5  C.	  difficile	  SPORE	  PURIFICATON	  
	   Early	  attempts	  at	  C.	  difficile	  spore	  purification	  included	  the	  use	  of	  an	  individual	  heat	  
treatment	  (60°C	  for	  20	  min)	  or	  alcohol	  treatment	  (100%	  ethanol	  for	  1	  h)	  (Burns	  and	  Minton	  
2011).	   However,	   Schaeffer	   and	   Fulton	   endospore	   staining	   (Schaeffer	   and	   Fulton	   1933)	  
revealed	  significant	  vegetative	  C.	  difficile	  contamination,	  suggesting	  that	  these	  are	  ineffective	  
purification	  methods	   (Figure	   4.3).	   C.	   difficile	   spores	   were	   therefore	   purified	   according	   to	  
methods	  described	  previously	  by	  Permpoonpattana	  and	  colleagues	  (Permpoonpattana	  et	  al.	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4.5.1   Promotion	  of	  C.	  difficile	  sporulation	  
C.	  difficile	   isolates	  were	   routinely	   cultured	  on	  BHIS	  agar	   in	  anaerobic	   conditions	  at	  
37°C,	  for	  48	  h.	  Following	  incubation,	  one	  single	  bacterial	  colony	  was	  removed	  from	  the	  agar	  
plate	   and	   used	   to	   inoculate	   10	   mL	   Tryptone	   Glucose	   Yeast	   (TGY)	   broth.	   After	   overnight	  
incubation,	   TGY	   culture	  medium	  was	   sub-­‐cultured	   (1:100)	   into	   Sorbitol	  MacConkey	   (SMC)	  
broth.	  The	  SMC	  culture	  medium	  was	  incubated	  at	  37°C	  until	  an	  OD600nm	  of	  0.5	  was	  reached.	  
Figure	   4.3	   Purification	   methods	   using	   only	   heat	   or	   alcohol	   treatment	   do	   not	   generate	   a	   pure	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
C.	  difficile	  spore	  sample.	  A	  representative	  Schaeffer	  and	  Fulton	  endospore	  stain	  of	  C.	  difficile	  98011	  
vegetative	  cell:	  spore	  suspension	  A)	  before	  and	  after	  B)	  heat	  treatment	  (60°C	  for	  20	  min)	  or	  C)	  alcohol	  
treatment	  (100%	  ethanol	   for	  1	  h).	  Cells	  were	   then	  stained	  with	  malachite	  green	  and	  safranin	  red,	  
subsequently	  resulting	  in	  red	  vegetative	  cells	  and	  green	  spores.	  
After  alcohol  treatment   After  heat  treatment 
Before  treatment  A  
C  B  
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Subsequently,	  100	  µL	  of	  this	  culture	  broth	  was	  used	  to	  inoculate	  SMC	  agar	  plates,	  which	  were	  
incubated	  in	  anaerobic	  conditions	  at	  37°C	  for	  7	  days.	  
	  
4.5.2   Purification	  of	  C.	  difficile	  spores	  	  
After	  the	  extended	  C.	  difficile	  incubation	  period,	  5	  mL	  sterile	  water	  was	  added	  to	  each	  
agar	  plate	  and	  bacterial	  growth	  was	  harvested	  by	  carefully	  scraping	  the	  surface	  of	  the	  agar	  to	  
dislodge	  C.	  difficile	  spores.	  Spores	  were	  then	  washed	  twice	  with	  sterile	  water	  (4500	  x	  g	  for	  15	  
min)	  and	  suspended	   in	  2	  mL	   lysis	  buffer	   (PBS	  containing	  125	  mM	  Tris,	  200	  mM	  EDTA,	  0.3	  
mg/mL	  proteinase	  K	  and	  1%	  (v/v)	  sarcosyl).	  The	  suspension	  was	  incubated	  with	  gentle	  shaking	  
at	  37°C	  for	  2h,	  and	  spores	  were	  then	  centrifuged	  (4500	  x	  g	  for	  20	  min),	  The	  pellet	  was	  next	  
resuspended	  in	  cold	  (2	  -­‐	  5°C)	  sterile	  water,	  which	  was	  repeated	  a	  further	  10	  times.	  After	  the	  
final	  wash,	  spores	  were	  heat-­‐treated	  (60°C	  for	  20	  min)	  to	  kill	  any	  residual	  vegetative	  cells.	  
Spores	  were	   then	   frozen	  at	   -­‐20°C	  until	   required.	   Schaeffer	   and	   Fulton	  endospore	   staining	  
confirmed	   the	   presence	   of	   a	   pure	   C.	   difficile	   spore	   sample,	   free	   from	   vegetative	   cell	  















4.5.3   Schaeffer	  and	  Fulton	  endospore	  stain	  
As	  already	  mentioned,	   an	  Schaeffer	   and	  Fulton	  endospore	   stain	  was	  performed	   to	  
confirm	  purity	  of	  the	  spore	  sample	  (Schaeffer	  and	  Fulton	  1933).	  Briefly,	  100	  µL	  was	  extracted	  
from	  the	  spore	  sample	  and	  smeared	  on	  a	  glass	  slide.	  The	  sample	  was	  then	  air	  dried	  and	  fixed	  
with	  a	  gentle	  heat.	  A	  piece	  of	  tissue	  paper	  was	  placed	  on	  top	  of	  the	  slide	  and	  flooded	  with	  
malachite	  green.	  The	  slide	  was	  then	  placed	  on	  a	  heat	  block	  set	  at	  100	  °C,	  and	  steamed	  for	  5	  
min.	   The	  wet	   tissue	  paper	  was	   then	   removed	   and	   the	   slide	  washed	  under	   a	   running	   tap,	  
before	  being	  counterstained	  with	  safranin	  red	   for	  30	  seconds.	  The	  slide	  was	  washed	  once	  
again	  with	  water	  and	  air-­‐dried.	   Images	  were	  captured	  at	  100x	  magnification	  using	  a	  Leica	  
DMLA	  microscope,	  then	  analysed	  using	  ImageJ	  software	  (Schneider	  et	  al.	  2012).	  	  
Before  treatment     After  lysis  treatment    
Figure	  4.4	  Purification	  methods	  involving	  vegetative	  cell	  lysis,	  serial	  washing	  and	  a	  heat	  treatment	  
generate	  a	  pure	  C.	  difficile	  spore	  sample.	  A	  representative	  Schaeffer	  and	  Fulton	  endospore	  stain	  of	  
C.	  difficile	  98011	  vegetative	  cell:	  spore	  suspension	  A)	  before	  and	  after	  B)	  purification,	  which	  involved	  
incubation	  with	  a	  lysis	  buffer	  (2	  h),	  serial	  washing	  with	  cold	  (2	  -­‐	  5°C)	  sterile	  water	  and	  a	  heat	  treatment	  
(60°C	  for	  20	  min)	  to	  kill	  any	  residual	  vegetative	  cells.	  Cells	  were	  then	  stained	  with	  malachite	  green	  
and	  safranin	  red,	  subsequently	  resulting	  in	  red	  vegetative	  cells	  and	  green	  spores.	  
B  A  
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4.5.4   Enumeration	  of	  purified	  C.	  difficile	  spores	  
To	  enumerate	  spore	  yield,	  spore	  aliquots	  were	  serially	  diluted	  in	  PBS	  and	  plated	  onto	  
BHIS	  agar	  supplemented	  with	  0.1%	  (w/v)	  sodium	  taurocholate.	  After	  48	  h,	  spore	  titre	  was	  
enumerated	   by	   counting	   vegetative	   bacterium	   CFUs.	   Sporulation	   efficiency	   was	   then	  






C.  difficile  isolate   Sporulation  efficiency  (%)  
  






















76.3  ±  1.3   8.0  ±  0.1  
Table	  4.2	  The	  sporulation	  characteristics	  of	  five	  C.	  difficile	  clinical	  isolates	  used	  in	  the	  study.	  
To	  determine	  spore	  yield,	  spores	  were	  serially	  diluted	  and	  plated	  onto	  BHIS	  agar	  supplemented	  
with	   0.1%	   (w/v)	   sodium	   taurocholate.	   After	   48h,	   germinated	   spores	   were	   enumerated	   by	  
quantifying	   bacterial	   CFU.	   Sporulation	   efficiency	   was	   determined	   by	   comparing	   CFU/mL	  
between	  treated	  and	  untreated	  samples	  (data	  expressed	  as	  mean	  ±	  SEM;	  for	  each	  isolate	  N=2,	  
n=3).	  
	  	   86	  
4.6  	  BACTERIAL	  ADHESION	  ASSAYS	  
Soluble	  NSPs	  were	  evaluated	  for	  their	  ability	  to	   inhibit	  the	  epithelial	  adhesion	  of	  C.	  
difficile	  and	  ETEC,	  as	  well	  as	  Salmonella	  Typhimurium,	  which	  was	  used	  as	  a	  positive	  control	  
(Parsons	  et	  al.	  2014).	  In	  addition,	  soluble	  plantain	  NSP	  was	  evaluated	  for	  its	  ability	  to	  inhibit	  
the	  epithelial	  adhesion	  of	  purified	  C.	  difficile	  spores.	  	  
Intestinal	  epithelial	  cell-­‐lines	  were	  seeded	  at	  1	  x	  105	  cells/well	  in	  24-­‐well	  tissue	  culture	  
plates,	  and	  incubated	  in	  complete	  DMEM	  at	  37°C	  in	  a	  humidified	  atmosphere	  of	  5%	  CO2	  and	  
95%	  air,	  for	  24	  h.	  The	  following	  day,	  confluent	  cell	  monolayers	  were	  washed	  three	  times	  with	  
pre-­‐warmed	  sterile	  PBS,	  before	  undergoing	  a	  30	  min	  pre-­‐treatment	  with	  or	  without	  soluble	  
NSP	  (0-­‐20	  mg/mL	  in	  antibiotic-­‐free	  DMEM).	  The	  soluble	  NSP	  concentrations	  that	  were	  tested	  
were	  within	   the	   range	   of	   effective	   luminal	   concentrations	   in	   the	   human	   distal	   colon	   that	  
would	  be	  readily	  achievable	  with	  dietary	  supplementation	  (Parsons	  et	  al.	  2014;	  Roberts	  et	  al.	  
2010;	  Roberts	  et	  al.	  2013).	  	  
Cell	  monolayers	  were	  then	  infected	  with	  C.	  difficile	  bacteria	  or	  spores	  (2	  h),	  ETEC	  (1.5	  
h)	  or	  S.	  Typhimurium	  (1.5	  h)	  at	  a	  multiplicity	  of	  infection	  (MOI)	  of	  100.	  Following	  infection,	  
cells	  were	  washed	  three	  times	  with	  sterile	  PBS	  to	  remove	  any	  non-­‐adherent	  bacteria	  and	  then	  
lysed	  using	  sterile	  1%	  (v/v)	  Triton	  X-­‐100	  in	  deionised	  water.	  The	  epithelial	  adhesion	  of	  bacteria	  
and	  spores	  was	  enumerated	  by	  performing	  serial	  dilutions	  of	  cell	  lysates,	  then	  plating	  out	  20	  
µL	  lysate	  on	  agar	  in	  triplicate.	  C.	  difficile	  bacteria	  and	  spores	  were	  plated	  out	  on	  BHIS	  agar	  and	  
BHIS	   agar	   supplemented	   with	   0.1%	   (w/v)	   sodium	   taurocholate,	   respectively,	   before	  
incubation	  for	  48	  h	  at	  37°C	  in	  anaerobic	  conditions.	  All	  other	  bacteria	  were	  plated	  onto	  LB	  
agar	  and	  incubated	  for	  24	  h	  at	  37°C	  in	  aerobic	  conditions.	  Bacterial	  CFUs	  were	  then	  quantified	  
to	  assess	  bacterial	  adhesion.	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4.7  BACTERIAL	  GROWTH	  ASSAYS	  
To	  assess	  the	  effect	  of	  plantain	  NSP	  on	  bacterial	  growth,	  plantain	  NSP	  was	  incubated	  
with	   bacteria	   in	   the	   absence	   of	   intestinal	   epithelial	   cells.	   Plantain	   NSP	   was	   solubilised	   in	  
antibiotic-­‐free	  DMEM	  to	  make	  final	  concentrations	  of	  0,	  5,	  10	  and	  20	  mg/mL.	  1mL	  of	  each	  
concentration	  was	  then	  added	  to	  a	  24-­‐well	  culture	  plate	  in	  triplicate.	  Subsequently,	  C.	  difficile	  
or	  ETEC	  was	  added	  to	  each	  well	  at	  1	  x	  105	  CFU/mL,	  and	  the	  plate	  incubated	  for	  2	  h	  and	  1.5	  h,	  
respectively.	  At	  specific	  time	  points,	  200	  µL	  media	  was	  removed	  from	  each	  well	  (C.	  difficile	  -­‐	  
0,	  60	  and	  120	  min;	  ETEC	  –	  0,	  30	  and	  90	  min).	  Serial	  dilutions	  were	  then	  performed	  and	  20	  µL	  
of	  media	  plated	  on	  agar.	  C.	  difficile	  was	  grown	  on	  BHIS	  agar	  in	  anaerobic	  conditions	  at	  37°C	  
for	  48	  h,	  whilst	  ETEC	  was	  grown	  on	  LB	  agar	  in	  aerobic	  conditions	  for	  24	  h.	  Bacterial	  numbers	  
were	  then	  assessed	  by	  quantifying	  CFU/mL.	  	  
	  
4.8  TREATMENT	  OF	  CACO2	  CELLS	  WITH	  C.	  difficile	  TcdA	  AND	  TcdB	  
Plantain	   NSP	   was	   assessed	   for	   its	   ability	   to	   reduce	   epithelial	   cell	   damage	   and	  
inflammation	   induced	   by	   purified	   native	   C.	   difficile	   toxins	   TcdA	   and	   TcdB,	   which	   were	  
generously	  provided	  by	  Dr	  Fabio	  Miyajima	  (Institute	  of	  Translational	  Medicine,	  University	  of	  
Liverpool).	  The	  purified	  C.	  difficile	  toxins,	  derived	  from	  reference	  C.	  difficile	  strain	  vpi10463,	  
were	   originally	   obtained	   through	   collaboration	  with	   Dr	   Clifford	   Shone	   from	   Public	   Health	  
England	  (formerly	  Health	  Protection	  Agency;	  Porton,	  UK)	  (Maynard-­‐Smith	  et	  al.	  2014).	  
Caco2	   cells	   were	   seeded	   at	   2	   x	   105	   cells/well	   in	   6-­‐well	   tissue	   culture	   plates	   and	  
maintained	  in	  complete	  DMEM	  at	  37°C	  with	  5%	  CO2,	  95%	  air,	  for	  24	  h.	  Cell	  monolayers	  were	  
then	   washed	   three	   times	   with	   pre-­‐warmed	   sterile	   PBS	   before	   undergoing	   a	   30	   min	   pre-­‐
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treatment	  with	  or	  without	  10	  mg/mL	  plantain	  NSP.	  Subsequently,	  cells	  were	  treated	  with	  C.	  
difficile	   TcdA	  or	  TcdB	  at	   concentrations	   ranging	   from	  1-­‐100	  ng/mL	   for	  0-­‐48	  h.	  Cell	   culture	  
media	  was	  then	  harvested	  for	  future	  analysis.	  	  
	  
4.9  TREATMENT	  OF	  HT29	  CELLS	  WITH	  MUCOSALLY	  ASSOCIATED	  E.	  coli	  FLAGELLIN	  
Plantain	   NSP	  was	   assessed	   for	   its	   ability	   to	   reduce	   the	   epithelial	   cell	   damage	   and	  
inflammation	  induced	  by	  bacterial	  components	  such	  as	  flagellin.	  Cells	  were	  seeded	  in	  24-­‐well	  
plates	  at	  2	  x	  105	  cells/well	  and	  incubated	  for	  24	  h	  to	  form	  confluent	  monolayers.	  Cells	  were	  
then	  washed	  three	  times	  with	  pre-­‐warmed	  sterile	  PBS	  and	  pre-­‐incubated	  for	  30	  min	  with	  10	  
mg/mL	  plantain	  NSP.	  	  
Five	  UC	  E.	  coli	  strains	  (HM250,	  HM295,	  HM378,	  HM380	  and	  HM387)	  were	  grown	  as	  
described	   in	  Section	  4.4.2	  and	  suspended	  in	  sterile	  water	  following	  three	  washes.	  Bacteria	  
were	  pooled	  to	  generate	  a	  bacterial	  suspension	  of	  OD	  0.125	  at	  550nm	  and	  E.	  coli	  were	  then	  
filtered	   using	   a	   sterile	   0.2	   µm	   filter.	   The	   resultant	   bacteria-­‐free	   supernatant,	   containing	  
flagellae	   (flagellin)	   and	   outer	  membrane	   vesicles	   (OMVs),	   as	   shown	   by	   Subramanian	   and	  
colleagues	  (Subramanian	  et	  al.,	  2008)	  was	  then	  used	  to	  treat	  cells	  at	  a	  volume	  of	  50	  µL/well.	  
In	  parallel,	  cells	  were	  individually	  treated	  with	  each	  UC	  E.	  coli	  isolate	  at	  an	  MOI	  of	  10,	  or	  with	  
1	  µg/mL	  purified	  flagellin	  (or	  vehicle	  control),	   for	  4	  h	  at	  37°C.	  Cell	  culture	  media	  was	  then	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4.10   TREATMENT	  OF	  CACO2	  CELLS	  WITH	  BACTERIAL	  LIPOPOLYSACCHARIDE	  (LPS)	  
Plantain	   NSP	   was	   assessed	   for	   its	   ability	   to	   inhibit	   the	   epithelial	   cell	   damage	   and	  
inflammation	  mediated	  by	  bacterial	  LPS.	  Caco2	  cells	  were	  seeded	  at	  1	  x	  105	  cells/mL	  in	  24-­‐
well	  tissue	  culture	  plates,	  and	  incubated	  for	  24	  h	  at	  37°C	  in	  humidified	  conditions	  of	  5%	  CO2	  
and	  95%	  air.	  The	  next	  day,	  cell	  monolayers	  were	  washed	  three	  times	  with	  sterile	  PBS	  and	  pre-­‐
treated	  for	  30	  min	  with	  or	  without	  10	  mg/mL	  plantain	  NSP.	  Cells	  were	  then	  treated	  with	  LPS	  
(E.	   coli	   0111:	   B4;	   Sigma-­‐Aldrich)	   at	   1,	   100	   or	   1000	   µg/mL	   (or	   saline	   vehicle	   control)	   and	  
incubated	   for	  24	  h.	  Cell	   culture	  media	  was	   then	  harvested	  and	   stored	  at	   -­‐20°C	   for	   future	  
analysis.	  	  
	  
4.11   MODIFIED	  BACTERIAL	  ADHESION	  ASSAYS	  
To	  determine	   if	   the	   inhibitory	   action	  of	  plantain	  NSP	  against	  diarrhoeal	   pathogens	  
occurred	  via	  an	  action	  of	  the	  epithelial	  monolayer	  or	  through	  direct	  interaction	  with	  bacteria,	  
modifications	  were	  made	  to	  the	  bacterial	  adhesion	  assays	  described	  in	  Section	  4.6	  (Parsons	  
et	  al.	  2014).	  	  
To	  test	  if	  soluble	  plantain	  NSP	  exhibited	  its	  inhibitory	  effect	  via	  interaction	  with	  the	  
intestinal	  epithelium,	  plantain	  NSP	  was	  added	  to	  cell	  monolayers	  30	  min	  prior	  to	  infection	  as	  
earlier	  described,	  but	   then	   removed	  by	   three	  washes	  with	  pre-­‐warmed	  sterile	  PBS	   (1	  min	  
each;	  37°C).	  Monolayers	  were	  then	  provided	  fresh	  antibiotic-­‐free	  DMEM	  and	  infected	  with	  
bacteria	  as	  normal.	  To	  test	  if	  soluble	  plantain	  NSP	  exhibited	  its	  inhibitory	  effect	  via	  a	  direct	  
interaction	  with	  bacteria,	  plantain	  NSP	  was	  pre-­‐incubated	  with	  bacteria	  for	  30	  min,	  followed	  
by	   centrifugation,	   re-­‐suspension	   of	   bacteria	   in	   antibiotic-­‐free	   media	   and	   inoculation	   of	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epithelial	   cell	  monolayers.	   These	   alternative	   conditions	  were	   performed	   according	   to	   the	  
methods	  described	  in	  Section	  4.6.	  
	  
4.12   CHLORIDE	  CHANNEL	  ACTIVITY	  ASSAYS	  
Studies	   were	   performed	   to	   assess	   if	   the	   inhibitory	   action	   of	   plantain	   NSP	   against	  
diarrhoeal	   pathogens	  was	  mediated	   by	   increased	   electrogenic	   chloride	   secretion.	   Cellular	  
chloride	   secretion	   was	   assessed	   using	   a	   simple	   colorimetric	   assay	   that	   measures	   cellular	  
iodide	  efflux	  as	  a	  means	  of	  monitoring	  chloride	  channel	  activity,	  as	  previously	  described	  (Tang	  
and	  Wildey	  2004).	  	  
	  
4.12.1   Chloride	  channel	  activation	  	  
Plantain	  NSP	  was	  first	  evaluated	  for	  its	  ability	  to	  activate	  epithelial	  chloride	  channel	  
activation	  alongside	  known	  chloride	  channel	  activators,	  forskolin	  and	  RP107	  (Noel	  et	  al.	  2006)	  
which	  were	  used	  as	  positive	  controls.	  Caco2	  cells	  were	  seeded	  in	  a	  96-­‐well	  plate	  at	  2.5	  x	  104	  
cells/well	  and	  incubated	  for	  24	  h	  at	  37°C.	  Cells	  were	  then	  loaded	  with	  100	  µL	  pre-­‐warmed	  
iodine	  loading	  buffer	  (containing	  150	  mM	  NaI;	  see	  Appendix	  1	  for	  full	  recipe)	  and	  incubated	  
for	  4	  h	  at	  37°C	  (iodine	  loading	  step).	  Subsequently,	  cells	  were	  washed	  three	  times	  with	  sterile	  
PBS	  (pH	  7.4),	  and	  incubated	  for	  30	  min	  with	  100	  µL	  plantain	  NSP	  (2.5	  -­‐	  10	  mg/mL),	  forskolin	  
(12.5	  –	  200	  µM),	  RP107	  (12.5	  –	  200	  µM)	  or	  saline	  vehicle	  control.	  Following	  incubation,	  cells	  
were	  lysed	  with	  1%	  (v/v)	  Triton-­‐X-­‐100	  in	  deionised	  water.	  Intracellular	  iodine	  concentration	  
was	  determined	  using	  the	  modified	  Sandell-­‐Kolthoff	  (SK)	  reaction,	  in	  which	  100	  µL	  cell	  lysate	  
was	  mixed	  in	  a	  1:1	  ratio	  with	  detection	  buffer	  2.	  Detection	  buffer	  1	  (100	  µL)	  was	  then	  added	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to	  the	  mixture,	  and	  incubated	  for	  5	  min	  at	  room	  temperature	  before	  measuring	  absorbance	  
at	  OD	  410nm.	  For	  full	  recipes	  of	  the	  reagents	  used	  in	  chloride	  channel	  activation	  assays,	  see	  
Appendix	  1.	  	  
	  
4.12.2   Chloride	  channel	  inhibition	  
Chloride	   channel	   antagonists,	   cystic	   fibrosis	   conductance	   regulator	   (CFTR)	   inhibitor	  
172	   (CFTR-­‐inh-­‐172)	   and	   5-­‐nitro-­‐2-­‐(-­‐3-­‐phenylpropyl-­‐amino)	   benzoic	   acid	   (NPPB),	  were	   next	  
evaluated	  for	  their	  ability	  to	  block	  cellular	  chloride	  channel	  activation	  (Keeling	  et	  al.	  1991;	  
Linsdell	  2014).	  Caco2	  cells	  were	  treated	  with	  100	  µL	  CFTR-­‐inh-­‐172	  (12.5	  –	  200	  µM)	  or	  NPPB	  
(50	   –	   800	   µM)	   during	   the	   iodine-­‐loading	   step.	   As	   previously	   described,	   cells	   were	   then	  
incubated	  for	  4	  h	  before	  undergoing	  30	  min	  incubation	  with	  plantain	  NSP,	  forskolin	  or	  RP107.	  
Cells	  were	  subsequently	   lysed	  and	  the	   intracellular	   iodine	  concentration	  determined	  using	  
the	  SK	  reaction.	  	  
	  
4.12.3  Use	  of	  chloride	  channel	  modulators	  in	  bacterial	  adhesion	  assays	  
Following	  confirmation	  that	  chloride	  channel	  modulators	  had	  a	  measurable	  effect	  on	  
cellular	  chloride	  channel	  activity,	  these	  drugs	  were	  used	  in	  bacterial	  adhesion	  assays	  to	  assess	  
their	  effect	  on	  bacterial	  adhesion.	  Bacterial	  adhesion	  assays	  were	  carried	  out	  as	  previously	  
described	  in	  Section	  4.6,	  with	  some	  modifications.	  	  
To	   assess	   the	   effect	   of	   chloride	   channel	   activation	   on	   bacterial	   adhesion,	   cell	  
monolayers	  were	  pre-­‐treated	  with	  or	  without	  10	  mg/mL	  plantain	  NSP,	  and	  in	  parallel,	  100	  µM	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RP107	  or	  100	  µM	  forskolin,	  for	  30	  min	  prior	  to	  infection	  with	  bacteria.	  The	  remainder	  of	  the	  
bacterial	  adhesion	  assay	  was	  performed	  as	  usual.	  	  
To	   assess	   the	   effect	   of	   chloride	   channel	   inhibition	   on	   bacterial	   adhesion,	   cell	  
monolayers	  underwent	  an	  additional	  pre-­‐treatment	  with	  200	  µM	  CFTR-­‐inh-­‐172	  or	  800	  µM	  
NPPB	   for	   1	   h	   prior	   to	   treatment	   with	   plantain	   NSP	   or	   chloride	   channel	   activators	   and	  
subsequent	  bacterial	  inoculation.	  	  
	  
4.13   FLUORESCENCE	  MICROSCOPY	  
	  
4.13.1   Phalloidin/4’,6-­‐diamidino-­‐2-­‐phenylindole	   (DAPI)	   staining	   to	   assess	   cellular	  
cytotoxicity	  
Cell	  rounding	  was	  assessed	  using	  fluorescence	  microscopy.	  Briefly,	  Caco2	  cells	  were	  
seeded	  at	  1	  x	  10	  5	  cells/mL	  in	  a	  24-­‐well	  culture	  plate	  on	  13mm	  coverslips,	  and	  incubated	  for	  
48h.	  Following	  toxin	  treatment,	  cells	  were	  fixed	  with	  2%	  (v/v)	  paraformaldehyde	  (PFA)	  for	  10	  
min,	  and	   then	  washed	  3	   times	  with	   sterile	  PBS.	  Actin	   filaments	  were	  visualised	  by	  adding	  
AlexaFluor®488-­‐phalloidin	  (Life	  Technologies	  Ltd,	  Paisley,	  UK)	  (Excitation/Emission:	  350/470	  
nm)	  to	  cells	  at	  a	  ratio	  of	  1:100	  for	  30	  min.	  Cells	  were	  washed	  three	  times	  with	  sterile	  PBS	  and	  
the	   coverslips	   then	   air	   dried.	   Cell	   nuclei	   were	   visualised	   by	   counterstaining	   with	   4’6-­‐
diamidino-­‐2-­‐phenylindole	   (DAPI),	   in	   which	   coverslips	   were	  mounted	   on	   glass	   slides	   using	  
VectaShield	   +	   DAPI	   mounting	   media	   (Vector	   Laboratories	   Ltd,	   Peterborough,	   UK)	  
(Excitation/Emission:	  495/519).	   Images	  were	  captured	  using	  an	  Olympus	  BX51	   fluorescent	  
microscope.	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4.13.2   Immunocytoflourescence	  to	  assess	  nuclear	  translocation	  of	  β-­‐catenin	  
The	  intracellular	  localisation	  of	  β-­‐catenin	  was	  visualised	  by	  immunocytofluorescence	  
microscopy.	   Cells	   were	   seeded	   at	   1	   x	   105	   cells/mL	   in	   a	   24-­‐well	   culture	   plate	   on	   13mm	  
coverslips,	  and	  incubated	  for	  48h	  at	  37°C.	  Following	  treatment,	  cells	  were	  washed	  three	  times	  
with	   sterile	   PBS	   and	   fixed	   with	   100%	   methanol	   for	   15	   min	   at	   -­‐20°C.	   To	   aid	   cell	  
permeabilisation,	   cells	  were	   treated	  with	  1	  mL	  PBS	  containing	  5%	   (w/v)	  BSA	  and	  1%	   (v/v)	  
Triton-­‐X100	   for	  15	  min.	  Cells	  were	   then	  washed	   three	   times	  with	   sterile	  PBS	  and	  blocked	  
overnight	  with	  PBS	  containing	  5%	  (w/v)	  BSA	  at	  4°C.	  Subsequently,	  cells	  were	  incubated	  with	  
primary	  mouse	  monoclonal	   IgG	  anti	  human	  β-­‐catenin	  antibody	   (Clone	  14;	  BD	  Biosciences;	  
Oxford,	   UK)	   (1:1000)	   followed	   by	   secondary	   fluorescein	   isothiocyanate	   (FITC)-­‐conjugated	  
rabbit	  polyclonal	  anti-­‐mouse	  Ig	  antibody	  (Abcam;	  Cambridge,	  UK)	  (1:2000),	  each	  for	  1	  h	  at	  
room	  temperature.	  Three	  5	  min	  washes	  with	  sterile	  PBS	  washes	  were	  performed	  in-­‐between	  
and	  after	  each	  antibody	  incubation.	  Finally,	  coverslips	  were	  mounted	  onto	  glass	  slides	  using	  
VectaShield	  +	  DAPI	  mounting	  media	  (Vector	  Laboratories	  Ltd).	  Images	  were	  captured	  using	  
an	  Olympus	  BX51	  fluorescent	  microscope.	  	  
	  	  
4.14   GIEMSA	  MICROSCOPY	  
Giemsa	  microscopy	  was	  performed	  to	  visually	  assess	  bacterial	  adhesion	  to	   intestinal	  
epithelial	  cells.	  First,	  intestinal	  epithelial	  cells	  were	  grown	  on	  13	  mm	  glass	  coverslips	  in	  12-­‐
well	  tissue	  culture	  plates	  at	  2	  x	  105	  cells/well.	  The	  plate	  was	  incubated	  at	  37°C	  for	  24	  h	  and	  
washed	  three	  times	  with	  sterile	  PBS.	  Cells	  were	  then	  pre-­‐incubated	  with	  or	  without	  10	  mg/mL	  
soluble	  plantain	  NSP	  for	  30	  min	  prior	  to	  infection	  with	  bacteria	  at	  an	  MOI	  of	  100.	  Following	  
incubation	  with	  bacteria	   (C.	  difficile,	  2	  h;	  ETEC,	  1.5	  h),	  cells	  were	  washed	  three	  times	  with	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sterile	   PBS	   and	   then	   fixed	   with	   70%	   (v/v)	   ethanol	   for	   20	  min	   at	   room	   temperature.	   The	  
coverslips	  were	  washed	  three	  times	  with	  sterile	  PBS	  and	  then	  stained	  with	  10%	  (v/v)	  Giemsa	  
solution	  (Sigma	  Aldrich)	  for	  30	  min	  at	  room	  temperature.	  Coverslips	  were	  mounted	  with	  cell	  
monolayers	  face	  down,	  onto	  glass	  slides	  using	  DPX	  (Distrene,	  Plasticiser,	  Xylene)	  mounting	  
media	  (Leica	  Microsystems;	  Milton	  Keynes,	  UK).	  Images	  were	  captured	  at	  100x	  magnification	  
using	  a	  Leica	  DMLA	  microscope,	  then	  analysed	  using	  ImageJ	  software	  (Schneider	  et	  al.	  2012).	  	  
	  
4.15   QUANTIFICATION	  OF	  PRO-­‐INFLAMMATORY	  INTERLEUKIN	  8	  (IL-­‐8)	  RELEASE	  BY	  ELISA	  
Harvested	  media	  from	  cells	  was	  measured	  for	  the	  presence	  of	  IL-­‐8	  using	  a	  solid	  phase	  
sandwich	  ELISA	  (IL-­‐8	  Human	  Elipair	  Kit;	  Abcam;	  ab48483).	  50	  µL	  capture	  antibody	  specific	  for	  
IL-­‐8	  (B-­‐K8)	  was	  diluted	  in	  10	  mL	  0.5M	  carbonate-­‐bicarbonate	  buffer	  (pH	  9.6).	  100	  µL	  diluted	  
capture	   antibody	   was	   then	   coated	   into	   96	   well	   high-­‐binding	   γ-­‐irradiated	   ELISA	   plates	  
(Corning/Co-­‐star)	  overnight	  at	  4°C.	  Following	  three	  washes	  with	  120µL	  PBS-­‐0.1%	  (v/v)	  Tween-­‐
20	  buffer	  (pH	  7.4),	  capture	  antibody	  coated	  plates	  were	  blocked	  using	  250µL	  1%	  (w/v)	  BSA	  in	  
PBS-­‐Tween	   for	   2h	  at	   room	   temperature.	   Triplicate	   treatment	   samples	   (100µL)	  of	   cell	   free	  
medium	  were	  then	  incubated	  overnight	  at	  4°C,	  plates	  washed	  three	  times	  with	  120	  µL	  PBS-­‐
0.1%	  (v/v)	  Tween-­‐20	  and	  50	  µL	  anti-­‐IL8	  biotinylated	  detection	  antibody	  added	  for	  2	  h	  at	  room	  
temperature.	  Subsequently,	  100	  µL	  HRP-­‐streptavidin	  was	  added	  to	  each	  well,	  incubated	  for	  
20	  min	  at	  room	  temperature	  and	  then	  washed	  three	  times	  with	  120	  µL	  PBS-­‐Tween.	  The	  ELISA	  
was	  developed	  with	  o-­‐phenylenediamine	  (OPD)	  substrate	  (SigmaFast),	  as	  per	  manufactures	  
instructions,	   incubated	   in	   the	  dark	   for	   10	  min	   and	   stopped	  with	   100µL	   4M	  H2SO4.	  Optical	  
density	  was	  then	  measured	  at	  OD	  492	  nm.	  Recombinant	  IL-­‐8	  standards	  (0-­‐2000	  pg/mL)	  and	  
water	   blanks	   were	   also	   included	   on	   each	   ELISA	   plate.	   IL-­‐8	   concentration	   of	   cell	   culture	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samples	  was	  determined	  against	  the	  IL-­‐8	  standard	  calibration	  curve	  (Figure	  4.5).	  The	  within-­‐




















Figure	  4.5	  IL-­‐8	  calibration	  curve	  used	  to	  determine	  the	  unknown	  IL-­‐8	  concentration	  of	  
culture	  medium	  harvested	  from	  intestinal	  epithelial	  cells.	  Recombinant	  IL-­‐8	  standards	  (0-­‐
2000	   pg/mL	   in	   cell	   culture	   medium)	   were	   added	   in	   triplicate	   and	   IL-­‐8	   concentration	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4.16   MEASUREMENT	  OF	  CASPASE-­‐3	  ACTIVATION	  
Caco2	  cells	  were	  seeded	  at	  1	  x	  104	  cells/mL	  in	  clear	  bottomed,	  white	  walled	  96-­‐well	  
tissue	  culture	  plates	  (Corning/Costar)	  and	  cultured	  overnight	  at	  37°C	  in	  humidified	  conditions	  
of	  95%	  air,	  5%	  CO2.	  Following	  treatment,	  cell	  monolayers	  were	  assayed	  for	  active	  caspase-­‐3	  
using	   a	   commercial	   Caspase-­‐Glo®	   3/7	   Assay	   (Promega;	   Southampton,	   UK)	   as	   per	  
manufacturer’s	  instructions.	  Luminescence	  was	  detected	  using	  the	  Tecan	  Infinite	  F200	  plate	  
reader	   (Tecan,	   Reading,	   UK).	   Experiments	   were	   performed	   in	   triplicate,	   with	   background	  
luminescence	   determined	   from	  wells	   containing	   culture	  medium	  without	   cells	   subtracted	  
from	  results.	  	  
	  
4.17   MEASUREMENT	  OF	  ADENYLATE	  KINASE	  
Media	  harvested	  from	  cell	  monolayers	  and	  was	  assessed	  for	  the	  presence	  of	  adenylate	  
kinase	   (AK)	   using	   Toxilight	   Bioassay	   Kit	   (Lonza;	   Slough,	   UK).	   The	   assay	   was	   performed	  
according	  to	  the	  manufacturer’s	  instructions,	  using	  white	  walled	  96-­‐well	  tissue	  culture	  plates	  
with	  flat	  clear	  bottoms.	  Luminescence	  was	  detected	  using	  the	  Tecan	  F200	  plate	  reader	  (as	  
above	  Section	  4.16).	  Experiments	  were	  performed	  in	  triplicate	  and	  results	  were	  expressed	  as	  
a	  percentage	  of	   total	   cell	  adenylate	  kinase	   (AK)	   released	   from	  untreated	  cells,	   lysed	  using	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4.18   IMMUNOBLOTTING	  
Intestinal	   epithelial	   cells	  were	   lysed	   in	   ice	   cold	   20	  mM	   Tris-­‐HCl	   buffer,	   p.H	   7.4	   and	  
resultant	  whole	  cell	  lysates	  then	  resuspended	  in	  250	  µL	  sample	  buffer.	  The	  suspension	  was	  
then	  vortexed	  for	  30	  seconds	  to	  ensure	  a	  homogenous	  sample	  and	  boiled	  at	  90°C	  for	  5	  min.	  	  
Whole	  cell	  lysates	  (25	  µL)	  were	  separated	  by	  SDS-­‐PAGE	  using	  4	  –	  15%	  Mini-­‐PROTEAN®	  
TGX™	  precast	   protein	   gels	   (Biorad;	  Hemel	  Hempstead,	  UK)	   for	   2	   h,	   at	   150	  V,	   followed	  by	  
electrotransfer	  to	  nitrocellulose	  (1	  h,	  100	  V).	  Nitrocellulose	  membranes	  were	  blocked	  using	  
1%	  (v/v)	  bovine	  serum	  albumin	  (BSA)	  in	  PBS	  containing	  0.1%	  (v/v)	  Tween-­‐20	  overnight	  at	  4°C,	  
then	  probed	  with	   the	  primary	  antibody;	  anti-­‐Rac1	  102	   (BD	  Transduction	  Lab;	  Oxford,	  UK),	  
which	  has	  been	  shown	  to	  lose	  affinity	  for	  Rac1	  following	  monoglucosylation,	  or	  anti-­‐Rac	  238a	  
(Abcam;	  Cambridge,	  UK),	  which	  recognises	  both	  unglucosylated	  and	  mono-­‐glucosylated	  Rac1	  
(Gerhard	  et	  al.	  2008).	  Both	  antibodies	  were	  diluted	  1:1000	  in	  PBS-­‐0.1%	  (v/v)	  Tween-­‐20	  and	  
incubated	  for	  2h	  at	  room	  temperature,	  followed	  by	  three	  5	  min	  washes	  with	  the	  same	  buffer.	  	  
Blots	   were	   then	   incubated	   with	   an	   appropriate	   rabbit	   anti-­‐mouse	   Ig	   horseradish	  
peroxidase	   (HRP)-­‐conjugated	   secondary	   antibody	   (1:2000)	   for	   1	   h	   at	   room	   temperature.	  
Membranes	  were	  again	  washed	  three	  times	  with	  PBS-­‐0.1%	  (v/v)	  Tween-­‐20	  and	  protein	  bands	  
visualised	  with	  SuperSignal	  West	  Dura	  Extended	  Duration	  Substrate	  (Fischer	  Scientific	  UK	  Ltd;	  
Loughborough,	  UK).	  Using	   Image	  Lab	  Software	  v.	  3.0.1	   (Biorad),	   images	  were	  subjected	  to	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4.19   STATISTICAL	  ANALYSIS	  
Data	  is	  expressed	  as	  mean	  ±	  standard	  error	  of	  the	  mean	  (SEM).	  N	  numbers	  indicate	  the	  
total	   number	   of	   independent	   experiments	   performed,	   where	   each	   experiment	   was	  
performed	  with	  at	  least	  n=3	  replicates	  for	  any	  individual	  treatment	  group,	  unless	  otherwise	  
indicated.	   Independent	   sample	   groups	   were	   first	   assessed	   for	   normality	   and	   equality	   of	  
variance	   using	   Shapiro	  Wilks	   and	   F-­‐test.	   Two-­‐sample	   comparisons	   were	   performed	   using	  
unpaired	  Students	  t-­‐test	  or	  Mann	  Whitney	  U	  as	  appropriate.	  Multiple	  treatment	  groups	  were	  
analysed	  using	  either	  the	  one-­‐way	  analysis	  of	  variance	  (ANOVA)	  or	  non-­‐parametric	  Kruskal-­‐
Wallis	  ANOVA,	  followed	  by	  pair-­‐wise	  comparisons	  of	  treatment	  means	  (Stats-­‐Direct	  v2.6.6;	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5.1   INTRODUCTION	  
C.	   difficile	   and	   ETEC	   represent	   two	   significant	   diarrhoeal	   pathogens	   that	   cause	  
significant	   morbidity	   and	   mortality	   worldwide.	   Indeed,	   incidence	   and	   mortality	   rates	  
associated	  with	  CDI	  have	  increased	  due	  to	  the	  emergence	  of	  hyper-­‐virulent	  strains,	  such	  as	  
the	  BI/NAP1/027	   strain	   (Freeman	   et	   al.	   2010).	   In	   addition,	   there	  has	  been	  a	   considerable	  
increase	  in	  recurrence	  and	  relapse	  rates	  associated	  with	  CDI	  (Kelly	  2012),	  thought	  to	  be	  due	  
to	   the	  production	  of	   robust	  C.	  difficile	   endospores.	   Prevention	  of	   ETEC	   infection	   is	   clearly	  
related	   to	   improvements	   in	   sanitation	   and	   food	   preparation	   in	   endemic	   regions	   where	  
prevalence	  is	  high.	  However,	  such	  improvements	  would	  require	  significant	  investment	  and	  
likely	  take	  a	   long	  time	  (Qadri	  et	  al.	  2005).	  With	  a	   lack	  of	  broadly	  protective	  ETEC	  vaccines	  
(Zhang	  and	  Sack	  2012)	  and	  a	  low	  availability	  of	  effective	  microbials	  in	  endemic	  regions	  (Nataro	  
and	  Kaper	  1998),	  ETEC	  therapy	  mainly	  relies	  on	  use	  of	  oral	  rehydration,	  which	  only	  manages	  
symptoms	   rather	   than	   treating	   the	   cause	  of	   infection	   (King	   et	  al.	   2003)	  Therefore,	   it	   is	  of	  
paramount	   importance	  that	  alternative	  therapeutic	  strategies	  are	  developed	  to	  effectively	  
combat	  these	  diarrhoeal	  diseases.	  	  
Adhesion	  of	  pathogenic	  bacteria	  to	  host	  tissues	  represents	  an	  early,	  but	  critical	  step	  
in	  the	  pathogenesis	  of	  virtually	  all	  infections	  (Lehmann	  et	  al.	  2006).	  To	  mediate	  this	  process,	  
C.	   difficile	   and	   ETEC	   possess	   adhesins,	   which	   recognise	   and	   bind	   to	   complementary	  
carbohydrates	  on	  the	  surface	  of	  host	  cells,	  promoting	  bacterial-­‐epithelial	  adherence	  (Sharon	  
2006).	  	  Indeed,	  close	  proximity	  of	  C.	  difficile	  and	  ETEC	  to	  the	  intestinal	  epithelium	  is	  likely	  to	  
be	  essential	  for	  the	  subsequent	  release	  of	  their	  respective	  toxins.	  In	  addition,	  studies	  have	  
also	   shown	   that	  C.	   difficile	   spores	   interact	  with	   the	   intestinal	   epithelium,	   leading	   to	   their	  
persistence	  within	  the	  colonic	  tract	  (Paredes-­‐Sabja	  and	  Sarker	  2012).	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It	  is	  clear	  that	  C.	  difficile	  and	  ETEC	  adhesins,	  as	  well	  as	  C.	  difficile	  spores,	  play	  a	  key	  role	  
in	   the	   pathogenesis	   of	   infection.	   Interrupting	   these	   potentially	   harmful	   bacteria-­‐epithelial	  
interactions	  could	  therefore	  represent	  a	  promising	  therapeutic	  strategy	  to	  prevent	  and	  treat	  
CDI	  and	  ETEC	  infection.	  
Recent	  studies	  from	  our	  laboratory	  have	  demonstrated	  that	  soluble	  dietary	  plant	  NSPs	  
can	   block	   the	   epithelial	   adhesion	   of	   a	   range	   of	   diarrhoeal	   pathogens	   (including	   S.	  
Typhimurium,	  Shigella	  sonnei	  and	  E.	  coli	  pathovars)	  both	  in	  vitro	  and	  in	  vivo	  (Parsons	  et	  al.	  
2014;	  Roberts	  et	  al.	  2010;	  Roberts	  et	  al.	  2013).	  Out	  of	  all	  the	  soluble	  fibres	  tested,	  NSP	  from	  
plantain	  bananas	  (Musa	  spp.)	  has	  shown	  the	  greatest	  efficacy.	  Preliminary	  results	  have	  also	  
indicated	   that	   plantain	   NSP	   is	   effective	   at	   inhibiting	   the	   in	   vitro	   epithelial	   adhesion	   of	  










	  	  102	  
5.2   HYPOTHESIS	  
Soluble	   plant	   fibres,	   including	   those	   from	   plantain	   bananas,	   can	   inhibit	   the	   in	   vitro	  
epithelial	  adhesion	  of	  C.	  difficile	  and	  ETEC	  bacteria,	  as	  well	  as	  C.	  difficile	  spores	  
	  
5.3   AIMS	  
	  
1.   To	  evaluate	  soluble	  plantain	  fibre,	  as	  well	  as	  a	  range	  of	  other	  soluble	  dietary	  fibres,	  for	  
their	  efficacy	  at	  inhibiting	  C.	  difficile	  and	  ETEC	  adhesion	  to	  intestinal	  epithelial	  cells	  
	  
2.   To	  evaluate	  soluble	  plantain	  fibre	  for	  its	  ability	  to	  inhibit	  the	  epithelial	  adhesion	  of	  eleven	  
C.	  difficile	  clinical	  isolates,	  which	  vary	  in	  their	  toxin	  expression	  and	  ribotype	  status	  
	  
3.   To	  evaluate	  soluble	  plantain	  fibre	  for	  its	  ability	  to	  inhibit	  the	  epithelial	  adhesion	  of	  purified	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5.4   METHODS	  
An	  initial	  inhibitory	  screen	  was	  first	  performed	  to	  evaluate	  a	  range	  of	  different	  soluble	  
plant	   fibres	   for	   their	   ability	   to	   inhibit	  C.	  difficile	  and	  ETEC	  adhesion	   to	   intestinal	   epithelial	  
Caco2	  cells.	  Apple,	  bean,	  blueberry,	  leek,	  pear,	  strawberry	  and	  tomato	  NSP	  were	  selected	  as	  
they	  represent	  common	  sources	  of	  dietary	  fibre	  from	  monocots	  (monocotyledon	  plants,	  i.e.	  
having	   one	   seed	   leaf,	   or	   cotyledon),	   whilst	   oat	   and	   plantain	   NSP	   are	   classified	   as	   dicots	  
(dicotyledon	  plants	  with	  two	  seed	  leaves).	  NSP	  fibres	  that	  exhibited	  the	  highest	  efficacy	  in	  the	  
inhibitory	  screen	  were	  selected	  for	  further	  evaluation	  in	  dose-­‐response	  studies.	  In	  addition,	  
soluble	  NSP	  was	  assessed	  for	  its	  ability	  to	  inhibit	  the	  epithelial	  adhesion	  of	  eleven	  C.	  difficile	  
clinical	  isolates	  of	  differing	  ribotype	  and	  toxin	  type,	  as	  well	  as	  five	  purified	  C.	  difficile	  spore	  
samples,	  prepared	  by	  the	  methods	  described	  in	  Section	  4.5.	  	  
The	  inhibitory	  activity	  of	  soluble	  dietary	  fibre	  was	  assessed	  using	  bacterial	  adhesion	  
assays,	  for	  which	  detailed	  methods	  can	  be	  found	  in	  Section	  4.6.	  Briefly,	  Caco2	  cell	  monolayers	  
were	   pre-­‐incubated	   for	   30	   min	   with	   or	   without	   soluble	   NSP	   (2.5	   –	   20	   mg/mL)	   and	   then	  
infected	  with	  C.	  difficile	  080042	  (Ribotype	  027a)	  (MOI	  of	  100;	  2	  h)	  or	  ETEC	  C410	  (serotype	  
0160,	  LT+/ST+)	  (MOI	  100;	  1.5	  h)	  versus	  uninfected	  controls.	  Following	  incubation,	  cells	  were	  
washed	  three	  times	  to	  remove	  any	  non-­‐adherent	  bacteria,	  then	  lysed	  and	  grown	  overnight	  
on	   bacterial	   agar	   plates	   to	   enumerate	   bacteria	   adherent	   to	   the	   epithelial	   monolayer.	   C.	  
difficile	  and	  ETEC	  were	  cultured	  on	  BHIS	  and	  LB	  agar	  plates,	  respectively.	  The	  same	  method	  
was	   used	   for	  C.	   difficile	   spore	   adhesion	   assays,	   but	   cell	   lysates	  were	   plated	   on	   BHIS	   agar	  
supplemented	   with	   0.1%	   (w/v)	   sodium	   taurocholate	   to	   aid	   spore	   germination	   and	  
enumeration	  of	  resultant	  vegetative	  cells.	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5.5   RESULTS	  
5.5.1   Evaluation	  of	  various	  soluble	  dietary	  fibres	  for	  their	  ability	  to	  inhibit	  the	  in	  vitro	  
epithelial	  adhesion	  of	  C.	  difficile	  and	  ETEC	  
A	   screen	   of	   inhibitory	   activity	   was	   first	   performed,	   in	   which	   a	   number	   of	   soluble	  
dietary	   fibres	   (apple,	   bean,	   blueberry,	   broccoli,	   celery,	   leek,	   oats,	   pear,	   pepper,	   plantain,	  
strawberry	  and	  tomato	  NSP)	  were	  assessed	  for	  their	  ability	  to	  inhibit	  the	  epithelial	  adhesion	  
of	  C.	  difficile.	  Pre-­‐incubation	  of	   intestinal	   cells	  with	  5	  mg/mL	  bean,	  broccoli,	   leek,	  pepper,	  
plantain	   and	   tomato	   NSP	   all	   resulted	   in	   significant	   inhibition	   of	   bacterial	   adhesion.	   In	  
particular,	  plantain	  NSP	  affected	  the	  highest	  level	  of	  blockade,	  reducing	  C.	  difficile	  adhesion	  
by	  77.0	  ±	  1.7%	  in	  comparison	  to	  the	  untreated	  control	  (P	  <	  0.001;	  Kruskal-­‐Wallis;	  N=3,	  n=4).	  
In	  addition,	  broccoli	  and	  leek	  NSP	  also	  resulted	  in	  considerable	  levels	  of	  inhibition,	  reducing	  

















Figure	   5.1.	   Evaluation	   of	   a	   range	   of	   soluble	   NSPs	   for	   their	   ability	   to	   inhibit	   the	   in	   vitro	  
epithelial	  adhesion	  of	  C.	  difficile.	  Adhesion	  of	  C.	  difficile	  to	  confluent	  Caco2	  cell	  monolayers	  
was	  significantly	  inhibited	  in	  the	  presence	  of	  5	  mg/mL	  bean,	  broccoli,	  leek,	  pepper,	  plantain	  
and	  tomato	  NSP.	  Adhesion	  was	  measured	  as	  relative	  to	  CFU/mL	  quantified	  in	  the	  absence	  of	  
any	  NSP	  (set	  as	  100%)	  (All	  N=3,	  n=3-­‐4	  excepting	  #N=1,	  n=3;	  *	  P	  <	  0.05,	  **	  P	  <	  0.01,	  ***	  P	  <	  
0.001;	  Kruskal-­‐Wallis).	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Due	   to	   a	   limited	   availability	   of	   sufficient	   quantities	   of	   alternative	   dietary	   fibres,	   a	  
smaller	  number	  of	   soluble	  NSPs	  were	  selected	  and	  assessed	   for	   their	  ability	   to	   inhibit	   the	  
epithelial	  adhesion	  of	  ETEC	  (including	  apple,	  broccoli,	  leek,	  oat	  and	  plantain	  NSP	  only).	  Pre-­‐
incubation	  of	  Caco2	  cells	  with	  5	  mg/mL	  plantain	  and	  leek	  NSP	  significantly	  inhibited	  bacterial	  
adhesion	  by	  40.9	  ±	  9.3%	  (P	  <	  0.001)	  and	  53.7	  ±	  13.6%	  (P	  <	  0.01),	  respectively.	  Pre-­‐incubation	  
of	   Caco2	   cells	   with	   broccoli,	   apple	   and	   oat	   NSP	   did	   not	   have	   a	   significant	   effect	   on	   the	  









Figure	  5.2.	  Evaluation	  of	  a	  range	  of	  soluble	  NSPs	  for	  their	  ability	  to	  inhibit	  the	  in	  vitro	  
epithelial	  adhesion	  of	  ETEC.	  Adhesion	  of	  ETEC	  to	  confluent	  Caco2	  cell	  monolayers	  was	  
significantly	  inhibited	  in	  the	  presence	  of	  5	  mg/mL	  leek	  and	  plantain	  NSP.	  Adhesion	  was	  
measured	  as	  relative	  to	  CFU/mL	  quantified	  in	  the	  absence	  of	  any	  NSP	  (set	  at	  100%)	  (N=3,	  
n=3	  excepting	  #N=1,	  n=3;	  *	  P	  <	  0.05,	  ***	  P	  <	  0.001;	  One	  way	  ANOVA).	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5.5.2   Soluble	  plantain	  NSP	  inhibits	  the	  epithelial	  adhesion	  of	  C.	  difficile	  and	  ETEC	  in	  a	  dose-­‐
dependent	  manner	  
Due	  to	  the	  promising	  results	  seen	  with	  plantain	  NSP	  in	  the	  initial	  screen,	  the	  soluble	  
fibre	  was	   selected	   for	   further	   analysis	   in	   dose-­‐response	   studies.	   Plantain	  NSP	   exhibited	   a	  
dose-­‐dependent	   inhibitive	   effect	   on	   C.	   difficile-­‐epithelial	   cell	   adhesion,	   in	   which	   NSP	  
concentrations	  of	  2.5,	  5,	  10	  and	  20	  mg/mL	  all	  significantly	  reduced	  epithelial	  interaction	  of	  
adherent	   bacterial	   numbers.	   The	   optimum	  dosage	   of	   plantain	  NSP	  was	   10	  mg/mL,	  which	  
reduced	  C.	  difficile	  adhesion	  by	  68.7	  ±	  8.7%	  in	  comparison	  to	  the	  untreated	  control	  (P	  <	  0.001;	  
Kruskal-­‐Wallis;	  N=3,	  n=3).	  Whilst	  still	  significant,	  a	  decreased	  inhibitive	  effect	  was	  observed	  
in	  the	  presence	  of	  20	  mg/mL	  plantain	  NSP,	  decreasing	  C.	  difficile	  adhesion	  by	  42.1	  ±	  11.4%	  (P	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Figure	  5.3.	  Soluble	  plantain	  NSP	  inhibits	  C.	  difficile	  adhesion	  to	  intestinal	  epithelial	  
cells	  in	  a	  dose-­‐dependent	  manner.	  	  A)	  Adhesion	  of	  C.	  difficile	  to	  confluent	  Caco2	  cell	  
monolayers	   is	   significantly	   inhibited	   in	   the	   presence	   of	   2.5,	   5,	   10	   and	   20	   mg/mL	  
plantain	  NSP.	  Adhesion	  is	  expressed	  relative	  to	  CFU/mL	  found	  in	  the	  absence	  of	  any	  
fibre	  (set	  as	  100%)	  (N=3,	  n=3;	  *	  P	  <	  0.05,	  **	  P	  <	  0.01,	  ***	  P	  <	  0.001;	  Kruskal-­‐Wallis)	  B)	  
Giemsa	  stained	  C.	  difficile	  infected	  Caco2	  cells	  in	  the	  absence	  and	  C)	  presence	  of	  10	  
mg/mL	  plantain	  NSP.	  Black	  arrows	  indicate	  adherent	  bacteria.	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   Plantain	  NSP	  also	  had	  a	  dose-­‐dependent	   inhibitive	  effect	  on	  ETEC	  adhesion.	   In	   the	  
presence	   of	   5	   mg/mL	   plantain	   NSP,	   there	   was	   significant	   blockade	   of	   bacterial	   epithelial	  
adhesion,	  which	  decreased	  by	  74.7	  ±	  13.3%	  (P	  <	  0.05;	  One-­‐way	  ANOVA;	  N=3,	  n=3).	  As	  seen	  
with	  C.	   difficile,	   higher	   concentrations	   of	   plantain	   NSP	   (10	   and	   20	  mg/mL)	   also	   exhibited	  










Figure	  5.4.	  Soluble	  plantain	  NSP	  inhibits	  ETEC	  adhesion	  to	  intestinal	  epithelial	  cells	  in	  
a	  dose-­‐dependent	  manner.	  	  Adhesion	  of	  ETEC	  to	  confluent	  Caco2	  cell	  monolayers	  was	  
significantly	   inhibited	   in	   the	   presence	   of	   5	   mg/mL	   plantain	   NSP.	   Adhesion	   was	  
expressed	  relative	  to	  CFU/mL	  found	  in	  the	  absence	  of	  plantain	  NSP	  (set	  as	  100%)	  (N=3,	  
n=3;	  *	  P	  <	  0.05;	  One-­‐way	  ANOVA)	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5.5.3   Soluble	   plantain	   NSP	   increases	   bacterial	   pathogen	   growth	   in	   a	   time	   and	  
concentration	  dependent	  manner	  
In	  order	  to	  investigate	  the	  decreased	  inhibitive	  effect	  seen	  with	  higher	  concentrations	  
of	  plantain	  NSP	  (Figure	  5.3,	  Figure	  5.4),	  an	  experiment	  was	  performed	  without	  Caco2	  cells	  to	  
directly	  determine	  the	  effect	  of	  plantain	  NSP	  on	  C.	  difficile	  and	  ETEC	  growth	  (Figure	  5.5A).	  	  
Results	   indicated	   that	  plantain	  NSP	  enhances	  bacterial	   growth	   in	  a	   time	  and	  dose-­‐
dependent	  manner.	  In	  the	  absence	  of	  plantain	  NSP,	  there	  was	  an	  8.0	  ±	  1.4-­‐fold	  increase	  in	  C.	  
difficile	   growth	  observed	  between	  0	  and	  2	  hours.	  However,	   in	   the	  presence	  of	  10	  and	  20	  
mg/mL	  plantain	  NSP,	  bacterial	  growth	  over	  the	  same	  period	  was	  enhanced	  by	  10.6	  ±	  1.5	  fold	  
and	  13.1	  ±	  1.9	  fold	  respectively	  (P	  <	  0.05;	  One-­‐way	  ANOVA)	  (Figure	  5.5A).	  	  
Similar	   results	   were	   observed	   for	   ETEC.	   In	   the	   absence	   of	   plantain	   NSP,	   bacterial	  
growth	  increased	  by	  8.1	  ±	  1.3	  fold,	  but	   in	  the	  presence	  of	  10	  and	  20	  mg/mL	  plantain	  NSP,	  
growth	  between	  0	  to	  2	  hours	  was	  enhanced	  by	  11.6	  ±	  1.2	  fold	  and	  12.1	  ±	  1.1	  fold	  respectively	  






















Figure	   5.5.	   Soluble	   plantain	   NSP	   increases	   bacterial	   pathogen	   growth	   in	   a	   time	   and	  
concentration	  dependent	  manner.	  Whilst	  there	  was	  a	  natural	  increase	  in	  A)	  C.	  difficile	  and	  
B)	   ETEC	   CFU/mL	   during	   their	   respective	   incubation	   periods	   of	   2h	   and	   1.5h,	   this	   was	  
significantly	  enhanced	  in	  the	  presence	  of	  plantain	  NSP	  (N=3,	  n=2;	  *	  P	  <	  0.01,	  **	  P	  <	  0.01,	  
***	  P	  <	  0.001;	  Kruskal-­‐Wallis).	  
A  
B  
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5.5.4   Soluble	  broccoli	  and	  leek	  NSP	  also	  inhibit	  C.	  difficile	  epithelial	  adhesion	  in	  a	  dose-­‐
dependent	  manner,	  but	  not	  as	  effectively	  as	  plantain	  NSP	  
Due	  to	  the	  promising	  results	  observed	  in	  the	  inhibitory	  screen,	  broccoli	  and	  leek	  NSP	  
were	  also	  evaluated	  for	  their	  dose-­‐dependent	  effects	  on	  C.	  difficile	  epithelial	  adhesion.	  These	  
indicated	  a	  dose-­‐dependent	  inhibitory	  effect	  for	  leek	  NSP	  on	  epithelial	  adhesion,	  with	  peak	  
effect	  seen	  at	  20	  mg/mL	  (57.5	  ±	  6.5%;	  P	  <	  0.001;	  Figure	  5.6A).	  Broccoli	  was	  similarly	  effective	  
at	  20	  mg/mL	  (56.9	  ±	  7.2	  %;	  P	  <	  0.001;	  Figure	  5.6B).	  Both	  of	  these	  soluble	  dietary	  fibres	  had	  a	  
lower	  efficacy	  than	  that	  seen	  with	  plantain	  NSP;	  used	  as	  a	  positive	  control	  at	  10	  mg/mL,	  the	  
























Figure	  5.6.	  Soluble	  leek	  and	  broccoli	  fibre	  also	  inhibit	  C.	  difficile	  epithelial	  adhesion	  in	  a	  
dose-­‐dependent	  manner.	  The	  epithelial	  adhesion	  of	  C.	  difficile	  was	  inhibited	  in	  the	  presence	  
of	  A)	  leek	  and	  B)	  broccoli	  NSP.	  Plantain	  NSP	  was	  used	  as	  a	  positive	  control.	  Adhesion	  was	  
expressed	  relative	  to	  CFU/mL	  found	  in	  the	  absence	  of	  any	  fibre	  (set	  as	  100%)	  (N=2,	  n	  ≥	  3;	  *	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3.5.3	  Plantain	  NSP	  inhibits	  the	  epithelial	  adhesion	  of	  a	  panel	  of	  C.	  difficile	  clinical	  isolates	  
that	  vary	  in	  their	  toxin	  expression	  and	  ribotype	  status	  
Out	   of	   all	   of	   the	   soluble	   fibres	   tested,	   soluble	   plantain	   NSP	   exhibited	   the	   most	  
efficacious	  and	  significant	   inhibitive	  effect	  against	  C.	  difficile	  and	  ETEC	  epithelial	  adhesion.	  	  
Therefore,	  soluble	  plantain	  fibre	  was	  selected	  for	  further	  validation	  experiments	  where	  it	  was	  
evaluated	  for	   its	  ability	  to	  block	  the	  adhesion	  of	  eleven	  C.	  difficile	  clinical	   isolates	  differing	  
according	  to	  their	  toxin	  expression	  and	  ribotype	  status	  (Table	  4.1;	  Section	  4.4.1).	  	  
These	  studies	   illustrated	  that	  pre-­‐incubation	  of	  Caco2	  cells	  with	  10	  mg/mL	  plantain	  
NSP	  (previously	  determined	  to	  be	  the	  optimum	  dose;	  Figure	  5.3)	  significantly	  inhibited	  the	  
epithelial	  adhesion	  of	  all	  eleven	  C.	  difficile	  clinical	  isolates,	  reducing	  adhesion	  by	  range	  of	  52.2	  
±	  3.0	  to	  98.6	  ±	  1.0%,	  with	  a	  median	  reduction	  of	  73.8%	  in	  comparison	  to	  the	  vehicle-­‐treated	  
control	   monolayers	   (Figure	   5.7A-­‐D;	   for	   all;	   P<	   0.001;	   Kruskal-­‐Wallis).	   These	   results	  
demonstrate	   that	   the	   inhibitory	   effect	   of	   plantain	  NSP	   is	   independent	   of	  C.	   difficile	   toxin	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Figure	  5.7.	  Soluble	  plantain	  NSP	  inhibits	  the	  epithelial	  adhesion	  of	  a	  range	  of	  C.	  difficile	  clinical	  
isolates,	  which	  differ	   in	  their	  toxin	  expression	  and	  ribotype	  status.	  Pre-­‐incubation	  of	  Caco2	  
cells	  with	  the	  optimum	  dosage	  of	  10	  mg/mL	  plantain	  NSP	  significantly	  inhibited	  the	  epithelial	  
adherence	  of	  A)	  TcdA+	  TcdB+	  Binary+	  C.	  difficile	  strains,	  B)	  TcdA+	  TcdB+	  Binary-­‐	  C.	  difficile	  strains,	  
C)	  TcdA-­‐	  TcdB+	  Binary-­‐	  C.	  difficile	  strains,	  as	  well	  as	  D)	  TcdA-­‐	  TcdB-­‐	  Binary-­‐	  C.	  difficile	  strains.	  Our	  
original	  clinical	  C.	  difficile	  isolate	  (080042,	  Rb	  027)	  was	  also	  used	  as	  a	  positive control. Adhesion	  
is	  expressed	  relative	  to	  CFU/mL	  found	  in	  the	  absence	  of	  any	  fibre	  (set	  as	  100%)	  (N=3,	  n	  =	  3;	  ***	  
P	  <	  0.001;	  Kruskal-­‐Wallis).	  	  
A   B  
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5.5.5   Soluble	  plantain	  NSP	  inhibits	  the	  epithelial	  adhesion	  of	  purified	  C.	  difficile	  spores	  
Soluble	  plantain	  NSP,	  at	  10	  mg/mL,	  significantly	  reduced	  the	  adhesion	  of	  C.	  difficile	  
spores	  purified	  from	  clinical	  isolate	  CD98011	  (TcdA+/TcdB+/Binary+)	  (Figure	  5.8)	  and	  all	  four	  
other	  C.	  difficile	  isolate	  spore	  preparations	  tested	  (Table	  5.1).	  Inhibition	  of	  C.	  difficile	  spores	  
ranged	  from	  27.9	  ±	  5.4%	  to	  33.8	  ±	  6.9%	  (For	  all;	  P	  ≤	  0.05;	  Kruskal-­‐Wallis;	  Table	  5.1).	  Blockade	  
of	  spores	  was	  less	  than	  that	  observed	  with	  the	  corresponding	  vegetative	  C.	  difficile	  bacterium	  
from	  which	  the	  spores	  were	  purified,	  at	  the	  same	  MOI	  100,	  where	  pre-­‐incubation	  with	  10	  
mg/mL	  plantain	  NSP	   resulted	   in	   inhibition	   ranging	   from	  78.9	  ±	  3.1	   to	  97.9	  ±	  1.5%	   (For	   all	  
isolates;	  P	  <	  0.001,	  Kruskal-­‐Wallis).	   It	   is	  of	  significant	  note,	  however,	  that	  C.	  difficile	  spores	  
(from	  all	  five	  clinical	  isolates	  tested)	  showed	  markedly	  greater	  adhesion	  to	  Caco2	  cells	  (85	  ±	  
7.3%	   spore	   adherence	   versus	   4	   ±	   0.6%	   vegetative	   adherence	   of	   the	   original	   inoculum);	  























Figure	  5.8.	  Soluble	  plantain	  NSP	  inhibits	  the	  in	  vitro	  epithelial	  adhesion	  of	  C.	  difficile	  spores	  
purified	   from	   clinical	   isolate	   CD98011.	   A)	   Pre-­‐incubation	   of	   Caco2	   cells	   with	   10	   mg/mL	  
plantain	   NSP	   significantly	   inhibited	   the	   adhesion	   of	   purified	   CD98011	   spores	   and	  
corresponding	  vegetative	  CD98011,	  used	  as	  a	  positive	  control.	  Adhesion	  is	  expressed	  relative	  
to	  CFU/mL	  found	  in	  the	  absence	  of	  any	  fibre	  (set	  as	  100%)	  (N=3,	  n=3;	  **	  P	  <	  0.01,	  ***	  P	  <	  
0.001;	  Kruskal-­‐Wallis).	  B)	  Schaeffer	  and	  Fulton	  endospore	  stain	  of	  the	  purified	  CD98011	  spores	  
used	  in	  bacterial	  adhesion	  assays.	  Arrows	  indicate	  C.	  difficile	  spores,	  stained	  green.	  	  
B  A   CD98011  (TcdA+/TcdB+/Binary+)  
C.  difficile  +  
10  mg/mL  
plantain  
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97.9    ±  1.5   <  0.001   32.8    ±  14.9   <  0.01  
Table	  5.1	  Soluble	  plantain	  NSP	  inhibits	  the	   in	  vitro	  epithelial	  adhesion	  of	  C.	  difficile	  spores	  
purified	   from	   five	   clinical	  C.	  difficile	   isolates.	  Pre-­‐incubation	  of	  Caco2	  cells	  with	  10	  mg/mL	  
plantain	  NSP	  inhibited	  the	  epithelial	  adhesion	  of	  all	  C.	  difficile	  spores	  and	  their	  corresponding	  
vegetative	  C.	  difficile	  bacterium,	  used	  as	  a	  positive	  control.	  















Figure	  5.9	  C.	  difficile	  spores	  are	  more	  adhesive	  to	  intestinal	  epithelial	  cells	  than	  their	  
vegetative	   C.	   difficile	   counterparts.	   	   Vegetative	   bacterium	   and	   spore	   adhesion	   is	  
expressed	  as	  a	  percentage	  of	  the	  original	  inoculum	  (1	  x	  107	  CFU/mL,	  set	  as	  100%).	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5.6   SUMMARY	  OF	  RESULTS	  
	  
1.   A	   range	  of	   soluble	  dietary	   fibres	   significantly	   inhibit	  C.	  difficile	   and	  ETEC	  adhesion	   to	  
intestinal	  Caco2	  cells.	  Out	  of	  all	  fibres	  tested,	  soluble	  plantain	  NSP	  exhibits	  the	  highest	  
efficacy,	  with	  an	  optimum	  inhibitive	  concentration	  of	  10	  mg/mL	  
	  
2.   	  Plantain	   NSP	   increases	   C.	   difficile	   and	   ETEC	   growth	   in	   a	   concentration	   and	   time-­‐
dependent	  manner,	   suggesting	   that	   it	  may	  be	  utilised	   as	   an	  energy	   source	   for	   these	  
bacteria	  
	  
3.   Plantain	   NSP	   inhibits	   the	   epithelial	   adhesion	   of	   eleven	   C.	   difficile	   clinical	   isolates,	  
irrespective	  of	  their	  toxin	  expression	  or	  ribotype	  status	  
	  
4.   Plantain	  NSP	  significantly	  inhibits	  the	  epithelial	  adhesion	  of	  five	  purified	  C.	  difficile	  spore	  
preparations,	   but	   to	   a	   lesser	   extent	   than	   that	   observed	   with	   vegetative	   C.	   difficile.	  
However,	  C.	  difficile	  spores	  are	  over	  20	  times	  more	  adhesive	  to	  Caco2	  cells	  so	  inhibition	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5.7   DISCUSSION	  
Dietary	   fibre	   is	   widely	   recognised	   as	   being	   beneficial	   for	   intestinal	   health.	   A	   high	  
dietary	  fibre	  intake	  increases	  faecal	  bulking	  and	  viscosity,	  resulting	  in	  increased	  transit	  time	  
through	  the	  colon	  (Lattimer	  and	  Haub	  2010).	  Furthermore,	  its	  fermentation	  by	  resident	  gut	  
microbiota	   produces	   short	   chain	   fatty	   acids	   (SCFAs),	   such	   as	   butyrate,	   that	   act	   as	   energy	  
sources	   for	   the	   gut	   epithelium	   (Macfarlane	   et	   al.	   2006)	   and	   possess	   anti-­‐carcinogenic	  
properties	  (Lattimer	  and	  Haub	  2010).	  Fibre	  has	  also	  attracted	  considerable	  attention	  due	  to	  
its	  role	  in	  the	  prebiotic	  effect,	  where	  it	  may	  selectively	  promote	  the	  growth	  of	  resident	  health	  
promoting	  bacteria,	  such	  as	  Lactobacilli	  and	  Bifidobacteria	  (Hamer	  et	  al.	  2008).	  Our	  studies	  
suggest	  an	  alternative	  role	  of	  soluble	  fibre	  in	  the	  ‘contrabiotic’	  effect,	  where	  it	  also	  has	  the	  
ability	  to	  promote	  health	  by	  disrupting	  potentially	  harmful	  interactions	  between	  bacteria	  and	  
the	  gut	  epithelium.	  	  
Here,	   we	   provide	   evidence	   towards	   the	   inhibitory	   effect	   of	   plantain	   NSP	   against	  
diarrhoeal	   pathogens	  C.	   difficile	   and	   ETEC.	  Whilst	   a	   range	   of	   soluble	   plant	   fibres	   (such	   as	  
broccoli	   and	   leek	   NSP)	   do	   significantly	   inhibit	   the	   epithelial	   adhesion	   of	   these	   bacteria,	  
plantain	   NSP	   exhibits	   a	   much	   more	   significant	   effect.	   Furthermore,	   plantain	   NSP	   also	  
significantly	  inhibits	  the	  epithelial	  adhesion	  of	  a	  range	  of	  clinically	  relevant	  C.	  difficile	  isolates,	  
irrespective	  of	  their	  toxin	  or	  ribotype	  status.	  Indeed,	  these	  results	  imply	  that	  soluble	  plantain	  
fibre	  could	  be	  developed	  as	  a	  potential	  prophylaxis	  or	  treatment	  for	  CDI	  and	  ETEC	  infection.	  
Importantly,	  we	  illustrate	  here	  that	  soluble	  plantain	  fibre	  can	  also	  inhibit	  the	  epithelial	  
adhesion	  of	  C.	  difficile	  spores,	  which	  represent	  the	  main	  vehicle	  of	  transmission	  of	  CDI.	  Whilst	  
the	  level	  of	  C.	  difficile	  spore	  inhibition	  appears	  to	  be	  less	  than	  compared	  with	  vegetative	  C.	  
difficile,	   we	   observed	   in	   our	   studies	   that	   C.	   difficile	   spores	   are	   much	   more	   adhesive	   to	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intestinal	  epithelial	   cells.	   Therefore,	   the	   level	  of	   inhibition	  may	  be	  under-­‐represented	  and	  
thus	  hold	  greater	  significance.	  These	  results	  are	  in	  agreement	  with	  previous	  studies,	  which	  
have	   also	   demonstrated	   that	   C.	   difficile	   spores	   are	  much	  more	   adhesive	   to	   the	   gut	   than	  
vegetative	   cells	   (Dingle	   et	   al.	   2010;	   Paredes-­‐Sabja	   and	   Sarker	   2012),	   and	   provide	   further	  
evidence	   to	   suggest	   that	   spore	   adhesion	  might	   be	   exploited	   by	  C.	   difficile	   as	   a	  means	   of	  
persistence	  in	  the	  host	  (Paredes-­‐Sabja	  and	  Sarker	  2012).	  C.	  difficile	  spore	  persistence	  within	  
the	   colon	   of	   CDI	   patients	   not	   only	   complicates	   treatment	   options,	   but	   also	   increases	  
recurrence	   rates	  associated	  with	   the	  disease.	   Indeed,	  25	  –	  85%	  of	  all	  CDI	   recurrences	  are	  
attributed	  to	  the	  C.	  difficile	  strain	  that	  caused	  the	  initial	  infection	  (Barbut	  et	  al.	  2000;	  Oka	  et	  
al.	   2012).	   Therefore,	   the	   ability	   to	   inhibit	   C.	   difficile	   spore	   interactions	   enhances	   the	  
therapeutic	  potential	  of	  soluble	  plantain	  fibre,	  and	  suggests	  that	  its	  dietary	  supplementation	  
might	  also	  help	  maintain	  remission	  from	  CDI.	  	  
Plantain	   banana	   (Musa	   spp.)	   is	   traditionally	   cooked	   as	   a	   vegetable,	   and	   forms	   an	  
important	  part	  of	  the	  staple	  diet	  in	  parts	  of	  the	  world	  such	  as	  Africa,	  India	  and	  Central	  America	  
(Imam	  and	  Akter	  2011),	  where	  the	  incidence	  of	  IBD	  and	  colorectal	  cancer	  is	  lower	  than	  that	  
observed	  in	  Westernised	  nations.	  Other	  evidence	  to	  support	  a	  protective	  role	  of	  plantain	  NSP	  
against	  diarrhoeal	  disease	  include	  a	  study	  using	  banana	  flakes	  supplemented	  to	  enteral	  feed	  
to	  control	  diarrhoeal	  episodes	  (Emery	  et	  al.	  1997),	  and	  another	  controlled	  trial	  in	  Bangladesh	  
in	  which	  green	  boiled	  banana	  pulp	  or	  pectin	  was	  shown	  to	  be	  effective	  in	  treating	  persistent	  
childhood	  diarrhoea	  (Rabbani	  et	  al.	  2004;	  Rabbani	  et	  al.	  2001).	  Other	  clinical	  studies	  have	  
reported	  that	  the	  juice	  from	  boiled	  green	  bananas	  was	  effective	  in	  reducing	  the	  severity	  and	  
duration	  of	  persistent	  diarrhoeas	  (Alvarez-­‐Acosta	  et	  al.	  2009).	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The	   results	  presented	  here	  support	  previous	   findings	   from	  our	  group	  showing	   that	  
soluble	  plantain	  NSP	  can	  block	  the	  intestinal	  interactions	  of	  a	  range	  of	  other	  gut	  pathogens.	  
Indeed,	  studies	  have	   illustrated	  that	  soluble	  plantain	  NSP	  can	   inhibit	   the	   in	  vitro	  epithelial	  
adhesion,	   invasion	   and	   M-­‐cell	   translocation	   of	   Crohn’s	   mucosa	   associated	   AIEC,	   S.	  
Typhimurium	  and	  S.	  sonnei	  (Parsons	  et	  al.	  2014;	  Roberts	  et	  al.	  2013).	  The	  inhibitory	  effect	  of	  
soluble	   plantain	   fibre	   has	   also	   been	   confirmed	   in	   ex-­‐vivo	   studies,	   whereby	   plantain	   NSP	  
significantly	   reduced	   AIEC	   and	   S.	   Typhimurium	   translocation	   across	   isolated	   human	   ileal	  
follicle-­‐associated	  epithelium	  (FAE)	  and	  villous	  epithelium	  (VE)	  mounted	  in	  Ussing	  chambers	  
(Roberts	   et	   al.	   2010;	   Roberts	   et	   al.	   2013).	   Moreover,	   inhibitory	   activity	   has	   been	  
demonstrated	   in	  vivo	  where	  supplementation	  of	  poultry	  feed	  with	  plantain	  NSP	  effectively	  
reduces	  salmonellosis	  in	  the	  chicken	  (Parsons	  et	  al.	  2014).	  
We	  suggest	  that	  the	  diverse	  array	  of	  oligosaccharides	  present	  in	  plantain	  NSP	  allow	  it	  
the	   capability	   to	   inhibit	   a	   wide	   range	   of	   bacterial	   epithelial	   interactions.	   However,	   it	   is	  
important	  to	  note	  that	  plantain	  NSP	  does	  not	  exhibit	  inhibitory	  activity	  against	  all	  adherent	  
gut	  bacteria.	   Indeed,	  previous	   studies	  demonstrated	   that	  plantain	  NSP	   lacks	   the	  ability	   to	  
inhibit	  the	  adhesion	  of	  Enteropathogenic	  E.	  coli	  (EPEC)	  (Roberts	  et	  al.	  2013),	  which	  is	  a	  major	  
cause	  of	  neonatal	  gastroenteritis	  (Ochoa	  and	  Contreras	  2011).	  Studies	  have	  illustrated	  that	  
EPEC	  binds	   intimately	  to	   intestinal	  epithelial	  cell	   lines	  (including	  Caco2)	  using	  key	  adhesins	  
α1-­‐bundlin	   and	   intimin,	   which	   are	   blocked	   specifically	   by	   N-­‐acetyllactosamine	   (LacNac)	  
(Hyland	   et	   al.	   2008).	   This	  might	   suggest	   that	   oligosaccharides	   bearing	   this	   glycoform	   are	  
perhaps	  not	  present	  within	  soluble	  plantain	  fibre,	  and	  therefore	  this	  very	  specific	  interaction	  
may	  not	  inhibited	  (Roberts	  et	  al.	  2013).	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Here,	  we	  report	  that	  C.	  difficile	  and	  ETEC	  interact	  with	  plantain	  NSP	  and	  use	  this	  as	  an	  
energy	  source.	  This	  could	  provide	  an	  explanation	  as	  to	  why	  higher	  concentrations	  of	  plantain	  
NSP	  exhibit	  decreased	  inhibitory	  activity	  against	  bacterial	  epithelial	  adhesion.	  	  This	  has	  also	  
been	  observed	  with	  respect	  to	  E.	  coli	  (Roberts	  et	  al.	  2010)	  and	  Salmonella	  spp.,	  including	  S.	  
Typhimurium	  (Parsons	  et	  al.	  2014)	  and	  S.	  Gallinarum	  (Parsons	  et	  al.	  2014).	  	  In	  the	  gut	  lumen	  
however,	  this	  would	  not	  be	  harmful,	  as	  bacterial	  adhesion	  to	  the	  intestinal	  epithelium	  would	  
be	  inhibited.	  As	  such,	  bacteria	  would	  simply	  ‘flush	  through’	  the	  gut	  lumen	  without	  releasing	  
their	  respective	  toxins.	  Additionally,	  the	  level	  of	  blockade	  of	  bacterial	  adhesion	  is	  also	  being	  
under-­‐estimated	  if	  only	  expressed	  relative	  to	  the	  original	  inoculum	  and	  not	  those	  bacterial	  
numbers	  actually	  in	  the	  medium	  at	  the	  time	  of	  sampling.	  These	  results	  suggest	  that	  soluble	  
plantain	  fibre	  might	  also	  act	  as	  a	   fermentable	  substrate	  for	  bacteria	   in	  the	   large	   intestine,	  
however,	   modelling	   of	   soluble	   plantain	   NSP	   breakdown	   using	   mixed	   faecal	   microbiota	  
obtained	  from	  healthy	  volunteers	  has	  shown	  that	  25-­‐75%	  of	  ingested	  plantain	  NSP	  is	  likely	  to	  
avoid	  fermentation	  in	  the	  human	  colon	  (Backman	  2009;	  Roberts	  et	  al.	  2010).	  In	  vitro	  studies	  
have	  suggested	  that	  Bacteroides	  are	  the	  major	  fermenters	  of	  plantain	  NSP,	  whereas	  species	  
tested	   from	   key	   bacterial	   groups	   such	   as	   Bifidobacteria,	   Lactobacolli,	   Streptococci	   and	  
Ruminococci	  cannot	  easily	   ferment	  this	  soluble	  dietary	  fibre	  source,	  suggesting	   little	  or	  no	  
prebiotic	  effect	  for	  soluble	  plantain	  NSP	  (Backman	  2009).	  	  
Soluble	  plantain	  fibre,	  at	  concentrations	  of	  5	  mg/mL	  or	  higher,	  is	  shown	  here	  exhibit	  
inhibitory	  activity	  against	  bacterial	  adhesion.	  Importantly,	  this	  concentration	  of	  fibre	  is	  readily	  
achievable	   in	  the	  distal	  colon	  by	  dietary	  supplementation,	  even	  after	  partial	   fermentation.	  
Assuming	  passage	  of	  1	   litre	  of	   fluid	  daily	   into	  the	  caecum,	  oral	  dosing	  of	  humans	  with	  5	  g	  
plantain	   NSP	   twice	   daily,	   with	   25%	   fermentation,	   would	   produce	   effective	   luminal	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concentrations	  of	  10	  mg/mL	  and	  7.5	  mg/mL	  in	  the	  caecum	  and	  rectum,	  respectively	  (Roberts	  
et	  al.	  2010).	  
Overall,	   these	   results	   provide	   convincing	   evidence	   to	   suggest	   that	   dietary	  
supplementation	  with	  soluble	  plantain	  fibre	  could	  have	  a	  protective	  effect	  against	  intestinal	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6.1   	  INTRODUCTION	  
Following	  successful	  colonisation	  of	   the	   intestinal	  epithelium,	  C.	  difficile	  mediates	  
epithelial	  cellular	  damage	  and	   inflammation	  through	  the	  secretion	  of	  two	  main	  virulence	  
factors,	  TcdA	  and	  TcdB.	  These	  potent	  exotoxins	  are	  involved	  in	  the	  monoglucosylation	  and	  
subsequent	   inactivation	   of	   small	   regulatory	   Rho-­‐GTPases,	   which	   includes	   Rho,	   Rac	   and	  
Cdc42	  (Voth	  and	  Ballard	  2005).	  The	  irreversible	  modification	  of	  Rho	  proteins	  prevents	  their	  
interaction	  with	  downstream	  signalling	  proteins	  such	  as	  Rho-­‐kinase	  (Fujisawa	  et	  al.	  1998),	  
citron	  K	  (Madaule	  et	  al.	  1998)	  and	  phosphatidylinositol	  4-­‐phosphate	  5-­‐kinase	  (Chong	  et	  al.	  
1994).	   This	   results	   in	   a	   number	   of	   toxin-­‐mediated	   cytopathic	   effects	   in	   the	   actin	  
cytoskeleton,	  including	  loss	  of	  actin	  stress	  fibres,	  increased	  cell	  rounding	  and	  disruption	  of	  
intracellular	  tight	  junctions	  (Sehr	  et	  al.	  1998;	  Voth	  and	  Ballard	  2005).	  
In	  addition	  to	  modulating	  cytoskeletal	  function,	  C.	  difficile	  toxins	  can	  activate	  a	  variety	  
of	  intracellular	  signalling	  cascades	  responsible	  for	  the	  induction	  of	  gene	  transcription	  and	  
the	  production	  and	  release	  of	  inflammatory	  mediators,	  leading	  to	  the	  induction	  of	  the	  pro-­‐
inflammatory	  response	  (Shen	  2012).	  Indeed,	  TcdA	  and	  TcdB	  have	  been	  shown	  to	  mediate	  
the	  production	  of	  several	  pro-­‐inflammatory	  cytokines	  such	  as	  IL-­‐8	  (Kim	  et	  al.	  2006),	  which	  is	  
a	   potent	   neutrophil	   chemoattractant	   (Sun	   and	   Hirota	   2015),	   as	   well	   as	   other	   pro-­‐
inflammatory	  mediators	   such	  as	  growth-­‐related	  oncogene	  alpha	   (GRO-­‐α)	  and	  monocyte-­‐
chemotactic	  protein	  1	  (MCP-­‐1)	  (Sun	  and	  Hirota	  2015;	  Sun	  et	  al.	  2010).	  Other	  toxin-­‐mediated	  
effects	   include	  cell	  cytotoxicity,	  which	  results	   in	  eventual	  cell	  death.	  Cellular	  apoptosis	   is	  
triggered	  by	   the	  activation	  of	  executioner	   caspase-­‐3,	   via	   intrinsic	   and	  extrinsic	   apoptotic	  
pathways	  (Gerhard	  et	  al.	  2008;	  Sun	  et	  al.	  2010).	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To	  induce	  their	  cytotoxic	  and	  pro-­‐inflammatory	  effect,	  both	  C.	  difficile	  TcdA	  and	  TcdB	  
must	  first	  be	  internalised	  into	  host	  epithelial	  cells	  (Voth	  and	  Ballard	  2005).	  Receptor	  binding	  
is	  an	  essential	  step	  in	  toxin	  internalisation,	  and	  as	  such,	  this	  plays	  an	  important	  role	  in	  the	  
pathogenesis	   of	   infection	   (Just	   and	   Gerhard	   2004).	   Studies	   have	   demonstrated	   that	   C.	  
difficile	   toxins	   express	   lectin	   activity,	   whereby	   they	   bind	   specifically	   to	   carbohydrate	  
structures	  present	  on	  the	  host-­‐cell	  surface	  (Just	  and	  Gerhard	  2004;	  Voth	  and	  Ballard	  2005).	  
Indeed,	   TcdA	   has	   been	   shown	   to	   possess	   binding	   affinity	   for	   the	   disaccharide	   Galβ1-­‐
4GlcNAc,	  which	  is	  expressed	  on	  I,	  LewisX	  and	  LewisY	  carbohydrate	  antigens	  present	  on	  the	  
human	  intestinal	  epithelium	  (Tucker	  and	  Wilkins	  1991).	  	  
The	   results	   from	   Chapter	   5	   demonstrate	   that	   soluble	   plantain	   fibre	   can	   disrupt	  
potentially	  harmful	  interactions	  between	  C.	  difficile	  bacterium	  and	  the	  intestinal	  epithelium.	  
As	  both	  C.	  difficile	  and	  its	  toxins	  possess	  lectin	  activity,	   it	   is	  possible	  that	  soluble	  plantain	  
fibre	  will	  also	  inhibit	  the	  interaction	  between	  C.	  difficile	  toxins	  and	  the	  intestinal	  epithelium,	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6.2   HYPOTHESIS	  
	  
Soluble	   plantain	   fibre	   can	   inhibit	   the	   epithelial	   cell	   damage	   and	   inflammation	  
mediated	  by	  C.	  difficile	  and	  its	  toxins.	  
	  
6.3   AIMS	  
	  
1.   To	   determine	   whether	   soluble	   plantain	   fibre	   can	   inhibit	   cellular	   Rac1	  
monoglucosylation	  and	  associated	  morphological	  changes	  mediated	  by	  purified	  C.	  difficile	  
TcdA	  and	  TcdB	  
	  
2.   To	   determine	   whether	   soluble	   plantain	   fibre	   can	   inhibit	   the	   pro-­‐inflammatory,	  









	  	  130	  
6.4   METHODS	  
Detailed	  methods	  can	  be	  found	  in	  Chapter	  4.	  Briefly,	  Caco2	  cell	  monolayers	  were	  pre-­‐
incubated	  for	  30	  min	  with	  or	  without	  10	  mg/mL	  plantain	  NSP.	  Cells	  were	  then	  treated	  with	  
purified	  native	  C.	  difficile	  TcdA	  or	  TcdB	  (0	  –	  100	  ng/mL	  over	  48h),	  and	  in	  parallel,	  infected	  
with	  C.	  difficile	  clinical	  isolates	  CD98011	  (TcdA+/TcdB+)	  or	  CD108519	  (TcdA-­‐/TcdB+)	  at	  a	  MOI	  
100	  for	  4h.	  To	  assess	  if	  soluble	  plantain	  fibre	  could	  block	  the	  epithelial	  action	  of	  C.	  difficile	  
toxins,	  a	  number	  of	   toxin	  and	  bacterium-­‐mediated	  cellular	  effects	  were	   then	  monitored,	  
which	  included	  cytopathic	  effects	  such	  as	  Rac1	  monoglucosylation	  and	  cell	  rounding,	  as	  well	  
as	  induction	  of	  the	  pro-­‐inflammatory,	  apoptotic	  and	  cytotoxicity	  response.	  
Cellular	  Rac1	  monoglucosylation	  was	  monitored	  by	  immunoblotting	  (see	  Section	  4.18)	  
using	   two	  monoclonal	   anti-­‐Rac1	  antibodies;	   clone	  102	   (BD	  Transduction	   Lab),	  which	  has	  
previously	   been	   shown	   to	   lose	   affinity	   for	   Rac1	   following	   its	   glucosylation	   (Genth	   et	   al.	  
2006),	   and	   clone	   238a	   (Abcam),	   which	   recognises	   Rac1	   in	   both	   its	   glucosylated	   and	  
unglucosylated	   form	   (Genth	   et	   al.	   2006).	   Cell	   rounding	   was	   assessed	   by	   fluorescence	  
microscopy	  (Section	  4.13.1),	  where	  actin	  filaments	  were	  visualised	  by	  staining	  Caco2	  cells	  
with	  Phalloidin	  conjugated	  to	  the	  fluorophore	  Alexa	  Fluor	  488	  (Life	  Technologies)	  at	  a	  ratio	  
of	  1:100	  for	  30	  min.	  Cell	  nuclei	  were	  visualised	  using	  Vectashield	  mounting	  media	  containing	  
DAPI	  (Vector	  Laboratories).	  	  
To	  monitor	  the	  induction	  of	  the	  inflammatory	  response,	  harvested	  culture	  media	  from	  
bacterium-­‐	   and	   toxin-­‐treated	   Caco2	   cells	   were	   measured	   for	   the	   presence	   of	   pro-­‐
inflammatory	   cytokine	   IL-­‐8,	   using	   a	   solid-­‐phase	   sandwich	   ELISA	   (Abcam)	   (Section	   4.15).	  	  
Cellular	  apoptosis	  was	  measured	  using	  a	  Caspase-­‐Glo®	  3/7	  Assay	  (Promega)	  (Section	  4.16).	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To	  assess	  the	  cytotoxicity	  response,	  harvested	  cell	  culture	  media	  was	  also	  measured	  for	  the	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6.5   	  	  RESULTS	  
	  
6.5.1  Soluble	   plantain	   fibre	   does	   not	   block	   C.	   difficile	   TcdA	   and	   TcdB	   mediated	   Rac1	  
monoglucosylation	  
Peak	  responses	  were	  first	  determined	  by	  treating	  Caco2	  cells	  with	  10	  ng/mL	  TcdA	  or	  
TcdB	   over	   a	   time-­‐course	   of	   48	   h	   (Figure	   6.1).	   Treatment	   of	   10	   mg/mL	   TcdA	   revealed	  
elevation	  of	  cellular	   levels	  of	  mono-­‐glucosylated	  Rac1	   (as	   indicated	  by	  a	   loss	  of	  antibody	  
clone	  102	  binding	  to	  Rac1)	  10	  h	  post-­‐toxin	  treatment,	  with	  peak	  Rac1	  mono-­‐glucosylation	  
observed	  at	  24	  h	  compared	  to	  vehicle	  treated	  control	  cells	  (P	  <	  0.01;	  Kruskal-­‐Wallis;	  N=3,	  
n=3;	  Figure	  6.1A).	   	  Treatment	  of	  cells	  with	  10	  ng/mL	  TcdB	  also	  revealed	  elevated	  cellular	  
levels	  of	  mono-­‐glucosylated	  Rac1,	  but	  this	  was	  only	  significant	  48	  h	  post-­‐toxin	  treatment	  (P	  




























Figure	  6.1.	  C.	  difficile	  TcdA	  and	  TcdB	  mediate	  increased	  Rac1	  glucosylation	  in	  intestinal	  epithelial	  
cells.	   Immunoblot	  analysis	   shows	  an	  increase	  in	  Rac1	  glucosylation	   following	   treatment	  with	  A)	  
TcdA	  for	  24	  h	  and	  B)	  TcdB	  for	  48	  h.	  Protein	  bands	  were	  analysed	  densitometrically.	  Glucosylated	  
Rac1	   levels	   were	   normalised	   to	   total	   Rac1	   (238a)	   (N=3,	   n=3;	   **	   P	   <	   0.01;	   Kruskal-­‐Wallis;	  
representative	  blots	  shown).	  	  
A
*	   **	  
B
**	  
C.  difficile  Toxin  B;;  10  ng/mL  
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Caco2	  cells	  were	  then	  treated	  with	  0-­‐100	  ng/mL	  C.	  difficile	  TcdA	  or	  TcdB	  for	  24	  h	  and	  
48	   h,	   respectively,	   in	   the	   absence	   or	   presence	   of	   10	   mg/mL	   plantain	   NSP	   (Figure	   6.2).	  
Elevated	  cellular	  levels	  of	  mono-­‐glucosylation	  Rac1	  were	  observed	  following	  treatment	  with	  
1,	  10	  and	  100	  ng/mL	  TcdA,	  indicated	  by	  a	  loss	  of	  anti-­‐Rac1	  clone	  102	  antibody	  binding	  to	  
Rac1	   (100	  ng/mL	   TcdA;	   P	   <	   0.01;	   Kruskal-­‐Wallis).	   However,	   this	  was	   not	   reversed	   in	   the	  
presence	  of	  10	  mg/mL	  plantain	  NSP	  (Figure	  6.2A).	  	  
Treatment	  of	  Caco2	  cells	  with	  1,	  10	  and	  100	  ng/mL	  TcdB	  also	  resulted	  in	   increased	  
cellular	   levels	  of	  mono-­‐glucosylated	  Rac1,	  with	  peak	   levels	  of	  activation	  observed	  at	  100	  
ng/mL	   TcdB.	   (P	   <	   0.01;	   Kruskal-­‐Wallis;	  N=3,	   n=3).	   Similarly,	   this	  was	   not	   reversed	   in	   the	  
presence	   of	   10	  mg/mL	   plantain	   NSP	   (Figure	   6.2B).	   These	   results	   therefore	   suggest	   that	  
plantain	  NSP	  does	  not	  block	   the	  TcdA	  and	  TcdB	  mediated	  monoglucosylation	  of	  Rac1	   in	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Figure	  6.2.	  C.	  difficile	  TcdA	  and	  TcdB	  mediated	  Rac1	  glucosylation	  is	  unaffected	  by	  pre-­‐treatment	  
of	   Caco2	   cells	   with	   soluble	   plantain	   fibre.	   Immunoblot	   analysis	   shows	   an	   increase	   in	   Rac1	  
glucosylation	  following	  treatment	  with	  A)	  100	  ng/mL	  TcdA	  for	  24h	  or	  B)	  10	  and	  100	  ng/mL	  TcdB	  for	  
48h,	   which	   is	   unaffected	   by	   pre-­‐treatment	   of	   Caco2	   cells	   with	   10	  mg/mL	   soluble	   plantain	  NSP.	  
Protein	  bands	  were	  analysed	  densitometrically.	  Glucosylated	  Rac1	  levels	  were	  normalised	  to	  total	  
Rac1	  (238a)	  (N=3,	  n=3;	  *	  P	  <	  0.05,	  **	  P	  <	  0.01;	  Kruskal-­‐Wallis;	  representative	  blots	  shown).	  	  
**	   **	  
*	  *	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6.5.2  Soluble	   plantain	   NSP	   has	   no	   effect	   on	   the	   morphological	   changes	   observed	   in	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
C.	  difficile	  toxin-­‐treated	  cells	  
To	  assess	  the	  effect	  of	  soluble	  plantain	  NSP	  treatment	  on	  the	  morphological	  change	  
observed	   in	   C.	   difficile	   toxin-­‐treated	   cells,	   cellular	   actin	   filaments	   were	   visualised	   using	  
fluorescent	  microscopy.	  Untreated	  Caco2	  cells	  had	  a	  normal	  morphology	  with	  a	  uniform	  
actin	  cytoskeleton	  (Figure	  6.3A),	  whilst	  cells	  treated	  with	  100	  ng/mL	  C.	  difficile	  TcdA	  for	  24	  
h	  exhibited	  clear	  morphological	  changes.	  In	  toxin-­‐treated	  cells,	  there	  was	  a	  loss	  of	  the	  actin	  
cytoskeleton,	   which	   shrank	   around	   cell	   nuclei	   resulting	   in	   obvious	   cell	   rounding	   (Figure	  
6.3B).	   These	  morphological	   effects	  were	  not	   reversed	   following	  pre-­‐incubation	  of	   Caco2	  

















Untreated     TcdA  (100  ng/mL)    
TcdA  +  plantain  NSP   TcdA  +  plantain  NSP  
A   B  
C   D  
Figure	  6.3.	  Plantain	  NSP	  has	  no	  effect	  on	  the	  morphological	  changes	  observed	  in	  TcdA-­‐
treated	  cells,	  as	  assessed	  by	  fluorescence	  microscopy.	  A)	  Untreated	  Caco2	  cells,	  B)	  TcdA-­‐
treated	  Caco2	  cells	  and	  C)	  TcdA-­‐treated	  Caco2	  cells	  that	  underwent	  pre-­‐incubation	  with	  10	  
mg/mL	  plantain	  NSP	  were	  all	  fixed	  with	  2%	  (v/v)	  paraformaldehyde	  (PFA)	  for	  10	  min	  and	  
washed	  three	  times	  with	  sterile	  PBS.	  Actin	  filaments	  were	  visualised	  by	  treating	  fixed	  cells	  
with	   AlexaFluor®488-­‐phalloidin	   (1:100;	   30	   min).	   Cell	   nuclei	   were	   visualised	   by	  
counterstaining	  with	  DAPI	  (N=1,	  n=3;	  representative	  images	  shown).	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6.5.3  Soluble	  plantain	  NSP	  reduces	  C.	  difficile	  bacterium	  and	  C.	  difficile	  toxin-­‐mediated	  IL-­‐
8	  release	  from	  intestinal	  epithelial	  cells	  
Treatment	  of	  Caco2	  cells	  with	  1,	  10	  and	  100	  ng/mL	  TcdA	  and	  TcdB	  for	  24	  h	  elicited	  
dose-­‐dependent	   increases	   in	  pro-­‐inflammatory	   IL-­‐8	   release,	  with	  peak	   responses	  seen	  at	  
100	  ng/mL	   for	  both	   toxins.	   Interestingly,	   the	   IL-­‐8	   response	  was	  observed	   to	  be	  higher	   in	  
those	   Caco2	   cells	   that	   had	   been	   treated	   with	   TcdA	   (At	   100	   ng/mL,	   TcdA-­‐elicited	   IL-­‐8	  
response	  was	  1.9-­‐fold	  higher	  than	  that	  induced	  by	  TcdB;	  P	  <	  0.01;	  Kruskal-­‐Wallis;	  Figure	  6.4A	  
and	  B).	  The	  toxin-­‐mediated	  IL-­‐8	  response	  was	  blocked	  by	  pre-­‐treatment	  of	  Caco2	  cells	  with	  
10	  mg/mL	  plantain	  NSP.	   Plantain	  NSP	  decreased	   IL-­‐8	   response	   to	   100	  ng/mL	   TcdA	   from	  
438.6	  ±	  30.9	  pg/mL	  to	  270.9	  ±	  21.1	  pg/mL,	  and	  also	  reduced	  IL-­‐8	  response	  to	  100	  ng/mL	  
TcdB	  from	  228.2	  ±	  18.5	  to	  96.0	  ±	  3.3	  pg/mL	  (both	  P	  <	  0.001;	  N=2,	  n=3,	  Kruskal-­‐Wallis;	  Figure	  
6.4A	  and	  B)	  
Treatment	  of	  Caco2	  cells	  with	  C.	  difficile	  isolate	  CD98011	  (TcdA+/TcdB+),	  at	  MOI	  100	  
for	  4	  h,	  also	  resulted	  in	  increased	  IL-­‐8	  release	  from	  basal	  levels	  of	  206.7	  ±	  7.8	  pg/mL	  to	  915.6	  
±	  20.6	  pg/mL.	  In	  the	  presence	  of	  10	  mg/mL	  plantain	  NSP,	  C.	  difficile	  mediated	  IL-­‐8	  release	  
was	   significantly	   decreased	   to	   683.6	   ±	   63.7	   (P	   <	   0.05;	  Figure	   6.4A).	   Similarly,	   10	  mg/mL	  
plantain	   NSP	   also	   decreased	   C.	   difficile	   isolate	   CD108519	   (TcdA-­‐/TcdB+)	   mediated	   IL-­‐8	  
release	  from	  Caco2	  cells	  (2.8-­‐fold	  decrease;	  P	  <	  0.001;	  Figure	  6.4B).	  Notably,	  IL-­‐8	  response	  
4	  h	  post	  infection	  with	  CD108519	  was	  significantly	  lower	  (at	  only	  366.5	  ±	  31.0	  pg/mL)	  than	  
that	  seen	  with	  the	  TcdA+	  isolate	  CD98011.	  Of	  note	  too,	  in	  Caco2	  cells	  that	  underwent	  pre-­‐
treatment	   with	   10	   mg/mL	   plantain	   NSP	   but	   were	   not	   treated	   with	   C.	   difficile	   toxin	   or	  
bacterium,	  it	  was	  observed	  that	  there	  was	  also	  a	  decrease	  in	  cellular	  IL-­‐8	  response	  (reduced	  
from	  206.7	  ±	  7.8	  to	  135.5	  ±	  25.9	  pg/mL	  upon	  pre-­‐treatment	  with	  plantain	  NSP	  (Figure	  6.4).	  




























Figure	   6.4.	   Soluble	   plantain	   NSP	   reduces	   C.	   difficile	   bacterium	   and	   toxin-­‐mediated	   IL-­‐8	  
release	  in	  intestinal	  epithelial	  cells.	  Caco2	  cell	  monolayers	  were	  treated	  with	  A)	  TcdA	  (0-­‐100	  
ng/mL;	  24h)	  and	  CD98011	  (MOI	  100;	  4h)	  or	  B)	  TcdB	  (0-­‐100	  ng/mL;	  48	  h)	  and	  CD108519	  (MOI	  
100;	  4h)	  in	  the	  absence	  (black	  bars)	  or	  presence	  of	  10	  mg/mL	  plantain	  NSP	  (white	  bars).	  Media	  
harvested	  from	  cells	  was	  analysed	  for	  the	  presence	  of	  IL-­‐8	  by	  ELISA.	  (N=2,	  n=3;	  *	  P<0.05,	  **	  
P<0.01,	  ***	  P	  <0.001;	  Kruskal-­‐Wallis).	  
A  
B  
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6.5.4  Soluble	   plantain	   NSP	   reduces	   C.	   difficile	   bacterium	   and	   C.	   difficile-­‐mediated	  
activation	  of	  pro-­‐apoptotic	  caspase-­‐3/7	  in	  intestinal	  epithelial	  cells	  
	  
C.	   difficile	   TcdA	   and	   TcdB	  both	   elicited	   increased	   cellular	   caspase-­‐3/7	   activation	   in	  
Caco2	  cells	   in	  a	  dose-­‐dependent	  manner,	  with	  peak	  response	  observed	  at	  100	  ng/mL	  for	  
both	  toxins	  (Figure	  6.5A	  and	  B).	  As	  per	  observed	  toxin-­‐mediated	  IL-­‐8	  responses,	  caspase	  3/7	  
activation	  was	  also	  observed	  to	  be	  higher	  in	  Caco2	  cells	  that	  had	  been	  treated	  with	  TcdA	  
compared	  to	  those	  treated	  with	  TcdB	  (At	  100	  ng/mL,	  TcdA-­‐elicited	  caspase	  3/7	  activation	  
was	  2.2-­‐fold	  higher	   than	   that	   induced	  by	  TcdB;	  Figure	  6.5A).	   Incubation	  of	   cells	  with	  10	  
mg/mL	   plantain	   NSP	   resulted	   in	   significant	   decrease	   in	   caspase-­‐3/7	   activation	   post-­‐
treatment	  with	  either	  10	  or	  100	  ng/mL	  toxin.	  In	  Caco2	  cells	  treated	  with	  100	  ng/mL	  TcdA	  
and	  TcdB,	  plantain	  NSP	  decreased	  caspase	  3/7	  activation	  by	  63.8	  ±	  1.6%	  and	  58.2	  ±	  10.4%,	  
respectively	  (both	  P	  <	  0.05;	  Kruskal-­‐Wallis;	  Figure	  6.5A	  and	  B).	  	  
Following	  4	  h	  infection	  of	  Caco2	  cells	  with	  C.	  difficile	  isolate	  CD9811	  (TcdA+/TcdB+),	  
there	  was	  a	  13.1	  ±	  3.3-­‐fold	  increase	  in	  caspase-­‐3/7	  activation	  in	  comparison	  to	  untreated	  
controls	  (P	  <	  0.001;	  Kruskal-­‐Wallis;	  N=2,	  n=3).	  In	  the	  presence	  of	  10	  mg/mL	  plantain	  NSP,	  
there	  was	  a	  significant	  reduction	  in	  CD98011-­‐mediated	  caspase-­‐3/7	  activation	  (84.1	  ±	  7.0%	  
reduction	  compared	  to	  that	  seen	  in	  the	  absence	  of	  plantain	  NSP;	  P	  <	  0.001;	  Figure	  6.5A).	  
Cellular	  caspase-­‐3/7	  activation	  was	  also	   increased	  (10.1	  ±	  1.6	  fold)	  after	   infection	  with	  C.	  
difficile	  isolate	  CD108519	  (TcdA-­‐/TcdB+)	  albeit	  at	  a	  lower	  level	  than	  that	  seen	  with	  CD98011	  
(Figure	  6.5B).	  Again,	  pre-­‐incubation	  10	  mg/mL	  plantain	  NSP	  resulted	  in	  a	  marked	  reduction	  
in	   caspase-­‐3/7	   activation,	   of	   87.6	   ±	   1.4%	   (P<	   0.001;	  Figure	   6.5B).	   As	  was	   seen	  with	   IL-­‐8	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response,	  there	  was	  a	  decrease	  in	  caspase-­‐3	  activation	  in	  cells	  pre-­‐treated	  with	  plantain	  NSP	  
























Figure	  6.5.	  Soluble	  plantain	  NSP	  reduces	  C.	  difficile	  bacterium	  and	  toxin-­‐mediated	  caspase-­‐
3	  activation	  in	  intestinal	  epithelial	  cells.	  Caco2	  cell	  monolayers	  were	  treated	  with	  A)	  TcdA	  (0-­‐
100	  ng/mL;	  24h)	  and	  CD98011	  (MOI	  100;	  4h)	  or	  B)	  TcdB	  (0-­‐100	  ng/mL;	  48	  h)	  and	  CD108519	  
(MOI	  100;	  4h)	  in	  the	  absence	  (black	  bars)	  or	  presence	  of	  10	  mg/mL	  plantain	  NSP	  (white	  bars).	  
Caspase-­‐3	  activation	  was	  measured	  using	  a	  Caspase-­‐Glo®	  3/7	  Assay,	  as	  per	  manufacturer’s	  
instructions.	  (N=2,	  n=3;	  *	  P<0.05,	  **	  P<0.01,	  ***	  P	  <0.001;	  Kruskal-­‐Wallis).	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6.5.5  Soluble	  plantain	  NSP	  reduces	  C.	  difficile	  bacterium-­‐mediated	  and	  C.	  difficile-­‐toxin-­‐
mediated	  adenylate	  kinase	  release	  from	  intestinal	  epithelial	  cells	  
As	  seen	  with	  other	  toxin-­‐mediated	  effects,	  C.	  difficile	  TcdA	  and	  TcdB	  evoked	  a	  dose-­‐
dependent	   increase	   in	   cytotoxicity	   (as	  measured	   by	   release	   of	   adenylate	   release	   to	   the	  
culture	  supernatant	  from	  Caco2	  cell	  monolayers),	  with	  the	  peak	  response	  seen	  at	  100	  ng/mL	  
for	  both	  toxins	  (Figure	  6.6A	  and	  B).	  Again,	  adenylate	  kinase	  release	  was	  higher	  in	  Caco2	  cells	  
treated	  with	  TcdA	  (TcdA,	  8.2	  ±	  0.9-­‐fold	  increase	  in	  AK	  release;	  TcdB,	  1.8	  ±	  0.2-­‐fold	  increase;	  
P	  <	  0.01;	  Kruskal-­‐Wallis;	  N=2,	  n=3).	  Pre-­‐incubation	  with	  10	  mg/mL	  plantain	  NSP	  significantly	  
decreased	  adenylate	  kinase	  release	  in	  1,	  10	  and	  100	  ng/mL	  TcdA	  and	  TcdB	  treated	  cells	  (For	  
all,	   P	   ≤	  0.01).	   For	   example,	   in	   cells	   treated	  with	  100	  ng/mL	  TcdA	  and	  TcdB,	   there	  was	   a	  
significant	  decrease	  in	  adenylate	  kinase	  release	  by	  63.3	  ±	  4.1%	  and	  35.7	  ±	  9.2%,	  respectively	  
(P	  <	  0.001;	  Figure	  6.6A	  and	  B).	  	  
Following	  4	  h	  infection	  of	  Caco2	  cells	  with	  CD98011	  (TcdA+/TcdB+),	  there	  was	  an	  8.9	  
±	  0.3-­‐fold	   increase	   in	  adenylate	  kinase	  release	   in	  comparison	  to	  vehicle	  treated	  controls,	  
which	  was	   significantly	   decreased	   following	   pre-­‐incubation	  with	   10	  mg/mL	  plantain	  NSP	  
(47.3	  ±	  1.03%;	  P	  <	  0.001;	  Figure	  6.6A).	  Whilst	  adenylate	  kinase	  release	  increased	  by	  2.1	  ±	  
0.3-­‐fold	  in	  cells	  infected	  with	  CD108519	  (TcdA-­‐/TcdB+),	  the	  response	  was	  lower	  than	  that	  
seen	   with	   CD98011.	   Again,	   pre-­‐incubation	   of	   Caco2	   cells	   with	   10	   mg/mL	   plantain	   NSP	  
resulted	   in	  a	   significant	   reduction	  of	   cellular	  adenylate	  kinase	   release,	  by	  56.2	  ±	  1.9%	   in	  
comparison	  to	  that	  seen	  in	  the	  absence	  of	  plantain	  NSP	  (P	  <	  0.001;	  Figure	  6.6B).	  As	  seen	  
previously,	  basal	  levels	  of	  adenylate	  kinase	  release	  were	  observed	  to	  be	  decreased	  in	  Caco2	  
cells	  pre-­‐treated	  with	  soluble	  plantain	  NSP	  alone,	   i.e.	  untreated	  with	  either	  bacterium	  or	  
toxin	  (Figure	  6.6B)	  



















Figure	  6.6.	  Soluble	  plantain	  NSP	  reduces	  C.	  difficile	  bacterium	  and	  toxin-­‐mediated	  cytotoxicity	  
response	   intestinal	   epithelial	   cells.	  Caco2	   cell	   monolayers	  were	   treated	   with	  A)	   TcdA	   (0-­‐100	  
ng/mL	  24	  h)	  and	  CD98011	  (MOI	  100;	  4	  h)	  or	  B)	  TcdB	  (0-­‐100	  ng/mL;	  48	  h)	  and	  CD108519	  (MOI	  100;	  
4h)	   in	   the	   absence	   (black	   bars)	   or	   presence	   of	   10	   mg/mL	   plantain	   NSP	   (white	   bars).	   Media	  
harvested	   from	   cells	   was	   analysed	   for	   the	   presence	   of	   adenylate	   kinase	   using	   a	   ToxiLight™	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6.6   SUMMARY	  OF	  RESULTS	  
	  
1.   C.	  difficile	  TcdA	  induces	  a	  higher	  level	  of	  epithelial	  cell	  damage	  and	  inflammation	  than	  
C.	  difficile	  TcdB	  
	  
2.   Soluble	  plantain	  NSP	  has	  little	  or	  no	  effect	  on	  C.	  difficile	  toxin-­‐mediated	  cellular	  Rac1	  
mono-­‐glucosylation	  or	  cell	  rounding	  
	  
3.   Soluble	   plantain	   NSP	   does	   however	   significantly	   block	   the	   pro-­‐inflammatory,	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6.7   DISCUSSION	  
Here,	  we	  demonstrate	  that	   treatment	  of	  Caco2	  cells	  with	  10	  ng/mL	  purified	  native	  
TcdA	  and	  TcdB	  for	  24	  h	  and	  48	  h,	  respectively,	  results	  in	  a	  significant	  increase	  in	  cellular	  Rac1	  
monoglucosylation.	  Whilst	   other	  Rho-­‐GTPases	   are	   targeted	   for	  mono-­‐glucosylation	  by	  C.	  
difficile	   TcdA	   and	   TcdB,	  we	   chose	   to	   focus	   on	  Rac1	   in	   particular	   due	   to	   the	   fact	   that	   its	  
inactivation	   has	   been	   deemed	   the	   main	   mechanism	   responsible	   for	   toxin-­‐mediated	  
cytopathic	  effects	  (Popoff	  and	  Geny	  2011).	  In	  addition,	  cellular	  Rac1	  monoglucosylation	  can	  
be	   easily	  monitored	   using	   the	   commonly	   available	   anti-­‐Rac1	   clone	   102	   antibody,	   which	  
exhibits	  impaired	  recognition	  of	  Rac1	  following	  its	  mono-­‐glucosylation	  at	  amino	  acid	  Thr-­‐35	  
(Genth	  et	  al.	  2006).	  Our	  findings	  reflect	  those	  from	  other	  studies,	  which	  have	  also	  shown	  
TcdA	  and	  TcdB	  induced	  Rac1	  mono-­‐glucosylation	  in	  fibroblasts	  (Genth	  et	  al.	  2006)	  and	  HT29	  
cells	  (Gerhard	  et	  al.	  2008).	  	  
Other	  early	  effects	  of	  C.	  difficile	   toxins	   include	   the	  expression	  of	  pro-­‐inflammatory	  
cytokines	   and	   loss	   of	   cell	  membrane	   integrity,	   followed	   by	   programmed	   cell	   death.	   The	  
induction	  of	  the	  pro-­‐inflammatory	  response	  has	  been	  demonstrated	  previously	  in	  epithelial	  
cells	  (Kim	  et	  al.	  2006),	  neutrophils	  (Linevsky	  et	  al.	  1997)	  and	  monocytes	  (Flegel	  et	  al.	  1991).	  
The	  exact	  mechanism	  of	  C.	  difficile	  toxin	  induced	  mucosal	  inflammation	  has	  not	  been	  fully	  
elucidated,	  but	  it	  has	  been	  suggested	  that	  C.	  difficile	  TcdA	  might	  mediate	  this	  response	  via	  
IκB	   kinase	   (IKK)	   activation,	   which	   subsequently	   phosphorylates	   and	   targets	   inhibitory	  
protein	  IκB	  for	  ubiquitin-­‐mediated	  proteolysis,	  resulting	  in	  the	  activation	  of	  NF-­‐κB	  (Kim	  et	  
al.	  2006).	  Studies	  have	  also	  demonstrated	  that	  C.	  difficile	  TcdA	  and	  TcdB	  induce	  cytotoxic	  
responses	   in	   intestinal	   epithelial	   cells,	   as	   well	   as	   a	   number	   of	   other	   cell	   types,	   such	   as	  
neuronal	  cells	  (Stankiewicz	  et	  al.	  2015),	  fibroblasts	  (Genth	  et	  al.	  2006)	  and	  endothelial	  cells	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(Hippenstiel	  et	  al.	  2002).	  Similarly,	  in	  our	  own	  studies,	  24	  h	  treatment	  of	  Caco2	  cells	  with	  1-­‐
100	  ng/mL	  TcdA	  or	  TcdB	  significantly	  increased	  the	  cellular	  pro-­‐inflammatory	  IL-­‐8	  response,	  
caspase-­‐3	   activation	   and	   adenylate	   kinase	   release	   in	   a	   dose	   dependent	   manner.	  
Additionally,	  these	  cellular	  responses	  were	  also	  increased	  following	  infection	  of	  Caco2	  cells	  
for	  4	  h	  with	  C.	  difficile	  isolates	  CD98011	  (TcdA+/TcdB+)	  and	  CD108519	  (TcdA-­‐/TcdB+)	  at	  MOI	  
100.	  	  
In	  our	   studies,	   it	   is	   interesting	   that	  C.	  difficile	   TcdA	   induced	  a	  more	  potent	  cellular	  
response	  than	  C.	  difficile	  TcdB.	   Indeed,	  there	  has	  been	  great	  debate	  about	  the	   individual	  
importance	  of	  TcdA	  and	  TcdB	  during	  the	  course	  of	  clinical	  infection,	  and	  many	  conflicting	  
studies	  exist.	  Whilst	  our	  results	  are	   in	  agreement	  with	  studies	  that	  suggest	  TcdA	  exhibits	  
higher	  potency	  and	  cytotoxicity	   in	  vitro	   (Kuehne	  et	  al.	  2010),	  other	  contradictory	  studies	  
indicate	  that	  TcdB	  is	  the	  more	  potent	  toxin	  (Riegler	  et	  al.	  1995;	  Shen	  2012).	  In	  vivo	  animal	  
studies	  have	  also	  created	  a	  paradox	  over	  the	  relative	  importance	  of	  TcdA	  and	  TcdB;	  whilst	  
TcdA+/TcdB-­‐	  mutants	  used	  in	  a	  study	  by	  Keuhne	  and	  colleagues	  were	  able	  to	  induce	  an	  in	  
vivo	  pathogenic	  effect	  (Kuehne	  et	  al.	  2010),	  Lyras	  and	  colleagues	  determined	  that	  equivalent	  
mutants	  were	  avirulent	   (Lyras	  et	  al.	  2009).	   In	  addition,	  TcdA-­‐/TcdB+	  C.	  difficile	   stains	  are	  
routinely	  isolated	  from	  CDI	  patients	  and	  are	  capable	  of	  causing	  extensive	  disease,	  whilst	  very	  
few	  TcdA+/TcdB-­‐	  strains	  have	  been	  reported	  (Sun	  et	  al.	  2010).	  It	  is	  important	  to	  note	  that	  
inherent	  variability	  exists	  between	  the	  toxins	  of	  different	  C.	  difficile	  strains,	  which	  include	  
differences	  in	  enzymatic	  activity	  and/or	  host	  cell	  specificity	  (Kuehne	  et	  al.	  2010),	  and	  could	  
explain	  the	  conflicting	  results.	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Instead,	  it	  is	  likely	  that	  both	  TcdA	  and	  TcdB	  play	  an	  important	  role	  in	  CDI	  pathogenesis.	  
Indeed,	   the	  majority	  of	  CDI	  patients	  are	   infected	  with	  bacterial	   strains	   that	  express	  both	  
TcdA	  and	  TcdB	   (Sutton	   et	  al.	  2008).	  Moreover,	   studies	  have	  shown	  that	  hypervirulent	  C.	  
difficile	  strains	  (such	  as	  027/BI/NAP1)	  produce	  greater	  amounts	  of	  both	  TcdA	  and	  TcdB	  in	  
vitro	  (Warny	  et	  al.	  2005).	  	  In	  our	  own	  studies,	  we	  demonstrate	  that	  whilst	  infection	  of	  Caco2	  
cells	  with	  TcdA-­‐/TcdB+	  CD108519	  did	  mount	  a	  considerable	  cellular	  response,	  the	  response	  
was	  much	  higher	  when	  cells	  were	  treated	  with	  a	  TcdA+/TcdB+	  CD98011,	  suggesting	  that	  the	  
toxins	  might	  work	  together	  in	  synergy	  to	  produce	  an	  additive	  effect.	  	  	  
Our	  results	  indicate	  that	  soluble	  plantain	  fibre	  (plantain	  NSP)	  had	  no	  effect	  on	  toxin-­‐
mediated	  Rac1	  monoglucosylation,	  with	  a	  limited	  effect	  on	  toxin-­‐mediated	  cell	  rounding.	  In	  
contrast,	   soluble	   plantain	   fibre	   did	   significantly	   reduce	   cellular	   pro-­‐inflammatory	   IL-­‐8	  
release,	   caspase-­‐3	   activation	   and	   adenylate	   kinase	   release	   induced	   by	   purified	   native	  C.	  
difficile	   toxins	  and	  C.	  difficile	  bacteria.	  Although	  most	  of	   the	  cellular	  effects	  of	  C.	  difficile	  
toxins	  are	  attributed	  to	  the	  monoglucosylation	  and	  subsequent	  inactivation	  of	  Rho	  proteins,	  
numerous	   studies	   have	   demonstrated	   that	   toxin-­‐mediated	   epithelial	   cell	   damage	   and	  
inflammation	   can	   in	   fact	   occur	   independently	   of	   this	   event.	   Indeed,	   Materrese	   and	  
colleagues	   demonstrated	   that	   TcdB	   causes	   apoptosis	   in	   human	   epithelial	   HEp-­‐2	   cells	   by	  
directly	   acting	   on	   mitochondria,	   which	   does	   not	   require	   the	   N-­‐terminal	   Rho-­‐inhibiting	  
activity	  of	  the	  toxin	  (Matarrese	  et	  al.	  2007).	  Another	  study	  illustrated	  that	  IL-­‐8	  release	  from	  
TcdA-­‐treated	  enterocytes	  is	  dependent	  on	  an	  oxidative	  burst	  originating	  from	  mitochondria,	  
which	   is	   transduced	   via	   the	   IκB-­‐	  NF-­‐κB	  pathway.	   Interestingly,	   early	   events	   in	   this	   signal	  
transduction	   pathway	  were	   observed	  within	   30	  min	   of	   toxin	   exposure,	   occurring	   before	  
detectable	  glucosylation	  activity	  of	  Rho	  proteins	  (He	  et	  al.	  2002).	  These	  findings	  suggest	  that	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plantain	   NSP	   might	   inhibit	   toxin-­‐mediated	   effects	   that	   occur	   independently	   of	   Rho	  
inactivation.	  However,	  it	  is	  also	  important	  to	  note	  that	  basal	  levels	  of	  IL-­‐8,	  apoptosis	  and	  cell	  
death	  were	  also	  reduced	  by	  plantain	  NSP	  pre-­‐treatment	  in	  untreated	  control	  Caco2	  cells.	  
This	   suggests	   that	   to	   some	  extent,	   dietary	   fibre	  might	   instead	  have	  a	   general	   protective	  
effect	  against	  the	  induction	  of	  epithelial	  damage	  and	  inflammation.	  	  
Whilst	  our	  findings	  are	  inconclusive	  as	  to	  whether	  soluble	  plantain	  fibre	  inhibits	  the	  
specific	  mechanisms	  of	  action	  of	  C.	  difficile	  toxins	  within	  intestinal	  epithelial	  cells,	  its	  ability	  
to	  reduce	  C.	  difficile	  bacterium	  and	  toxin	  mediated	  epithelial	  cell	  damage	  and	  inflammation	  
is	   likely	   to	   be	   of	   significant	   clinical	   benefit.	   In	   fact,	   anti-­‐inflammatory	   agents	   have	   been	  
shown	  to	  reduce	  CDI	  severity	  in	  a	  number	  of	  animal	  models	  of	  infection	  (Anton	  et	  al.	  2004;	  
Chen	  et	  al.	  2006;	  Cottrell	  et	  al.	  2007;	  Kokkotou	  et	  al.	  2009;	  Pothoulakis	  et	  al.	  1993;	  Warny	  
et	   al.	   2005).	   Our	   results	   therefore	   add	   to	   the	   already	   existing	   evidence	   to	   suggest	   that	  
dietary	  supplementation	  with	  soluble	  plantain	  fibre	  might	  represent	  an	  effective	  therapy	  to	  
treat	  CDI.	  In	  addition,	  these	  findings	  suggest	  that	  soluble	  plantain	  fibre	  might	  also	  reduce	  
the	  epithelial	  cell	  damage	  and	  inflammation	  associated	  with	  other	  intestinal	  inflammatory	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7.1   INTRODUCTION	  
UC,	   a	   major	   form	   of	   IBD,	   is	   characterised	   by	   chronic	   inflammation	   that	   extends	  
proximally	  from	  the	  rectum	  (Danese	  and	  Fiocchi	  2011).	  UC	  is	  a	  cause	  of	  significant	  morbidity	  
worldwide,	  and	  moreover,	   its	   incidence	  appears	   to	  be	   increasing	  with	  time	  (da	  Silva	  et	  al.	  
2014).	  The	  hallmark	  symptom	  of	  UC	  is	  bloody	  diarrhoea,	  with	  or	  without	  mucus.	  Depending	  
on	   the	   severity	   of	   disease,	   diarrhoea	   can	   be	   accompanied	   by	   abdominal	   pain,	   urgency,	  
tenesmus,	  fever,	  malaise	  and	  weight	  loss	  (Feuerstein	  and	  Cheifetz	  2014).	  The	  onset	  of	  disease	  
is	  typically	  gradual,	  whilst	  the	  clinical	  course	  is	  marked	  by	  exacerbations	  and	  remissions	  that	  
may	  occur	  spontaneously	  in	  response	  to	  treatment	  changes	  or	  illness	  (Kornbluth	  et	  al.	  2010;	  
Danese	  and	  Fiocchi	  2011).	  	  
Conventional	   therapies	   for	  UC	   (such	  as	  mesalazine,	   corticosteroids,	   thiopurines	  and	  
anti-­‐TNF	  agents)	  fail	  to	  successfully	   induce	  remission	  and	  prevent	  relapse,	  and	  in	  addition,	  
cause	  various	  side	  effects	  (Kornbluth	  et	  al.	  2010).	  Indeed,	  approximately	  50%	  of	  patients	  with	  
UC	  have	  chronically	  active	  disease,	  which	  has	  a	  hugely	  negative	  impact	  on	  quality	  of	  life	  (Lix	  
et	   al.	   2008).	  More	   severe	   cases	   of	   UC	   require	   colectomy,	   which	   is	   considered	   a	   curative	  
strategy	   (Dignass	   et	  al.	  2012).	  However,	   this	  puts	  a	  considerable	  economic	  burden	  on	   the	  
healthcare	  system,	  and	  can	  be	  associated	  with	  complications	  (Lindsay	  et	  al.	  2015).	  As	  such,	  
the	  development	  of	  alternative	  treatment	  strategies	  for	  UC	  is	  of	  great	  interest.	  	  
In	  order	  to	  develop	  new	  treatment	  strategies	  for	  UC,	  it	  is	  important	  to	  understand	  the	  
pathogenesis	  of	  disease.	  Whilst	  the	  exact	  pathophysiology	  of	  UC	  is	  not	  clearly	  understood,	  it	  
is	   likely	  that	  pre-­‐disposition	  to	  a	  number	  of	  genetic	  and	  environmental	  factors	  can	   lead	  to	  
alterations	  in	  barrier	  function	  of	  the	  intestinal	  mucosa,	  which	  can	  lead	  to	  harmful	  interactions	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between	   bacteria,	   bacterial	   components	   and	   the	   surface	   epithelium	   (Cooney	   and	   Jewell	  
2009).	  
In	   active	  UC,	   the	   normally	   continuous	   adherent	   colonic	  mucus	   layer	   is	   depleted	   or	  
completely	  absent	  (Johansson	  2014).	  This	  has	  been	  attributed	  to	  a	  lack	  of	  predominant	  mucus	  
component,	  mucin	  glycoprotein	  MUC2,	  which	  is	  normally	  secreted	  by	  goblet	  cells	  (Johansson	  
2014).	  Indeed,	  a	  number	  of	  studies	  have	  shown	  that	  patients	  with	  UC	  exhibit	  reduced	  goblet	  
cell	   numbers	   and	   depleted	   mucus	   secretion	   (Boltin	   et	   al.	   2013),	   whilst	   others	   have	  
documented	   the	  development	  of	   spontaneous	   colitis	   in	   several	  mouse	   strains	  with	  MUC2	  
defects	  (Johansson	  et	  al.	  2014;	  Wenzel	  et	  al.	  2014).	  	  
As	   a	   consequence	   of	   the	   loss	   of	   the	   protective	   colonic	   mucus	   layer,	   the	   surface	  
epithelium	   becomes	   exposed	   to	   colonic	   bacteria	   and	   their	   components	   (Johansson	   et	   al.	  
2010;	  Wenzel	   et	   al.	   2014;	   Johansson	   et	   al.	   2014).	   In	   addition,	   impaired	   cell	   adhesion	   and	  
defective	  regulation	  of	  tight	  junctions	  between	  intestinal	  epithelial	  cells	  leads	  to	  an	  increase	  
in	  the	  permeability	  of	  the	  intestinal	  epithelium,	  which	  also	  brings	  about	  increased	  bacterial	  
translocation	   through	   the	   lamina	   propria	   (Ohkusa	   et	   al.	   2009;	   Hotte	   et	   al.	   2012).	  
Subsequently,	  bacterial	  antigens	  can	  interact	  with	  toll-­‐like	  receptors	  (TLRs),	  resulting	  in	  the	  
activation	  of	  NF-­‐κB	  signalling	  and	  release	  of	  pro-­‐inflammatory	  cytokines	  such	  as	  TNF-­‐α,	  IL-­‐12,	  
IL-­‐23,	  IL-­‐	  6	  and	  IL-­‐1β	  (Ordas	  et	  al.	  2012),	  	  as	  well	  as	  potent	  neutrophil	  chemoattractant	  IL-­‐8	  
(Danese	  and	  Fiocchi	  2011;	  Mitsuyama	  et	  al.	  1994),	  which	  results	  in	  the	  subsequent	  activation	  
of	  innate	  and	  adaptive	  immune	  responses	  (Ordas	  et	  al.	  2012).	  
It	  is	  becoming	  increasingly	  evident	  that	  enteric	  bacteria	  play	  an	  important	  role	  in	  the	  
initiation	  and	  development	  of	  inflammation	  in	  UC.	  Indeed,	  several	  studies	  have	  reported	  an	  
increase	  in	  adherent,	  invasive	  E.	  coli	  (AIEC)	  in	  the	  colonic	  mucosa	  of	  UC	  patients	  (Kotlowski	  et	  
	  	  153	  
al.	   2007;	  Mylonaki	   et	   al.	   2005;	   Sokol	   et	   al.	   2006;	   Swidsinski	   et	   al.	   2002).	   Moreover,	   the	  
dysregulation	   of	   intestinal	   barrier	   function	   results	   in	   direct	   contact	   between	   bacteria,	  
bacterial	   components	   such	   as	   flagellin	   and	   LPS	   and	   the	   surface	   epithelium,	   with	   major	  
potential	   for	   interaction	  with	  TLRs	  and	  consequent	  release	  of	  pro-­‐inflammatory	  cytokines.	  
Hence,	   the	  ability	   to	  prevent	   these	  harmful	  bacteria-­‐epithelial	   interactions	   is	  an	  attractive	  
therapeutic	  strategy.	  	  
In	  Chapter	  6	  of	  this	  thesis,	  it	  was	  shown	  that	  soluble	  plantain	  fibre	  could	  significantly	  
reduce	   the	   epithelial	   damage	   and	   inflammation	   mediated	   by	   C.	   difficile	   and	   its	   toxins,	  
suggesting	  that	   it	  could	  be	  developed	  as	  potential	  prophylaxis	  or	  treatment	  for	  CDI.	  These	  
results	  suggest	  that	  soluble	  plantain	  fibre	  might	  also	  have	  the	  ability	  to	  reduce	  the	  epithelial	  
cell	  damage	  and	  inflammation	  induced	  by	  other	  bacterial	  components,	  such	  as	  E.	  coli	  flagellin	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7.2   HYPOTHESIS	  
	  
Soluble	   plantain	   fibre	   can	   reduce	   the	   epithelial	   cell	   damage	   and	   inflammation	  
mediated	  by	  bacterial	  flagellin	  and	  LPS	  
	  
	  
7.3   AIMS	  
	  
1.   To	   determine	   if	   soluble	   plantain	   fibre	   can	   reduce	   the	   cytotoxicity,	   apoptotic	   and	   pro-­‐
inflammatory	  response	  mediated	  by	  five	  different	  mucosally-­‐associated	  UC	  E.	  coli	  isolates,	  
as	  well	   as	   their	   pooled,	   bacteria-­‐free	   filtrate	  of	   culture	  media	   supernatant	   (containing	  
OMVs	  and	  flagellin)	  
	  
	  
2.   To	   determine	   if	   soluble	   plantain	   fibre	   can	   reduce	   the	   cytotoxicity,	   apoptotic	   and	   pro-­‐
inflammatory	  response	  mediated	  by	  purified	  bacterial	  flagellin	  
	  
	  
3.   To	   determine	   if	   soluble	   plantain	   fibre	   can	   reduce	   the	   cytotoxicity,	   apoptotic	   and	   pro-­‐
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7.4   METHODS	  
The	  mucosally-­‐associated	  E.	  coli	  strains	  (HM250,	  HM295,	  HM378,	  HM380	  and	  HM387;	  
Appendix	  3)	  used	  in	  this	  study	  were	  previously	  isolated	  from	  colonic	  biopsies	  of	  five	  patients	  
with	  UC,	  as	  described	  elsewhere	   (Martin	   et	  al.	   2004;	  Subramanian	   et	  al.	   2008).	  UC	  E.	   coli	  
isolates	  were	  grown	  as	  described	  in	  Section	  4.4.1,	  and	  then	  pooled	  to	  generate	  a	  bacterial	  
suspension	  of	  OD	  0.125	  at	  550nm.	  The	  culture	  suspension	  was	  then	  sterile	  filtered	  using	  a	  0.2	  
µm	   filter	   (Corning/Costar)	   to	   generate	   a	   bacteria-­‐free	   filtrate,	   confirmed	   bacteria-­‐free	   by	  
overnight	  culture	  on	  LB	  agar.	  This	  preparation	  has	  previously	  been	  shown	  to	  contain	  OMVs	  
and	   associated	   flagellae	   (Subramanian	   et	   al.	   2008).	   HT29	   cell	   monolayers,	   which	   had	  
undergone	  pre-­‐treatment	  with	  or	  without	  10	  mg/mL	  plantain	  NSP,	  were	  then	  treated	  with	  50	  
µL	  of	  the	  bacteria-­‐free	  filtrate	  for	  4h.	   In	  parallel,	  HT29	  cell	  monolayers	  were	   infected	  with	  
each	  individual	  UC	  E.	  coli	  isolate	  at	  an	  MOI	  of	  10,	  or	  treated	  with	  1	  µg/mL	  flagellin	  purified	  
from	  S.	  Typhimurium	  LT2	  (Sigma-­‐Aldrich)	  each	  for	  4	  h	  at	  37°C	  (Section	  4.9)	  (Subramanian	  et	  
al.	  2008).	  HT29	  cells	  were	  used	  in	  these	  studies	  as	  this	  particular	  cell	  line	  expresses	  TLR5	  on	  
the	  apical	  membrane	  of	  intestinal	  epithelial	  cells.	  This	  is	  important	  as	  E.	  coli	  flagellin	  acts	  in	  a	  
TLR5-­‐dependent	  manner	  to	  induce	  cellular	  IL-­‐8	  release	  (Subramanian	  et	  al.	  2008).	  	  
To	  assess	  the	  effect	  of	  plantain	  NSP	  on	  the	  epithelial	  cell	  damage	  and	  inflammation	  
induced	  by	  bacterial	  LPS,	  Caco2	  cell	  monolayers	  were	  also	  pre-­‐incubated	  with	  or	  without	  10	  
mg/mL	  plantain	  NSP	  prior	  to	  treatment	  with	  1,	  100	  or	  1000	  µg/mL	  LPS	  purified	  from	  E.	  coli	  
0111:	  B4	  for	  24	  h	  (Section	  4.10).	  	  
To	  assess	  the	  pro-­‐inflammatory	  response	  induced	  by	  flagellin	  and	  LPS,	  harvested	  media	  
from	  HT29	   cell	  monolayers	  was	  measured	   for	   the	   presence	   of	   released	  pro-­‐inflammatory	  
cytokine	  IL-­‐8	  using	  a	  human	  IL-­‐8	  ELISA	  (Section	  4.15).	  To	  assess	  the	  apoptotic	  response,	  the	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cellular	  activation	  of	  caspase-­‐3/7	  was	  measured	  using	  a	  commercial	  Caspase-­‐Glo®	  3/7	  assay,	  
as	  per	  manufacturer	  instructions	  (Section	  4.16).	  Finally,	  to	  assess	  for	  any	  evidence	  of	  cellular	  
cytotoxicity,	  harvested	  cell	  culture	  media	  was	  analysed	  for	  the	  presence	  of	  adenylate	  kinase	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7.5   RESULTS	  
	  
7.5.1   Soluble	   plantain	   fibre	   reduces	   the	   epithelial	   cell	   damage	   and	   inflammation	  
induced	  by	  mucosally-­‐associated	  UC	  E.	  coli	  isolates	  
As	  observed	  previously	  by	   Subramanian	  and	   colleagues	   (Subramanian	   et	   al.	   2008),	  
infection	  of	  HT29	  cells	  with	  each	  of	  the	  five	  individual	  UC	  E.	  coli	   isolates	  (at	  an	  MOI	  of	  10)	  
evoked	  comparable	  levels	  of	  pro-­‐inflammatory	  IL-­‐8	  release	  (median	  of	  1009.1	  pg/mL;	  range	  
of	  849.1	  ±	  82.3	  to	  1068	  ±	  105.4	  pg/mL	  in	  comparison	  to	  the	  basal	  level	  of	  258.2	  ±	  18.7	  pg/mL)	  
(Figure	  7.1).	  Pre-­‐treatment	  of	  HT29	  cells	  with	  10	  mg/mL	  plantain	  NSP	   for	  30	  min	  prior	   to	  
infection,	  reduced	  four	  out	  of	  five	  pro-­‐inflammatory	  responses	  mediated	  by	  UC	  E.	  coli	  isolate	  
(HM250,	   HM295,	   HM378,	   HM387),	   but	   with	   significant	   inhibition	   observed	   for	   only	   one	  
isolate,	  HM250.	  Plantain	  NSP	  significantly	  reduced	  HM250	  mediated	  IL-­‐8	  response	  by	  32.5	  ±	  
6.2%	  in	  comparison	  to	  the	  untreated	  control	  (P	  <	  0.05;	  Figure	  7.1),	  whilst	  inhibition	  of	  the	  IL-­‐
8	  response	  to	  the	  other	  four	  isolates	  ranged	  from	  23.0	  ±	  1.8%	  to	  31.7	  ±	  17.5%.	  Conversely,	  IL-­‐
8	   release	   in	   response	   to	  UC	  E.	   coli	   isolate	  HM380	  was	  not	   reduced	   following	  30	  min	  pre-­‐

























Figure	  7.1	  Soluble	  plantain	  fibre	  reduces	  the	  release	  of	  pro-­‐inflammatory	  IL-­‐8	  induced	  by	  
mucosally	   associated	   UC	   E.	   coli	   from	   HT29	   colonocytes.	   HT29	   cell	   monolayers	  were	   pre-­‐
incubated	  with	  (white	  bars)	  or	  without	  (black	  bars)	  10	  mg/mL	  plantain	  NSP	  for	  30	  min	  and	  
infected	  with	  five	  different	  UC	  E.	  coli	  isolates	  (MOI	  10;	  4	  h).	  Cell	  culture	  media	  harvested	  from	  
cells	  was	  analysed	  for	   the	  presence	  of	  pro-­‐inflammatory	  cytokine	   IL-­‐8	  using	  an	   IL-­‐8	  human	  
ELISA	  kit	  (N=2,	  n=3;	  *	  P	  <	  0.05;	  Kruskal-­‐Wallis).	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Cellular	  cytotoxicity	  induced	  in	  response	  to	  infection	  of	  HT29	  cells	  with	  each	  individual	  
UC	  E.	   coli	   isolate	  was	   observed	   to	   be	   highly	   variable.	   	  E.	   coli	   isolates	  HM295	   and	  HM378	  
induced	  much	  higher	  cytotoxicity	  responses	  than	  other	  UC	  isolates	  tested	  (13.1	  ±	  2.7	  and	  16.8	  
±	  3.3-­‐fold	   increase,	  respectively).	  Despite	  this,	  pre-­‐treatment	  of	  HT29	  cells	  with	  10	  mg/mL	  
plantain	  NSP	  reduced	  the	  cytotoxicity	  response	  induced	  by	  all	  five	  UC	  E.	  coli	  isolates	  (Figure	  
7.2).	  Interestingly,	  whilst	  plantain	  NSP	  had	  no	  effect	  on	  the	  cellular	  IL-­‐8	  response	  induced	  by	  
E.	  coli	  HM380,	  it	  significantly	  reduced	  release	  of	  cellular	  adenylate	  kinase	  to	  the	  culture	  media	  
by	  18.6	  ±	  2.2%	   in	   comparison	   to	   the	  untreated	   control	   cells	   (P	  <	  0.05;	  Figure	  7.2).	  Whilst	  
plantain	  NSP	  did	  not	  significantly	  inhibit	  adenylate	  kinase	  release	  in	  response	  to	  all	  other	  UC	  
E.	   coli	   isolates	   tested,	   smaller	   reductions	   in	   the	   cytotoxicity	   response	  were	   still	   observed,	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Figure	   7.2	   Soluble	   plantain	   fibre	   reduces	   the	   cellular	   cytotoxicity	   response	   induced	   by	  
mucosally-­‐associated	  UC	  E.	  coli.	  HT29	  cell	  monolayers	  were	  pre-­‐incubated	  with	  (white	  bars)	  
or	  without	  (black	  bars)	  10	  mg/mL	  plantain	  NSP	  and	  infected	  with	  five	  UC	  E.	  coli	  isolates	  (MOI	  
10;	  4	  h).	  Cell	  culture	  media	  harvested	  from	  cell	  monolayers	  was	  analysed	  for	  the	  presence	  of	  
adenylate	  kinase	  using	  a	  Toxilight™	  bioassay	  kit	  (N=2,	  n=3;	  *	  P	  <	  0.05;	  Kruskal-­‐Wallis).	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7.5.2   Soluble	   plantain	   fibre	   reduces	   the	   epithelial	   cell	   damage	   and	   inflammation	  
induced	  by	  mucosally-­‐associated	  UC	  E.	  coli	  flagellin	  
Treatment	   of	   HT29	   cells	   with	   50	   µL	   of	   0.2	   µm-­‐filtered	   pooled	   UC	   E.	   coli	   culture	  
supernatant	  increased	  the	  pro-­‐inflammatory	  IL-­‐8	  response	  from	  258.2	  ±	  18.7	  pg/mL	  to	  1060.7	  
±	  95.7	  pg/mL	  (Figure	  7.3),	  which	  was	  a	  similar	  level	  to	  the	  IL-­‐8	  response	  evoked	  by	  individual	  
mucosal	  UC	  E.	  coli	  isolates	  (Figure	  7.1),	  as	  has	  been	  observed	  previously	  (Subramanian	  et	  al.	  
2008).	  However,	  10	  mg/mL	  plantain	  NSP	  exhibited	  a	  more	  significant	  effect	  against	  the	  IL-­‐8	  
response	  evoked	  by	  the	  pooled	  UC	  E.	  coli	  supernatant,	  which	  was	  reduced	  by	  66.0	  ±	  7.2%	  (P	  
<	   0.05;	   Figure	   7.3).	   Similarly,	   plantain	   NSP	   also	   had	   a	  more	   significant	   effect	   against	   the	  
epithelial	  cell	  damage	  mediated	  by	  the	  pooled	  UC	  E.	  coli	  supernatant,	  significantly	  reducing	  
release	  of	  cellular	  adenylate	  kinase	  to	  the	  culture	  medium	  by	  39.7	  ±	  0.5%	  (P	  <	  0.01;	  Figure	  





























Figure	  7.3	  Soluble	  plantain	  fibre	  reduces	  the	  cellular	  IL-­‐8	  response	  induced	  by	  the	  pooled	  
supernatant	  of	  five	  UC	  E.	  coli	  isolates.	  HT29	  cell	  monolayers	  were	  pre-­‐incubated	  with	  (white	  
bars)	  or	  without	  (black	  bars)	  10	  mg/mL	  plantain	  NSP	  and	  treated	  with	  50	  µL	  0.2	  µm-­‐filtered	  
culture	  supernatant	  pooled	  from	  five	  mucosal	  UC	  E.	  coli	  isolates	  (HM250,	  HM295,	  HM378,	  
HM380,	  HM387)	  (50	  µL;	  4	  h).	  	  Cell	  culture	  media	  harvested	  from	  cells	  was	  analysed	  for	  the	  
presence	  of	  pro-­‐inflammatory	  cytokine	  IL-­‐8	  using	  an	  IL-­‐8	  Human	  ELISA	  kit	  (N=2,	  n=3;	  *	  P	  <	  
0.05;	  Kruskal-­‐Wallis).	  
























Figure	  7.4	  Soluble	  plantain	  fibre	  reduces	  cellular	  adenylate	  kinase	  release	  induced	  by	  the	  
pooled	  supernatant	  of	  five	  UC	  E.	  coli	  isolates.	  HT29	  cell	  monolayers	  were	  pre-­‐incubated	  
with	  (white	  bars)	  or	  without	  (black	  bars)	  10	  mg/mL	  plantain	  NSP	  and	  treated	  with	  50	  µL	  0.2	  
µm-­‐filtered	   culture	   supernatant	   pooled	   from	   five	   mucosal	   UC	   E.	   coli	   isolates	   (HM250,	  
HM295,	  HM378,	  HM380,	  HM387)	  (50	  µL;	  4	  h).	  	  Cell	  culture	  media	  harvested	  from	  cells	  was	  
analysed	  for	  the	  presence	  of	  adenylate	  kinase	  using	  a	  Toxilight™	  bioassay	  kit	  (N=2,	  n=3;	  **	  
P	  <	  0.01;	  Kruskal-­‐Wallis).	  























Figure	  7.5	  Soluble	   plantain	   fibre	   reduces	   cellular	   caspase-­‐3/7	   activation	   induced	  by	   the	  
pooled	   supernatant	  of	   five	  UC	  E.	   coli	   isolates.	  HT29	  cell	  monolayers	  were	  pre-­‐incubated	  
with	  (white	  bars)	  or	  without	  (black	  bars)	  10	  mg/mL	  plantain	  NSP	  and	  treated	  with	  50	  µL	  0.2	  
µm-­‐filtered	   culture	   supernatant	   pooled	   from	   five	   mucosal	   UC	   E.	   coli	   isolates	   (HM250,	  
HM295,	  HM378,	  HM380,	  HM387)	  (50	  µL;	  4	  h).	  	  Caspase-­‐3/7	  activation	  was	  measured	  using	  
a	  Caspase-­‐Glo®	  3/7	  Assay,	  as	  per	  manufacturer’s	  instructions	  (N=1,	  n=3;	  *	  P	  <	  0.05;	  Kruskal-­‐
Wallis).	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7.5.3   Soluble	   plantain	   fibre	   reduces	   the	   epithelial	   cell	   damage	   and	   inflammation	  
induced	  by	  purified	  flagellin	  
Treatment	  of	  HT29	  cells	  with	  1	  µg/mL	  purified	  bacterial	   flagellin	  for	  24	  h	   increased	  
release	  of	  pro-­‐inflammatory	  IL-­‐8	  and	  adenylate	  kinase	  by	  5.3	  ±	  0.5	  fold	  (Figure	  7.6)	  and	  38.5	  
±	   0.3	   fold	   (Figure	   7.7)	   respectively,	   in	   comparison	   to	   basal	   levels.	   Again,	   plantain	   NSP	  
exhibited	   a	   more	   significant	   effect	   against	   the	   epithelial	   inflammation	   and	   cell	   damage	  
induced	   by	   purified	   flagellin	   than	   compared	  with	   that	   seen	  with	   the	   individual	   UC	  E.	   coli	  
isolates.	  In	  comparison	  to	  the	  vehicle-­‐treated	  controls,	  pre-­‐treatment	  with	  10	  mg/mL	  plantain	  
NSP	  significantly	  reduced	  flagellin-­‐mediated	  release	  of	  both	  IL-­‐8	  and	  adenylate	  kinase	  by	  69.1	  






























Figure	   7.6	   Soluble	   plantain	   fibre	   reduces	   cellular	   IL-­‐8	   response	   induced	   by	   purified	  
bacterial	  flagellin.	  HT29	  cell	  monolayers	  were	  pre-­‐incubated	  with	  (white	  bars)	  or	  without	  
(black	  bars)	  10	  mg/mL	  plantain	  NSP	  and	  treated	  with	  purified	  flagellin	   (1µg/mL;	  4	  h).	  Cell	  
culture	   media	   harvested	   from	   cells	   was	   analysed	   for	   the	   presence	   of	   pro-­‐inflammatory	  
cytokine	  IL-­‐8	  using	  an	  IL-­‐8	  Human	  ELISA	  kit	  (N=2,	  n=3;	  ***	  P	  <	  0.001;	  Kruskal-­‐Wallis).	  	  
Untreated   Flagellin   
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Figure	   7.7	   Soluble	   plantain	   fibre	   reduces	   cellular	   adenylate	   kinase	   release	   induced	   by	  
purified	  bacterial	  flagellin.	  HT29	  cell	  monolayers	  were	  pre-­‐incubated	  with	  (white	  bars)	  or	  
without	  (black	  bars)	  10	  mg/mL	  plantain	  NSP	  and	  treated	  with	  purified	  flagellin	  (1µg/mL;	  4	  
h).	   Cell	   culture	  media	   harvested	   from	   cells	   was	   analysed	   for	   the	   presence	   of	   adenylate	  
kinase	  using	  a	  Toxilight™	  bioassay	  kit	  (N=2,	  n=3;	  ***	  P	  <	  0.001;	  Kruskal-­‐Wallis).	  	  
*** 
Untreated   Flagellin  
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7.5.4   Soluble	   plantain	   fibre	   reduces	   the	   epithelial	   cell	   damage	   and	   inflammation	  
induced	  by	  bacterial	  LPS	  
	  
Treatment	  of	  intestinal	  Caco2	  cells	  with	  1	  –	  1000	  µg/mL	  LPS	  isolated	  from	  E.	  coli	  for	  
24	  h	  resulted	  in	  a	  dose-­‐dependent	  increase	  in	  the	  pro-­‐inflammatory	  IL-­‐8	  response,	  which	  was	  
reduced	  in	  the	  presence	  of	  10	  mg/mL	  plantain	  NSP	  (Figure	  7.8).	  Treatment	  of	  Caco2	  cells	  with	  
1000	  µg/mL	  LPS	  increased	  IL-­‐8	  release	  from	  the	  observed	  basal	  level	  of	  629.4	  ±	  159.3	  pg/mL	  
to	  1242.0	  ±	  361.3	  pg/mL	  which	  was	  reduced	  by	  69.4	  ±	  21.9%	  following	  pre-­‐treatment	  with	  
plantain	   NSP	   (Figure	   7.8).	   Similarly,	   LPS	   mediated	   a	   dose-­‐dependent	   increase	   in	   cellular	  
cytotoxicity	  and	  apoptosis,	  which	  were	  both	  significantly	  inhibited	  by	  30	  min	  pre-­‐treatment	  
with	  10	  mg/mL	  plantain	  NSP;	  LPS,	  at	  1000	  µg/mL,	  increased	  adenylate	  kinase	  release	  from	  
3642.7	  ±	  685.7	  to	  35589.3	  ±	  7873	  (arbitrary	  units	  of	  luminescence,	  AUL)	  which	  was	  markedly	  
reduced	  by	  93.5	  ±	  0.3%	  in	  the	  presence	  of	  10mg/mL	  plantain	  NSP	  (P	  <	  0.001;	  Figure	  7.9),	  and	  
increased	   cellular	   caspase-­‐3/7	   activation	   by	   2.7	   ±	   0.12	   fold	   in	   comparison	   to	   basal	   levels,	  




























Figure	   7.8	   Soluble	   plantain	   fibre	   reduces	   cellular	   IL-­‐8	   response	   induced	  by	   bacterial	   LPS.	  
Caco2	  cell	  monolayers	  were	  pre-­‐incubated	  with	  (white	  bars)	  or	  without	  (black	  bars)	  10	  mg/mL	  
plantain	  NSP	  and	  treated	  with	  LPS	  purified	  from	  E.	  coli	   (1	  –	  1000	  µg/mL;	  24	  h).	  Cell	  culture	  
media	  harvested	  from	  cells	  was	  analysed	  for	  the	  presence	  of	  pro-­‐inflammatory	  cytokine	  IL-­‐8	  








































Figure	  7.9	  Soluble	  plantain	  fibre	  reduces	  cellular	  adenylate	  kinase	  release	  induced	  by	  
bacterial	  LPS.	  Caco2	  cell	  monolayers	  were	  pre-­‐incubated	  with	  (white	  bars)	  or	  without	  
(black	   bars)	   10	  mg/mL	  plantain	  NSP	   and	   treated	  with	   purified	   E.	   coli	   LPS	   (1	   –	   1000	  
µg/mL;	  24	  h).	  Cell	  culture	  media	  harvested	  from	  cells	  was	  analysed	  for	  the	  presence	  of	  
































Figure	  7.10	  Soluble	   plantain	   fibre	   reduces	   cellular	   caspase-­‐3/7	  activation	   induced	  by	  
bacterial	   LPS.	  Caco2	   cell	  monolayers	  were	  pre-­‐incubated	  with	   (white	  bars)	  or	  without	  
(black	  bars)	  10	  mg/mL	  plantain	  NSP	   and	   treated	  with	  purified	  E.	   coli	   LPS	   (100	  –	   1000	  
µg/mL;	  24	  h).	  Caspase-­‐3/7	  activation	  was	  measured	  using	  a	  Caspase-­‐Glo®	  3/7	  Assay,	  as	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7.6   SUMMARY	  OF	  RESULTS	  
	  
1.   Soluble	   plantain	   fibre	   reduces	   the	   cellular	   pro-­‐inflammatory	   and	   cytotoxic	   response	  
induced	  by	  five	  individual	  mucosally-­‐associated	  UC	  E.	  coli	  isolates	  
	  
	  
2.   Soluble	  plantain	   fibre	   reduces	   the	  pro-­‐inflammatory,	   cytotoxic	  and	  apoptotic	   response	  




3.   Soluble	  plantain	  fibre	  reduces	  the	  pro-­‐inflammatory	  and	  cytotoxic	  response	  induced	  by	  
purified	  bacterial	  flagellin	  
	  
	  
4.   Soluble	   plantain	   fibre	   reduces	   the	   cellular	   pro-­‐inflammatory,	   cytotoxic	   and	   apoptotic	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7.7   DISCUSSION	  
Intestinal	   inflammation	   in	   IBD	   is	   initiated	  as	  a	  consequence	  of	  an	  aberrant	   immune	  
response	  to	  the	  commensal	  microbiota	  (Cooney	  and	  Jewell	  2009).	  Therefore,	  it	  is	  plausible	  
that	   dietary	   components	   with	   the	   ability	   to	   modify	   the	   intestinal	   microflora	   or	   disrupt	  
bacterial	  interaction	  with	  the	  intestinal	  epithelium	  might	  have	  a	  protective	  effect	  (Simpson	  
and	  Campbell	  2014).	  
The	   traditional	   rationale	   for	   the	   use	   of	   dietary	   fibre	   in	  managing	   IBD	   relates	   to	   its	  
beneficial	   effects	   on	   gastrointestinal	   function	   (Lattimer	   and	  Haub	   2010),	   SCFA	  production	  
(Macfarlane	  et	  al.	  2006)	  and	  subsequent	  prebiotic	  effect	  (Hamer	  et	  al.	  2008).	  Indeed,	  several	  
studies	  have	  reported	  that	  some	  prebiotics	  exert	  protective	  effects	  against	  colitis	  in	  humans.	  
For	  example,	  number	  of	   in	  vivo	  human	  studies	  have	  demonstrated	  the	  role	  of	  germinated	  
barley	  foodstuff	  (GBF)	  in	  the	  maintenance	  of	  UC	  remission	  (Kanauchi	  et	  al.	  2002),	  as	  well	  as	  
inducing	  remission	  in	  patients	  with	  mild-­‐moderate	  active	  UC	  (Bamba	  et	  al.	  2002;	  Kanauchi	  et	  
al.	  2002;	  Scaldaferri	  et	  al.	  2013).	  Inulin	  supplementation	  has	  also	  showed	  some	  promise	  with	  
respect	   to	   acute	   UC;	   a	   randomised,	   placebo	   controlled	   trial	   using	   oligofructose-­‐enriched	  
inulin	  was	  associated	  with	  lowered	  faecal	  calprotectin,	  a	  marker	  of	  intestinal	  inflammation	  
(Casellas	  et	  al.	  2007).	  Some	  benefit	  was	  also	  accrued	  to	  the	  use	  of	  pysillium	  (Isphaghula	  husk	  
fibre)	  in	  maintaining	  remission	  in	  UC	  patients	  (Kanauchi	  et	  al.	  2013),	  where	  one	  trial	  reported	  
no	   significant	   difference	   between	   the	   fibre	   and	   conventional	   antibiotic	   mesalazine	  
(Fernandez-­‐Banares	  et	  al.	  1999).	  	  
Previous	   work	   performed	   by	   our	   group	   has	   shown	   that,	   unlike	   other	   dietary	   fibre	  
components,	   soluble	   plantain	   fibre	   possesses	   limited	   prebiotic	   activity	   (Backman	   2009).	  
Instead,	  we	  propose	   that	   soluble	  plantain	  NSP	   can	   inhibit	  potentially	  harmful	   interactions	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between	  bacteria,	  bacterial	   components	   and	   the	  gut	  epithelium	  via	   a	   ‘contrabiotic’	   effect	  
(Simpson	  and	  Campbell	  2015;	  Simpson	  et	  al.	  2014).	  Indeed,	  we	  have	  previously	  shown	  that	  
soluble	  plantain	  fibre	  can	  inhibit	  the	  epithelial	  interactions	  of	  a	  range	  of	  different	  bacteria,	  
such	  as	  Crohn’s	  mucosa-­‐associated	  AIEC,	  Salmonella	  Typhimurium,	  Shigella	  sonnei,	  C.	  difficile	  
and	  ETEC	   (Parsons	   et	  al.	  2014;	  Roberts	   et	  al.	  2010;	  Roberts	   et	  al.	  2013),	  as	  well	  as	  down-­‐
regulate	   the	  epithelial	   inflammatory	   response	   to	  bacterial	   components,	   such	  as	  C.	  difficile	  
toxins	  (Chapter	  6	  of	  this	  thesis).	  Importantly,	  inhibition	  of	  these	  cellular	  responses	  occurred	  
at	   soluble	   fibre	   concentrations	   readily	   achievable	  within	   the	  human	  distal	   colon	   following	  
dietary	  supplementation	  (Parsons	  et	  al.	  2014;	  Roberts	  et	  al.	  2013),	  suggesting	  that	  soluble	  
dietary	  fibre	  might	  have	  a	  protective	  effect	  against	  intestinal	  pathogens	  implicated	  in	  a	  range	  
of	  different	  diarrhoeal	  diseases.	  	  
Here,	  we	  wanted	  to	  assess	   if	   soluble	  plantain	   fibre	  would	  have	  the	  ability	   to	  down-­‐
regulate	   the	  epithelial	   inflammation	   and	  damage	   induced	  by	  other	  bacterial	   components,	  
such	  as	  mucosally-­‐associated	  flagellin	  and	  LPS,	  which	  are	  implicated	  in	  the	  pathogenesis	  of	  
UC.	   In	   active	  UC	  disease,	   the	   normally	   continuous	   adherent	   colonic	  mucus	   is	   depleted	   or	  
completely	  absent	  (Johansson	  2014).	  Consequently,	  the	  surface	  epithelium	  becomes	  exposed	  
to	  colonic	  bacteria	  and	  their	  components,	  which	  leads	  to	  excessive	  TLR	  stimulation,	  secretion	  
of	   pro-­‐inflammatory	   cytokines	   and	   subsequent	   activation	   of	   innate	   and	   adaptive	   immune	  
responses	   (Ordas	   et	  al.	  2012).	   Indeed,	   it	  has	  previously	  been	  demonstrated	   that	  mucosal-­‐
associated	  E.	  coli,	  which	  are	  markedly	  increased	  in	  UC	  (Kotlowski	  et	  al.	  2007;	  Mylonaki	  et	  al.	  
2005;	  Sokol	  et	  al.	  2006;	  Swidsinski	  et	  al.	  2002),	  mediate	  cellular	  pro-­‐inflammatory	  IL-­‐8	  release	  
via	  an	  interaction	  between	  E.	  coli	  flagellin	  and	  TLR5	  (Subramanian	  et	  al.	  2008).	  LPS,	  an	  integral	  
component	  of	  Gram-­‐negative	  bacteria	  such	  as	  E.	  coli,	  is	  known	  to	  activate	  the	  innate	  immune	  
	  	  175	  
response	  via	  an	  interaction	  with	  TLR4	  (Beutler	  et	  al.	  2003).	  Promisingly,	  we	  illustrate	  here	  that	  
soluble	   plantain	   fibre	   can	   in	   fact	   reduce	   the	   cellular	   pro-­‐inflammatory,	   cytotoxicity	   and	  
apoptotic	   response	   mediated	   by	   mucosally-­‐associated	   UC	   E.	   coli,	   as	   well	   as	   mucosal	  
interacting	   flagellin	   and	   LPS,	   suggesting	   a	   possible	   role	   for	   soluble	   plantain	   fibre	   in	   the	  
treatment	  of	  UC.	  	  
It	  is	  interesting	  that	  soluble	  plantain	  NSP	  exhibited	  a	  more	  significant	  effect	  against	  the	  
epithelial	  cell	  damage	  and	  inflammation	  induced	  by	  the	  pooled	  UC	  E.	  coli	  supernatant	  and	  
purified	  flagellin	  than	  compared	  to	  individual	  UC	  E.	  coli	  isolates.	  As	  already	  mentioned,	  the	  
0.2um	   filtered	  pooled	  UC	  E.	   coli	   culture	   supernatant	   is	   known	   to	   contain	   shed	  OMVs	  and	  
associated	  flagellae/flagellin	  (Subramanian	  et	  al.	  2008).	  OMVs	  are	  known	  to	  express	  proteins	  
relevant	  to	  pathogenicity	  (Davis	  et	  al.	  2006),	  however,	  previous	  work	  has	  suggested	  that	  the	  
IL-­‐8	  response	  to	  the	  bacteria-­‐free	  supernatant	  is	  largely	  due	  to	  the	  presence	  of	  flagellin,	  which	  
has	  been	  shown	  to	  evoke	  IL-­‐8	  release	  in	  a	  TLR5	  dependent	  manner	  (Subramanian	  et	  al.	  2008).	  
Conversely,	  only	  two	  out	  of	  the	  five	  UC	  E.	  coli	  isolates	  used	  in	  this	  study	  elicited	  IL-­‐8	  release	  
in	   a	   TLR5-­‐dependent	   manner	   (Subramanian	   et	   al.	   2008).	   As	   all	   five	   isolates	   evoked	   a	  
comparable	   cellular	   pro-­‐inflammatory	   IL-­‐8	   response	   (median	   of	   1009.1	   pg/mL	   IL-­‐8),	   this	  
indicates	  that	  other	  TLR5-­‐independent	  mechanisms	  are	  involved	  in	  the	  mediation	  of	  the	  pro-­‐
inflammatory	  IL-­‐8	  response.	  Indeed,	  plantain	  NSP	  might	  lack	  the	  ability	  to	  effectively	  inhibit	  
IL-­‐8	   release	   mediated	   by	   TLR-­‐5	   independent	   mechanisms,	   explaining	   the	   less	   significant	  
results	  observed	  with	  respect	  to	  mucosal-­‐associated	  UC	  E.	  coli	  isolates.	  
Due	   to	   the	   promising	   in	   vitro	   results	   observed	   in	   these	   studies,	   it	   would	   next	   be	  
beneficial	   to	   assess	   if	   supplementation	   with	   plantain	   NSP	  might	   have	   a	   protective	   effect	  
against	   an	   in	   vivo	   colitis	  model.	  One	   such	  experimental	  model	   includes	   the	  TNBS-­‐induced	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colitis	  model,	   in	  which	  green	  banana	  flour	   (Musa	  spp.	  AAA)	  has	  been	  previously	  shown	  to	  
prevent	  colonic	  inflammation	  (Scarminio	  et	  al.	  2012)	  The	  impact	  of	  plantain	  supplementation	  
on	   colonic	   inflammation	   could	   also	   be	   examined	   in	   mice	   with	   acute	   DSS-­‐induced	   colitis	  
(Valatas	  et	  al.	  2015),	  as	  well	  as	  in	  Muc2-­‐/-­‐	  	  mice	  (Wenzel	  et	  al.	  2014).	  	  
It	  would	  also	  be	  interesting	  to	  determine	  efficacy	  of	  plantain	  NSP	  in	  vivo	  on	  epithelial	  
cell	   apoptosis	   and	   shedding	  observed	   in	   a	  model	   of	   acute	   LPS-­‐induced	  murine	   gut	   injury,	  
described	  by	  Williams	  and	  colleagues	  (Williams	  et	  al.	  2015;	  Williams	  et	  al.	  2013).	  	  However,	  
as	  LPS	  is	  administered	  systemically	  in	  this	  particular	  model	  (Williams	  et	  al.	  2013),	  it	  is	  possible	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8.1   INTRODUCTION	  
	  
In	  the	  previous	  chapters	  of	  this	  thesis,	  it	  has	  been	  shown	  that	  soluble	  plantain	  fibre	  
can	  inhibit	  the	  epithelial	  interactions	  of	  C.	  difficile	  and	  ETEC	  bacteria,	  as	  well	  as	  C.	  difficile	  
spores	  (Chapter	  5).	  Furthermore,	  soluble	  plantain	  fibre	  also	  reduces	  the	  cellular	  damage	  
and	  inflammatory	  response	  induced	  by	  bacterial	  components,	  such	  as	  C.	  difficile	  toxin	  TcdA	  
and	   TcdB	   (Chapter	   6),	   as	   well	   as	   bacterial	   flagellin	   and	   LPS	   (Chapter	   7).	   These	   results	  
provide	  considerable	  evidence	  to	  suggest	  that	  soluble	  plantain	  fibre	  can	  disrupt	  potentially	  
harmful	   bacterial-­‐epithelial	   interactions.	   To	   further	   elucidate	   the	   exact	   nature	   of	   this	  
interaction,	  it	  would	  be	  beneficial	  to	  characterise	  the	  polysaccharide	  component	  of	  soluble	  
plantain	  NSP	  that	  confers	  its	  bioactivity.	  	  
The	   main	   source	   of	   dietary	   fibre	   is	   from	   the	   primary	   plant	   cell	   wall,	   which	   is	  
composed	  of	  three	  main	  polysaccharides:	  cellulose,	  hemicellulose	  and	  pectin	  (Blackwood	  
et	  al.	  2000).	  Plant	  cells	  are	  surrounded	  by	  layers	  of	  long	  cellulose	  fibrils	  that	  are	  composed	  
of	  30	  –	  36	  chains	  of	  β-­‐1,4-­‐linked	  glucose,	  which	  are	  hydrogen	  bonded	  to	  form	  an	  insoluble	  
and	  inelastic	  structural	  framework	  (Vorwerk	  et	  al.	  2004).	  Structural	  cellulose	  microfibrils	  
are	  also	   interconnected	  via	  hydrogen	  bonds	  with	  high	  molecular	  weight	  polysaccharide	  
hemicellulose,	  which	  is	  thought	  to	  be	  embedded	  in	  a	  matrix	  of	  pectin	  (Carpita	  and	  McCann	  
2000;	  Somerville	  et	  al.	  2004).	  Pectins	  are	  galacturonate	  (GalA)	  rich	  acidic	  polysaccharides,	  
which	   include	   homogalacturonans	   (HG),	   as	   well	   as	   rhamnogalacturonans	   (RG)	   I	   and	   II	  
(Carpita	  and	  McCann	  2000;	  Fry	  2004).	  Conversely,	  hemicelluloses	  are	  GalA-­‐free,	  neutral	  or	  
slightly	  acidic	  polysaccharides	  (Carpita	  and	  McCann	  2000;	  Fry	  2004),	  which	  include	  xylans	  
(such	   as	   arabinoxylans,	   glucuronoarabinoxylans),	   xyloglucans	   (composed	   mainly	   of	  
glucose,	  fucose,	  galactose,	  xylose)	  and	  mannans	  (Scheller	  and	  Ulvskov	  2010).	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The	   structure	   and	   composition	   of	   plant	   cell	   walls	   exhibit	   significant	   intra-­‐species	  
variation.	  Significant	  differences	  can	  also	  occur	  within	  species	  according	  to	  a	  number	  of	  
factors	   including	   cultivar,	   stage	   of	   ripeness	   and	   environmental	   conditions	   (Carpita	   and	  
McCann	  2000;	  Knox	  2008;	  Popper	  2008).	  As	  such,	  it	  was	  essential	  that	  the	  plantain	  NSP	  
used	  in	  these	  studies	  originated	  from	  a	  consistently	  reproducible	  source	  of	  soluble	  fibre.	  
Our	   preferred	   source	   of	   soluble	   NSP	   was	   from	   green	   plantain	   (ripeness	   stage	   1)	   flour	  
produced	   in	   Ecuador	   from	   locally	   grown	  cultivars	  Musa	   AAB	   (Horn)	   variation	  Dominico	  
(Roberts	  et	  al.	  2010).	  The	  use	  of	  green	  plantain	  ensures	  that	  water-­‐soluble	  components	  of	  
the	  cell	  wall,	   in	  particular	  pectins,	  have	  a	  wider	  range	  of	  structural	  characteristics	  and	  a	  
higher	  molecular	  weight	  than	  that	  obtained	  from	  ripe	  plantain	  fruits	  (Shiga	  et	  al.	  2011).	  
The	  yield	  of	  soluble	  non-­‐starch	  fibre	  from	  green	  plantain	  is	  6-­‐7%	  dry	  matter,	  with	  a	  ratio	  
of	  acidic	  to	  neutral	  polysaccharides	  of	  approximately	  9:1	  (See	  Appendix	  2).	  In	  addition,	  the	  
soluble	  plantain	   fibre	  used	   in	   these	  studies	  contains	  45%	  by	  weight	  of	  plantain-­‐derived	  
maltodextrin,	   which	   was	   added	   as	   part	   of	   the	   bulk	   manufacturing	   process	   to	   aid	  
solubilisation.	   Maltodextrin	   is	   a	   polysaccharide	   that	   is	   commonly	   added	   to	   processed	  
foods,	   cosmetics,	   and	   medications	   as	   a	   filler,	   thickener,	   texturiser	   or	   coating	   agent	  
(Nickerson	   et	   al.	   2014).	   The	   complex	   carbohydrate	   is	   created	   through	   chemical	   and	  
enzymatic	   processing	   of	   a	   variety	   of	   starches	   to	   produce	   chains	   of	   up	   to	   20	   glucose	  
molecules,	  which	  are	  linked	  by	  α(1-­‐4)	  and	  α(1-­‐6)	  glycosidic	  bonds	  (Chronakis	  1998).	  
Preliminary	  work	  has	  previously	  been	  performed	  by	  our	  research	  group	  to	  begin	  to	  
characterise	   the	   polysaccharide	   component	   of	   plantain	   NSP	   that	   is	   responsible	   for	   its	  
inhibitory	  activity	   (Parsons	   et	  al.	  2014).	  As	  part	  of	   this	  work,	   soluble	  plantain	   fibre	  was	  
fractionated	   into	   acidic	   and	   neutral	   polysaccharide	   containing	   fractions	   by	   small-­‐scale,	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analytical	  strong	  anion-­‐exchange	  chromatography	  (Figure	  8.1A).	  These	  purified	  fractions	  
were	   then	   assessed	   for	   their	   efficacy	   at	   inhibiting	   the	   in	   vitro	   adhesion	   of	   Salmonella	  
enterica	  serovar	  Typhimurium	  to	  porcine	  intestinal	  epithelial	  B1OX1	  cells.	  S.	  Typhimurium	  
is	  one	  of	  the	  most	  frequent	  causes	  of	  food-­‐borne	  gastroenteritis	  in	  humans,	  and	  is	  also	  an	  
important	  pathogen	   in	   food-­‐producing	  animals,	   including	  pigs	  and	   chickens	   (Ibarra	  and	  
Steele-­‐Mortimer	  2009).	  Pre-­‐treatment	  of	  cell	  monolayers	  with	  5	  mg/mL	  acidic	  fraction	  of	  
plantain	  NSP	  resulted	  in	  significant	  blockade	  of	  S.	  Typhimurium	  adhesion	  by	  up	  to	  50%,	  
which	  was	  a	  similar	  level	  of	  inhibition	  to	  that	  seen	  with	  soluble	  plantain	  NSP	  (Figure	  8.1B).	  
These	   preliminary	   results	   suggested	   that	   the	   active	   component	   conferring	   inhibitory	  
activity	  against	  S.	   Typhimurium	   to	   the	  host	  epithelium	   lies	  within	   the	  acidic	   fraction	  of	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Figure	   8.1	   Purified	   analytical	   acidic	   polysaccharide	   fractions	   of	   plantain	   NSP	   significantly	   inhibit	  
Salmonella	  adhesion	  to	  intestinal	  epithelial	  cells.	  A)	  High	  performance	  on	  exchange	  fractionation	  of	  
soluble	  plantain	  NSP	  was	  performed	  on	  an	  analytical	  scale	  using	  a	  HiPrepTM	  Q	  Sepharose	  FF	  16/10	  
column	   on	   the	   AKTA	   Prime	   Plus	   chromatography	   system.	   	   Column	   unbound	   (neutral	   fraction)	   was	  
retained	  and	  bound	  material	  (acid	  fraction)	  was	  eluted	  step-­‐wise	  with	  50	  mM	  Tris-­‐HCl,	  pH	  7.4	  containing	  
0.1,	  0.5	  and	  1M	  NaCl)	  at	  5	  mL/min.	  The	  neutral	  and	  acid	  fractions	  were	  subsequently	  desalted	  on	  PD-­‐
MidiTrap	  G-­‐10	  columns.	  This	  work	  was	  performed	  by	  Dr	  D	  O’Brien,	  Provexis	  plc,	  Windsor;	  2011).	   	  B)	  
Acidic	  fractions	  of	  plantain	  NSP	  blocked	  adhesion	  of	  S.	  Typhimurium	  to	  B10XI	  intestinal	  epithelial	  cells;	  
N=4,	  n=4.	  All	  fractions	  tested	  at	  5	  mg/ml.	  *,	  P<0.05,	  ***,	  P<0.001	  Kruskal-­‐Wallis,	  compared	  to	  untreated	  
control	  (i.e.	  in	  the	  absence	  of	  plantain	  NSP	  [set	  as	  100%]).	  This	  work	  was	  performed	  by	  Dr	  B.	  Parsons	  
(Parsons	  et	  al.	  2014).	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To	   confirm	   previous	   findings,	   it	   was	   necessary	   to	   perform	   strong-­‐anion	   exchange	  
chromatography	  on	  a	  larger	  scale	  to	  produce	  a	  bulk	  preparation	  of	  acidic	  and	  neutral	  plantain	  
NSP	  fractions.	  These	  purified	  fractions	  could	  then	  be	  evaluated	  for	  their	  ability	  to	  disrupt	  a	  
range	  of	  bacterial-­‐host	  epithelium	  interactions.	  It	  was	  also	  important	  to	  assess	  the	  inhibitory	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8.2  HYPOTHESIS	  
	  
The	   inhibitory	   activity	   of	   plantain	   NSP	   against	   pathogen-­‐host	   epithelium	  





1.   Produce	  a	  bulk	  preparation	  of	  acidic	  and	  neutral	  polysaccharide	  fractions	  of	  plantain	  
NSP	  via	  scaled	  up,	  preparative	  scale	  strong	  anion	  exchange	  chromatography	  	  
	  
	  
2.   Assess	   the	   inhibitory	   activity	   of	   polysaccharide	   fractions	   against	   the	   epithelial	  
adhesion	  of	  diarrhoeal	  pathogens	  C.	  difficile,	  ETEC	  and	  Salmonella	  
	  
	  
3.   Perform	   composition	   analysis	   on	   acidic	   and	   neutral	   polysaccharide	   fractions	   of	  
plantain	  NSP	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8.4  METHODS	  
	  
According	  to	  the	  results	  from	  the	  small-­‐scale	  analytical	  fractionation	  of	  plantain	  NSP	  
performed	  previously	  by	  Provexis	  Plc	  (Parsons	  et	  al.	  2014),	  a	  bulk	  preparation	  of	  purified	  
neutral	   and	   acidic	   fractions	   of	   soluble	   plantain	   fibre	   was	   carried	   out.	   This	   was	   also	  
performed	  using	  strong-­‐anion	  exchange	  chromatography,	  but	  in	  the	  absence	  of	  a	  column	  
(Clark	  1976).	  Detailed	  methods	  of	  strong-­‐anion	  exchange	  fractionation	  can	  be	  found	  in	  
Section	  4.3.2.2.	  	  
Neutral	  and	  acidic	  fractions	  were	  desalted	  using	  PD	  MidiTrap	  G-­‐10	  gravity	  columns	  
(GE	   Healthcare	   Sciences),	   as	   per	   the	   manufacturer’s	   instructions.	   Columns	   were	   pre-­‐
calibrated	  with	   small	  molecular	   size	  marker	   phenol	   red	   (354	  Da)	   (Section	   4.3.2.3).	   	   To	  
determine	   column	   fractionation	   elution	   profiles,	   carbohydrate	   content	   was	  measured	  
using	  a	  phenol-­‐sulphuric	  acid	  total	  hexose	  assay	  (Section	  4.3.2.4)	  	  
Following	   their	   lyophilisation	   (Section	   4.3.4.5),	   neutral	   and	   acidic	   plantain	   NSP	  
fractions	  were	  evaluated	  for	  their	  ability	  to	  inhibit	  the	  epithelial	  adhesion	  of	  C.	  difficile,	  
ETEC	  and	  S.	  Typhimurium.	  Inhibitory	  activity	  was	  assessed	  using	  bacterial	  adhesion	  assays,	  
in	  which	  Caco2	  cell	  monolayers	  were	  pre-­‐incubated	  for	  30	  min	  with	  5	  mg/mL	  neutral	  or	  
acidic	  plantain	  NSP	  fractions	  prior	  to	  bacterial	  infection	  (MOI	  100).	  	  In	  parallel,	  cells	  were	  
also	  pre-­‐incubated	  for	  30	  min	  with	  5	  mg/mL	  whole	  plantain	  NSP	  or	  5	  mg/mL	  maltodextrin.	  
Full	  methods	  for	  bacterial	  culture	  and	  bacterial	  adhesion	  assays	  can	  be	  found	  in	  Section	  
4.6	  and	  Section	  4.5,	  respectively.	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To	   further	   assess	   the	   inhibitory	   effect	   of	   maltodextrin	   on	   bacterial-­‐epithelial	  
interaction,	  HT29	  colonocytes	  were	  pre-­‐incubated	  with	  5	  or	  10	  mg/mL	  maltodextrin	  prior	  
to	   treatment	   with	   50	   µL	   pooled	   supernatant	   of	   5	   UC	   mucosally-­‐associated	   isolates	  
(HM250,	  HM295,	  HM378,	  HM380	  and	  HM387)	  for	  4h.	  As	  a	  positive	  control,	  cells	  were	  
also	  pre-­‐incubated	  with	  5	  or	  10	  mg/mL	  plantain	  NSP	  prior	  to	  treatment.	  To	  assess	  the	  the	  
effect	  of	  maltodextrin	  on	  the	  pro-­‐inflammatory	  response	  mediated	  by	  UC	  E.	  coli	  flagellin,	  
harvested	  media	  from	  cells	  was	  measured	  for	  the	  presence	  of	  pro-­‐inflammatory	  cytokine	  
IL-­‐8	  using	  a	  human	  IL-­‐8	  ELISA	  kit	  (Section	  4.15).	  To	  assess	  the	  level	  of	  apoptosis,	  cellular	  
activation	  of	  caspase-­‐3/7	  was	  measured	  using	  a	  commercial	  Caspase-­‐Glo®	  3/7	  Assay,	  as	  
per	  the	  manufacturer’s	  instructions	  (Section	  4.16).	  To	  assess	  cell	  cytotoxicity,	  harvested	  
cell	  culture	  media	  was	  also	  assessed	  for	  the	  presence	  of	  adenylate	  kinase	  using	  a	  Toxilight	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8.5  RESULTS	  
	  
8.5.1   The	  inhibitory	  activity	  of	  plantain	  NSP	  against	  the	  epithelial	  adhesion	  of	  diarrhoeal	  
pathogens	  lies	  in	  its	  acidic	  polysaccharide	  fraction	  
When	   human	   intestinal	   Caco2	   cells	   were	   pre-­‐treated	   with	   5	  mg/mL	   Q-­‐Sepharose-­‐
purified	   acidic	   polysaccharide	   fraction	   of	   plantain	   NSP,	   there	   was	   significant	   blockade	   of	  
diarrhoeal	  pathogen	  adhesion	  (Figure	  8.2).	  In	  comparison	  to	  the	  untreated	  control,	  the	  acidic	  
polysaccharide	  fraction	  of	  plantain	  NSP	  reduced	  the	  epithelial	  adhesion	  of	  C.	  difficile	  by	  52.3	  
±	  7.3%	  (Figure	  8.2A;	  P	  <	  0.01),	  whilst	  ETEC	  and	  S.	  Typhimurium	  adhesion	  was	  reduced	  by	  86.2	  
±	   5.7%	   (Figure	   8.2B;	   P	   <	   0.001)	   and	   92.0	   ±	   2.9%	   (Figure	   8.2C;	   P	   <	   0.001),	   respectively.	  
Conversely,	   pre-­‐treatment	  of	  Caco2	   cells	  with	  5	  mg/mL	  neutral	   polysaccharide	   fraction	  of	  
plantain	  NSP	  (that	  was	  unbound	  to	  Q-­‐Sepharose)	  exhibited	  a	  significantly	  reduced	  ability	  to	  
inhibit	   bacterial	   adhesion	   (Figure	   8.2).	   	   These	   results	   suggest	   that	   the	   activity	   conferring	  
soluble	  plantain	  fibre’s	  ability	  to	  block	  pathogen-­‐host	  intestinal	  epithelium	  interactions	  lies	  
predominantly	  in	  the	  acidic	  (pectic)	  component	  of	  plantain	  fibre.	  	  
Interestingly,	   maltodextrin	   also	   exhibited	   significant	   inhibitory	   activity	   against	   the	  
epithelial	   adhesion	  of	   gut	  pathogens.	  However,	  with	  C.	  difficile	   as	   the	  only	  exception,	   the	  
inhibitory	  activity	  of	  maltodextrin	  was	  less	  than	  that	  observed	  with	  respect	  to	  whole	  plantain	  
NSP	   or	   its	   acidic	   fraction.	   In	   comparison	   to	   the	   untreated	   control,	   5	  mg/mL	  maltodextrin	  
significantly	  reduced	  the	  epithelial	  adhesion	  of	  C.	  difficile	  by	  61.8	  ±	  5.5%	  (Figure	  8.2A;	  P	  <	  
0.01),	  ETEC	  by	  54.5	  ±	  8.1%	  (Figure	  8.2B;	  P	  <	  0.05)	  and	  S.	  Typhimurium	  by	  67.4	  ±	  1.8%	  (Figure	  
8.2C;	  P	  <	  0.01).	  	  
	  






























Figure	   8.2	   The	   action	   of	   soluble	   plantain	   NSP	   to	   block	   gut	   pathogen-­‐host	   intestinal	   epithelium	  
interaction	  lies	  within	  its	  acidic	  polysaccharide	  fraction.	  	  Pre-­‐incubation	  of	   intestinal	  epithelial	  cells	  
with	  5	  mg/mL	  acidic	  polysaccharide	  fraction	  of	  plantain	  NSP	  significantly	  blocked	  the	  adhesion	  of	  gut	  
pathogens	  A)	  C.	  difficile,	  B)	  ETEC	  and	  C)	  S.	  Typhimurium.	  The	  neutral	  polysaccharide	  fraction	  of	  plantain	  
NSP	   and	   maltodextrin	   (both	   5mg/mL)	   exhibited	   reduced	   ability	   to	   block	   bacterial	   adhesion.	  
Photographs	  are	  also	   included	  showing	  D)	  whole	  plantain	  NSP,	  E)	   acidic	   fraction	  of	  plantain	  NSP,	  F)	  
neutral	   fraction	   of	   plantain	   NSP	   and	   G)	  maltodextrin.	   	   Bacterial	   adhesion	   is	   expressed	   relative	   to	  
CFU/mL	  found	  in	  the	  absence	  of	  any	  fibre	  (set	  as	  100%)	  (N=2,	  n=3;	  *	  P	  <	  0.05,	  **	  P	  <	  0.01,	  ***	  P	  <	  0.001;	  
Kruskal-­‐Wallis).	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8.5.2   Maltodextrin	  significantly	  reduces	  the	  epithelial	  adhesion	  of	  C.	  difficile,	  but	  has	  no	  
significant	   effect	   on	   the	   epithelial	   cell	   damage	   and	   inflammation	   mediated	   by	  
flagellin	  	  
As	  it	  was	  shown	  that	  5	  mg/mL	  maltodextrin	  exhibited	  inhibitory	  activity	  against	  the	  
epithelial	   adhesion	   of	   diarrhoeal	   pathogens	   (Figure	   8.2),	   its	   ability	   to	   inhibit	   bacterial-­‐
epithelial	  interactions	  was	  further	  assessed	  in	  dose-­‐related	  studies,	  using	  soluble	  plantain	  NSP	  
as	  a	  positive	  control.	  	  
Maltodextrin	  was	  first	  further	  evaluated	  for	  its	  ability	  to	  inhibit	  the	  epithelial	  adhesion	  
of	  diarrhoeal	  pathogens.	  As	  part	  of	  this	  work,	  Caco2	  cells	  were	  pre-­‐incubated	  with	  or	  without	  
maltodextrin	  or	  plantain	  NSP	   (1,	  5	  or	  10	  mg/mL)	   for	  30	  minutes	  prior	   to	   infection	  with	  C.	  
difficile	   (Figure	   8.3).	   Pre-­‐incubation	   of	   Caco2	   cells	   with	   1,	   5	   and	   10	  mg/mL	  maltodextrin	  
significantly	   reduced	   the	   epithelial	   adhesion	   of	  C.	   difficile	   (P	  ≤	   0.01)	   in	   a	   dose-­‐dependent	  
manner,	  with	  the	  optimum	  concentration	  occurring	  at	  10	  mg/mL	  (69.7	  ±	  11.1%;	  P	  <	  0.001).	  
However,	   it	   was	   also	   observed	   that	   maltodextrin	   exhibited	   a	   much	   lower	   efficacy	   than	  
compared	  with	  plantain	  NSP,	  which	  at	  10	  mg/mL,	  reduced	  C.	  difficile	  adhesion	  by	  92.6	  ±	  2.5%	  



















Figure	   8.3	   Soluble	   plantain	   fibre	   and	   maltodextrin	   both	   significantly	   inhibit	   C.	   difficile	   epithelial	  
adhesion	   in	   a	   dose	   dependent	   manner.	   Caco2	   cells	   were	   pre-­‐incubated	   with	   1,	   5	   or	   10	   mg/mL	  
maltodextrin	  or	  plantain	  NSP	  (used	  as	  a	  positive	  control)	  for	  30	  min	  prior	  to	  infection	  with	  C.	  difficile	  
(MOI	  100)	  for	  2h.	  Adhesion	  is	  expressed	  relative	  to	  CFU/mL	  found	  in	  the	  untreated	  control	  (set	  as	  100%)	  
(N=3,	  n=3;	  **	  P	  <	  0.01,	  ***	  P	  <	  0.001;	  Kruskal-­‐Wallis).	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Maltodextrin	  was	  next	  assessed	  for	  its	  ability	  to	  reduce	  the	  epithelial	  cell	  damage	  and	  
inflammation	  mediated	  by	  E.	  coli	  flagellin.	  Similarly,	  HT29	  cells	  were	  pre-­‐incubated	  with	  or	  
without	  5	  and	  10	  mg/mL	  maltodextrin	  or	  plantain	  NSP	  prior	  to	  treatment	  with	  pooled	  UC	  E.	  
coli	  supernatant,	  which	  contained	  flagellin	  and	  OMVs.	  	  
Pre-­‐incubation	   of	   cells	   with	   5	   or	   10	  mg/mL	   plantain	   NSP	   resulted	   in	   considerable	  
inhibition	  of	  the	  flagellin-­‐mediated	  pro-­‐inflammatory	  response,	  reducing	  IL-­‐8	  release	  by	  33.6	  
±	  5.3%	  and	  46.4	  ±	  7.4%,	  respectively.	  Oppositely,	  pre-­‐treatment	  of	  cells	  with	  5	  or	  10	  mg/mL	  
maltodextrin	  had	  little	  effect	  on	  the	  flagellin-­‐mediated	  pro-­‐inflammatory	  response,	  resulting	  
only	  in	  small	  inhibitory	  levels	  of	  IL-­‐8	  release	  (7.4	  ±	  19.2%	  and	  8.5	  ±	  12.0%,	  respectively)	  (Figure	  
8.4).	  	  
Similarly,	   5	   and	   10	   mg/mL	   plantain	   NSP	   significantly	   reduced	   flagellin-­‐mediated	  
cytotoxicity	  (P-­‐NSP	  at	  10	  mg/mL	  reduced	  adenylate	  kinase	  release	  by	  86.0	  ±	  3.4%;	  P	  <	  0.001;	  
Figure	   8.5)	   and	   reduced	   cellular	   apoptosis	   (P-­‐NSP	   at	   10	   mg/mL	   reduced	   caspase-­‐3/7	  
activation	  by	  49.7	  ±	  7.3%;	  P	  <	  0.001;	  Figure	  8.6).	  Maltodextrin,	  however,	  exhibited	   limited	  
inhibitory	  activity	  (10	  mg/mL	  reduced	  adenylate	  kinase	  release	  and	  caspase-­‐3/7	  activation	  in	  




























Figure	  8.4	  Soluble	  plantain	  fibre	  reduces	  the	  cellular	  IL-­‐8	  response	  induced	  by	  the	  pooled	  UC	  E.	  coli	  
supernatant	  of	  five	  UC	  E.	  coli	  isolates,	  but	  maltodextrin	  has	  no	  effect.	  HT29	  cell	  monolayers	  were	  pre-­‐
incubated	  with	  or	  without	  maltodextrin	  (5	  or	  10	  mg/mL)	  for	  30	  min	  prior	  to	  treatment	  with	  50	  µL	  0.2	  
µm-­‐filtered	  culture	  supernatant	  pooled	  from	  five	  mucosal	  UC	  E.	  coli	  isolates	  (HM250,	  HM295,	  HM378,	  
HM380,	  HM387)	  (50	  µL;	  4	  h).	  As	  a	  positive	  control,	  cells	  were	  pre-­‐incubated	  in	  parallel	  with	  or	  without	  
plantain	  NSP	  (5	  or	  10	  mg/mL)	  prior	  to	  treatment.	  Cell	  culture	  media	  harvested	  from	  cells	  was	  analysed	  
for	  the	  presence	  of	  pro-­‐inflammatory	  cytokine	  IL-­‐8	  using	  an	  IL-­‐8	  Human	  ELISA	  kit	  (N=3,	  n=3;	  One	  Way	  
ANOVA).	  
	  























Figure	  8.5	  Soluble	  plantain	  fibre	  significantly	  reduces	  the	  cellular	  adenylate	  kinase	  release	  induced	  
by	   the	   pooled	   supernatant	   of	   five	   UC	   E.	   coli	   isolates,	   but	  maltodextrin	   has	   no	   effect.	   	   HT29	   cell	  
monolayers	  were	   pre-­‐incubated	  with	   or	   without	  maltodextrin	   (5	   or	   10	  mg/mL)	   for	   30	  min	   prior	   to	  
treatment	  with	  50	  µL	  0.2	  µm-­‐filtered	  culture	  supernatant	  pooled	  from	  five	  mucosal	  UC	  E.	  coli	  isolates	  
(HM250,	  HM295,	  HM378,	  HM380,	  HM387)	  (50	  µL;	  4	  h).	  As	  a	  positive	  control,	  cells	  were	  pre-­‐incubated	  
in	   parallel	   with	   or	   without	   plantain	   NSP	   (5	   or	   10	   mg/mL)	   prior	   to	   treatment.	   Cell	   culture	   media	  
harvested	  from	  cells	  was	  analysed	  for	  the	  presence	  of	  adenylate	  kinase	  using	  a	  Toxilight™	  bioassay	  kit	  
(N=3,	  n=3;	  ***	  P	  <	  0.001;	  Kruskal-­‐Wallis).	  
	  















Figure	  8.6	  Soluble	  plantain	  fibre	  significantly	  reduces	  the	  cellular	  caspase-­‐3/7	  activation	  induced	  by	  
the	   pooled	   supernatant	   of	   five	   UC	   E.	   coli	   isolates,	   but	   maltodextrin	   has	   no	   effect.	   HT29	   cell	  
monolayers	  were	  pre-­‐incubated	  with	  or	  without	  10	  mg/mL	  maltodextrin	  or	  10	  mg/mL	  plantain	  NSP	  
(used	  as	  a	  positive	  control)	  for	  30	  min	  prior	  to	  treatment	  with	  50	  µL	  0.2	  µm-­‐filtered	  culture	  supernatant	  
pooled	  from	  five	  mucosal	  UC	  E.	  coli	   isolates	  (HM250,	  HM295,	  HM378,	  HM380,	  HM387)	  (50	  µL;	  4	  h).	  
Caspase-­‐3/7	   activation	   was	   measured	   using	   a	   Caspase-­‐Glo®	   3/7	   Assay,	   as	   per	   manufacturer’s	  
instructions	  (N=2,	  n=3;	  ***	  P	  <	  0.001;	  Kruskal-­‐Wallis).	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8.6  SUMMARY	  OF	  MAIN	  RESULTS	  
	  
	  
1.   The	   acidic,	   pectic	   polysaccharide	   fraction	   of	   plantain	   NSP	   is	   responsible	   for	   its	  
inhibitory	  activity	  against	  the	  epithelial	  adhesion	  of	  diarrhoeal	  pathogens	  C.	  difficile,	  
ETEC	  and	  Salmonella	  
	  
	  
2.   Maltodextrin	   also	   exhibits	   dose-­‐dependent	   inhibitory	   activity	   against	   the	   epithelial	  
adhesion	  of	  diarrhoeal	  pathogens,	  but	  has	  no	  significant	  effect	  on	  the	  epithelial	  cell	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8.7  DISCUSSION	  
	  
In	  these	  studies,	  we	  wanted	  to	  further	  characterise	  the	  polysaccharide	  or	  structure	  
present	  in	  plantain	  NSP	  that	  is	  responsible	  for	  bioactivity,	  which	  was	  achieved	  by	  fractionation	  
of	  plantain	  NSP	  into	  its	  neutral	  and	  acidic	  fractions.	  Results	  from	  bacterial	  adhesion	  assays	  
demonstrated	   that	   pre-­‐treatment	   of	   intestinal	   epithelial	   cells	   with	   the	   acidic	   fraction	   of	  
plantain	   NSP	   significantly	   inhibited	   the	   epithelial	   adhesion	   of	   C.	   difficile,	   ETEC	   and	   S.	  
Typhimurium,	  which	  was	  similar	  to	  the	  level	  of	  inhibitory	  activity	  exhibited	  by	  whole	  plantain	  
NSP.	   Conversely,	   the	   neutral	   polysaccharide	   fraction	   of	   soluble	   plantain	   NSP	   exhibited	   a	  
decreased	   inhibitive	   effect	   on	   bacterial	   adhesion.	   Overall,	   these	   results	   suggest	   that	   the	  
inhibitory	  activity	  of	  soluble	  plantain	  NSP	  against	  bacteria-­‐epithelial	  interaction	  is	  largely	  due	  
to	  the	  acidic,	  pectic	   fraction	  of	  plantain	  NSP.	  These	   findings	  reflect	   the	  preliminary	  results	  
previously	   shown	   by	   our	   group,	   which	   also	   demonstrated	   that	   pre-­‐treatment	   of	   porcine	  
B1OX1	  cells	  with	  the	  acidic,	  pectin	  fraction	  of	  plantain	  NSP	  resulted	  in	  significant	  inhibition	  of	  
S.	  Typhimurium	  adhesion	  (Parsons	  et	  al.	  2014).	  	  
Pectins	  comprise	  approximately	  one-­‐third	  the	  dry	  weight	  of	  primary	  cell	  walls	  in	  non-­‐
poalean	  monocots	  such	  as	  plantain,	  playing	  key	  roles	  in	  cell-­‐wall	  structure	  and	  function	  (Dick-­‐
Perez	  et	  al.	  2012;	  Mohnen	  2008).	  Its	  three	  distinct	  domains	  are	  covalently	  linked,	  with	  RGs	  
containing	   large	   proportions	   of	   neutral	   sugars,	   especially	   L-­‐rhamnose,	   D-­‐galactose	   and	   L-­‐
arabinose,	  in	  addition	  to	  D-­‐galacturonic	  acid	  (Fry	  2011).	  Some	  pectins	  also	  carry	  methyl	  and	  
acetyl	  ester	  groups	  (Perrone	  et	  al.	  2002).	  Pectic	  polysaccharides	  interlink	  to	  each	  other,	  e.g.	  
homogalacturonan	  domains	  via	  Ca2+	  bridges	  (Mohnen	  2008),	  and	  RG-­‐II	  domains	  via	  borate	  
bridges	   (ONeill	   et	   al.	   1997).	   Composition	   analysis	   performed	   previously	   by	   our	   group	  
demonstrated	   that	   the	   acidic	   fraction	   contained	   approximately	   25%	   by	   weight	   of	   pectic	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material,	  which	  was	  mainly	  or	  only	  homogalacturonan.	   In	   this	   study,	  negligible	   rhamnose,	  
galactose	  or	   arabinose	  was	   formed	   following	   acid	  hydrolysis	   or	  Driselase	  digestion,	  which	  
indicated	  the	  absence	  of	  RG-­‐I	  and	  RG-­‐II.	  Composition	  analysis	  also	  revealed	  the	  presence	  of	  
pectic	  material	  in	  the	  whole	  plantain	  NSP	  fraction,	  whilst	  the	  neutral	  fraction,	  which	  showed	  
much	   reduced	   blockade	   of	   C.	   difficile,	   ETEC	   and	   S.	   Typhimurium	   here	   in	   these	   studies,	  
contained	  no	  detectable	  pectic	  material	  (Parsons	  et	  al.	  2014).	  	  
These	  findings	  reflect	  those	  of	  other	  studies	  which	  indicate	  that	  bacterial	  adherence	  
to	  epithelial	  cells	  can	  often	  be	  blocked	  by	  monosaccharides	  or	  oligosaccharides	  present	   in	  
dietary	  constituents.	  Human	  milk,	  rich	  in	  oligosaccharides,	  has	  been	  known	  for	  some	  time	  to	  
be	  potentially	  beneficial	  in	  preventing	  certain	  bacterial	  infections,	  inhibiting	  the	  adhesion	  of	  
a	  range	  of	  bacteria	  such	  as	  Campylobacter	  jejuni	  	  (Ofek	  et	  al.	  2003),	  diffusely	  adherent	  E.	  coli	  
(DEAC)	  (de	  Araujo	  and	  Giugliano	  2000)	  and	  enteroaggregative	  E.	  coli	  (EAEC)	  in	  vitro	  (de	  Araujo	  
and	   Giugliano	   2000).	   More	   specifically,	   pectic	   oligosaccharides	   have	   also	   been	   shown	   to	  
inhibit	  C.	  jejuni	  intestinal	  epithelial	  adherence	  in	  vitro	  (Ganan	  et	  al.	  2010).	  In	  addition,	  pectin	  
from	   ginseng	   has	   also	   been	   shown	   to	   possess	   anti-­‐adhesive	   activity	   against	   other	   gut	  
pathogens	   such	   as	   Helicobacter	   pylori,	   and	   some	   ability	   to	   inhibit	   haemagglutination	   by	  
bacteria,	  including	  that	  caused	  by	  Staphylococcus	  aureus	  and	  Propionibacterium	  acnes,	  but	  
not	  that	  affected	  by	  E.	  coli	  and	  Lactobacillus	  acidophilus	  (Lee	  et	  al.	  2006a).	  	  
Interestingly,	   it	  was	  also	   illustrated	   in	   these	   studies	   that	  maltodextrin,	  which	  was	  
added	  to	  soluble	  plantain	  fibre	  during	  its	  manufacturing	  process,	  exhibited	  inhibitory	  activity	  
against	   the	   epithelial	   adhesion	   of	   C.	   difficile,	   ETEC	   and	   S.	   Typhimurium.	   However,	   the	  
inhibitory	  activity	  of	  maltodextrin	  was	  generally	  less	  than	  that	  observed	  with	  respect	  to	  whole	  
plantain	  NSP	  or	   its	   acidic	   fraction.	   Furthermore,	  whilst	  whole	   plantain	  NSP	  was	   shown	   to	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significantly	  reduce	  the	  epithelial	  cell	  damage	  and	  inflammation	  mediated	  by	  E.	  coli	  flagellin,	  
pre-­‐incubation	  of	  cells	  with	  maltodextrin	  had	  no	  significant	  effect.	  Composition	  analysis	  also	  
demonstrated	  that	  maltodextrin	  was	  present	  in	  whole,	  acidic	  and	  neutral	  fractions,	  however,	  
this	   did	   not	   correlate	  with	   the	   level	   of	   inhibitory	   activity	   that	  was	   observed.	   Instead,	   the	  
inhibitory	   activity	   of	   each	   fraction	   correlated	   with	   the	   presence	   of	   pectic	   material.	  
Collectively,	   these	   results	   suggest	   that	  maltodextrin	   only	   contributes	   slightly	   towards	   the	  
inhibitory	  activity	  of	  plantain	  NSP	  against	  bacterial-­‐epithelial	  interactions,	  and	  indeed,	  they	  
add	   to	   the	   evidence	   to	   suggest	   that	   the	   acidic,	   pectic	   polysaccharide	   fraction	   is	   largely	  
responsible	  for	  bioactivity.	  	  
Our	   findings	   presented	   here	   are	   in	   contrast	   to	   those	   reported	   by	   other	   groups.	  
Indeed,	  previous	  studies	  have	  suggested	   that	  maltodextrin	  alters	   the	   intestinal	  microbiota	  
namely	  through	  its	  ability	  to	  enhance	  bacterial	  survival	  and	  mucosal	  adhesion.	  Using	  an	   in	  
vivo	  mouse	  model,	  one	  study	  reported	  that	  maltodextrin	  enhanced	  Salmonella	  survival	  and	  
mucosal	  colonisation	  (Nickerson	  and	  McDonald	  2012),	  whilst	  another	  study	  suggested	  that	  
maltodextrin	  promoted	  AIEC	  biofilm	  production	  and	  adhesion	  to	  intestinal	  epithelial	  HT29	  cell	  
monolayers	  (Nickerson	  et	  al.	  2014).	  Maltodextrins	  are	  classified	  according	  to	  glucose	  chain	  
length,	  known	  as	  dextrose	  equivalent	  (DE),	  which	  varies	  from	  3	  –	  20	  (Chronakis	  1998).	  Thus,	  
the	  contrasting	  results	  might	  be	  explained	  by	  the	  difference	  in	  DE	  between	  studies.	  	  
It	  is	  also	  important	  to	  note	  that	  starches	  such	  as	  maltodextrin	  are	  hydrolysed	  in	  vivo	  
by	   oral	   and	   ileal	   amylases	   (Quezada-­‐Calvillo	   et	   al.	   2007a),	   before	   undergoing	   further	  
degradation	   by	   epithelial	   cell	   membrane-­‐bound	  maltases	   (Quezada-­‐Calvillo	   et	   al.	   2007b).	  
Therefore,	  it	  is	  likely	  that	  maltodextrin	  would	  undergo	  almost	  complete	  fermentation	  during	  
transit	  through	  the	  gastrointestinal	  tract.	  As	  such,	  a	  high	  dosage	  of	  maltodextrin	  would	  be	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needed	  to	  achieve	  effective	  luminal	  concentrations	  in	  the	  distal	  colon	  and	  thus	  have	  an	  effect	  
on	  bacterial-­‐epithelial	  interaction	  in	  vivo.	  Conversely,	  it	  has	  been	  shown	  that	  the	  inhibitory	  
concentrations	  exhibited	  by	  plantain	  NSP	  in	  vitro	  are	  readily	  achievable	  in	  vivo	  by	  twice	  daily	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9.1  INTRODUCTION	  
The	  work	  performed	  by	  our	  group	  to	  date	  has	  confirmed	  that	  soluble	  plantain	  fibre,	  
particularly	   its	   pectin	   fraction,	   can	   significantly	   reduce	   bacterial	   epithelial	   adhesion	   and	  
translocation,	  as	  well	  as	  down-­‐regulate	  the	  epithelial	  cell	  damage	  and	  inflammatory	  response	  
to	   bacterial	   components.	   However,	   the	   molecular	   mechanism	   underlying	   the	   inhibitory	  
activity	  of	  plantain	  NSP	  is	  currently	  unclear.	  
There	  are	  a	  number	  of	  potential	  mechanisms	  by	  which	  plantain	  NSP	  could	  mediate	  its	  
inhibitory	  effect	  against	   the	  epithelial	   interactions	  of	  diarrhoeal	  pathogens.	   It	   is	   likely	   that	  
soluble	   plantain	   fibre	   exhibits	   its	   effect	   through	   one	   of	   two	   ways;	   either	   through	   direct	  
interaction	  with	  the	  bacteria	  or	  via	   interaction	  with	   intestinal	  epithelial	  cells.	   Interestingly,	  
there	  is	  evidence	  to	  support	  both	  of	  these	  hypotheses.	  	  
We	  originally	  hypothesised	  that	  plantain	  NSP	  inhibited	  bacterial	  adhesion	  via	  direct	  
contact	  with	  bacteria,	  whereby	  the	  diverse	  array	  of	  partially	  or	  non-­‐digested	  oligosaccharides	  
present	   in	   soluble	   fibre	   might	   competitively	   bind	   to	   bacterial	   adhesins,	   thus	   inhibiting	  
bacterial	  interaction	  with	  the	  intestinal	  epithelium.	  We	  have	  shown	  in	  Chapter	  5	  of	  this	  thesis	  
that	  soluble	  plantain	  NSP	  does	  indeed	  interact	  with	  diarrhoeal	  pathogens	  C.	  difficile	  and	  ETEC,	  
and	  in	  fact,	  provides	  an	  energy	  source	  for	  their	  growth	  in	  the	  absence	  of	  cells.	  	  
In	  contrast,	  previous	  studies	  by	  our	  group	  and	  others	  offer	   substantial	  evidence	   to	  
suggest	  that	  plantain	  NSP	  might	  mediate	  its	  inhibitory	  effect	  via	  interaction	  with	  the	  intestinal	  
epithelium.	   	   We	   have	   previously	   shown	   that	   pre-­‐treatment	   with	   5	   mg/mL	   plantain	   NSP	  
significantly	   inhibited	   the	   translocation	   of	   EGFP-­‐expressing	   S.	   Typhimurium	   LT2	   across	  
isolated	  human	  ileal	  FAE	  mounted	  in	  Ussing	  chambers	  (Roberts	  et	  al.	  2013).	  Interestingly,	  we	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also	  reported	  that	  pre-­‐treatment	  of	  human	  ileal	  FAE	  with	  plantain	  NSP	  was	  associated	  with	  a	  
marked	  increase	  in	  transmucosal	  short	  circuit	  current	  (Isc)	  (Parsons	  et	  al.	  2014).	  This	  suggests	  
that	  the	  inhibitory	  effect	  of	  plantain	  NSP	  could	  be	  mediated	  by	  increased	  epithelial	  chloride	  
secretion,	   which	   as	   a	   physiological	   effect	   will	   cause	   efflux	   of	   ions	   and	   water	   transport,	  
potentially	   impeding	  bacterial-­‐epithelial	   interaction	   (Strober	  and	  McGhee	  2005).	   Indeed,	  a	  
study	  by	  Keeley	  and	  colleagues	  showed	  that	  secretagogue	  enhanced	  epithelial	  Cl-­‐	  secretion	  
and	   water	   transport	   reduced	   Salmonella	   internalisation	   to,	   and	   translocation	   across	   T84	  
colonocytes	  by	  over	  70%	  (Keely	  et	  al.	  2012).	  	  	  
The	  observed	  mucosally	  protective	  and	  anti-­‐inflammatory	  effects	  of	  soluble	  plantain	  
fibre	  in	  many	  ways	  mimic	  the	  dense	  continuous	  mucus	  layer	  lining	  the	  healthy	  colon,	  which	  
shields	   the	   underlying	   intestinal	   epithelium	   from	   bacterial	   interaction	   (Turner	   2009).	   The	  
protective	  mucus	  barrier	  is	  organised	  around	  the	  highly	  O-­‐glycosylated	  MUC2	  mucin,	  which	  
is	  secreted	  by	  goblet	  cells	  to	  form	  a	  large	  net-­‐like	  polymer	  (Johansson	  et	  al.	  2011).	  Recently,	  
it	  has	  been	  shown	  that	  MUC2,	  via	  an	  action	  dependent	  on	  its	  numerous	  O-­‐glycans,	  has	  an	  
important	  anti-­‐inflammatory	  effect	  on	  the	  mucosa	  that	  is	  mediated	  by	  interaction	  with	  cell-­‐
surface	  galectin-­‐3	  and	  subsequent	  recruitment	  of	  Dectin-­‐1.	  This	  complex	  interaction	  leads	  to	  
the	   activation	   and	   nuclear	   translocation	   of	   β-­‐catenin,	   subsequent	   inactivation	   of	   NF-­‐κβ,	  
consequent	  suppression	  of	  a	  range	  of	  pro-­‐inflammatory	  cytokine	  genes	  and	  increase	  in	  anti-­‐
inflammatory	  IL-­‐10	  (Shan	  et	  al.	  2013).	   Indeed,	  preliminary	  results	  from	  our	  research	  group	  
have	   shown	   that	   soluble	   plantain	   fibre,	   like	  MUC2	   glycans,	   also	   interacts	   with	   galectin-­‐3	  
(Shapanis	  A,	  Gastroenterology	  Research	  Unit,	  Department	  of	  Cellular	  &	  Molecular	  Physiology,	  
University	  of	  Liverpool;	  unpublished	  data).	  Therefore,	  it	  is	  possible	  that	  the	  inhibitory	  effect	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of	  plantain	  NSP	  might	  lie	  in	  its	  ability	  to	  mimic	  MUC2	  glycans	  and	  interact	  with	  cell-­‐surface	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9.2  HYPOTHESES/AIMS	  
	  
To	  address	  the	  hypotheses	  that:	  
	  
1.   Soluble	   plantain	   NSP	   inhibits	   bacterial	   adhesion	   via	   an	   interaction	   with	   the	   intestinal	  
epithelium	  or	  through	  direct	  interaction	  with	  bacteria	  
	  
2.   The	   inhibitory	   activity	   of	   plantain	   NSP	   is	   mediated	   by	   increased	   epithelial	   chloride	  
secretion	  	  
	  
3.   Soluble	  plantain	  NSP	  can	  induce	  the	  nuclear	  translocation	  of	  β-­‐catenin	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9.3  METHODS	  
To	   determine	   whether	   the	   inhibitory	   action	   of	   plantain	   NSP	   against	   diarrhoeal	  
pathogens	   occurs	   via	   an	   interaction	   with	   the	   epithelial	   cell	   monolayer	   or,	   alternatively,	  
through	  direct	  interaction	  with	  bacteria,	  modifications	  were	  made	  to	  the	  bacterial	  adhesion	  
assays	   described	   in	   Section	   4.6	   (Parsons	   et	   al.	   2014).	   To	   evaluate	   if	   soluble	   plantain	   NSP	  
exhibits	  its	  inhibitory	  effect	  via	  interaction	  with	  the	  intestinal	  epithelium,	  plantain	  NSP	  was	  
added	  to	  cell	  monolayers	  30	  min	  prior	  to	  infection	  as	  earlier	  described,	  but	  then	  removed	  by	  
three	   washes	   with	   pre-­‐warmed	   sterile	   PBS	   (1	   min	   each,	   37°C).	   	   Monolayers	   were	   then	  
provided	  with	  fresh	  antibiotic-­‐free	  DMEM	  and	  infected	  with	  C.	  difficile,	  ETEC	  or	  Salmonella	  as	  
normal.	  To	  test	  if	  soluble	  plantain	  NSP	  exhibits	  its	  inhibitory	  effect	  via	  a	  direct	  interaction	  with	  
bacteria,	   plantain	  NSP	  was	   pre-­‐incubated	  with	  C.	   difficile,	   ETEC	  or	  Salmonella	   for	   30	  min,	  
followed	  by	  centrifugation,	  resuspension	  of	  bacteria	  in	  antibiotic-­‐free	  DMEM	  and	  inoculation	  
of	  epithelial	  cell	  monolayers.	  The	  remainder	  of	  the	  bacterial	  adhesion	  assays	  were	  performed	  
according	  to	  the	  methods	  described	  fully	  in	  Section	  4.6.	  	  
Ussing	  chamber	  experiments	  that	  were	  carried	  out	  previously	  by	  our	  group	  suggested	  
that	  plantain	  NSP	  might	  mediate	  increased	  epithelial	  chloride	  secretion	  (Parsons	  et	  al.	  2014).	  
Therefore,	  plantain	  NSP	  was	  further	  assessed	  in	  vitro	  for	  its	  ability	  to	  induce	  cellular	  chloride	  
channel	  activation,	  and	  importantly,	  if	  this	  mediated	  its	  inhibitory	  action.	  	  The	  first	  part	  of	  this	  
work	   was	   performed	   using	   a	   functional	   chloride	   channel	   activity	   assay,	   which	   measures	  
cellular	  iodide	  efflux	  as	  a	  surrogate	  for	  monitoring	  cellular	  chloride	  channel	  activation	  (Tang	  
and	  Wildey	   2004)	   (Section	   4.12).	   First,	   dose-­‐response	   studies	   were	   used	   to	   determine	   if	  
soluble	  plantain	  NSP	  (0	  –	  20	  mg/mL)	  could	  activate	  cellular	  chloride	  channel	  activity	  in	  Caco2	  
cells	  compared	  with	  known	  chloride	  channel	  activators	  forskolin	  and	  RP107	  (0	  –	  200	  µM	  for	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both),	  which	  were	  used	  as	  positive	  controls	  (Section	  4.12.1).	  Secondly,	  dose-­‐response	  studies	  
were	  performed	  using	  chloride	  channel	  antagonists	  CFTR-­‐inh-­‐172	  (0	  –	  200	  µM)	  and	  NPPB	  (0	  
–	   800	   µM)	   to	   assess	   if	   cellular	   chloride	   channel	   activity	   could	   be	   knocked	   down	   (Section	  
4.12.2).	   To	   determine	   if	   the	   inhibitory	   activity	   of	   plantain	   NSP	  was	  mediated	   by	   chloride	  
secretion,	  the	  chloride	  channel	  modulators	  (at	  optimum	  concentrations	  determined	  in	  dose-­‐
response	  studies)	  were	  then	  used	  alongside	  plantain	  NSP	  in	  bacterial	  adhesion	  assays	  (Section	  
4.12.3).	  	  
To	   assess	   whether	   the	   inhibitory	   activity	   of	   plantain	   NSP	   is	   mediated	   by	   the	  
expression	  of	  galectin-­‐3,	  the	  mucosally	  protective	  and	  anti-­‐inflammatory	  effect	  of	  plantain	  
NSP	  were	   compared	   between	   stable	   galectin-­‐3	   knockdown	   SW620	   colonic	   epithelial	   cells	  
(SW620Gal3-­‐)	  and	  galectin-­‐3	  expressing	  colonic	  epithelial	  cells	  (SW620Gal3+).	  SW620	  cells	  were	  
transfected	  by	  Paulina	  Sindrewicz	  (Gastroenterology	  Research	  Unit,	  Department	  of	  Cellular	  &	  
Molecular	  Physiology,	  University	  of	  Liverpool)	  according	  to	  the	  methods	  described	  in	  Section	  
4.2.2.	  Stable	  transfected	  SW620Gal3-­‐	  cells	  showed	  an	  84%	  reduction	  of	  galectin-­‐3	  expression	  
in	  comparison	   to	  negatively	   transfected	  SW620Gal3+	   cells,	  as	  confirmed	  by	   immunoblotting	  
and	  immunohistochemistry	  performed	  by	  Duckworth	  and	  colleagues	  (Duckworth	  et	  al.	  2015).	  	  
To	  assess	  whether	  the	  inhibitory	  effect	  of	  plantain	  NSP	  against	  bacterial	  adhesion	  is	  
mediated	   by	   cell-­‐surface	   galectin-­‐3	   expression,	   SW620Gal3-­‐	   and	   SW620Gal3+	   cells	  were	   pre-­‐
treated	  with	  or	  without	  10	  mg/mL	  plantain	  NSP	  for	  30	  min	  prior	  to	  infection	  with	  C.	  difficile	  
(MOI	  100;	  2	  h).	  The	  bacterial	  adhesion	  assay	  was	  then	  performed	  as	  previously	  (Section	  4.6).	  
To	  assess	  whether	  the	  anti-­‐inflammatory	  effect	  of	  plantain	  NSP	   is	  mediated	  by	   interaction	  
with	  cell-­‐surface	  galectin-­‐3,	  SW620Gal3-­‐	  and	  SW620Gal3+	  cells	  were	  pre-­‐treated	  with	  10	  mg/mL	  
plantain	  NSP	  for	  30	  min	  prior	  to	  treatment	  with	  50	  µl	  pooled	  0.2	  um	  filtered	  UC	  E.	  coli	  culture	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supernatant	  (containing	  E.	  coli	  flagellae	  and	  OMVs)	  for	  2	  h	  (Section	  4.9).	  Cell	  media	  was	  then	  
harvested	   and	   assessed	   for	   the	   presence	   of	   pro-­‐inflammatory	   IL-­‐8	   using	   a	   solid	   phase	  
sandwich	  ELISA	  (Section	  4.15).	  
The	  intracellular	  localisation	  of	  β-­‐catenin	  was	  visualised	  by	  immunocytofluorescence	  
microscopy,	   in	  which	   fixed	  SW480	  colon	   cancer	   cells	  were	   incubated	  with	  primary	  mouse	  
monoclonal	   IgG	  anti-­‐human	  β-­‐catenin	   antibody	   (1:1000;	   1	  h)	   followed	  by	   secondary	   FITC-­‐
conjugated	   rabbit	   polyclonal	   anti-­‐mouse	   Ig	   antibody	   (1:2000;	   1	   h).	   Cell	   nuclei	   were	   then	  
counterstained	  with	  DAPI	  (Section	  4.13.2).	  SW480	  cells	  were	  used	  in	  this	  part	  of	  the	  study	  
purely	  for	  practical	  reasons,	  which	  was	  due	  to	  a	  lack	  of	  cultured	  Caco2	  cells	  and	  time	  restraints	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9.4  RESULTS	  
	  
9.4.1   Soluble	  plantain	  fibre	  inhibits	  the	  epithelial	  adhesion	  of	  diarrhoeal	  pathogens	  via	  an	  
effect	  on	  the	  intestinal	  epithelium	  
	  
When	  Caco2	  cells	  were	  pre-­‐incubated	  for	  30	  min	  with	  0	  –	  10	  mg/mL	  plantain	  NSP	  that	  
was	   removed	   by	   three	   washes	   with	   sterile	   PBS	   prior	   to	   bacterial	   inoculation,	   levels	   of	  
adherent	  bacteria	  were	  observed	  to	  be	  significantly	  reduced.	  In	  comparison	  to	  the	  untreated	  
control,	  10	  mg/mL	  plantain	  significantly	  reduced	  C.	  difficile,	  ETEC	  and	  S.	  Typhimurium	  by	  78.5	  
±	  7.0%	  (Figure	  9.1B),	  39.4	  ±	  1.1%	  (Figure	  9.2B)	  and	  75.1	  ±	  1.2%	  (Figure	  9.3B),	  respectively	  (All	  
P	   <	   0.001;	   Kruskal-­‐Wallis).	   Whilst	   there	   was	   significant	   residual	   inhibition	   following	   the	  
removal	  of	  plantain	  NSP,	  there	  was	  a	  higher	  level	  of	  inhibition	  observed	  in	  experiments	  where	  
plantain	  NSP	  was	  added	   to	  cells	   for	  30	  min	  without	   removal	  before	  bacterial	   infection	   (in	  
comparison	  to	  the	  untreated	  control,	  10	  mg/mL	  plantain	  NSP	  reduced	  C.	  difficile;	  ETEC	  and	  S.	  
Typhimurium	  by	  94.9	  ±	  0.9	  [Figure	  9.1A],	  64.4	  ±	  5.7	  [Figure	  9.2A]	  and	  92.9	  ±	  2.0%	  [Figure	  
9.3A],	  respectively;	  All	  P	  <	  0.001,	  Kruskal-­‐Wallis).	  In	  contrast,	  pre-­‐incubation	  of	  plantain	  NSP	  
with	  bacteria	  for	  30	  min,	  followed	  by	  removal	  of	  soluble	  fibre	  by	  centrifugation,	  resulted	  in	  
no	   significant	   inhibition	  of	  C.	  difficile,	   ETEC	  and	  S.	   Typhimurium	  compared	  with	  untreated	  
controls	  (Figure	  9.1C,	  Figure	  9.2C	  and	  Figure	  9.3C,	  respectively).	  These	  results	  suggest	  that	  
soluble	  plantain	  NSP	  exhibits	  its	  inhibitory	  effect	  via	  interaction	  with	  the	  intestinal	  epithelium	  





























Figure	  9.1	  Soluble	  plantain	  NSP	  acts	  on	  the	  epithelium	  to	  inhibit	  the	  interaction	  of	  C.	  difficile.	  
Plantain	  NSP	  blockade	  of	  C.	  difficile	  adhesion	  to	  Caco2	  cells	  was	  assessed	  under	  different	  pre-­‐
treatment	  conditions.	  A)	  Standard	  pre-­‐treatment	  of	  cell	  monolayers	  with	  plantain	  NSP	  (30	  min),	  
followed	  by	  infection	  for	  2	  h.	  B)	  Pre-­‐treatment	  of	  cell	  monolayers	  with	  soluble	  plantain	  NSP	  (30	  
min),	  followed	  by	  removal	  from	  monolayers	  with	  three	  sterile	  PBS	  washes	  prior	  to	  infection	  for	  
2	   h.	   C)	   Pre-­‐treatment	   of	   C.	   difficile	  with	   plantain	   NSP	   (30	   min),	   followed	   by	   centrifugation,	  
resuspension	  of	  bacteria	  in	  antibiotic-­‐free	  media	  and	   infection	  for	  2	  h.	  Adhesion	   is	  expressed	  
relative	  to	  CFU/mL	  found	  in	  untreated	  control	  (set	  as	  100%)	  (N	  ≥1,	  n=3;	  **	  P	  <	  0.01,	  ***	  P<	  0.001;	  























Figure	   9.2	   Soluble	   plantain	   NSP	   acts	   on	   the	   epithelium	   to	   inhibit	   the	   interaction	   of	   ETEC.	  
Plantain	   NSP	   blockade	   of	   ETEC	   adhesion	   to	   Caco2	   cells	   was	   assessed	   under	   different	   pre-­‐
treatment	  conditions.	  A)	  Standard	  pre-­‐treatment	  of	  cell	  monolayers	  with	  plantain	  NSP	  (30	  min),	  
followed	  by	  infection	  for	  1.5	  h.	  B)	  Pre-­‐treatment	  of	  cell	  monolayers	  with	  soluble	  plantain	  NSP	  
(30	  min),	  followed	  by	  removal	  from	  monolayers	  with	  three	  sterile	  PBS	  washes	  prior	  to	  infection	  
for	   1.5	   h.	  C)	   Pre-­‐treatment	   of	   ETEC	  with	   plantain	   NSP	   (30	   min),	   followed	   by	   centrifugation,	  
resuspension	  of	  bacteria	  in	  antibiotic-­‐free	  media	  and	  infection	  for	  1.5	  h.	  Adhesion	  is	  expressed	  
relative	  to	  CFU/mL	  found	  in	  untreated	  control	  (set	  as	  100%)	  (N	  ≥1,	  n=3;	  **	  P	  <	  0.01,	  ***	  P<	  0.001;	  























Figure	   9.3	   Soluble	   plantain	   NSP	   acts	   on	   the	   epithelium	   to	   inhibit	   the	   interaction	   of	   S.	  
Typhimurium	   LT2.	  Plantain	  NSP	   blockade	   of	   S.	   Typhimurium	   LT2	   adhesion	   to	   B1OXI	   porcine	  
epithelial	   cells	   was	   assessed	   under	   different	   pre-­‐treatment	   conditions.	   A)	   Standard	   pre-­‐
treatment	  of	  cell	  monolayers	  with	  plantain	  NSP	  (30	  min),	  followed	  by	  infection	  for	  1.5	  h.	  B)	  Pre-­‐
treatment	   of	   cell	  monolayers	  with	   soluble	   plantain	  NSP	   (30	  min),	   followed	  by	   removal	   from	  
monolayers	  with	   three	   sterile	   PBS	  washes	  prior	   to	   infection	   for	   1.5	  h.	  C)	  Pre-­‐treatment	  of	  S.	  
Typhimurium	  with	  plantain	  NSP	  (30	  min),	  followed	  by	  centrifugation,	  resuspension	  of	  bacteria	  in	  
antibiotic-­‐free	  media	  and	  infection	  for	  1.5	  h.	  Adhesion	  is	  expressed	  relative	  to	  CFU/mL	  found	  in	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9.4.2   Soluble	  plantain	  fibre	  mediates	  increased	  cellular	  chloride	  channel	  activity	  in	  vitro	  	  	  
Our	  group	  has	  previously	  shown	  that	  5	  mg/mL	  plantain	  NSP	  significantly	  reduces	  the	  
translocation	   of	   EGFP-­‐expressing	   S.	   Typhimurium	   LT2	   across	   isolated	   human	   ileal	   FAE	  
mounted	  in	  Ussing	  chambers	  (Roberts	  et	  al.	  2013).	  Interestingly,	  we	  also	  reported	  that	  this	  
was	  associated	  with	  a	  significant	  increase	  in	  transmucosal	  Isc,	  which	  was	  likely	  due	  to	  increased	  
epithelial	   chloride	   secretion	   (Parsons	   et	   al.	   2014).	   As	   such,	   further	   experiments	   were	  
performed	  to	  assess	  if	  plantain	  NSP	  could	  induce	  cellular	  chloride	  channel	  activation	  in	  vitro.	  
This	  was	  monitored	  using	  a	  functional	  chloride	  channel	  activity	  assay.	  
As	  a	  positive	  control,	  Caco2	  cells	  were	  first	  treated	  with	  0	  –	  200	  µM	  of	  known	  chloride	  
channel	  agonists	  forskolin	  and	  RP107,	  which	  significantly	  increased	  cellular	  chloride	  channel	  
activity	  in	  a	  dose-­‐dependent	  manner.	  Treatment	  of	  Caco2	  cells	  with	  200	  µM	  forskolin	  and	  100	  
µM	  RP107	  resulted	  peak	  levels	  of	  activation,	  increasing	  chloride	  channel	  activity	  by	  5.4	  ±	  0.5	  
fold	  and	  8.2	  ±	  1.0	  fold,	  respectively,	  in	  comparison	  to	  the	  untreated	  vehicle	  control	  (both	  P	  <	  


























Figure	   9.4.	  Chloride	   channel	   agonists	   forskolin	   and	  RP107	   induce	   increased	   cellular	   chloride	  
channel	   activation	   in	   a	   dose-­‐dependent	  manner.	   Chloride	   channel	   activity	   was	  measured	   by	  
monitoring	  cellular	  iodide	  efflux.	  Caco2	  cell	  monolayers	  were	  loaded	  with	  iodine-­‐loading	  buffer	  
for	  4	  h,	  and	  then	  incubated	  with	  chloride	  channel	  activator	  A)	  forskolin	  (0	  –	  200	  µM)	  or	  B)	  RP107	  
(0	  –	  200	  µM)	  for	  30	  min.	  Following	  cell	  lysis,	  the	  Modified	  Sandell-­‐Kolthoff	  (SK)	  reaction	  was	  used	  
to	  measure	  cellular	  iodide	  concentration.	  Chloride	  channel	  activity	  was	  expressed	  as	  fold	  change	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Treatment	  of	  Caco2	  cells	  with	  2.5	  –	  20	  mg/mL	  plantain	  NSP	  also	  resulted	  in	  a	  dose-­‐
dependent	  increase	  in	  cellular	  chloride	  channel	  activity,	  where	  10	  and	  20	  mg/mL	  plantain	  NSP	  
resulted	  in	  5.3	  ±	  0.5	  fold	  and	  5.4	  ±	  0.4	  fold	  increase	  in	  chloride	  channel	  activity	  in	  comparison	  
to	  the	  untreated	  control	  (both	  P	  <	  0.001,	  Kruskal-­‐Wallis,	  Figure	  9.5).	  Other	  NSP	  fibres	  that	  
have	  previously	  shown	  no	  inhibitory	  effect	  against	  bacterial	  adhesion	  were	  also	  evaluated	  for	  
their	  ability	  to	  induce	  chloride	  channel	  activation.	  These	  fibres	  exhibited	  less	  efficacy;	  oat	  and	  
bean	   NSP	   increased	   chloride	   channel	   activation	   by	   2.2	   ±	   0.6	   fold	   and	   2.0	   ±	   0.3	   fold,	  
respectively	   (P	  <	  0.001,	  Kruskal-­‐Wallis),	  whilst	  NSP	   from	  neither	   tomato,	  pear,	  pepper	  nor	  






























Figure	  9.5	  Plantain	  NSP	  induces	  cellular	  chloride	  channel	  activity	  in	  a	  dose-­‐dependent	  manner.	  
Chloride	   channel	   activity	   was	   measured	   by	   monitoring	   cellular	   iodide	   efflux.	   Caco2	   cell	  
monolayers	  were	   loaded	  with	   iodine-­‐loading	   buffer	   for	   4	   h,	   and	   then	   incubated	  with	   soluble	  
plantain	  NSP	  (0-­‐20	  mg/mL)	  or	  other	  soluble	  NSP	  (5	  mg/mL)	  for	  30	  min.	  Following	  cell	  lysis,	  cellular	  
iodide	  concentration	  was	  measured	  using	  the	  Modified	  Sandell-­‐Kolthoff	  (SK)	  reaction.	  2.5	  –	  20	  
mg/mL	  plantain	  NSP	  significantly	  induced	  chloride	  channel	  activity	  in	  a	  dose-­‐dependent	  manner.	  	  
5	  mg/mL	  oat	   and	   bean	  NSP	   also	   significantly	   increased	   chloride	   channel	   activity,	  whilst	   pear,	  
pepper	  and	  apple	  NSP	  exhibited	  no	  significant	  effect.	  Chloride	  channel	  activity	  was	  expressed	  as	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Next,	  it	  was	  assessed	  if	  cellular	  chloride	  channel	  activity	  could	  be	  knocked	  down	  in	  the	  
presence	  of	  known	  chloride	  channel	  antagonists	  NPPB	  and	  CFTR-­‐inh-­‐172.	  In	  Caco2	  cells	  pre-­‐
treated	  with	  10	  mg/mL	  plantain	  NSP,	  chloride	  channel	  activity	  was	   inhibited	  by	  NPPB	  and	  
CFTR-­‐inh-­‐172	  in	  dose-­‐dependent	  manner	  (Figure	  9.6).	  Treatment	  of	  Caco2	  cells	  with	  800	  µM	  
NPPB	  and	  200	  µM	  CFTR-­‐inh-­‐172	  resulted	  in	  the	  optimum	  level	  of	  inhibition,	  reducing	  chloride	  
channel	  activity	  by	  94.7	  ±	  10.0%	  (P	  <	  0.001;	  Figure	  9.6A)	  and	  86.9	  ±	  8.5%	  (P	  <	  0.001;	  Figure	  
9.6B),	  respectively,	  in	  comparison	  to	  the	  untreated	  control.	  
Similarly,	  NPPB	  and	  CFTR-­‐inh-­‐172	  also	  dose-­‐dependently	  reduced	  the	  cellular	  chloride	  
channel	   activity	   evoked	  by	  200	  µM	   forskolin	   (Figure	  9.7)	   and	  100	  µM	  RP107	   (Figure	  9.8).	  
NPPB,	   at	   800	   µM,	   resulted	   in	   peak	   levels	   of	   inhibition,	   reducing	   forskolin-­‐	   and	   RP107-­‐
mediated	   chloride	   channel	   activity	  by	  103.3	  ±	  3.2%	   (Figure	  9.7A)	   and	  86.7	  ±	  8.9%	   (Figure	  
9.8A),	  respectively	  (P	  <	  0.001	  for	  both;	  Kruskal-­‐Wallis).	  	  CFTR-­‐inh-­‐172,	  at	  200	  µM,	  also	  resulted	  
in	  peak	  levels	  of	  inhibition,	  reducing	  forskolin-­‐	  and	  RP107-­‐mediated	  chloride	  channel	  activity	  
by	  99.6	  ±	  5.0	  (Figure	  9.7B)	  and	  105.7	  ±	  3.3%	  (Figure	  9.8B),	  respectively,	  in	  comparison	  to	  the	  


























Figure	   9.6	   Soluble	   plantain	   fibre-­‐mediated	   cellular	   chloride	   channel	   activity	   is	   significantly	  
reduced	   in	   the	   presence	   of	   chloride	   channel	   antagonists	   A)	   NPPB	   and	   B)	   CFTR.	   Chloride	  
channel	  activity	  was	  measured	  by	  monitoring	  cellular	  iodide	  efflux.	  Caco2	  cells	  were	  loaded	  with	  
iodine	   loading	  buffer	  containing	  A)	  NPPB	  (0	  –	  800	  µM)	  or	  B)	   Inh172	  (0	  –	  200	  µM),	  and	  then	  
treated	  with	  10	  mg/mL	  plantain	  NSP	  for	  30	  min.	  Following	  cell	  lysis,	  cellular	  iodide	  concentration	  
was	  measured	   using	   the	  Modified	   Sandell-­‐Kolthoff	   (SK)	   reaction.	  Chloride	   channel	   activity	   is	  
expressed	  relative	  to	  the	  untreated	  vehicle	  control	  (set	  as	  100%)	  (N=3,	  n	  ≥	  3;	  ***	  P	  <	  0.001,	  **	  





























Figure	  9.7	  Forskolin-­‐mediated	  cellular	  chloride	  channel	  activity	  is	  significantly	  reduced	  in	  the	  
presence	   of	   chloride	   channel	   antagonists	   NPPB	   and	   Inh172.	   Chloride	   channel	   activity	   was	  
measured	   by	  monitoring	   cellular	   iodide	   efflux.	   Caco2	   cells	  were	   loaded	  with	   iodine	   loading	  
buffer	  containing	  A)	  NPPB	  (0	  –	  800	  µM)	  or	  B)	  Inh172	  (0	  –	  200	  µM),	  and	  then	  treated	  with	  200	  
µM	  RP107	  for	  30	  min.	  Following	  cell	  lysis,	  cellular	  iodide	  concentration	  was	  measured	  using	  the	  
Modified	  Sandell-­‐Kolthoff	   (SK)	  reaction.	  Chloride	  channel	  activity	   is	  expressed	  relative	   to	   the	  





























Figure	  9.8	   RP107-­‐mediated	   cellular	   chloride	  channel	   activity	   is	   significantly	   reduced	   in	   the	  
presence	   of	   chloride	   channel	   antagonists	   NPPB	   and	   CFTR.	   Chloride	   channel	   activity	   was	  
measured	   by	  monitoring	   cellular	   iodide	   efflux.	   Caco2	   cells	  were	   loaded	  with	   iodine	   loading	  
buffer	  containing	  A)	  NPPB	  (0	  –	  800	  µM)	  or	  B)	  Inh172	  (0	  –	  200	  µM),	  and	  then	  treated	  with	  200	  
µM	  RP107	  for	  30	  min.	  Following	  cell	  lysis,	  cellular	  iodide	  concentration	  was	  measured	  using	  the	  
Modified	  Sandell-­‐Kolthoff	   (SK)	  reaction.	  Chloride	  channel	  activity	   is	  expressed	  relative	   to	   the	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9.4.3   The	  inhibitory	  activity	  of	  plantain	  NSP	  is	  not	  mediated	  by	  increased	  cellular	  chloride	  
channel	  activity	  
The	  chloride	  channel	  activity	  assays	  confirmed	  that	  soluble	  plantain	  NSP	  could	  induce	  
increased	  chloride	  channel	  activation,	  which	  was	  significantly	  knocked	  down	  in	  the	  presence	  
of	  chloride	  channel	  antagonists	  NPPB	  and	  CFTR-­‐inh-­‐172.	  If	  the	  inhibitory	  activity	  of	  plantain	  
NSP	  was	  mediated	   by	   increased	   chloride	   secretion,	   then	   plantain	  NSP	  would	   also	   lose	   its	  
ability	   to	   inhibit	   bacterial	   adhesion	   in	   this	   instance.	   However,	   bacterial	   adhesion	   assays	  
indicated	  that	  even	  in	  the	  presence	  of	  800	  µM	  NPPB	  or	  200	  µM	  CFTR-­‐inh-­‐172,	  pre-­‐treatment	  
of	  Caco2	  cells	  with	  10	  mg/mL	  plantain	  NSP	  significantly	  reduced	  both	  C.	  difficile	  (74.9	  ±	  3.6%	  
and	  76.8	  ±	  3.4%	  reduction,	  respectively;	  Figure	  9.9A)	  and	  ETEC	  adhesion	  (91.8	  ±	  2.7	  and	  95.0	  
±	  2.1,	  respectively;	  Figure	  9.9B).	  Indeed,	  similar	  levels	  of	  bacterial	  adhesion	  were	  observed	  
when	  Caco2	  cells	  were	  pre-­‐treated	  with	  plantain	  NSP	  alone	  (in	  comparison	  to	  the	  untreated	  
control,	   C.	   difficile	   and	   ETEC	   adhesion	   was	   reduced	   by	   80.9	   ±	   2.5%	   and	   84.7	   ±	   3.7%,	  

























Figure	   9.9	   The	   effect	   of	   plantain	   NSP	   on	   C.	   difficile	   and	   ETEC	   epithelial	   adhesion	   in	   the	  
presence	  of	  chloride	  channel	  antagonists	  NPPB	  and	  CFTR-­‐inh-­‐172.	  A)	  C.	  difficile	  and	  B)	  ETEC	  
adhesion	  was	  assessed	  following	  pre-­‐treatment	  of	  Caco2	  cells	  with	  or	  without	  800	  µM	  NPPB	  or	  
200	  µM	  Inh172	  (1	  h),	  followed	  by	  treatment	  with	  or	  without	  10	  mg/mL	  plantain	  NSP	  (30	  min).	  	  
Bacterial	  adhesion	  is	  expressed	  relative	  to	  the	  CFU/mL	  found	  in	  the	  untreated	  control	  (set	  as	  
100%)	  (N=3,	  n=3;	  ***	  P	  <	  0.001,	  Kruskal-­‐Wallis).	  
	  
  ***   ***   *** 
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The	  chloride	  channel	  activity	  assays	  also	  indicated,	  that	  as	  expected,	  chloride	  channel	  
agonists	  forskolin	  and	  RP107	  mediated	  an	  increase	  in	  chloride	  channel	  activity.	  Similarly,	   if	  
the	   inhibition	   of	   bacterial	   adhesion	   was	   mediated	   by	   increased	   chloride	   secretion,	   then	  
treatment	  of	  Caco2	  cells	  with	  chloride	  channel	  agonists	  would	  also	  inhibit	  bacterial	  adhesion.	  
When	   Caco2	   cells	   were	   treated	   with	   100	   µM	   RP107,	   C.	   difficile	   adhesion	   significantly	  
decreased	  by	  23.7	  ±	  9.0%	  in	  comparison	  to	  the	  untreated	  control	  (P	  <	  0.01;	  Kruskal-­‐Wallis;	  
Figure	  9.10A).	  This	  was	  reversed	  in	  the	  presence	  of	  chloride	  channel	  antagonists	  NPPB	  and	  
CFTR-­‐inh-­‐172,	   causing	   bacterial	   adhesion	   to	   increase	   by	   7.9	   ±	   8.1%	   and	   4.5	   ±	   4.1%,	  
respectively,	  in	  comparison	  to	  the	  untreated	  control	  (Figure	  9.10A).	  	  
However,	  whilst	  100	  µM	  RP107	  also	  significantly	  reduced	  ETEC	  epithelial	  adhesion	  by	  
19.5	  ±	  7.8%	  in	  comparison	  to	  the	  untreated	  control	  (P	  <	  0.05,	  Kruskal-­‐Wallis),	  ETEC	  inhibition	  
was	  similar	  or	  only	  slightly	  reversed	  in	  the	  presence	  of	  NPPB	  and	  CFTR-­‐inh-­‐172	  (Figure	  9.10B).	  
Similarly,	   a	   small	   level	   of	   bacterial	   inhibition	  was	   also	   seen	   in	   cells	   treated	  with	   200	   µM	  
forskolin,	  which	  reduced	  C.	  difficile	  and	  ETEC	  epithelial	  adhesion	  by	  8.4	  ±	  10.7%	  (Figure	  9.11A)	  
and	  23.1	  ±	  5.7	  (P	  <	  0.01;	  Figure	  9.11B),	  respectively,	  however,	  bacterial	  inhibition	  was	  again	  
similar	  or	  only	  partly	  reversed	  in	  the	  presence	  of	  chloride	  channel	  antagonists	  (Figure	  9.11A	  
and	  B).	  Collectively,	  these	  results	  suggest	  that	  increased	  cellular	  chloride	  secretion	  plays	  little	  
























Figure	  9.10.	  The	  effect	  of	  RP107	  on	  C.	  difficile	  and	  ETEC	  epithelial	  adhesion,	  both	  alone	  and	  in	  
the	  presence	  of	  chloride	  channel	  antagonists	  NPPB	  and	  CFTR-­‐inh-­‐172.	  A)	  C.	  difficile	  and	  B)	  ETEC	  
adhesion	  was	  assessed	  following	  pre-­‐treatment	  of	  Caco2	  cells	  with	  or	  without	  800	  µM	  NPPB	  or	  
200	  µM	  Inh172	  (1	  h),	  followed	  by	  treatment	  with	  or	  without	  100	  µM	  RP107	  (30	  min).	  Bacterial	  
adhesion	  is	  expressed	  relative	  to	  the	  CFU/mL	  found	  in	  the	  untreated	  control	  (set	  as	  100%)	  (N=2,	  


























Figure	  9.11	  The	  effect	  of	  forskolin	  on	  C.	  difficile	  and	  ETEC	  epithelial	  adhesion	  in	  the	  presence	  
of	  chloride	  channel	  antagonists	  NPPB	  and	  CFTR-­‐inh-­‐172.	  A)	  C.	  difficile	  and	  B)	  ETEC	  adhesion	  
was	  assessed	  following	  pre-­‐treatment	  of	  Caco2	  cells	  with	  or	  without	  800	  µM	  NPPB	  or	  200	  µM	  
Inh172	   (1	   h),	   followed	   by	   treatment	   with	   or	   without	   200	   µM	   forskolin	   (30	   min).	   Bacterial	  
adhesion	  is	  expressed	  relative	  to	  the	  CFU/mL	  found	  in	  the	  untreated	  control	  (set	  as	  100%)	  (N=2,	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9.4.4   Plantain	  NSP	  induces	  the	  nuclear	  translocation	  of	  β-­‐catenin	  
As	  revealed	  by	  immunocytofluorescent	  staining,	  pre-­‐treatment	  of	  intestinal	  epithelial	  
cells	  with	  10	  mg/mL	  plantain	  NSP	  for	  30	  min	  markedly	  induced	  the	  activation	  and	  subsequent	  
nuclear	  translocation	  of	  β-­‐catenin,	  which	  was	  a	  similar	  level	  to	  that	  induced	  by	  1	  µM	  PGE2	  











Figure	  9.12	  Plantain	  NSP	  induces	  the	  nuclear	  translocation	  of	  β-­‐catenin.	  Colonic	  SW480	  cells	  
were	  treated	  with	  10	  mg/mL	  plantain	  NSP	  or	  1	  µM	  PGE2	  (as	  a	  positive	  control),	  then	  fixed	  and	  
stained	  with	  primary	  mouse	  monoclonal	  IgG	  anti-­‐β-­‐catenin	  antibody	  (1:1000;	  1	  h)	  followed	  by	  
secondary	  FITC-­‐conjugated	  rabbit	  polyclonal	  anti-­‐mouse	  antibody	  (1:2000;	  2	  h).	  A)	  Cell	  nuclei	  
were	   then	   counterstained	  with	  DAPI	   and	   cells	   visualised	   by	   fluorescent	  microscopy.	  B)	   The	  
nuclear	  translocation	  of	  β-­‐catenin	  is	  also	  apparent	  in	  the	  expanded	  image	  of	  FITC	  stained	  SW480	  
cells	  treated	  with	  10	  mg/mL	  plantain	  NSP.	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Previous	  unexplained,	  unpublished	  observations	   from	  our	  Department,	  undertaken	  
by	  Dr	  Paul	  Collins	  (Department	  of	  Gastroenterology,	  University	  of	  Liverpool),	  had	  also	  shown	  
that	  plantain	  NSP	  could	  affect	  the	  nuclear	  translocation	  of	  β-­‐catenin	  in	  colonocytes.	  Here,	  
DLD-­‐1	  colon	  cancer	  cells	  treated	  with	  5	  mg/mL	  plantain	  NSP	  (containing	  approximately	  0.85	  
mg/mL	  pectin)	  for	  30	  min	  showed	  increased	  nuclear	  translocation	  of	  β-­‐catenin	  above	  that	  
induced	  by	  1μM	  PGE2,	  compared	  to	  untreated	  controls	   (P	  <	  0.01;	  P	  <	  0.001	  respectively;	  







Figure	  9.13	  Plantain	  NSP	  induces	  the	  nuclear	  translocation	  of	  β-­‐catenin	  in	  DLD-­‐1	  colonocytes.	  
DLD-­‐1	  cells	  were	   treated	  with	  5	  mg/mL	  plantain	  NSP	  (containing	  approximately	  0.85	  mg/mL	  
pectin)	   or	   1	   µM	   PGE2	   (as	   a	   positive	   control),	   then	   fixed	   and	   stained	   with	   primary	   mouse	  
monoclonal	  IgG	  anti-­‐β-­‐catenin	  antibody	  (1:1000;	  1	  h)	  followed	  by	  secondary	  FITC-­‐conjugated	  
rabbit	   polyclonal	   anti-­‐mouse	   antibody	   (1:2000;	   2	   h).	  A)	   Cells	  were	   visualised	   by	   fluorescent	  
microscopy	  and	  B)	  nuclear:cytoplasmic	   localisation	  quantified	  using	   Image	  J	  software	  (**	  P	  <	  
0.01;	   ***	   P	   <	   0.001).	   This	   work	   was	   performed	   by	   Dr	   Paul	   Collins,	   Department	   of	  
Gastroenterology,	  University	  of	  Liverpool	  (unpublished	  data).	  	  	  
	  
	  	  227	  
	  
9.4.5   The	  inhibitory	  effect	  of	  plantain	  NSP	  is	  not	  mediated	  by	  cellular	  galectin-­‐3	  
expression	  
To	  assess	  if	  the	  inhibitory	  activity	  of	  soluble	  plantain	  fibre	  was	  mediated	  by	  the	  cellular	  
expression	  of	  galectin-­‐3,	  SW620Gal3-­‐	  cells	  and	  SW620Gal3+	  cells	  were	  pre-­‐treated	  for	  30	  min	  
with	  10	  mg/mL	  plantain	  NSP	  and	  subsequently	  infected	  with	  either	  C.	  difficile	  at	  an	  MOI	  of	  
100	  (Figure	  9.14)	  or	  50	  µL	  pooled	  UC	  E.	  coli	  supernatant	  (Figure	  9.15).	  	  
Pre-­‐treatment	  of	  SW620Gal3-­‐	   cells	  with	  10	  mg/mL	  plantain	  NSP	  resulted	   in	  a	  similar	  
level	  of	  bacterial	  adhesion	  to	  that	  seen	  in	  SW620Gal3+	  cells,	  reducing	  C.	  difficile	  adhesion	  by	  
64.0	  ±	  0.9%	  and	  69.2	  ±	  3.0%,	  respectively,	  compared	  to	  the	  untreated	  control	  (Figure	  9.14).	  
Whilst	   10	   mg/mL	   plantain	   NSP	   also	   reduced	   the	   IL-­‐8	   response	   to	   bacterial	   flagellin	   in	  
SW620Gal3-­‐	   cells	   (reduction	  of	   36.5	   ±	   5.8%	   in	   comparison	   to	   the	  untreated	   control;	  Figure	  
9.15),	  the	  level	  of	  inhibition	  higher	  was	  higher	  when	  SW620Gal3+	  cells	  were	  pre-­‐incubated	  with	  
10	  mg/mL	  plantain	  NSP	  prior	  to	  flagellin	  treatment	  (reduction	  of	  62.7	  ±	  1.6%	  in	  comparison	  

























Figure	  9.14.	  The	  ability	  of	  plantain	  NSP	  to	  inhibit	  C.	  difficile	  epithelial	  adhesion	  is	  not	  affected	  
by	  cell-­‐surface	  galectin-­‐3	  expression.	  Pre-­‐treatment	  of	  SW620Gal3+	  (galectin-­‐3	  expressing)	  and	  
SW620Gal3-­‐	  (galectin-­‐3	  knockdown)	  cells	  with	  10	  mg/mL	  prior	  to	  infection	  with	  C.	  difficile	  (MOI	  
100;	  2h)	  significantly	  reduced	  bacterial	  adhesion.	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Figure	  9.15.	  	  The	  ability	  of	  plantain	  NSP	  to	  significantly	  reduce	  IL-­‐8	  response	  to	  E.	  coli	  filtrate	  
is	   not	   affected	   by	   the	   expression	   of	   cell-­‐surface	   galectin-­‐3.	   Pre-­‐treatment	   of	   SW620Gal3+	  
(galectin-­‐3	   expressing)	   and	   SW620Gal3-­‐	   (galectin-­‐3	   knockdown)	   cells	   with	   10	  mg/mL	   prior	   to	  
treatment	  with	  0.2µm	  filtered	  pooled	  UC	  E.	  coli	  culture	  supernatant	  (50	  µL;	  4	  h)	  significantly	  
reduced	  pro-­‐inflammatory	  IL-­‐8	  response.	  Harvested	  media	  was	  measured	  for	  the	  presence	  of	  
IL-­‐8	  using	  an	  IL-­‐8	  Human	  Elipair	  kit.	  	  
	  
     
	  	  230	  
9.5   SUMMARY	  OF	  RESULTS	  
	  
1.   Soluble	   plantain	   fibre	   inhibits	   bacterial	   adhesion	   via	   an	   interaction	  with	   the	   intestinal	  
epithelium,	  rather	  than	  through	  direct	  interaction	  with	  bacteria	  
	  
2.   Soluble	  plantain	  fibre	  significantly	  increases	  cellular	  chloride	  channel	  activity,	  but	  this	  has	  
little	  or	  no	  effect	  on	  its	  inhibitory	  activity	  against	  bacterial	  adhesion	  
	  
3.   Soluble	  plantain	  fibre	  induces	  the	  nuclear	  translocation	  of	  β-­‐catenin	  in	  intestinal	  epithelial	  
cells	   suggesting	   that,	   like	   MUC2	   glycans,	   its	   inhibitory	   effect	   might	   be	   mediated	   by	  
interacting	  with	  cell-­‐surface	  galectin-­‐3	  
	  
4.   The	  ability	  of	  soluble	  plantain	  fibre	  to	  inhibit	  bacterial	  adhesion	  and	  the	  IL-­‐8	  response	  to	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9.6   DISCUSSION	  
Here,	  a	  further	  insight	  into	  the	  mechanism	  of	  the	  inhibitory	  action	  of	  soluble	  plantain	  
fibre	  is	  provided.	  Interestingly,	  soluble	  plantain	  fibre	  was	  shown	  to	  exert	  its	  inhibitory	  effect	  
against	  diarrhoeal	  pathogens	  C.	  difficile,	   ETEC	  and	   S.	   Typhimurium	  via	   an	   interaction	  with	  
intestinal	  epithelial	  cells,	  rather	  than	  through	  interaction	  with	  bacterial	  adhesins.	  Whilst	  we	  
have	   previously	   shown	   that	   plantain	   NSP	   interacts	   with	   and	   provides	   a	   fuel	   source	   for	  
diarrhoeal	  pathogens	  (Chapter	  5	  of	  this	  thesis),	  the	  results	  presented	  here	  suggest	  that	  this	  
interaction	  is	  likely	  unrelated	  to	  the	  underlying	  mechanism	  of	  its	  inhibitory	  effect.	  	  
Previous	  studies	  by	  our	  research	  group	  demonstrated	  that	  pre-­‐treatment	  of	  isolated	  
human	  FAE,	  mounted	   in	  Ussing	  chambers,	  with	  5	  mg/mL	  soluble	  plantain	  fibre	  resulted	   in	  
significantly	  increased	  transmucosal	  Isc	  (Parsons	  et	  al.	  2014;	  Roberts	  et	  al.	  2013).	  We	  therefore	  
postulated	  that	  soluble	  plantain	  NSP	  might	  inhibit	  bacterial	  epithelial	  adhesion	  via	  increased	  
chloride	  secretion,	  which	  is	  associated	  with	  increased	  ion	  efflux	  and	  water	  transport	  (Parsons	  
et	  al.	   2014).	   Indeed,	  epithelial	   secretion	  of	   fluid	   is	   already	   recognised	  as	  a	   form	  of	   innate	  
immunity,	  thought	  to	  serve	  as	  a	  non-­‐specific	  method	  of	  clearing	  bacteria	  and	  their	  toxins	  from	  
the	  intestinal	  mucosa	  (Strober	  and	  McGhee	  2005).	  
Functional	   chloride	   channel	   activity	   assays	   illustrated	   that	   pre-­‐incubation	  of	   Caco2	  
cells	   with	   2.5	   –	   20	   mg/mL	   plantain	   NSP	   significantly	   increased	   cellular	   chloride	   channel	  
activation,	   thus	   confirming	   the	   findings	   from	   Ussing	   chamber	   experiments	   performed	  
previously	  (Parsons	  et	  al.	  2014).	  Importantly,	  it	  was	  also	  shown	  that	  other	  soluble	  plant	  fibres,	  
previously	  shown	  not	  to	  exhibit	  an	  inhibitory	  effect	  on	  bacterial	  adhesion	  (in	  Chapter	  5	  of	  this	  
thesis),	  either	  completely	  lacked	  the	  ability	  to	  induce	  chloride	  channel	  activation,	  or	  induced	  
activity	  at	  a	  significantly	  lower	  level	  than	  that	  seen	  with	  plantain	  NSP.	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Whilst	   we	   showed	   that	   cellular	   chloride	   channel	   activation	   induced	   by	   10	  mg/mL	  
plantain	  NSP	  was	  significantly	  knocked	  down	  in	  the	  presence	  of	  chloride	  channel	  antagonists	  
NPPB	  and	  CFTR-­‐inh-­‐172	  (Linsdell	  2014),	  this	  had	  no	  significant	  effect	  on	  C.	  difficile	  or	  ETEC	  
epithelial	  adhesion.	  Conversely,	  chloride	  channel	  agonists,	  forskolin	  and	  RP107	  (Noel	  et	  al.	  
2006),	   significantly	   reduced	   bacterial	   epithelial	   adhesion	   in	   most	   cases,	   but	   bacterial	  
inhibition	  was	  similar	  or	  only	  slightly	   reversed	   in	   the	  presence	  of	  NPPB	  and	  CFTR-­‐inh-­‐172.	  
Furthermore,	  despite	  similar	  levels	  of	  evoked	  cellular	  chloride	  channel	  activity	  (forskolin	  and	  
RP107;	  5.4	  ±	  0.5	  and	  8.2	  ±	  1.0-­‐fold	  increase	  vs.	  plantain;	  5.3	  ±	  0.5	  fold	  increase),	  the	  level	  of	  
inhibition	  caused	  by	  forskolin	  and	  RP107	  was	  much	  less	  than	  that	  observed	  with	  10	  mg/mL	  
plantain	  NSP.	  Collectively,	  these	  results	  suggest	  that	  whilst	  plantain	  NSP	  mediates	  increased	  
epithelial	  chloride	  secretion,	  this	  has	  little	  or	  no	  effect	  on	  the	  inhibition	  of	  bacterial	  adhesion.	  
It	   is	   therefore	   likely	   that	   soluble	   plantain	   fibre	   inhibits	   bacterial	   adhesion	   via	   another	  
mechanism.	  It	  is	  worth	  noting	  that	  the	  chloride	  channel	  experiments	  are	  limited	  as	  they	  have	  
only	   been	   performed	   in	   vitro.	   Indeed,	   it	   is	   possible	   that	   chloride	   secretion	   in	   such	   static	  
conditions	  might	  not	  have	  the	  same	  physiological	  effect	  as	  would	  be	  observed	  in	  vivo,	  thus	  
resulting	  in	  a	  limited	  effect	  on	  bacterial	  adhesion.	  Therefore,	  whilst	  these	  results	  suggest	  that	  
soluble	  plantain	  fibre	  inhibits	  bacterial	  adhesion	  via	  another	  mechanism,	  the	  role	  of	  chloride	  
secretion	  should	  not	  be	  cast	  aside	  without	  further	  investigation	  in	  an	   in	  vivo	  setting	  where	  
chloride	  channel	  secretion	  is	  associated	  with	  more	  significant	  water	  transport.	  
Next,	  we	  hypothesised	  that	  the	  inhibitory	  activity	  of	  soluble	  plantain	  NSP	  might	  lie	  in	  
its	   ability	   to	  mimic	  MUC2	   glycans,	  which	   have	   been	   shown	   recently	   to	   interact	  with	   cell-­‐
surface	  galectin-­‐3	  with	  consequent	  anti-­‐inflammatory	  and	  mucosally	  protective	  effects	  (Shan	  
et	  al.	  2013).	  These	  effects,	  as	  described	  by	  Shan	  and	  colleagues,	  focussed	  predominantly	  on	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dendritic	  cells,	  but	  included	  preliminary	  data	  relating	  to	  intestinal	  epithelial	  cells	  (Shan	  et	  al.	  
2013).	  Our	  own	  preliminary	  studies	  have	  shown	  that	  plantain	  NSP	  also	  interacts	  with	  galectin-­‐
3	  at	  a	  similar	  concentration	  to	  that	  which	  has	  an	  anti-­‐inflammatory,	  anti-­‐bacterial	  effect.	  As	  
discussed	  in	  Chapter	  8	  of	  this	  thesis,	  the	  inhibitory	  activity	  of	  plantain	  NSP	  was	  shown	  to	  be	  
largely	  due	  to	  its	  acidic	  or	  pectin	  fraction.	  Indeed,	  various	  pectins	  have	  also	  previously	  been	  
shown	   to	   interact	   with	   galectin-­‐3,	   including	   citrus	   and	   ginseng	   pectins	   (Gao	   et	   al.	   2013;	  
Gunning	  et	  al.	  2009;	  Sathisha	  et	  al.	  2007).	  
Here,	  we	  demonstrated	  that	  treatment	  of	  colonic	  epithelial	  cells	  with	  soluble	  plantain	  
fibre	  induced	  a	  marked	  nuclear	  translocation	  of	  β-­‐catenin,	  which	  has	  also	  been	  implicated	  in	  
the	  MUC2-­‐galectin3-­‐Dectin	  1	  signalling	  pathway	  characterised	  previously	  (Shan	  et	  al.	  2013).	  
Conversely,	  our	  studies	  indicated	  that	  cell-­‐surface	  galectin-­‐3	  expression	  did	  not	  have	  an	  effect	  
on	  the	  inhibitory	  activity	  of	  soluble	  plantain	  NSP.	  Indeed,	  soluble	  plantain	  fibre	  retained	  its	  
ability	  to	  significantly	  inhibit	  C.	  difficile	  epithelial	  adhesion,	  as	  well	  as	  reduce	  the	  IL-­‐8	  response	  
to	  bacterial	  flagellin,	  in	  SW620Gal3-­‐	  knockdown	  cells.	  However,	  particularly	  with	  respect	  to	  the	  
IL-­‐8	  response	  to	  flagellin,	  it	  was	  apparent	  that	  soluble	  plantain	  fibre	  exhibited	  a	  lower	  level	  of	  
inhibitory	  activity	   in	  SW620Gal3-­‐	  cells	   in	  comparison	   to	  SW620Gal3+	  cells	   (%	   reduction	   in	   IL-­‐8	  
response;	  36.4	  ±	  5.8%	  vs.	  62.7	  ±	  1.6%).	  	  	  
It	  is	  important	  to	  note	  that	  galectin-­‐3	  expression	  was	  only	  knocked	  down	  by	  82%	  in	  
SW620Gal3-­‐	  cells	   (Duckworth	  et	  al.	  2015).	  Therefore,	   it	   is	   likely	  that	  an	   interaction	  between	  
plantain	  NSP	  and	  cell-­‐surface	  galectin-­‐3	  may	  still	  have	  occurred.	  If	  the	  mucosally	  protective	  
and	  anti-­‐inflammatory	  effects	  of	  plantain	  NSP	  were	  mediated	  by	  this	  interaction,	  this	  would	  
explain	  why	  plantain	  NSP	  retained	  some	  inhibitory	  activity	  in	  SW620Gal3-­‐	  cells.	  Alternatively,	  it	  
is	  possible	  that	  soluble	  plantain	  fibre	  does	  not	  mimic	  MUC2	  glycans	  and	  its	  inhibitory	  activity	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is	  therefore	  not	  mediated	  by	  interaction	  with	  galectin-­‐3.	  If	  this	  were	  the	  case,	  soluble	  plantain	  
fibre	  would	  activate	  β-­‐catenin	  by	  an	  independent	  mechanism.	  	  
In	  conclusion,	  the	  role	  of	  cell-­‐surface	  galectin-­‐3	  expression	  on	  the	  inhibitory	  activity	  
of	  plantain	  NSP	  needs	   further	   investigation,	  and	   therefore,	   it	   is	   currently	  unclear	  whether	  
soluble	  plantain	  NSP	  mimics	  MUC2	  glycans	  via	  galectin-­‐3	  interaction.	  SW620Gal3-­‐	  experiments	  
are	  limited	  as	  they	  were	  only	  performed	  once	  (with	  n=6	  replicates),	  and	  therefore,	  they	  need	  
to	  be	  repeated	  before	  any	  sound	  inferences	  are	  to	  be	  made.	  In	  addition,	  it	  might	  be	  beneficial	  
to	   also	   assess	   if	   treatment	  of	   intestinal	   epithelial	   cells	  with	   an	   anti-­‐galectin-­‐3	   antibody	  or	  
siRNA	  targeting	  the	  GAL3	  gene	  has	  an	  effect	  on	  the	  inhibitory	  effect	  of	  plantain	  NSP,	  or	  to	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10.1   SUMMARY	  OF	  KEY	  FINDINGS	  
	  
1.   A	   range	   of	   soluble	   dietary	   fibres	   are	   shown	   to	   significantly	   inhibit	   the	   epithelial	  
adhesion	   of	   toxin-­‐mediated	   diarrhoeal	   pathogens	   C.	   difficile	   and	   ETEC,	   of	   which	  
plantain	  NSP	  exhibits	  the	  highest	  efficacy	  
	  
2.   Soluble	  plantain	  fibre	  inhibits	  the	  epithelial	  adhesion	  of	  a	  range	  of	  clinically	  relevant	  
C.	  difficile	  isolates,	  irrespective	  of	  their	  toxin	  or	  ribotype	  status	  
	  
3.   Soluble	  plantain	  fibre	  inhibits	  the	  epithelial	  interactions	  of	  C.	  difficile	  spores	  
	  
4.   Soluble	   plantain	   fibre	   can	   also	   inhibit	   the	   epithelial	   interactions	   of	   other	   bacterial	  
components	   involved	   in	   the	   pathogenesis	   of	   inflammatory	   intestinal	   disease,	  
including	  C.	  difficile	  TcdA	  and	  TcdB,	  as	  well	  as	  mucosa-­‐associated	  E.	  coli	  flagellin	  and	  
LPS	  
	  
5.   Soluble	   plantain	   NSP	   has	   no	   effect	   on	   TcdA	   and	   TcdB-­‐mediated	   Rac1	  
monoglucosylation,	   but	   it	   reduces	   the	   pro-­‐inflammatory,	   cytotoxic	   and	   apoptotic	  
response	  induced	  by	  C.	  difficile	  and	  its	  toxins,	  suggesting	  a	  possible	  role	  in	  the	  therapy	  
of	  CDI	  
	  
6.   Soluble	  plantain	  fibre	  down-­‐regulates	  the	  cellular	  pro-­‐inflammatory,	  cytotoxicity	  and	  
apoptotic	   response	  mediated	   by	  mucosally-­‐associated	   UC	   E.	   coli,	   as	   well	   as	   other	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bacterial	  components	  such	  as	  mucosal	  flagellin	  and	  LPS,	  suggesting	  a	  possible	  role	  for	  
plantain	  NSP	  in	  the	  treatment	  of	  UC	  
	  
7.   The	  inhibitory	  effects	  of	  soluble	  plantain	  fibre	  against	  bacteria-­‐epithelial	  interactions	  
are	  shown	  to	  be	  largely	  a	  consequence	  of	  its	  acidic	  (pectic)	  component	  
	  
8.   Soluble	   plantain	   NSP	   inhibits	   the	   epithelial	   adhesion	   of	   C.	   difficile,	   ETEC	   and	   S.	  
Typhimurium	  via	   an	   interaction	  with	   intestinal	   epithelial	   cells,	   rather	   than	   through	  
interaction	  with	  bacterial	  cell-­‐surface	  components,	  such	  as	  adhesins	  
	  
9.   Whilst	  plantain	  NSP	  induces	  increased	  cellular	  chloride	  secretion,	  this	  has	  little	  or	  no	  
effect	  on	  its	  inhibitory	  activity	  against	  bacteria-­‐epithelial	  interaction,	  suggesting	  that	  
the	  latter	  is	  mediated	  by	  an	  alternative	  mechanism	  
	  
10.  Pre-­‐treatment	  of	   intestinal	  epithelial	   cells	  with	  plantain	  NSP	   induces	   the	  activation	  
and	  nuclear	  translocation	  of	  β-­‐catenin,	  which	  has	  been	  shown	  by	  others	  to	  mediate	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11.1  KEY	  FINDINGS	  OF	  THIS	  WORK	  
11.1.1   Soluble	   plantain	   fibre	   inhibits	   the	   in	   vitro	   epithelial	   interactions	   of	   diarrhoeal	  
pathogens	  C.	  difficile	  and	  ETEC	  
	   Previous	  findings	  from	  our	  group	  have	  demonstrated	  that	  soluble	  plantain	  fibre	  has	  
the	  ability	  to	  inhibit	  the	  epithelial	  interactions	  of	  a	  range	  of	  gut	  pathogens,	  including	  the	  in	  
vitro	  epithelial	  adhesion,	   invasion	  and	  M-­‐cell	   translocation	  of	  AIEC,	  S.	  Typhimurium	  and	  S.	  
sonnei.	   In	   ex-­‐vivo	   studies	   performed	   previously,	   we	   have	   also	   shown	   that	   plantain	   NSP	  
reduces	   AIEC	   and	   S.	   Typhimurium	   translocation	   across	   isolated	   human	   ileal	   FAE	   and	   VE	  
mounted	  in	  Ussing	  chambers	  (Roberts	  et	  al.	  2010;	  Roberts	  et	  al.	  2013).	  Furthermore,	  we	  have	  
previously	   illustrated	   that	   a	   diet	   supplemented	   with	   plantain	   NSP	   significantly	   reduces	  
Salmonellosis	  in	  an	  in	  vivo	  chicken	  model	  (Parsons	  et	  al.	  2014).	  
	   The	   data	   presented	   here	   in	   this	   thesis	   provides	   further	   evidence	   to	   support	   our	  
hypothesis	  that	  soluble	  plantain	  fibre	  might	  have	  a	  beneficial	  impact	  on	  intestinal	  health	  via	  
its	  ability	  to	  inhibit	  potentially	  harmful	  interactions	  between	  bacteria	  and	  the	  gut	  epithelium.	  
In	  Chapter	  5,	  we	  demonstrate	  that	  whilst	  a	  range	  of	  soluble	  dietary	  fibres	  exhibit	  inhibitory	  
activity	  against	  the	  epithelial	  adhesion	  of	  toxin-­‐mediated	  diarrhoeal	  pathogens	  C.	  difficile	  and	  
ETEC,	  plantain	  NSP	  exhibits	  the	  highest	  efficacy.	  	  Furthermore,	  we	  show	  that	  soluble	  plantain	  
fibre	  significantly	   inhibits	  the	  epithelial	  adhesion	  of	  a	  range	  of	  clinically	  relevant	  C.	  difficile	  
isolates,	   irrespective	   of	   their	   toxin	   or	   ribotype	   status.	   These	   results	   suggest	   that	   soluble	  
plantain	  NSP	  could	  be	  a	  promising	  candidate	  for	  development	  as	  a	  potential	  prophylaxis	  or	  
treatment	  for	  CDI	  and	  ETEC	  infection.	  Of	  significant	  note,	  we	  also	  show	  that	  soluble	  plantain	  
NSP	  can	   inhibit	   the	  epithelial	   interactions	  of	  C.	  difficile	  spores.	  As	   this	  dormant	   form	  of	  C.	  
difficile	  is	  also	  associated	  with	  high	  CDI	  re-­‐infection	  rates	  (Barbut	  et	  al.	  2000;	  Oka	  et	  al.	  2012),	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we	  suggest	  that	  dietary	  supplementation	  with	  soluble	  plantain	  NSP	  might	  also	  help	  maintain	  
remission	  from	  CDI.	  	  
	  
11.1.2   Soluble	  plantain	  fibre	  down-­‐regulates	  the	  epithelial	  cell	  damage	  and	  inflammatory	  
response	  to	  bacterial	  components	  
	   The	  results	  described	  in	  Chapter	  5	  provide	  convincing	  evidence	  to	  suggest	  that	  soluble	  
plantain	   fibre	   can	   disrupt	   the	   epithelial	   interactions	   of	   C.	   difficile	   and	   ETEC	   bacteria.	   In	  
addition,	  our	  findings	  in	  Chapter	  6	  and	  Chapter	  7	  demonstrate	  that	  soluble	  plantain	  fibre	  can	  
also	   inhibit	   the	   epithelial	   interactions	   of	   other	   bacterial	   components	   involved	   in	   the	  
pathogenesis	  of	  inflammatory	  intestinal	  disease,	  including	  C.	  difficile	  toxins	  TcdA	  and	  TcdB,	  as	  
well	  as	  E.	  coli	  mucosal	  associated	  flagellin	  and	  LPS.	  	  
	   In	  Chapter	  6,	  we	  show	  that	  whilst	  soluble	  plantain	  NSP	  has	  no	  effect	  on	  TcdA	  and	  TcdB-­‐
mediated	   Rac1	   monoglucosylation,	   it	   does	   significantly	   reduce	   the	   pro-­‐inflammatory,	  
cytotoxicity	   and	   apoptotic	   response	   induced	   by	   C.	   difficile	   and	   its	   toxins.	   Rac1	  
monoglucosylation	  is	  postulated	  to	  be	  the	  main	  pathway	  through	  which	  C.	  difficile	  TcdA	  and	  
TcdB	  exert	  their	  cellular	  effects	  (Popoff	  and	  Geny	  2011),	  however	  our	  findings	  conclude	  that	  
soluble	  plantain	  fibre	  is	  unlikely	  to	  inhibit	  this	  specific	  intracellular	  mechanism	  of	  action	  of	  C.	  
difficile	   toxins.	   As	   such,	   further	  work	   is	   required	   to	   determine	  whether	   plantain	   NSP	   can	  
abrogate	  C.	   difficile	   toxin-­‐mediated	   activation	   of	   alternative	   signalling	   pathways	   occurring	  
independently	  of	  Rho	  protein	  monoglucosylation	  (He	  et	  al.	  2002;	  Matarrese	  et	  al.	  2007),	  such	  
as	   the	   IκB-­‐NFκB	   pathway,	  which	   has	   been	   implicated	   in	   TcdA-­‐mediated	   IL-­‐8	   release	   from	  
enterocytes	  (He	  et	  al.	  2002).	  It	  is	  important	  to	  note,	  however,	  that	  whilst	  plantain	  NSP	  appears	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to	  have	  no	  effect	  on	  toxin-­‐mediated	  Rac1	  monoglucosylation,	  its	  marked	  ability	  to	  reduce	  the	  
epithelial	  cell	  damage	  and	  inflammatory	  response	  to	  C.	  difficile	  and	  its	  toxins	  is	  still	  likely	  to	  
be	  of	  great	  clinical	  benefit.	  Previously,	  a	  number	  of	  animal	  models	  have	  demonstrated	  that	  
anti-­‐inflammatory	  agents	  have	  a	  protective	  effect	  against	  CDI	  (Anton	  et	  al.	  2004;	  Chen	  et	  al.	  
2006;	  Cottrell	  et	  al.	  2007;	  Kokkotou	  et	  al.	  2009;	  Pothoulakis	  et	  al.	  1996;	  Warny	  et	  al.	  2005).	  
As	   such,	   these	   findings	   provide	   further	   evidence	   to	   support	   our	   hypothesis	   that	   dietary	  
supplementation	  with	  plantain	  NSP	  might	  represent	  an	  effective	  therapy	  to	  treat	  CDI.	  	  
	   In	  Chapter	  7,	  we	  also	  demonstrate	  that	  soluble	  plantain	  fibre	  has	  the	  ability	  to	  down-­‐
regulate	   the	   cellular	   pro-­‐inflammatory,	   cytotoxicity	   and	   apoptotic	   response	   mediated	   by	  
mucosally-­‐associated	   UC	   E.	   coli,	   as	   well	   as	   other	   bacterial	   components,	   such	   as	   mucosal	  
flagellin	   and	   LPS.	   Taken	   together,	   these	   findings	   also	   suggest	   a	   possible	   role	   of	   soluble	  
plantain	  fibre	  in	  the	  treatment	  of	  UC.	  	  
	  
11.1.3   The	  inhibitory	  activity	  of	  plantain	  NSP	  is	  mediated	  by	  its	  acidic,	  pectic	  polysaccharide	  
fraction	  
	   The	  results	  presented	  in	  Chapter	  8	  of	  this	  thesis	  demonstrate	  that	  neutral	  and	  acidic	  
fractions	   of	   plantain	   NSP,	   isolated	   by	   strong-­‐anion	   exchange	   chromatography,	   exhibit	  
differential	   inhibitory	   activity	   against	   bacteria-­‐epithelial	   interactions.	   We	   show	   that	   pre-­‐
treatment	  of	   intestinal	  epithelial	   cells	  with	   the	  acidic	   fraction	  of	  plantain	  NSP	  significantly	  
inhibits	   the	  epithelial	  adhesion	  of	  C.	  difficile,	  ETEC	  and	  S.	  Typhimurium,	  whilst	   the	  neutral	  
fraction	   of	   plantain	   NSP	   exhibits	   a	   decreased	   level	   of	   inhibitory	   activity.	   In	   addition,	  
composition	   analysis	   performed	   previously	   by	   our	   group	   has	   shown	   that	   the	   acidic	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polysaccharide	   fraction	   of	   plantain	   NSP	   is	   mainly	   composed	   of	   pectic	   material,	   which	   is	  
completely	  absent	  in	  the	  neutral	  plantain	  NSP	  fraction.	  	  Taken	  together,	  these	  results	  suggest	  
that	  the	  inhibitory	  activity	  of	  soluble	  plantain	  NSP	  against	  bacteria-­‐epithelial	  interactions	  is	  
largely	  due	  to	  its	  acidic,	  pectic	  polysaccharide	  fraction.	  These	  findings	  are	  in	  agreement	  with	  
preliminary	  work	  performed	  previously,	  which	  also	  demonstrated	  that	  the	  acidic	  fraction	  of	  
plantain	   NSP	   exhibited	   significant	   inhibitory	   activity	   against	   the	   epithelial	   adhesion	   of	   S.	  
Typhimurium	  (Parsons	  et	  al.	  2014).	  Indeed,	  other	  studies	  have	  shown	  that	  pectin	  also	  exhibits	  
anti-­‐adhesive	  activity	  against	  other	  gut	  pathogens	  including	  C.	  jejuni	  and	  H.	  pylori	  (Ganan	  et	  
al.	  2010;	  Lee	  et	  al.	  2006b).	  In	  addition,	  it	  has	  previously	  been	  demonstrated	  that	  pectin	  also	  
has	  the	  ability	  to	  inhibit	  haemagglutination	  by	  bacteria,	  such	  as	  that	  caused	  by	  S.	  areus	  and	  
P.	  acnes,	  but	  not	  that	  affected	  by	  E.	  coli	  and	  L.	  acidophilus	  (Lee	  et	  al.	  2006b).	  	  
	   Interestingly,	  we	   also	   present	   data	   to	   suggest	   that	  maltodextrin,	   derived	   from	   the	  
starch	  component	  of	  the	  plantain	  source	  material,	  which	  is	  added	  back	  to	  soluble	  plantain	  
fibre	   during	   the	   bulk	   manufacturing	   process	   to	   aid	   spray	   drying	   and	   aid	   solubilisation,	  
possesses	  some	  inhibitory	  activity	  against	  the	  epithelial	  adhesion	  of	  C.	  difficile,	  ETEC	  and	  S.	  
Typhimurium	  in	  vitro.	  However,	  whilst	  maltodextrin	  is	  present	  in	  whole	  and	  neutral	  plantain	  
NSP	  fractions,	   inhibitory	  activity	   is	   instead	  correlated	  with	  the	  presence	  of	  pectic	  material.	  
Additionally,	  pre-­‐incubation	  of	   intestinal	  epithelial	  cells	  with	  maltodextrin	  has	  no	  effect	  on	  
the	  epithelial	  cell	  damage	  and	  inflammation	  induced	  by	  bacterial	  components,	  whereas	  these	  
cellular	   responses	  are	  significantly	  suppressed	  by	  plantain	  NSP.	  We	  therefore	  suggest	   that	  
maltodextrin	   only	   contributes	   slightly	   to	   the	   inhibitory	   activity	   of	   plantain	   NSP	   in	   vitro.	  
Furthermore,	   it	   is	   likely	   that	   in	   vivo,	   maltodextrin	   would	   undergo	   almost	   complete	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fermentation	  before	  reaching	  the	  colon	  (Quezada-­‐Calvillo	  et	  al.	  2007a;	  Quezada-­‐Calvillo	  et	  al.	  
2007b),	  and	  as	  such,	  would	  have	  little	  or	  no	  	  protective	  effect.	  	  	  
	  
11.1.4   Soluble	  plantain	  NSP	  inhibits	  bacterial	  adhesion	  via	  an	  interaction	  with	  the	  intestinal	  
epithelium,	   however,	   the	  molecular	  mechanism	   underlying	   its	   inhibitory	   activity	  
remains	  unclear	  
	   As	  a	  result	  of	   the	  work	  presented	   in	  Chapter	  9,	  we	  provide	   further	   insight	   into	  the	  
molecular	  mechanism	  underlying	  the	  inhibitory	  activity	  of	  plantain	  NSP.	  We	  demonstrate	  that	  
soluble	   plantain	  NSP	   inhibits	   the	   adhesion	   of	  C.	   difficile,	   ETEC	   and	   S.	   Typhimurium	   via	   an	  
interaction	  with	  intestinal	  epithelial	  cells,	  rather	  than	  through	  interaction	  with	  bacterial	  cell-­‐
surface	  adhesins.	  	  
	   Our	  group	  had	  shown	  previously	  that	  pre-­‐treatment	  of	  human	  ileal	  FAE	  with	  plantain	  
NSP	  was	  associated	  with	  a	  marked	  increase	  in	  transmucosal	   Isc	  (Parsons	  et	  al.	  2014).	  These	  
preliminary	  results	  suggested	  that	  the	  inhibitory	  effect	  of	  plantain	  NSP	  might	  be	  mediated	  by	  
increased	   epithelial	   chloride	   secretion,	   which	   is	   a	   recognised	   part	   of	   our	   innate	   immune	  
system	   countering	   the	   invasion	   of	   luminal	   bacteria	   (Colgan	   2013).	   	   As	   an	   example,	  
secretagogue	  elicited	  epithelial	  chloride	  secretion	  and	  associated	  fluid	  transport	  was	  shown	  
to	  be	  effective	  in	  reducing	  Salmonella	  internalisation	  to,	  and	  translocation	  across	  colonocytes	  
(Keely	   et	   al.	   2012).	   In	   Chapter	   9,	   we	   confirm	   our	   previous	   findings	   and	   show	   that	   pre-­‐
incubation	  of	  intestinal	  epithelial	  cells	  with	  2.5	  –	  20	  mg/mL	  plantain	  NSP	  causes	  a	  significant	  
increase	   in	   cellular	   chloride	   channel	   activation.	   However,	   pre-­‐treatment	   of	   intestinal	  
epithelial	   cells	   with	   chloride	   channel	   inhibitors,	   whilst	   blocking	   plantain	   NSP	   induced	   Cl-­‐	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secretion,	   had	   little	   effect	   on	   plantain	   NSP	   blockade	   of	   bacterial	   adhesion.	   Similarly,	   the	  
chloride	   channel	   activators	   used	   in	   this	   study	   did	   not	   act	   to	   block	   bacterial	   adhesion.	  	  
Collectively,	   these	   findings	   indicate	   that	   whilst	   plantain	   NSP	   induces	   increased	   cellular	  
chloride	  secretion,	  this	  has	  little	  or	  no	  effect	  on	  its	  inhibitory	  activity	  within	  an	  in	  vitro	  setting.	  
We	  therefore	  suggest	  that	  the	  inhibitory	  activity	  of	  plantain	  NSP	  is	  mediated	  by	  an	  alternative	  
mechanism.	  	  
	   Another	   potential	   mechanism	   underlying	   plantain	   NSP’s	   inhibitory	   activity	   might	  
include	  its	  ability	  to	  mimic	  the	  protective	  colonic	  mucus	  barrier,	  which	  is	  mainly	  composed	  of	  
highly	  glycosylated	  MUC2,	  key	  to	  formation	  of	  the	  two	  distinct	  mucus	  layers	  that	  separate	  
luminal	  bacteria	  from	  the	  epithelium	  (Johansson	  et	  al.	  2011;	  Johansson	  et	  al.	  2008).	  MUC2	  O-­‐
glycans	  have	   recently	  been	  shown	  to	  have	  an	  anti-­‐inflammatory	  and	  mucosally	  protective	  
effects	  on	  the	  intestinal	  mucosa,	  which	  is	  mediated	  via	  interaction	  with	  cell-­‐surface	  galectin-­‐
3,	  and	  formation	  of	  a	  complex	  with	  dectin-­‐1	  and	  the	  inhibitory	  IgG	  Fc	  (crystallisable	  fragment)	  
Gamma	  Receptor-­‐IIB	  (FcγRIIB).	  This	  interaction	  triggers	  the	  translocation	  of	  β-­‐catenin	  into	  the	  
dendritic	   cell	   nucleus,	   which	   results	   in	   consequent	   reduced	   activation	   of	   NFκB,	   reduced	  
secretion	  of	  pro-­‐inflammatory	  cytokines	  (IL-­‐6,	  IL-­‐8,	  IL-­‐12p70	  and	  TNF)	  and	  enhancement	  of	  
anti-­‐inflammatory	   IL-­‐10	   (Shan	   et	   al.	   2013).	  Although	   studies	  of	   the	  anti-­‐inflammatory	   and	  
tolerogenic	   effects	   of	   MUC2	   glycans	   described	   in	   this	   study	   focused	   predominantly	   on	  
dendritic	  cells,	  preliminary	  data	  in	  relation	  to	  similar	  effects	  in	  intestinal	  epithelial	  cells	  was	  
included,	   as	   demonstrated	   by	   increased	   epithelial	   expression	   of	   Thymic	   stromal	  
lymphopoietin	   (Tslp),	  which	   also	   induces	   tolerogenic	   effects	   in	   dendritic	   cells	   (Shan	  et	   al.	  
2013).	  	  Previous	  studies	  have	  shown	  that	  pectic	  oligosaccharides,	  from	  citrus	  and	  ginseng,	  can	  
interact	  with	  galectin-­‐3	  (Gao	  et	  al.	  2013;	  Gunning	  et	  al.	  2009;	  Sathisha	  et	  al.	  2007),	  and	  recent	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data	  from	  our	  own	  group	  has	  demonstrated	  that	  plantain	  NSP	   interacts	  with	  recombinant	  
galectin-­‐3	   too	   (Shapanis	   A,	   Gastroenterology	   Research	   Unit,	   Department	   of	   Cellular	   and	  
Molecular	   Physiology,	   University	   of	   Liverpool;	   unpublished	   data).	   Supporting	   a	   role	   for	  
plantain	  NSP	  (and	  likely	  the	  pectic	  component)	  having	  a	  similar	  effect	  to	  that	  seen	  by	  MUC2	  
O-­‐glycans,	  we	  illustrate	  here	  that	  pre-­‐treatment	  of	  intestinal	  epithelial	  cells	  with	  plantain	  NSP	  
induces	   the	   activation	   and	   nuclear	   translocation	   of	   β-­‐catenin,	   as	   demonstrated	   by	  
immunohistochemistry.	  Conversely,	  we	  demonstrate	  that	  in	  SW620Gal3-­‐	  cells	  (where	  galectin-­‐
3	  expression	  has	  been	  	  knocked	  down	  by	  82%)	  (Duckworth	  et	  al.	  2015),	  plantain	  NSP	  retains	  
its	  ability	  to	  significantly	  reduce	  C.	  difficile	  epithelial	  adhesion,	  as	  well	  as	  down-­‐regulate	  the	  
IL-­‐8	  response	  to	  bacterial	  flagellin	  in	  SW620Gal3-­‐	  cells.	  Taken	  alone,	  these	  results	  might	  suggest	  
that	  soluble	  plantain	  fibre	  does	  not	  mimic	  MUC2	  glycans,	  and	  thus,	  its	  inhibitory	  activity	  is	  
not	  mediated	  by	  cell-­‐surface	  galectin-­‐3	  expression.	  However,	   it	   is	  worth	  noting	   that	   these	  
experiments	  are	  somewhat	  limited	  as	  they	  have	  only	  been	  performed	  once.	  Furthermore,	  as	  
galectin-­‐3	  expression	   is	  not	  completely	  abolished	   in	  SW620Gal3-­‐	  cells,	  a	   residual	   interaction	  
might	  still	  take	  place	  between	  plantain	  NSP	  and	  galectin-­‐3,	  which	  might	  have	  an	  impact	  on	  
bacterial	  adhesion.	  As	  a	  result	  of	  these	  inconclusive	  findings,	  the	  role	  of	  cell-­‐surface	  galectin-­‐
3	  expression	  on	  the	   inhibitory	  activity	  of	  plantain	  NSP	  is	  currently	  unclear.	  Further	  work	   is	  
therefore	  necessary	  to	  characterise	  the	  molecular	  mechanism	  underlying	  the	  bioactivity	  of	  
plantain	  NSP.	  	  
	  
11.2  FINAL	  CONCLUSIONS	  
	   Soluble	   plantain	   fibre,	   particularly	   its	   pectin	   fraction,	   can	   significantly	   inhibit	   the	  
epithelial	  adhesion	  of	  diarrhoeal	  pathogens	  C.	  difficile	  and	  ETEC,	  as	  well	  as	  C.	  difficile	  spores.	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Furthermore,	   soluble	   plantain	   NSP	   also	   down-­‐regulates	   the	   epithelial	   cell	   damage	   and	  
inflammatory	  response	  induced	  by	  bacterial	  components,	  such	  as	  C.	  difficile	  TcdA	  and	  TcdB,	  
as	  well	  as	  bacterial	  flagellin	  and	  LPS.	  These	  findings	  provide	  convincing	  evidence	  to	  support	  
our	  hypothesis	  that	  soluble	  plantain	  fibre	  can	  inhibit	  harmful	  interactions	  between	  bacteria	  
and	  the	  human	  intestinal	  epithelium,	  and	  thus,	  have	  a	  beneficial	  effect	  on	  intestinal	  health.	  	  
	   Importantly,	   inhibition	   of	   these	   cellular	   responses	   occurs	   at	   soluble	   fibre	  
concentrations	   readily	   achievable	   within	   the	   human	   distal	   colon	   following	   dietary	  
supplementation	  (Roberts	  et	  al.	  2010).	  Modelling	  of	  soluble	  plantain	  NSP	  breakdown	  using	  
mixed	  faecal	  microbiota	  from	  healthy	  volunteers	  has	  shown	  that	  25-­‐75%	  of	  ingested	  plantain	  
NSP	  is	  likely	  to	  avoid	  fermentation	  in	  the	  human	  colon	  (Backman	  2009;	  Roberts	  et	  al.	  2010).	  
Assuming	  passage	  of	  1	   litre	  of	   fluid	  daily	   into	  the	  caecum,	  we	  have	  estimated	  that	  readily	  
achievable	   oral	   dosing	   of	   humans	   with	   5	   g	   soluble	   plantain	   NSP	   twice	   daily	   will	   achieve	  
effective	  luminal	  concentrations	  of	  approximately	  10	  mg/mL	  and	  7.5	  mg/mL	  in	  the	  caecum	  
and	  rectum,	  respectively	  (Roberts	  et	  al.	  2010).	  	  
	   Overall,	   these	   studies	  provide	  convincing	  evidence	   to	   suggest	   that	   soluble	  plantain	  
fibre,	   acting	   as	   a	   ‘contrabiotic’	   (Simpson	   and	   Campbell	   2015),	   could	   be	   developed	   as	   a	  
potential	  prophylaxis	  or	   treatment	  against	   intestinal	  pathogens	  causing	  CDI	  and	  traveller’s	  
diarrhoea.	  In	  addition,	  dietary	  supplementation	  with	  soluble	  plantain	  NSP	  may	  also	  confer	  a	  
therapeutic	  benefit	  in	  IBD.	  	  
	   Soluble	  plantain	  fibre	  could	  be	  formulated	  with	  dairy	  products	  (e.g.	  milk,	  a	  milkshake	  
or	  yoghurt)	  or	  a	  fruit	  juice	  (e.g.	  orange	  juice	  or	  similar)	  to	  produce	  a	  palatable	  drink	  that	  would	  
be	   highly	   suitable	   sufferers	   of	   diarrhoeal	   conditions	   (Simpson	   and	   Campbell	   2015).	  Other	  
potential	   formulations	   include	   powder	   mixes,	   which	   could	   be	   combined	   with	   further	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ingredients	   added	   for	  nutritional	  or	  medical	   reasons,	  or	   for	   improved	  palatability.	   Soluble	  
fibre	  could	  also	  be	  presented	  as	  food	  supplements	  or	  food	  additives,	  incorporated	  into	  slow	  
release	  tablets,	  or	  alternatively,	  be	  administered	  as	  combination	  therapies	  alongside	  pre-­‐	  or	  
probiotic	  portions.	  	  
	  
11.3   IMPLICATIONS	  FOR	  FUTURE	  WORK	  
	   We	  show	  here	  that	   the	   inhibitory	  activity	  of	  plantain	  NSP	   is	  mediated	  by	   its	  acidic,	  
pectic	  fraction.	  Thus,	  it	  would	  be	  interesting	  to	  next	  screen	  a	  range	  of	  dietary	  pectins	  for	  their	  
anti-­‐inflammatory	  effects,	  as	  well	  as	  for	  their	  ability	  to	  inhibit	  the	  in	  vitro	  epithelial	  adhesion	  
of	   gut	   pathogens	   (including	   Salmonella	   spp.,	   AIEC	   and	   C.	   difficile).	   Total	   pectin	   could	   be	  
extracted	  from	  a	  taxonomic	  spectrum	  of	  edible	  plants,	  with	  particular	  emphasis	  on	  those	  that	  
have	   exhibited	   inhibitory	   activity	   in	   our	   own	   studies,	   such	   as	   plantain	   bananas,	   leek	   and	  
broccoli.	  The	  pectin	  fractions	  that	  exhibit	  the	  highest	  bioactivity	  could	  then	  be	  subjected	  to	  
further	  fractionation	  to	  identify	  specific	   inhibitory	  oligosaccharides.	   Indeed,	   if	  considerable	  
bioactivity	   is	   shown	   in	   vitro,	   then	   pectin	   and	   pectic	   polysaccharide	   components	   could	   be	  
assessed	  for	  their	  protective	  effect	  against	  inflammatory	  disease	  in	  both	  animal	  and	  human	  
models.	  It	  is	  important	  to	  note	  that	  some	  pectin	  components	  are	  more	  rapidly	  degraded	  in	  
the	   colon	   than	  others	   (Holloway	   et	   al.	   1983).	   If	   biologically	   active	  pectin	   components	   are	  
identified,	   it	   might	   therefore	   be	   necessary	   to	   develop	   an	   enteric-­‐coated	   formulation	   to	  
prevent	  their	  breakdown	  in	  the	  proximal	  colon.	  	  
	   Whilst	   the	  work	  performed	   in	   this	   thesis	  has	  provided	  a	   significant	   insight	   into	   the	  
mechanism	   underlying	   the	   inhibitory	   activity	   of	   plantain	  NSP,	   further	  work	   is	   required	   to	  
	  	  248	  
establish	  if	  it	  is	  mediated	  by	  an	  interaction	  with	  galectin-­‐3	  via	  the	  MUC2-­‐galectin3-­‐Dectin	  1	  
signalling	  pathway.	  As	  galectin-­‐3	  expression	  was	  only	  knocked	  down	  by	  82%	  in	  the	  SW620Gal3-­‐	  
cells	   used	   in	   our	   studies	   (Duckworth	   et	   al.	   2015),	   it	   would	   be	   beneficial	   to	   repeat	   the	  
experiments	  using	  a	  cell	  line	  that	  is	  completely	  devoid	  of	  cell-­‐surface	  galectin-­‐3	  expression.	  In	  
addition,	   it	   might	   be	   useful	   to	   treat	   intestinal	   epithelial	   cells	   with	   pre-­‐designed	   siRNAs	  
targeting	  the	  GAL3	  gene	  to	  assess	  if	  this	  has	  an	  effect	  on	  the	  inhibitory	  effect	  of	  plantain	  NSP.	  
It	  would	  also	  be	  possible	  to	  use	  these	  methods	  to	  examine	  the	  effect	  of	  Dectin-­‐1	  suppression,	  
as	  well	  as	  other	  key	  tolerogenic	  signalling	  partner	  moieties	  involved	  in	  the	  MUC2-­‐galectin3-­‐
Dectin	  1	  pathway,	  such	  as	  FcRn	  (FcγRIIB  in	  dendritic	  cells)	  and	  β-­‐catenin.	  
	   We	  present	  promising	  findings	  to	  suggest	  that	  soluble	  plantain	  fibre	  can	  inhibit	  the	  in	  
vitro	  epithelial	  interactions	  of	  C.	  difficile	  bacterium,	  toxins	  and	  spores.	  As	  such,	  it	  would	  next	  
be	  beneficial	  to	  assess	  if	  dietary	  supplementation	  with	  soluble	  plantain	  fibre	  has	  a	  protective	  
effect	  in	  an	  in	  vivo	  CDI	  model.	  Syrian	  hamsters	  represent	  a	  common	  CDI	  model	  as	  they	  exhibit	  
many	  of	  the	  clinical	  symptoms	  that	  are	  observed	  in	  human	  CDI	  (Best	  et	  al.	  2012).	  Similar	  to	  
humans,	  infection	  in	  Syrian	  hamsters	  must	  be	  induced	  by	  disrupting	  the	  microbiota	  through	  
the	  administration	  of	  antibiotics,	  most	  commonly	  clindamycin,	   followed	  by	  challenge	  with	  
toxigenic	  C.	  difficile	  strains	  or	  spores.	  This	  results	  in	  haemorrhagic	  caecitis,	  which	  manifests	  
as	  ‘wet	  tail’	  and	  is	  followed	  by	  death	  (Best	  et	  al.	  2012).	  To	  assess	  the	  effect	  of	  plantain	  NSP,	  
hamsters	  would	  have	  either	  soluble	  plantain	  fibre	  or	  control	  maltodextrin	  supplemented	  in	  
their	  diet	  for	  one	  week	  prior	  to	  antibiotic	  administration	  and	  subsequent	   infection	  with	  C.	  
difficile	  spores,	  then	  throughout	  the	  study.	  At	  12,	  24	  and	  36	  h	  post-­‐challenge,	  hamsters	  would	  
be	  culled	  for	  post-­‐mortem	  analysis,	  where	  the	  caecum	  and	  colon	  removed	  aseptically	  and	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their	  contents	  analysed	  for	  total	  bacterial	  load,	  as	  well	  as	  the	  presence	  of	  C.	  difficile	  toxins	  
(Buckley	  et	  al.	  2011).	  	  
	   To	  assess	  if	  the	  protective	  effect	  of	  plantain	  NSP	  translates	  into	  human	  clinical	  benefit,	  
it	   would	   also	   be	   necessary	   to	   conduct	   a	   placebo-­‐controlled	   clinical	   trial,	   where	  we	   could	  
assess	   plantain	   NSP	   for	   its	   ability	   to	   prevent	   CDI	   in	   high-­‐risk	   populations,	   such	   as	   those	  
receiving	   broad-­‐spectrum	   antibiotics	   (Ananthakrishnan	   2011).	   This	  might	   include	   patients	  
who	  are	  admitted	  to	  hospital	  with	  community-­‐acquired	  pneumonia.	  Primary	  endpoints	  of	  this	  
study	  would	  include	  the	  occurrence	  of	  diarrhoea,	  as	  well	  as	  laboratory	  analysis	  of	  stools	  to	  
confirm	  the	  presence	  of	  C.	  difficile	  toxins	  (Iv	  et	  al.	  2014).	  
	   Further	  work	  is	  also	  warranted	  to	  assess	  if	  dietary	  supplementation	  with	  plantain	  NSP	  
has	  a	  protective	  effect	  in	  an	  in	  vivo	  colitis	  model,	  and	  similarly,	  whether	  this	  translates	  into	  a	  
therapeutic	   benefit	   in	   human	   UC.	   Indeed,	   it	   has	   been	   shown	   previously	   that	   dietary	  
intervention	  with	  green	  dwarf	  banana	  flour	  (Musa	  spp.	  AAA)	  reduces	  the	  severity	  of	  TNBS-­‐
initiated	  colitis	  in	  mice	  (Scarminio	  et	  al.	  2012).	  It	  would	  therefore	  be	  interesting	  to	  determine	  
if	  the	  oral	  administration	  of	  plantain	  soluble	  fibre	  (and	  pectic	  oligosaccharide	  fractions)	  has	  a	  
similar	  protective	  effect	  in	  this	  particular	  colitis	  model.	  In	  addition,	  the	  impact	  of	  plantain	  NSP	  
dietary	  supplementation	  on	  amelioration	  of	  spontaneous	  colonic	  inflammation	  observed	  in	  
Muc2-­‐deficient	  mice	  (Wenzel	  et	  al.	  2014).	  	  
	   A	   future	  pilot	   phase	   IIA	   “placebo-­‐blinded”	   study	  has	   also	  been	  proposed,	   in	  which	  
patients	  with	  mild	   to	  moderately	   active	  UC	  will	   receive	   plantain	  NSP	   (15	   or	   30	   g/day)	   or	  
placebo	  (15	  g/day	  maltodextrin).	  The	  primary	  endpoint	  of	  this	  clinical	  trial	  would	  be	  remission	  
at	  6	  weeks	  based	  on	  a	  patient-­‐reported	  outcome	  measure	  derived	  from	  the	  Mayo	  Clinic	  score	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(Lewis	   et	   al.	   2008),	   as	  well	   as	   reduction	   in	   faecal	   calprotectin	   concentration	   (Leiper	   et	   al.	  
2011).	  Considerable	  emphasis	  would	  also	  be	  placed	  on	  palatability	  and	  dosing	  of	  plantain	  NSP.	  	  
	   If	  the	   in	  vivo	  studies	  described	  above	  suggest	  that	  plantain	  NSP	  is	  a	  promising	  anti-­‐
colitic	  agent,	  further	  studies	  could	  also	  be	  performed	  to	  evaluate	  its	  ability	  to	  prevent	  colon	  
carcinogenesis.	   This	   could	   be	   assessed	   using	   the	   mouse	   model	   of	   colon	   carcinogenesis	  
induced	  by	  the	  alkylating	  agent	  azoxymethane	  (Rosenberg	  et	  al.	  2009).	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  Further	   studies	   are	   also	   required	   to	   determine	   if	   soluble	   plantain	   NSP	   exerts	   a	  
protective	  effect	  against	  ETEC	  infection	   in	  vivo.	  However,	  the	  development	  of	  therapies	  to	  
treat	  ETEC	  infection	  has	  been	  limited	  by	  the	  lack	  of	  viable	  small-­‐animal	  models,	  and	  as	  a	  result,	  
further	  advances	  in	  this	  field	  will	  have	  to	  take	  place	  before	  we	  commence	  this	  work	  (Allen	  et	  
al.	  2006).	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Luria	  Burtani	  (LB)	  agar	  
	  
5	  g	   	   Yeast	  extract	  
10	  g	   	   Tryptone	  
10	  g	   	   NaCl	  
15	  g	   	   Agar	  
1	  L	   	   Distilled	  water	  
	  
Brain	  heart	  infusion	  agar	  supplemented	  with	  0.1%	  L-­‐cysteine	  and	  5	  mg/mL	  yeast	  extract	  (BHIS)	  
	  	  
37	  g	  	   	   Brain	  heart	  infusion	  broth	  
15	  g	  	   	   Agar	  
1	  g	   	   L-­‐cysteine	  
5	  g	  	   	   Yeast	  extract	  
1	  L	   	   Distilled	  water	  	  
	  
	  
Tryptic	  glucose	  yeast	  (TGY)	  broth	  	  
	  
30g	   	   Tryptic	  soy	  broth	  
20g	  	   	   Glucose	  
10g	   	   Yeast	  extract	  
1g	   	   L-­‐cysteine	  	  




	  	  310	  
Sorbitol	  MacConkey	  (SMC)	  broth	  	  
	  
90	  g	  	   	   Peptone	  
5	  g	  	   	   Proteose	  peptone	  
1	  g	  	   	   (NH4)2SO4	  
1.5	  g	   	   Tris	  base	  
1	  g	  	   	   L-­‐cysteine	  	  
1	  L	   	   Distilled	  water	  	  
	  
	  
Sorbitol	  MacConkey	  (SMC)	  agar	  
	  
90	  g	  	   	   Peptone	  
5	  g	  	   	   Proteose	  peptone	  
1	  g	  	   	   (NH4)2SO4	  
1.5	  g	   	   Tris	  base	  
1	  g	  	   	   L-­‐cysteine	  	  
15	  g	  	   	   Agar	  
1	  L	   	   Distilled	  water	  	  
	  
	  
CHLORIDE	  CHANNEL	  ACTIVITY	  ASSAYS:	  
	  
Iodine	  loading	  buffer	  
	  
0.88	  g	  	   	   NaI	  
8.9	  mg	   	   CaCl2	  
10	  mg	  	   	   NaH2PO4	  
9.5	  mg	   	   1	  mM	  MgCl2	  
89.6	  mg	   KI	  
100	  mL	  	   Distilled	  water	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Detection	  buffer	  1	  
	  
19.8	  g	  	   	   Arsenic	  (III)	  acid	  
50	  mL	   	   25%	  ammonia	  
50	  mL	   	   Sulphuric	  acid	  
25g	   	   Ammonium	  chloride	  
900	  mL	  	  Distilled	  water	  	  
	  
Detection	  buffer	  2	  
	  
10	  g	  	   	   Ammonia	  Ce	  (IV)-­‐sulfate	  
26	  mL	   	   Sulphuric	  acid	  





5	  x	  SDS-­‐PAGE	  sample	  buffer	  
	  
1	  mL	  	   	   0.5	  M	  Tris-­‐HCl	  
0.8	  mL	   	   Glycerol	  
1.6	  mL	   	   10%	  SDS	  
0.4	  mL	   	   Beta-­‐mercaptoethanol	  	  
0.2	  mL	  	   	   0.05%	  (w/v)	  bromophenol	  blue	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SDS-­‐PAGE	  transfer	  buffer	  
	  
14.4	  g	  	   	   Glycine	  
3.03	  g	   	   Tris	  base	  
200	  mL	  	   Methanol	   	  
800	  mL	  	   Distilled	  water	  
	  
SDS-­‐PAGE	  running	  buffer	  	  
	  
1	  g	   	   Sodium	  dodecyl	  sulphate	  (SDS)	  
14.4	  g	   	   Glycine	  
3.03	  g	   	   Tris	  base	  
1	  L	  	   	   Distilled	  water	  	  
	  
Phosphate	  buffered	  saline	  (PBS)	  
	  
8	  g	  	   	   NaCl	  
0.2	  g	   	   KCl	  
1.44	  g	   	   Na2HPO4	  
0.24	  g	  	   	   KH2PO4	  
1	  L	   	   Distilled	  water	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1	  Sourced	  from	  Ecuador	  (ripeness	  stage	  1).	  Average	  values	  obtained	  from	  plantains	  grown	  














Monosaccharide  composition  (µg/mg  NSP)  
Rhamnose	   Fucose	   Xylose	   Arabinose	   Mannose	   Galactose	   Glucose	  
Apple   19.9   3.2	   0.0	   0.0	   6.1	   2.3	   3.2	   3.7	  
Bean   31.7   2.8	   0.0	   0.0	   17.5	   1.8	   2.8	   2.1	  
Blueberry   19.2   6.3	   0.0	   0.0	   14.1	   4.7	   5.5	   8.2	  
Broccoli   17.5   1.2	   0.0	   0.0	   2.6	   2.3	   7.8	   5.3	  
Celery   45.8   2.4	   0.0	   0.0	   9.7	   1.6	   6.6	   0.8	  
Leek   23.0   11.4	   0.0	   0.0	   4.1	   8.1	   1.4	   32.8	  
Pear   32.7   1.4	   0.0	   0.0	   1.4	   1.9	   1.4	   3.1	  
Pepper  
(Red)   35.9   4.5	   0.0	   0.0	   6.7	   11.1	   2.8	   11.7	  
Plantain  
(Green)1   26.8   2.4	   2.6	   6.7	   9.0	   18.7	   8.6	   25.2	  
Strawberry   30.4   5.9	   0.0	   0.0	   12.4	   1.2	   2.1	   1.6	  
Tomato   29.9   7.0	   0.0	   0.0	   29.7	   4.4	   8.5	   9.6	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APPENDIX	  3	  –	  BACTERIAL	  CHARACTERISTICS	  OF	  ULCERATIVE	  COLITIS	  (UC)	  E.	  COLI	  STRAINS	  
SELECTED	  FOR	  STUDY	  IN	  THIS	  THESIS	  
	  
E.	  coli	  isolate	   Hemagluttination	  status1	  
Afa/Dr	  
cluster	   Curli	  Fimbriae	   Phylotype	  
HM250	   +	   -­‐	   +	   B2	  
HM295	   -­‐	   -­‐	   -­‐	   B2	  
HM378	   -­‐	   -­‐	   -­‐	   B2	  
HM380	   -­‐	   -­‐	   +	   B2	  
HM387	   -­‐	   -­‐	   +	   B2	  
	  
1	  Determined	  by	  the	  ability	  to	  haemagluttinate	  red	  blood	  cells	  (taken	  from	  [Subramanian	  et	  
al.	  2008])	  
	  
